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ADULT CONSERVATIVE 
MANAGEMENT 
C. DUMOULIN (CANADA)  
T. ADEWUYI (UK), J. BOOTH (UK), C. BRADLEY (USA), K. BURGIO (USA), S. HAGEN (UK), 
K. HUNTER (CANADA), M. IMAMURA (UK), M. MORIN (CANADA), S. MORKVED (NORWAY), 
R. THAKAR (UK), S. WALLACE (UK), K. WILLIAMS (UK) 
 INTRODUCTION 
Conservative management of urinary incontinence 
(UI) or pelvic organ prolapse (POP) is defined as any 
intervention not involving surgical or pharmacological 
approaches (1). These comprise lifestyle modifica-
tion, pelvic floor muscle training (PFMT) (either alone 
or with the addition of biofeedback), vaginal cones, 
electrical stimulation, magnetic stimulation, posterior 
tibial nerve stimulation, scheduled voiding regimens, 
complementary/alternative medicines and supportive 
rings/pessaries. In this chapter, we cover studies that 
provide comparative data between a conservative 
management approach and the absence of treatment 
or placebo, between two conservative management 
approaches or between a conservative management 
approach and medications or surgery.  
Conservative management approaches are consid-
ered relatively low cost and non-invasive, with mini-
mal adverse effects that are typically guided by a 
healthcare professional and depend on user partici-
pation. It is generally accepted that conservative in-
terventions are part of initial management at the pri-
mary care level for individuals suffering from either UI 
or POP. Conservative intervention is also indicated 
for those for whom other treatments are inappropri-
ate, for example, those unwilling to undergo or unfit 
for surgery and women who plan future pregnancies. 
Other indications include individuals awaiting surgery 
or who wish to delay surgery and those whose symp-
toms are not severe enough for surgical intervention. 
The research base on which to judge the effective-
ness of conservative interventions is growing alt-
hough some aspects, such as lifestyle modification 
interventions and alternative and complementary 
medicines in particular, require considerably more 
well-designed trials. In this chapter we add to the 
2013 5th Edition ICI chapter on conservative manage-
ment (2), integrate the evidence and upgrade the rec-
ommendations from the 5th ICI. We also add a new 
section on posterior tibial nerve stimulation with its 
levels of evidence and recommendation.  
The updated literature search covered publications 
from July 1st, 2011 to September 9th, 2015 according 
to the following search strategy: 
 Cochrane Incontinence systematic reviews 
Relevant Cochrane systematic reviews were identi-
fied, for each section of this Chapter, by two of the 
authors (CD, SW) assessing the full list of reviews 
(Cochrane Incontinence (3) or on request).  The leads 
for each section were given lists of these relevant re-
views. Additional searches of the Cochrane Inconti-
nence Specialised Register were provided to each 
section author to bring the searches up to date or, if 
there was a gap in review coverage, a full search of 
the Register was conducted (search date: September 
9th,  2015).   
 Additional searches for this ICI Chapter 
Electronic searches 
We identified relevant trials from the Cochrane Incon-
tinence Specialised Register. For more details of the 
search methods used to build the Register please see 
the Group's module in the Cochrane Library (4). The 
Register contains trials identified from the Cochrane 
Central Register of Controlled Trials (CENTRAL), 
MEDLINE, MEDLINE In-Process, ClinicalTrials.gov, 
WHO ICTRP, UK Clinical Research Network Portfolio 
and hand searching of journals and conference pro-
ceedings. The search covered: 
 For sections covered by existing Cochrane re-
views – from the date of last search for the pub-
lished version of the review to September 9th, 
2015. 
 For sections not covered by existing Cochrane 
reviews – complete search of all contents of the 
Register on September 9th, 2015. 
 Searching other sources 
We searched the reference lists of relevant articles 
for other relevant trials.  
We did not impose any language or other limitations 
on any of the searches described above. 
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In continuity with the last edition of the ICI chapter on 
conservative management and to ensure consistency 
throughout the chapter, the primary outcomes to be 
reported were patient-reported outcomes: cure and 
cure and improvement, UI-specific or POP-specific 
quality of life or symptoms-validated questionnaire 
and/or number of leakages (as per the diary). Cure 
and improvement were based on patients' self-report 
when available; if not, cure and improvement based 
on quantifiable measures such as a diary and pad 
tests were reported.  
Secondary outcomes were clinician-reported out-
comes (pad test, POPQ score, etc.). These were cho-
sen in relation to each subsection’s specificity and in 
continuity with our previous chapter.  
Each subsection concludes with the level of evi-
dence, grade of recommendations and factors affect-
ing outcome. Separate chapters in this 6th Edition ad-
dress incontinence in the frail older person, children, 
pessaries and products for continence, those with 
neurological conditions and those suffering from fae-
cal incontinence. 
Where summary statistics are presented, the raw 
data from which these are derived can be found in the 
tables within each subsection, in trial reports and sys-
tematic reviews cited in the chapter. The Chapter is 
intended as a stand-alone document and adds to the 
comprehensive reports from previous ICI editions.  
 URINARY INCONTINENCE IN 
WOMEN 
1. LIFESTYLE MODIFICATION 
INTERVENTIONS  
Lifestyle modification Interventions for women  
A number of lifestyle factors may play a role in either 
the development or resolution of UI. Lifestyle modifi-
cation interventions are defined as application of in-
terventions in management of lifestyle-related health 
problems (1). They are low cost, non-invasive altera-
tions in lifestyle such as weight loss; dietary changes; 
fluid intake modification; reduction in caffeinated, car-
bonated and alcoholic drinks; avoidance of constipa-
tion; stopping smoking; and physical activity.  
As reported in the 5th ICI (2013) evidence for the effi-
cacy of lifestyle modification interventions for urinary 
incontinence is lacking, there are few lifestyle modifi-
cation interventions that have received scrutiny in 
randomised controlled trials, although weight loss 
and dietary factors have been examined and pro-
spective studies and observational studies have been 
undertaken for diet, smoking and constipation. For 
more details, refer to ICI 5th Edition (2).  
This review section updates the evidence on the use 
of lifestyle modification interventions to improve in-
continence and related symptoms in females. It re-
vealed 10 potentially eligible new trials. Table 1 illus-
trates the number of studies included in the 5th ICI 
edition as well as the new studies identified in the cur-
rent update. Characteristics of each new trial are pre-
sented in subsequent tables for each lifestyle modifi-
cation intervention for which there is new data. 
 
Table 1 Studies included in the updated review 2016 
Lifestyle modification 
Interventions 
ICI 2013 ICI 2016 Total 
Weight loss 3 RCT  
4 prospective cohort 
7 cross sectional cohort 
1 retrospective cohort 
1 case control study 
  
2 RCT 
1 cohort study 
1 meta-analysis 
1 prospective longitudinal 
study 
5 RCT  
13 cohort studies 
1 case control study 
1 meta- analysis 
1 prospective longitudinal 
study 
Physical activity 2 prospective cohort 
2 observational cohort 
1 prospective cohort study 
1 case control study  
 
3 prospective cohort studies 
2 observational cohort study 
1 case control study 
Smoking 2 case control studies 1 RCT (pilot, secondary 
analysis)  
1 RCT pilot 
2 case control studies 
Dietary factors   3 observational studies 1 case control study 
1 prospective cohort study 
1 cross sectional cohort 
study 
3 observational studies 
1 case control study 
1 prospective cohort study 
1 cross sectional cohort 
study 
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Questions addressed are: 
 Are lifestyle modification interventions (e.g. 
weight loss, increased/decreased physical activ-
ity/ smoking cessation/ dietary or fluid change) 
effective in the prevention of UI? 
 Are lifestyle modification interventions (e.g. 
weight loss, increased/decreased physical activ-
ity/ smoking cessation/ dietary or fluid change) 
better than no treatment, placebo or control in 
the treatment of UI? 
 Is one lifestyle modification intervention (e.g. 
weight loss, increased/decreased physical activ-
ity/ smoking cessation/ dietary or fluid change) 
better than another? 
In 2015 a Cochrane review was published (5) which 
included all available trials of lifestyle modification in-
terventions for urinary incontinence. These trials are 
included in this review, along with new trial data since 
the Cochrane search was undertaken (October 27th, 
2014) as well as other cohort evidence where no trial 
data are available. 
1.1. Prevention 
Are lifestyle modification interventions (e.g. 
weight loss, increased/decreased physical activ-
ity/ smoking cessation/ dietary or fluid change) 
effective in the prevention of UI? 
In the last ICI chapter (5th ICI, 2013), there were no 
trials on prevention of UI. No new trials have been 
published.  
Based on the clear lack of evidence in the literature 
of RCTs or observational studies of lifestyle modifica-
tion interventions to prevent UI, no evidence based 
recommendations can be made.  
Prevention should be an area for future research in-
vestment and comprise robust economic evaluation 
to determine the benefits of prevention strategies in 
specific age groups. 
1.2. Treatment 
1.2.1 Weight Loss by Obese or Overweight 
Women 
Urinary incontinence and obesity are both common 
problems for women. It is recognised that obese 
women have higher intra-abdominal pressures than 
non-obese women, and it has been suggested that 
this chronically elevated pressure may predispose to 
incontinence by weakening pelvic floor support struc-
tures (6).  
One new trial was identified which examined weight 
loss in overweight/obese women (7) (Table 2). The 
study was conducted to determine the effect of an in-
tensive weight loss programme over 4 years on a 
subset of female participants (n=2739), previously 
outlined in the Look AHEAD trial(7). All participants 
were randomised to an intensive weight loss pro-
gramme or a diabetes support and education group. 
Self-report of incontinence, nocturia and daytime 
voiding frequency were recorded at baseline and 1 
year. Each kilogramme of weight loss reduced the 
odds of developing UI at one year by 3% (OR 0.97, 
95% CI (0.95-0.99); p=0.1). There was uncertainty 
over the risk of selection bias for several key param-
eters, including: random sequence generation and al-
location concealment. Performance bias was unclear 
as the blinding of participants and staff was not un-
dertaken. The study ensured the blinding of outcome 
assessment but did not provide complete outcome 
data and provided only selective reporting indicating 
possible reporting bias.  
A single study not identified in our previous searches 
from 2008 was discovered (8). This prospective lon-
gitudinal study examined the effect of weight loss of-
fered as part of a weight reduction programme which 
included low calorie diet and exercise, 64 obese in-
continent women were included. Weight loss of ≥5% 
of baseline weight was associated with significant re-
duction in pad test loss (median difference, 19 g; 95% 
confidence interval, 13-28 g; p < 0.001). They also 
report a statistically significant improvement in quality 
of life measures. They suggest that weight reduction 
of 5% of initial body weight can improve UI severity 
and its effects on quality of life in obese women. 
There was uncertainty over the risk of bias in all pa-
rameters for this study due to the poor reporting style. 
Further analysis on the effect of weight loss on 
changes in health-related quality of life are reported 
by Pinto et al. 2012 (9). In a study conducted for the 
Programme to Reduce Incontinence by Diet and Ex-
ercise (PRIDE), a longitudinal cohort analysis was 
undertaken of 338 obese and overweight women with 
UI and health related quality of life assessed at base-
line, 6 and 18 months. They concluded that weight 
loss and increased physical activity but not reduction 
in frequency of UI were strongly associated with im-
provements in QoL. 
More recently in 2014 a systematic review and meta-
analysis of non-surgical weight loss interventions in 
overweight women was published by Vissers et al. 
(10) drawing on the studies from the ICI 2013 chapter 
and the more recent Cochrane review (2015); this 
concluded that whilst few (n=6) studies were availa-
ble, non-surgical weight loss should be considered 
standard practice for overweight women with UI. This 
review did not identify any additional studies for inclu-
sion here. It is important to note that this review 
sought to determine the effect of non-surgical weight 
loss interventions on urinary incontinence in over-
weight women, but, in fact, included studies of both 
obese and overweight women. 
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Table 2 Summary of data on weight loss  
1. Phelan S, Kanaya AM, Subak LL, Hogan PE, Espeland MA, Wing RR, et al. Weight Loss Prevents Urinary Incontinence in Women With Type 2 Diabetes: Results 
From the Look AHEAD Trial. Journal of Urology. 2012;187(3):939-44. 
2. Breyer BN, Phelan S, Hogan PE, Rosen RC, Kitabchi AE, Wing RR, et al. Intensive Lifestyle Intervention Reduces Urinary Incontinence in Overweight/Obese Men 
with Type 2 Diabetes: Results from the Look AHEAD Trial. Journal of Urology. 2014;192(1):144-9. 
3. Auwad W, Steggles P, Bombieri L, Waterfield M, Wilkin T, Freeman R. Moderate weight loss in obese women with urinary incontinence: a prospective longitudinal 
study. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(9):1251-9. 
4. Pinto AM, Subak LL, Nakagawa S, Vittinghoff E, Wing RR, Kusek JW, et al. The effect of weight loss on changes in health-related quality of life among overweight 
and obese women with urinary incontinence. Quality of Life Research. 2012;21(10):1685-94. 
Author, 
year 
Comparator N 
Study    
population 
Age Outcomes/results Follow up 
Notes (side effects, loss of follow up, 
risk of bias) 
Phelan 
2012(1) 
Intensive weight-loss vs a 
structured education 
programme on weight 
loss 
 
2994 Women in a 
diabetes trial 
Group 1 
57.8 
Group 2 
58.1 
Decrease of at least 2 incontinence 
episodes a week assessed by a 
validated self report questionnaire. 
Mean weight loss at 1 year Group 1 : 7.7 
group 2 0.7; p value<0.0001 
12 months Random sequence generation: unclear 
Allocation concealment – unclear 
Blinding of participants – high risk 
Blinding of outcome assessment – low risk 
Incomplete outcome data – unclear risk 
Selective reporting – unclear risk 
Breyer 
2014(2)  
Intensive weight loss 
versus a structured 
education programme on 
weight loss 
1910 Men in a 
diabetes trial 
59.9 Decrease in incontinence episodes or 
cure assessed by a validated self-report 
questionnaire 
 
12 months Random sequence generation : unclear 
Allocation concealment – unclear 
Blinding of participants – high risk 
Blinding of outcome assessment – low risk 
Incomplete outcome data – unclear risk 
Selective reporting – unclear risk 
Auwad 
2008(3) 
Commercial programme 
of diet and exercise 
versus no control group 
64 Obese women 
with 
urodynamically 
proved urinary 
incontinence 
52.2 Decrease in pad test loss 18 months Blinding of outcome assessment – unclear 
risk 
Incomplete outcome data – unclear risk 
Selective reporting – unclear risk 
Pinto 
2012(4) 
Behavioural weight loss 
intervention versus a 
structured education 
programme on weight 
loss 
338 Overweight and 
obese women 
with UI 
53 +- 11 
years 
(SD) 
Health related QoL 18 months Secondary analysis of data: 
Random sequence generation : low risk 
Allocation concealment – low risk 
Blinding of participants – high risk 
Blinding of outcome assessment – low risk 
Incomplete outcome data – low risk 
Selective reporting – unclear risk 
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Summary 
Evidence from 1 RCT, 2 cohort studies and one meta-
analysis support lifestyle modification interventions 
promoting weight loss as a tool to reduce urinary in-
continence in women who are overweight or obese. 
Weight loss of 5% of initial body weight has an impact 
on the reduction of urinary incontinence symptoms 
and the odds of developing UI at one year can be re-
duced by 3% for every kilogram lost by overweight 
and obese women. (Level of Evidence: 1) 
Recommendations 
Weight loss as a non-surgical intervention, should be 
recommended to obese and overweight women with 
UI. (Grade of Recommendation: A) 
1.2.2 Physical Activity 
No new RCT data have been published on either the 
benefits of moderate physical activity or the adverse 
effect of strenuous activity on UI in women. One rele-
vant prospective cohort study (11) and one case con-
trol study have been reported since the last review 
Table 3. 
The prospective cohort study (11) determined that 
low physical activity may be a causal factor in the de-
velopment of overactive bladder. This study devel-
oped a hypothetical causative model for OAB involv-
ing secondary analysis from the Leicestershire UK 
MRC Incontinence study and included 3411 women 
free from OAB and 277 incident cases aged 40+. The 
study used graphical chain modelling to EStimate the 
associations between variables and identify the likely 
causal pathways. Low physical activity was a direct 
risk factor linked to the development of over active 
bladder (OAB) with incontinence (RR 2.47;95% CI 
1.82, 3.36). They identified the need for further re-
search to demonstrate a causal link between lifestyle 
and OAB. This study was difficult to combine as it 
used sophisticated statistical modelling to determine 
a causative model for use in future research. This re-
search indicated that poor lifestyle factors causally 
linked to diabetes and obesity and suggest that this 
may contribute to the onset of OAB. The authors iden-
tify that low physical activity could be an important 
modifiable causal factor for OAB operating via path-
ways involving obesity or diabetes. 
Summary 
Non RCT evidence is building which suggests that 
moderate exercise decreases the incidence of UI alt-
hough the level of evidence remains low (Level of 
Evidence: 3).  
Recommendations:  
In the absence of robust randomised controlled trials 
(Grade of Recommendation: C) 
1.2.3 Strenuous Physical Activity 
The previous ICI identified no research evidence 
which suggested that strenuous exercise causes UI. 
Minimal uncontrolled data did suggest that women 
engaged in occupations which involved heavy lifting 
may be predisposed to genital prolapse or UI (12). A 
case control study conducted by Nygaard et al. (13) 
to determine lifetime physical activity and stress in-
continence enrolled 1528 women between the ages 
of 39-65. Each participant underwent a Pelvic Organ 
Prolapse Quantification examination, 213 cases were 
identified and matched 1:1 to controls. Physical activ-
ity was measured using the Lifetime Physical Activity 
Questionnaire in which women recall their past phys-
ical activity. Lifetime strenuous activity was not asso-
ciated with SUI (OR, 1.11; 95% CI, 0.99-1.25) and in-
creased lifetime activity did not affect the odds of de-
veloping SUI (OR, 1.11; 0.99-1.25; p=0.06) (Table 3). 
Summary 
Evidence for the association between strenuous 
physical activity and incontinence need to be repli-
cated using larger populations and more robust de-
sign before recommendations can be made. No fur-
ther data was identified. (Level of Evidence: 3) 
Recommendations:  
In the absence of robust randomised controlled trials 
(Grade of Recommendation: C) 
1.2.4 Smoking 
In 2014, a pilot study investigated the effect of smok-
ing cessation on overactive bladder symptoms (14). 
The authors explored the hypothesis that smoking 
abstinence would be associated with improvements 
in OAB symptoms. The sample was randomised to 
one of three arms: 1) very low nicotine cigarettes; 2) 
very low nicotine cigarettes and a 21g nicotine patch; 
3) patch alone. All participants had at least one OAB 
symptom including urinary frequency, urgency, noc-
turia or urgency urinary incontinence, smoked 10-40 
cigarettes a day for a year and were in good physical 
and mental health. The ICIQ-OAB was used at base-
line and 12 weeks, 6 weeks after completion of the 
trial intervention. Outcomes included self-report of 
smoking cessation and OAB symptoms and score. 96 
(47%) of the 202 participants met the inclusion criteria 
for this secondary analysis and 57 (59%) (37 women 
and 20 men) completed the study and were included 
in the analysis. Data was not presented separately for 
women and men. Those who were abstinent from 
smoking at 12 weeks were more likely to have a re-
duction in urinary frequency (p=0.042) and the ICIQ-
OAB score showed no change for those who were 
abstinent or those who resumed smoking (4.6+0.5 vs 
4.3+0.3, respectively, p=ns). The authors conclude 
that smoking cessation and its effect on OAB would 
need to undergo more rigorous evaluation in further 
trials with larger sample size to determine the effect 
of smoking abstinence on OAB symptoms (Table 4). 
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Summary  
Data suggest that smoking increases the risk of more 
severe UI. This small new study indicates that urinary 
frequency may be improved by smoking abstinence. 
(Level of Evidence: 3) 
Recommendations 
There remains a need for further prospective studies 
of smoking cessation for urinary symptoms (Grade of 
Recommendation: C) 
1.2.5 Dietary Modification (Elimination Diet) 
Dietary factors can be divided into three groups: Diet; 
Fluid Intake and Caffeine. There have been no new 
published RCTs evaluating the effect of diet or fluid 
intake on urinary incontinence, but one small new 
RCT (15), three new observational studies (1 case 
control study, 1 prospective cohort study, 1 cross sec-
tional cohort study) examining the effect of caffeine 
on urinary incontinence, one in men presented in sec-
tion IV (16), one in women (17) and one in both men 
and women (18) (Table 5).  
A small double blind randomised crossover study by 
Wells et al. of 14 patients with OAB was conducted in 
which women were allocated to one of two groups. 
Group A were allocated to a 14 day caffeinated drink 
period followed by a 14 day de-caffeinated period. 
Groups B were allocated to a 14 day de-caffeinated 
period followed by a 14 day caffeinated period. Both 
were preceded by a 14 day run-in period. The primary 
outcome was reported episodes of urgency, fre-
quency and volume per void recorded in a 3 day di-
ary. Secondary outcomes included OAB symptom se-
verity and health related quality of life (QOL). Of the 
eleven women who completed the study, a significant 
reduction of urgency (p<0.1) and frequency (p<0.5) 
were reported. Risk of bias was minimised using a 
double blind design, but conclusions must be cau-
tious due to the very small sample size (15). 
Three studies examined the association between caf-
feine and UI, Gleason et al. (2013) (17) examined the 
association in women in the US and Hyrayama et al. 
(2012)(18) in men and women in Japan and Davis et 
al. (2012)(16) in a male sample in the US.  
In the cross sectional female US survey study, UI sta-
tus was collected using the Incontinence Severity In-
dex and food diaries were used to collect data on caf-
feine intake in 4309 women aged 20 or over. This 
study found an association between caffeine con-
sumption in the highest quartile (>204mg day) was 
associated with any UI (prevalence odds ratio 1.47, 
95% CI 1.07, 2.01), but not moderate or severe. Caf-
feine consumption at the very highest level was found 
to be associated with UI in a very large sample of US 
women. All parameters in terms of risk of bias report-
ing were unclear or high risk. The blinding of partici-
pants and personnel and blinding of outcome assess-
ment were at high risk of bias and the likelihood of 
incomplete outcome data and selective reporting was 
also high. 
Hirayama and Lees study comprised a sample of 683 
men and 298 women (results for men are reported 
separately) aged 40-75 who completed a food fre-
quency questionnaire and the Consultation on Incon-
tinence short Form (ICI-SF). The data showed a slight 
increase in the risk of UI at the highest level of caf-
feine consumption (similar to the US data), but this 
was not significant after adjusting for confounding 
factors with OR: 95% CI, 1.12 (0.57-2.22) for women. 
The risk of bias reporting was largely unclear in this 
study with blinding of participants and personnel and 
blinding of outcome assessment, incomplete out-
come data and selective reporting all of high risk. The 
sample of women did not show an association be-
tween caffeine and UI, they suggest the need for fur-
ther larger samples to explore any association fur-
ther.  
Summary  
There have been no new data on dietary content 
modification and UI since 2013, the existing evidence 
suggests that dietary content may play a role in uri-
nary incontinence (Level of Evidence: 3).  
Minimal evidence exists on the role of macronutrient 
intake and reduction of UI. Fluid intake may play a 
minor role in the pathogenesis of UI (Level of Evi-
dence: 2).  
Caffeine consumption is likely to play a role in exac-
erbating UI and related symptoms such as urgency 
and frequency. Small clinical trials suggest that de-
creasing caffeine intake improves continence. (Level 
of Evidence: 2), new epidemiological evidence from 
a large cross sectional study supports this conclusion 
however it does not change the Level of Evidence: 
Level 2. 
Recommendations 
Recommendations for fluid intake and dietary intake 
have not changed (Grade of Recommendation: B). 
Further RCTs to assess the role of diet in UI are war-
ranted.  
A reduction in caffeine intake is recommended for 
those with incontinence and related symptoms 
(Grade of Recommendation: B) Larger RCTs to as-
sess the effect of caffeine and other dietary factors 
are feasible and important. 
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Table 3 Summary of data on physical activity 
1. McGrother CW, Donaldson MMK, Thompson J, Wagg A, Tincello DG, Manktelow BN. Etiology of overactive bladder: A diet and lifestyle model for diabetes and 
obesity in older women. Neurourology and Urodynamics. 2012;31(4):487-95. 
2. Nygaard IE, Shaw JM, Bardsley T, Egger MJ. Lifetime physical activity and female stress urinary incontinence. American Journal of Obstetrics and Gynecology. 
2015;213(1). 
Table 4 Summary of data on smoking cessation 
1. Wyman J, Allen A, Hertsgaard L, Overson E, Allen S, Hatsukami D. Effect of Smoking Cessation on Overactive Bladder Symptoms in Adults: A Pilot Study. 
Neurourology and Urodynamics. 2014;33(6):866-7 
Table 5 Summary of data on caffeine consumption 
Author, year Comparator N Study population age Outcomes/results Follow 
up 
Notes (limitations) 
Davis 2013 (1) Association 
between caffeine 
and UI in US men 
3960 Publically available data 
from the National Health 
and Nutrition 
20+ Incontinence Severity 
Index (ISI) 
no Cross sectional design means that no 
causation can be determined. The ISI needs 
additional validation for use in men. 25% of 
Author, 
year 
Comparator 
groups 
N Study population Age Assessment 
Follow 
up 
Outcomes 
McGrother 
2012(1) 
Development of a 
Causative model 
for OAB 
3411 Women in a UK 
epidemiological study of 
UI free from OAB at 
baseline 
40+ Food frequency questionnaire 
and OAB recorded in a postal 
questionaire 
no Low physical activity linked to the onset of 
OAB. Older women reporting less activity 
than their peers had more than double the 
risk of developing OAB. 
Nygaard  
2015 (2) 
Case control study 1538 Women seeking 
gynaecological primary 
care 
39-
65 
POP assessment, severity 
index score (indicating SUI), 
Lifetime physical activity 
questionnaire 
no SUI odds increased with overall lifetime 
activity (OR 1.20 per 70 additional metabolic 
equivalent of task-h/wk; 95% CI, 1.02-1.41. 
Author, year Comparator N 
Study 
population 
Age Outcomes/results 
Follow 
up 
Notes (side effects, loss of follow up, 
risk of bias) 
Wyman et al.  
2014 (1) 
Low nicotine cigarette 
alone vs low nicotine 
cigarette combined with 
21mg nicotine patch vs 
patch alone 
202 Subset of adult 
participants in a 
smoking 
cessation trial 
18-70 ICIQ-OAB 
Self-reported smoking 
status and cessation 
12 weeks Subset of participants: 
Random sequence generation: uncertain 
Allocation concealment – uncertain 
Blinding of participants – uncertain 
Blinding of outcome assessment – 
uncertain 
Incomplete outcome data – low risk 
Selective reporting – unclear risk 
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Author, year Comparator N Study population age Outcomes/results Follow 
up 
Notes (limitations) 
Examination Surveys 
2005-2006 and 2007-
2008 in men 
Structured dietary 
recall 
the sample was excluded due to missing UI 
and dietary data. 
Gleason 2013 (2) Association 
between caffeine 
and UI in US 
women 
4309 Publically available data 
from the National Health 
and Nutrition 
Examination Surveys 
2005-2006 and 2007-
2008 in women 
20+ Incontinence Severity 
Index (ISI) 
Structured dietary 
recall 
no The cross sectional design means that no 
causation can be determined. Analysis 
depended on self report. Questions for UI 
type were not validated and data was not 
analysed according to UI type or severity. 
Hirayama 2012(3) Association 
between caffeine 
use and UI in 
Japanese adults 
981 Community dwelling 
Japanese men and 
women 
40-75 ICIQ-SF 18 
months 
Cross sectional study: No cause-effect 
relationship could be established due to the 
study design. Classification of urine loss was 
based on self report 
 
Wells 2014 (4)  Group A were 
allocated to a 14 
day caffeinated 
drink period 
followed by a 14 
day de-caffeinated 
period. Groups B 
were allocated to 
a 14 day de-
caffeinated period 
followed by a 14 
day caffeinated 
period. 
14 
community 
dwelling 
women 
Women patient with 
OAB  
18+ Reported episodes of 
urgency, frequency 
and volume per voids 
recorded in a 3 day 
diary 
no Small double blind randomised crossover 
study 
1. Davis NJ, Vaughan CP, Johnson TM, Goode PS, Burgio KL, Redden DT, et al. Caffeine Intake and its Association with Urinary Incontinence in United States Men: 
Results from National and Nutrition Examination Surveys 2005-2006 and 2007-2008. Journal of Urology. 2013;189(6):2170-4. 
2. Gleason JL, Richter HE, Redden DT, Goode PS, Burgio KL, Markland AD. Caffeine and urinary incontinence in US women. International Urogynecology Journal. 
2013;24(2):295-302. 
3. Hirayama F, Lee AH. Is caffeine intake associated with urinary incontinence in Japanese adults? J Prev Med Public Health. 2012;45(3):204-8. 
4. Wells MJ, Jamieson K, Markham TC, Green SM, Fader MJ. The effect of caffeinated versus decaffeinated drinks on overactive bladder: a double-blind, randomized, 
crossover study. Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society. 2014;41(4):371-8. 
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1.2.6 Constipation 
No new trials on constipation were found. Therefore, 
the evidence remains the same (small observational 
studies) suggesting that chronic straining may be a 
risk factor for the development of UI (Level of Evi-
dence: 3).  
Recommendation  
Further research is needed to define the role of strain-
ing in the pathogenesis of UI.  
1.3. Other LUTS 
No data were found.  
1.4. Factors Affecting Outcome 
No data were found.  
2. PELVIC FLOOR MUSCLE 
TRAINING (PFMT) 
Pelvic floor muscle training (PFMT) is defined as ex-
ercise to improve PFM strength, endurance, power, 
relaxation or a combination of these parameters (1). 
PFMT remains a key factor in the treatment of UI. Be-
cause pelvic floor muscle (PFM) integrity appears to 
play an important role in the continence mechanism 
(see report from Chapter 4: Pathophysiology), there 
is a biological rationale to support the use of PFMT in 
preventing and treating SUI in women (19-21). The 
role of PFMT in the treatment of UUI came later, when 
it was recognized that PFM contraction can also be 
used to occlude the urethra to prevent leakage during 
detrusor contraction, as well as inhibit and suppress 
detrusor contraction (22, 23). More details about the 
biological rationale regarding PFMT for SUI and UUI 
can be found in the last edition of this chapter (2). 
PFMT is an intervention that involves the understand-
ing of PFM activation and the pursuit of a repeated 
PFM exercise programme over time. Because effec-
tiveness depends on the participant's adherence dur-
ing the intervention and afterwards (in the mainte-
nance phase), a better understanding of adherence 
mechanisms and how they can be promoted is of ma-
jor importance. The 2011 International Continence 
Society State of the Science Seminar on Adherence 
produced 4 papers and a Consensus Statement re-
viewing present literature and making recommenda-
tions to increase PFMT adherence that could be use-
ful, both in the clinical and research settings UI (24-
28)  
This section presents evidence for the use of PFMT 
in the prevention and treatment of UI in women. 
Questions addressed are: 
 Is PFMT effective in the prevention of UI? 
 Is PFMT better than no treatment, placebo or 
control treatments in the treatment of UI? 
 Is one type of PFMT programme better than an-
other in the treatment of UI? 
 Is PFMT better than other treatments in the treat-
ment of UI? 
 Does the addition of PFMT to other treatments 
add any benefit in the treatment of UI? 
 What factors might affect the outcome of PFMT 
in the treatment of UI? 
 What is the effect of PFMT on other lower urinary 
tract symptoms (LUTS)? 
2.1. Prevention and Treatment (Pregnant 
and Postnatal Women Only) 
This subsection specifically considers PFMT for the 
prevention and treatment of UI in pregnant and post-
natal women (called childbearing women). As the 
physiological changes of childbearing can affect PFM 
function, it is possible that the effect of PFMT might 
differ in this group compared to non-childbearing 
women; therefore, this group is treated separately.  
Since the last ICI (2013), 11 randomised controlled 
trials aiming at prevention and/or treatment of UI were 
identified and reviewed for this subsection (29) (30) 
(31) (32) (33) (34) (35) (36) (37) (38) (39) (Table 6). 
An updated Cochrane review was published in 2012, 
analysing data from 22 trials involving 8485 women 
(40). Trials in this section have been grouped in 3 ar-
eas: 1) trials of PFMT for prevention of UI (performed 
in women without UI symptoms when randomised); 
2) trials of PFMT for treatment of UI; and 3) trials of 
PFMT for the prevention and treatment of UI (partici-
pants with and without UI symptoms enrolled). Trials 
were further separated into those beginning during 
pregnancy (antenatal) or postnatal.     
The primary outcome of interest was self-reported UI 
(cure, improvement, number of leakage episodes). 
Other outcomes of interest included adherence 
measures. 
2.1.1 Is PFMT Effective in the Prevention of 
UI in Childbearing Women? 
This section addresses the question of PFMT effec-
tiveness for primary and secondary prevention of UI 
in childbearing women. Clinically it can be difficult to 
effectively screen trial participants to ensure that a 
disease process is altogether absent (for primary pre-
vention studies) or present, although asymptomatic 
(for secondary prevention). Trials investigating pre-
vention of UI usually enrol people purely on the basis 
of the absence of symptoms. Thus, the trials in this 
section likely represent a combination of primary and 
secondary prevention effects.  
Since last chapter edition three new prevention trials 
were found (30, 36, 38) (Table 6) adding to the six 
previously existing trials.  
Two studies (30) (38) recruited nulliparous or primip-
arous women during pregnancy, and one recruited 
15 
"pregnant women" (36). Primigravidae were recruited 
at weeks 6-9 (30), 10-14 (38) and 14-20 (36). In all 
trials, PFMT began during pregnancy while controls 
received usual antenatal care, which may have in-
cluded advice on PFMT, from their maternity caregiv-
ers (30) (36) (38) There were some variations in the 
PFMT parameters (intensity and supervision) (Table 
6). 
Quality of data  
Two were RCTs (30, 38), while one was a quasi-ran-
domized trial (36). Allocation concealment appeared 
adequate only in the trial by Pelaez (2014) (38). The 
outcome assessors were not blinded in the trials by 
Kocaoz (2013) (36) and Pelaez (2014)(38), while 
Barakat (2011)(30) gives no information about blind-
ing of evaluators. Dropout rates were 16% (30), 10-
14% (38) and 22% (36), and quite similar in both 
study groups. Outcomes were measured at various 
times: outcome in late pregnancy was measured only 
after delivery (30), 36 weeks of pregnancy (38); 28 
and 32 weeks of pregnancy then at three months 
postpartum (36). None of the trials applied intention-
to treat analysis. 
Results  
 Late pregnancy (34 weeks or later): Pelaez (38) 
found a statistically significantly lower frequency 
of UI (p<0.001) in the intervention group com-
pared to the control group between 36 and 40 
weeks of pregnancy, and concluded that PFMT 
was effective in primary prevention of UI in pri-
miparous pregnant women, while Barakat (30) 
reported no difference in frequency of urine loss 
between the exercise (supervised moderate 
physical exercise including PFMT) and control 
groups in late pregnancy.  
 Mid postpartum (three to six month postpartum): 
Kocaoz (36) reported a statistically significant 
difference between the intervention and control 
groups in terms of development of stress urinary 
incontinence at the 28th and 32nd weeks of preg-
nancy and the 12th postpartum week (p<0.05). 
Summary  
Two studies documented the effectiveness of PFMT 
on primary prevention of UI during pregnancy (36, 
38). One study included only nulliparous women and 
reported UI in late pregnancy (38). The other study 
also included multiparous women and reported UI in 
late pregnancy and 12 weeks postpartum (36). (Level 
of Evidence: 1) 
Recommendations  
Offer continent, pregnant women a supervised (in-
cluding regular health professional contact) and in-
tensive strengthening PFMT programme to prevent 
antepartum and postpartum UI (Grade of Recom-
mendation: A) 
Research recommendation 
Additional trials with long-term follow-up (more than 
12 months postnatal) are needed to determine long-
term benefits of antenatal PFMT.  
The only study including multiparous women is a 
quasi-randomized trial. Thus, large and good-quality 
RCTs are needed to investigate the effect of antepar-
tum PFMT on preventing postpartum UI in multipa-
rous women. 
2.1.2 Is PFMT Effective in the Treatment of UI 
in Childbearing Women? 
Since last chapter edition two trials assessing the 
treatment effect of postnatal PFMT were found (29) 
(34) (Table 6) adding to the four previously existing 
trials.  
Kim (2012) recruited a mix of primiparous and multip-
arous incontinent women less than six weeks (34) af-
ter delivery, while Åhlund (2013) recruited only pri-
miparous women 10-16 weeks after delivery (29). 
The control group in the trial by Åhlund received 
standard care, which included ante and postpartum 
advice on PFMT (1), whereas the control group/unsu-
pervised training group in Kim’s study were instructed 
in PFMT and followed the same PFMT programme as 
the supervised training group (34). The PFMT inter-
ventions varied (Table 6).  
Quality of data  
Both studies were RCTs, but random allocation con-
cealment was inadequate. In one trial (34) evaluators 
were blinded to group allocation. Åhlund (2013) and 
Kim (2012) reported an 8% and 1% loss to follow up, 
respectively. Similar dropout rates were found in both 
study groups in both trials. Outcomes were meas-
ured, before, 3 months after delivery (34) and 6 
months after delivery (29). Kim did not report analysis 
by intention-to-treat, while information is lacking in the 
trial by Åhlund. 
Results  
In the trial by Åhlund the results showed significantly 
improved continence in both groups, however there 
was no between group comparison. Kim reported sig-
nificant difference in UI symptoms in favour of the su-
pervised PFMT group. 
Summary  
Data from one trial showed significantly better treat-
ment effect of supervised PFMT compared to unsu-
pervised PFMT. The other trial did not compare dif-
ference in treatment effect between groups. The ad-
dition of the new trials does not change the level of 
evidence. (Level of Evidence: 1)  
Recommendations  
PFMT should be offered as first line conservative 
therapy to women with persistent UI symptoms three 
16 
months after delivery. (Grade of Recommendation: 
A)  
An ‘intensive’ PFMT programme (in terms of supervi-
sion and exercise content) is likely to increase the 
treatment effect. (Grade of Recommendation: B) 
Research recommendation 
There is a need for at least one large, pragmatic, well-
conducted and explicitly reported trial with long term 
follow-up (five plus years) of postpartum PFMT that 
investigates the long term effect of ‘intensive’ PFMT. 
2.1.3 Is PFMT Effective in the Mixed Preven-
tion and Treatment of UI in Childbear-
ing Women? 
Since last chapter edition six mixed prevention and 
treatment trials were found adding to the ten previ-
ously existing trials. Five trials assessed the effect of 
antenatal PFMT (31) (35) (37) (39) (32), and one the 
effect of postnatal PFMT (33) (Table 6).  
In five trials, nulliparous, primiparous or multiparous 
women were randomised to either supervised ante-
partum PFMT or usual antepartum care (31) (32) (35) 
(37) (39). One study randomised nulliparous women 
to supervised postpartum PFMT or usual postpartum 
care (33). Ko (2011) and Miguelutti (2013) recruited 
nulliparous women and Stafne (2012) multiparous 
women between 16-24 weeks’ gestation. Bø’s study 
(2011) differed in that the primary aim was to assess 
the effect of regular exercise on weight gain in preg-
nancy. Primiparous, sedentary women within the first 
24 weeks of pregnancy were recruited. Fritel (2015) 
included nulliparous women between 20-28 weeks of 
gestation. 
i) Antepartum PFMT versus usual care 
The PFMT interventions varied (Table 6). 
Quality of data  
 Antepartum PFMT versus usual care: The four 
RCTs had adequate random allocation genera-
tion and concealment and thus had a low risk of 
bias (31) (32) (37) (39). In two of the trials a 
blinded method of collecting patient-reported in-
continence symptom data was used (32) (39). 
Sample sizes varied between 105 and 855 
women (31) (39), and the proportions of lost to 
follow up were 20%, 2%, 33% and 11% respec-
tively (31) (37) (32) (39). Losses to follow up in 
intervention and control groups were quite simi-
lar in all trials. Intention-to-treat analysis was per-
formed by all, except for Bø (2011). 
 Postpartum PFMT versus usual care or no 
PFMT: Random allocation generation and con-
cealment was adequate and a blinded method of 
collecting patient-reported incontinence symp-
tom was used in the trial by Hilde (2013) (33). 
Lost to follow up was 9%, in the control 14% and 
in the exercise group 3%. Analysis was by inten-
tion-to-treat. 
Results  
i) Antepartum PFMT versus usual care 
Ko (2011), Miquelutti (2013) and Stafne (2012) 
showed that women who were randomised to ante-
partum PFMT had significantly less risk of UI in late 
pregnancy compared to a group receiving usual care 
in late pregnancy.  
Three of the new five new mixed prevention and treat-
ment trials assessing the effect of antenatal PFMT 
(35) (37) (39), reported a significant effect of PFMT 
during pregnancy, and 3 months after delivery (35). 
Bø (2011) found no difference in late pregnancy and 
3 months postpartum, between a group following an 
aerobic fitness class including PFMT and a control 
group. While Fritel (2015) showed no difference in 
prevalence or severity of UI between a group receiv-
ing written instructions and a group receiving an ad-
ditional eight PFMT sessions with a midwife or phys-
iotherapist in late pregnancy, 2 and 12 months post-
partum. 
Some adherence outcomes were included for four 
antepartum (31) (35) (32) (39) trials; >80% of the 
PFMT women attended every group session, and at 
36 gestational weeks, 87% reported PFMT practice 
at least 75% of the time (35); 40% of the exercise 
group attended >80% of the weekly exercise classes 
(31); 67% of the women in the intervention group and 
40% in the control group performed PFMT three times 
per week or more (39); 54% in the intervention and 
63% in the control group performed postpartum 
PFMT (32). 
ii) Postpartum PFMT versus usual care or no PFMT  
The only new mixed prevention and treatment trial as-
sessing the effect of postnatal PFMT (33), found no 
differences in the prevalence of UI between a super-
vised PFMT group and a control group receiving in-
structions in correct PFM contractions and written in-
formation. Adherence was 96% in the intervention 
group (33). 
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Table 6 Summary of PFMT data on prevention and treatment (pregnant and postnatal women) 
Author, 
year 
Comparator N Study population  Modality details or parameters Outcomes/results Follow 
up 
Notes (side effects, 
loss of follow up…)  
Ahlund 
2013(1) 
Control group (n=49): 
instructions and control of 
correct PFM contractions 
and written information 
about PFMT. 
 
Intervention group (n=49): 
instructions and control of 
correct PFM contractions, 
written information about 
PFMT and follow up by 
midwife 
N=98 
 
Primiparous women 
with SUI, 10-16 
weeks after delivery 
 
Multi centre 
Sweden 
Three visits with midwife during the 
intervention period. A 6 months home 
PFM program including three fast 
contractions, three times 8-12 slow 
velocity (6 seconds), close to maximum 
contractions 
Significantly (p<0.05) 
improved continence 
score (0-20) in both 
groups at 6 months 
postpartum. 
Difference between 
groups was not reported.  
no Loss to follow up: 16%  
CG: 7/49 
IG: 9/49 
Bo 2011 
(2) 
Control (n=53): standard 
care 
 
Intervention (n=52): 12-16 
wk’ aerobic fitness class 
including PFMT 
N= 
105 
 
Nulliparous, 
sedentary women 
within the first 24 
weeks of pregnancy  
With and without UI 
at inclusion. 
 
Single centre 
Norway 
12 -16 weeks of aerobic exercise classes 
twice per week during pregnancy, 
including intensive PFMT (in a group) led 
by aerobic instructor. Additional home 
exercises 10 max contractions (each held 
for six seconds) and to the last 4 were 3-
4 fast contractions added x 3, per day. 
Correct VPFMC was not checked at 
enrolment. 
No significant difference 
between groups: 
 
Self reported UI at 36-38 
weeks of pregnancy: 
Control: 7/53 
Intervention: 9/52 
 
Self reported UI at 3 
months postpartum: 
Control: 6/53 
Intervention: 5/52 
 
no 
oss to follow up: 20%  
CG: 11/53 
IG: 10/52 
 
Barakat 
2011 (3) 
Control group (n=40): 
standard care 
 
Intervention group (n=40): 
Physical conditioning 
program 45 minutes 3 
times per week from 
inclusion to week 38-39. 
PFMT included during the 
last trimester. 
N= 80 
 
Sedentary women 
within 6-9 weeks of 
pregnancy.  
Without UI at 
inclusion. 
 
Single centre 
Spain 
Exercises to strengthen the PFM included 
in a general exercise program with 45 
minutes sessions x 3 per week, during 
the last trimester. No further details about 
the PFMT program.  
No significant difference 
in frequency of urine loss 
(CIQ-SF Incontinence 
classification) in late 
pregnancy. 
(Questionnaire answered 
after delivery). 
no Loss to follow up: 16%  
CG: 6/40 
IG: 7/40 
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Author, 
year 
Comparator N Study population  Modality details or parameters Outcomes/results Follow 
up 
Notes (side effects, 
loss of follow up…)  
Fritel 2015 
(4) 
Control group (n=142): 
standard care including 
written instructions about 
PFMT 
 
Intervention group 
(n=140): Individual 
supervised PFMT 
N=282 
 
Nulliparous women 
between 20-28  
weeks of gestation. 
With and without UI 
at inclusion. 
 
Multicentre 
France 
The PFMT group received eight individual 
training sessions supervised by a midwife 
or a physiotherapist, once per week 
between the sixth and eight month of 
pregnancy. Each session lasted 20-30 
minutes and included evaluation of pelvic 
floor muscle contraction. Sessions 
consisted of standing contractions (5 
minutes), lying contractions (10 minutes) 
and learning how to start a pelvic floor 
muscle contraction just before exerting 
intraabdominal pressure (the Knack). 
Women were encouraged to perform 
daily PFMT. No specific instructions on 
the number or intensity of the 
contractions were given. 
No significant difference 
between groups in UI 
severity (ICIQ-UI SF 
score) and prevalence at 
2 and 12 months 
postpartum: 
UI severity at 2 months 
postpartum (mean, SD): 
Control: 2.3 (±3.4) 
Intervention 1.7 (±2.9) 
 
UI severity at 12 months 
postpartum: 
Control: 2.1 (±3.3) 
Intervention: 1.9 (±3.7) 
 
Yes 
12 
months 
Loss to follow up: 33%  
CG: 45/142 
IG: 47/140 
Hilde 2013 
(5) 
Control group (n=88): 
receiving instructions in 
correct PFM contractions 
and written information 
 
Intervention group (n=87): 
supervised PFMT  
 
N=175 Singleton 
primiparous women 
Who delivered 
vaginally after more 
than 32 weeks of 
gestation 
 
Single centre 
Norway 
PFMT in groups supervised by 
physiotherapist once per week in 16 
weeks (starting 6-8 weeks after delivery), 
and daily home training with three sets of 
8 to 12 contractions close to maximum 
No significant differences 
in the percentage of 
women with UI at six 
months postpartum 
between a supervised 
PFMT group and a 
control group receiving 
instructions in correct 
PFM contractions and 
written information.  
UI 6 months postpartum: 
Control: 39% 
Intervention: 35% 
no Loss to follow up: 9%  
CG: 3/88 
IG: 12/87 
 
Kim 2012 
(6) 
Control (n=10): 
unsupervised PRMT 
 
Intervention (n=10): 
Supervised PFMT 
N=18, 
 
Mix of primiparous 
and multiparous 
incontinent women 
less than six weeks 
after delivery. All with 
UI at inclusion. 
 
Single centre 
Korea 
PFMT in various positions (20 repetitions 
with 10 second holding), abdominal 
strengthening exercises and trunk 
stabilisation using a therapeutic ball. 
Twenty three one-hour sessions of 
training with physiotherapist, three times 
per week in an 8 week period. Additional 
daily home training program 
Significant difference 
(p=0.001) in change in 
values for UI symptoms 
((BFLUTS) between 
groups, in favour of the 
IG 
(mean, SD): 
Control: -18 (± 5.5)  
Intervention: -27 (± 6.2)          
no Loss to follow up: 10%  
CG: 9/10 
IG: 9/10 
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Author, 
year 
Comparator N Study population  Modality details or parameters Outcomes/results Follow 
up 
Notes (side effects, 
loss of follow up…)  
Ko 
2011 (7) 
Control: Routine 
antenatal care. 
 
Intervention: Individual 
PFMT with 
physiotherapist once per 
week between 20-36 
weeks pregnancy with 
additional home exercises 
3 sets of 8 contractions 
(each held for 6 seconds) 
repeated twice daily. 
Instructed to contract the 
PFM when coughing or 
sneezing. 
N=300  
 
Nulliparous women 
recruited at 16-24 
weeks of pregnancy.  
With and without UI 
at inclusion. 
 
Single centre, 
Taiwan 
The PFMT group met individually with a 
physical therapist for instruction and 
assessment of correct contraction. The 
PFMT included three sets of eight 
contractions repeated twice daily. 
Additional group therapy occurred weekly 
in 45 minute sessions over a 12 week 
period. 
Self reported UI at 36 wk’ 
pregnancy p<0.01: 
Control: 76/150 (51%)  
Intervention: 52/150 
(34%)                
Self reported UI at 3days 
postpartum p=0.06: 
Control:62/150 (41%)  
Intervention:46/150 (30%) 
Self reported UI at 6 
weeks postpartum 
p=0.06: 
Control: 53/150 (35%)  
Intervention: 38/150 
(25%) 
Self reported UI at 6 
months postpartum 
p=0.04: 
Control: 42/150 (27%)  
Intervention:  
25/150 (16%) 
Yes 
6 
months 
Loss to follow up: 0%  
 
Kocaoz 
2013 (8) 
 
 
Quasi randomized trial  
Control group (n=68): ? 
 
Intervention group (n=68): 
Instructions in PFMT and 
information. 
N=136 Continent, pregnant 
women at week 14-
20 of pregnancy. 
Without UI at 
inclusion. 
 
Single centre 
Turkey 
Correct voluntary PFM contraction was 
checked prior to training 
Daily PFMT, three sets of 10 
contractions. Maximal contraction of the 
PFM and hold for 10 seconds, and quick 
contractions 
A statistically significant 
difference was found 
between control and 
intervention group in SUI 
development at 28th and 
32nd weeks of gestation 
and the 12th week 
postpartum. 
yes 
12th 
week 
postpar
tum 
Loss to follow up: 25%  
CG: 18/68 
IG: 16/68 
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Author, 
year 
Comparator N Study population  Modality details or parameters Outcomes/results Follow 
up 
Notes (side effects, 
loss of follow up…)  
Miquelutti 
2013 (9) 
Control group (n=100): 
standard care 
 
Intervention group (n=97): 
Additional physical and 
educational activities 
including information 
about PFMT. 
N=205 Nulliparous low risk 
women at 18 weeks 
of gestation. 
With and without UI 
at inclusion. 
 
Multi centre 
Brazil 
On the days of prenatal visits; consisted 
of physical exercises, educational 
activities and instructions on exercises to 
be performed at home. The PFMT should 
be performed daily at home and included 
rapid (30 times) and sustained maximal 
contractions (20 times holding for 10 
seconds) in sitting and standing positions. 
 
The risk of UI was 
significantly lower in the 
intervention group at 30 
 weeks of pregnancy: 
CG 62% 
IG 43%  
RR 0.69 (95% CI 0.51-
0.93) 
and 36 weeks of 
pregnancy: 
CG 68% 
IG 41% 
RR 0.60 (95% CI 0.45-
0.81) 
no Loss to follow up: 2%  
CG: 2/102 
IG: 6/103 
 
Pelaez 
2014 (10) 
Control group (n=96) 
 
Intervention group (n=73) 
N=169 
 
Healthy, primiparous 
pregnant women in 
gestational week 10-
14. 
Without UI at 
inclusion. 
 
Single centre 
Spain 
Correct voluntary PFM contraction was 
checked prior to training 
The intervention consisted of 70-78 group 
sessions; 10 minutes of PFMT three 
times per week in 22 weeks  
 
At 36 weeks of pregnancy 
there was statistically 
significant (p=0.001) 
difference in frequency of 
UI and in ICIQ-UI SF 
score in favour of the 
intervention group. 
CG 2.7 (SD4.1) 
IG 0.2 (SD 1.2) 
no Loss to follow up: 16%  
CG: 7/96 
IG: 10/73 
 
Stafne 
2012 (11) 
Control group (n=426): 
standard care 
 
Intervention group 
(n=429): 12 weeks of 
PFMT 
N=855 Multiparous women 
between 16-24 
weeks gestation. 
With and without UI 
at inclusion. 
 
Multi centre 
Norway 
The PFMT group met individually with a 
physical therapist for instruction and 
assessment of correct contraction, and 
PFMT protocol was similar to that 
described previously by Mørkved (1997, 
2003), including three sets of eight 
contractions repeated twice daily. 
Additional group therapy occurred weekly 
in 45 minute sessions over a 12 week 
period. 
Self-reported UI at 34-38 
weeks of pregnancy: 
Any UI (p=004):  
CG 192/365 (53%) 
IG 166/397 (42%) 
 
UI once per week or more 
(p=0.004): 
CG 68/365 (19%) 
IG 44/397 (11%) 
no Loss to follow up: 11%  
CG: 61/426 
IG: 32/429 
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21 
3. Barakat R, Pelaez M, Montejo R, Luaces M, Zakynthinaki M. Exercise during pregnancy improves maternal health perception: A randomized controlled trial. Amer-
ican journal of obstetrics and gynecology. 2011;204(5):402. 
4. Fritel X, de TR, Bader G, Savary D, Gueye A, Deffieux X, et al. Preventing Urinary Incontinence With Supervised Prenatal Pelvic Floor Exercises: A Randomized 
Controlled Trial. Obstetrics & Gynecology. 2015;126(2):370-7. 
5. Hilde G, Staer-Jensen J, Siafarikas F, Ellstrom EM, Bo K. Postpartum pelvic floor muscle training and urinary incontinence: a randomized controlled trial [Erratum 
appears in: Obstet Gynecol. 2014 Sep;124(3):639]. Obstetrics & Gynecology. 2013;122(6):1231-8. 
6. Kim EY, Kim SY, Oh DW. Pelvic floor muscle exercises utilizing trunk stabilization for treating postpartum urinary incontinence: randomized controlled pilot trial of 
supervised versus unsupervised training. Clinical Rehabilitation. 2012;26(2):132-41. 
7. Ko PC, Liang CC, Chang SD, Lee JT, Chao AS, Cheng PJ. A randomized controlled trial of antenatal pelvic floor exercises to prevent and treat urinary incontinence. 
Int Urogynecol J. 2011;22(1):17-22. 
8. Kocaoz S, Eroglu K, Sivaslioglu AA. Role of pelvic floor muscle exercises in the prevention of stress urinary incontinence during pregnancy and the postpartum 
period. Gynecologic & Obstetric Investigation. 2013;75(1):34-40. 
9. Miquelutti MA, Cecatti JG, Makuch MY. Evaluation of a birth preparation program on lumbopelvic pain, urinary incontinence, anxiety and exercise: A randomized 
controlled trial. BMC Pregnancy and Childbirth. 2013;13(154). 
10. Pelaez M, Gonzalez-Cerron S, Montejo R, Barakat R. Pelvic floor muscle training included in a pregnancy exercise program is effective in primary prevention of 
urinary incontinence: a randomized controlled trial. Neurourology & Urodynamics. 2014;33(1):67-71. 
11. Stafne S, Salvesen K, Romundstad P, Torjusen I, Morkved S. Does regular exercise including pelvic floor muscle training prevent urinary and anal incontinence 
during pregnancy? A randomised controlled trial. BJOG: an International Journal of Obstetrics & Gynaecology. 2012;119(10):1270-80. 
 
22 
Summary  
The effect of antepartum PFMT or postpartum PFMT, 
in groups of women where some did and some did 
not have prior UI symptoms, varied by study with 
some showing a benefit on UI prevalence whereas 
others did not. The characteristics of the new trials, 
all methodologically robust, that demonstrated re-
duced UI prevalence in late pregnancy (35) (37) (39) 
and six months postpartum (35), were high adher-
ence to a supervised PFM strength training program 
and home exercises. (Level of Evidence: 2) 
However, a similar training protocol in postpartum 
women by Hilde (2013) did not show any difference 
between groups. Even if the combined results from 
the published trials still are not conclusive, the benefit 
of PFMT in the majority of the studies and the lack of 
adverse effects of PFMT should be taken into ac-
count.  
Recommendations  
Health providers should carefully consider the 
cost/benefit of population-based approaches to 
health professional taught antepartum or postpartum 
PFMT, that is, health professional instruction to all 
pregnant or postpartum women regardless of their 
current or prior continence status  
(Grade of Recommendation antepartum PFMT: A) 
(Grade of Recommendation postpartum PFMT: B) 
Where a population approach is used, the ‘best’ evi-
dence to date suggests the following: (a) an interven-
tion comprising of a daily home PFMT and weekly 
physiotherapist-led exercise classes for 12 weeks, 
starting at 16-24 weeks’ gestation for pregnant 
women, and (b) an individually taught strengthening 
PFMT programme that incorporates adherence strat-
egies for postpartum women who have had a forceps 
delivery or a vaginal delivery of a large baby (4000g 
or more). (Grade of Recommendation: C) 
2.2. Prevention (Other Women) 
Although there are multiple trials of PFMT for preven-
tion of UI in peri-partum women (see section II.2.1) 
and in men undergoing prostatectomy (see section 
IV.2), there is little research on prevention of UI in 
non-childbearing women. A single randomised trial 
(41) was found that investigated the preventive ef-
fects of a multi-component behavioural modification 
program, including PFMT, Bladder Training (BT), and 
other behavioural skills, compared to no intervention 
in 359 older women who were essentially continent 
(0-5 days of incontinent episodes in previous year). 
The intervention was a 2-hour class followed 2-4 
weeks later with an individualized session to test 
PFMT technique and reinforce adherence. After 12 
months, continence status was the same or better in 
56% of the prevention group compared to 41% of the 
control (p=0.01).  
In this trial, randomisation was conducted prior to eli-
gibility assessment, leading to a relatively high rate of 
non-completion (97/238 in the treatment group and 
65/242 in the control group; 162/480 overall). Analy-
sis was not ITT. The method of randomisation was 
not described but the randomization block size was 
set at 16 to minimize the chance of prior recruiter 
knowledge of subject assignment. The assessors 
were not blinded. 
Summary  
There is preliminary evidence that PFMT may help 
prevent UI in older women. (Level of Evidence: 2) 
However, more definitive trials are needed to clarify 
the effects of this multi-component program or other 
approaches to using PFMT as a prevention strategy 
in older women.  
Recommendations 
Without robust randomised controlled trials on the 
preventive effect of PFMT on UI the Grade of Rec-
ommendation is Grade C (New).  
With limited new data on the effects of preventive 
PFMT on UI in older women, this association should 
be investigated further. 
2.3. Treatment (Other Women) 
2.3.1 Is PFMT Better than No Treatment, a 
Placebo, or a Control Group Treat-
ment? 
This updated literature review identified 19 new trials 
that compared PFMT to no treatment, sham treat-
ment, or control treatment. Six trials were excluded 
from this summary because they selected women 
with “OAB,” “lower urinary tract symptoms,” or “pelvic 
floor dysfunction,” thereby including women without 
urinary incontinence (42-47). Some included conti-
nent women, while others did not provide sufficient 
information to determine the continence status of par-
ticipants. One additional trial was excluded due to in-
sufficient detail about the intervention needed to dis-
cern whether PFMT was part of the treatment (48), 
and one was not considered because the sample 
consisted of residents in long-term care facilities (49). 
The 11 additional trials included in the analysis were 
diverse and included studies from 10 countries (See 
Table 7). Samples included young, nulliparous volley-
ball athletes, older women, peri-and post-menopau-
sal women, obese women, and gynaecological can-
cer survivors. Most samples were drawn from com-
munity-dwelling populations. 
PFMT Details 
Most trials involved 12 weeks (3 months) of interven-
tion, but some were of 6 weeks (50) or 8 weeks dura-
tion (51). Most involved supervised PFMT accompa-
nied by a regimen of home-based exercises by a 
physiotherapist or nurse. One study tested a new 
smart phone application (52) with no face-to-face 
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contact. In several trials, PFMT was delivered on an 
individual basis (50, 53-57), while others were con-
ducted in a group class (51, 58). Some trials were re-
stricted to PFMT with or without functional PFM con-
traction to prevent SUI episodes (stress strategies, 
the Knack) (50, 57), while in others, PFMT was em-
bedded in a multi-component programme with other 
behavioural or exercise components (Table 7). One 
trial included PFMT in a broader programme of gen-
eral physical exercise (58).  
Risk of Bias 
Some of these 11 trials may have been limited by 
small sample size. Only 3 included more than 100 
women, 3 included 50-100 women, and 5 had fewer 
than 50 participants. Two trials reported intent-to-
treat analysis (52, 55). Three reported the method of 
randomisation (54, 55, 58); five reported concealment 
(52, 55, 58-60); and two reported using blinded out-
come assessors (55, 58). Two studies were reported 
as abstracts making it difficult to assess some as-
pects of the methods and data quality (52, 55). 
Results 
A variety of outcome measures were used, including 
bladder diaries, validated questionnaires, global pa-
tient ratings, and pad test. Most trials used multiple 
measurements to evaluate outcomes. 
Bladder diaries were used in 7 studies to assess 
change in incontinent episode frequency (52, 54-59). 
In all studies, reductions in incontinence episode fre-
quency were significantly greater in the treatment 
group. 
The UDI or UDI-6 was used in 4 trials to report 
change in urinary symptoms (54, 55, 57, 60). Signifi-
cant differences were found in the two larger trials 
(54, 55). The ICIQ-UI was used as an outcome meas-
ure in two trials (51, 52), both demonstrating greater 
benefit for PFMT compared to control.  
In 4 trials, the IIQ-7 was used to assess change in 
impact of UI. Two found significant between group dif-
ferences (54, 59); one found significant change in the 
treatment group, but not in the control group; and the 
third did not observe improvement on this condition-
specific quality of life measure (60). 
The PGI-I was the primary outcome in one study that 
found 80% of women in the treatment group and 40% 
in the control group were “much better” or “very much 
better” (60). Similarly, in another trial, 55.7% of 
women in the treatment group were “better” com-
pared to 5% in the control group (52). 
 
Urine loss, assessed by 1-hour pad test (with provo-
cation), was the primary outcome for one trial (50). 
Reductions in urine loss were greater in both treat-
ment groups (individualized PFMT and group admin-
istered PFMT) compared to the control group. In four 
other studies that used a pad test as a secondary out-
come, significant reduction and group differences 
were reported in two (54, 56), no differences in a third 
(55), the within and between group differences did not 
reach statistical significance (57). 
Summary 
PFMT is effective as a stand-alone therapy, as part of 
multi-component therapies embedding PFMT with 
concomitant behavioural strategies, lifestyle 
changes, and as part of more general physical exer-
cise programmes to improve physical function in 
older women.  
Results expand the evidence base to include PFMT 
implemented by mobile technology, with a potentially 
broader reach, cost savings, and impact on rural 
health.  
Benefits are shown across age cohorts and UI type, 
in various cultural contexts, using several different 
training regimens, and assessed by multiple outcome 
measures. (Level of Evidence: 1) 
Recommendations 
Supervised PFMT should be offered as a first-line 
conservative therapy for women of all ages with uri-
nary incontinence (Grade of Recommendation: A). 
2.3.2 Is One Type of PFMT Programme Better 
than Another? 
A number of factors can influence the outcome of a 
PFMT programme such as the way it is taught and/or 
supervised, the parameters of the actual exercises, 
and adherence to the training regimen. What, there-
fore, is the most effective PFMT programme? 
This updated search revealed 24 new potentially eli-
gible RCTs to address this question. Of them, one 
was excluded due to insufficient information on the 
incontinence outcome and inter-group comparison 
(61) and three because they did not report any incon-
tinence outcomes but focused on PFM outcomes (62-
64). Table 8 shows the studies included in the previ-
ous edition as well as those identified in this update. 
Characteristics of each new RCT are presented in Ta-
ble 9. 
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Table 7 Summary of data on PFMT vs no treatment, a placebo or a control group treatment 
Study Comparator N Study Population Intervention Outcomes/Results Notes 
Abdulaziz 
2012 (1) 
No therapy N=56 
Tx: 29 
CG: 27 
Obese, older, peri-
menopausal Saudi 
women with SUI (40-
50 years) 
 
3 months of supervised PFMT taught 
at physio clinic; 10 repetitions of 8 
maximal contractions each, progressed 
to 12; 36 sessions  
Fewer UI episodes on self-report 
(not BD) and better score on VAS 
(but p>0.05 for group diff) 
Tx group: significant change and 
90% cured 
CG: no change and 19% cured 
Small N may have affected 
results 
Asklund 
2015 
Abstract 
(2) 
Delayed treatment N=123  
Tx: 62  
CG: 61 
Women with weekly 
SUI (>18 years; mean 
45 years) 
 
3 months of Smart phone app; PFMT 
exercises at different levels (6 basic 
and 6 advanced); graphic support and 
functions for statistics and reminders. 
No face-to-face contact  
Web-based questionnaires and 2-
day leakage diary; ICIQ-UI-SF, 
PGII, IEF, ICIQ-LUTSqol, use of 
incontinence aids, patient 
satisfaction (Tx group only). 
Tx group showed greater 
improvements on all outcomes 
(p<0.001). 
ITT analysis 
Allocation concealment with 
sequentially numbered 
envelopes 
 
 
Celiker 
2015 (3) 
 
Wait-list N=130  
Tx: 65  
CG: 65 
 
Women with SUI/MUI 
Excluded weak 
muscles 
12-weeks of PFMT, 30 min sessions, 
supervised by physiotherapist, X3 per 
week initially, taught by perineal 
palpation, individually prescribed, 
home-based exercise. Included advice 
on bladder hygiene 
UDI-6, IIQ-7, 3-day bladder diary, 
stop test, pad test.  
Tx group showed significant 
improvement on all outcomes and 
greater improvements than CG 
(p<0.0001). 
Not ITT; randomization 
computer generated; 
allocation concealment 
Tx included 
behavioral/lifestyle advice. 
Dumoulin 
2011 (4) 
Abstract 
Education 
program on 
osteoporosis (3 
hours) and follow-
up phone calls 
N=48 
Tx: 24  
CG: 24 
Postmenopausal 
women with 
osteoporosis and SUI, 
UUI, or MUI 
(55+ years) 
 
12 weeks of Individualized PFMT, 
weekly 30-min PT sessions; daily 
home exercise; BF, urge control, BT, 
dietary advice and constipation advice. 
7-day BD, 24-hour pad test, UDI. 
Post-treatment, Tx group had 
greater improvements on IEF 
(p=0.04) and UDI (p=0.04), but not 
pad test. 
At 1-year follow up, there were 
significant differences on IEF 
(p=0.04), UDI (p=0.03) and pad 
test (p=0.01). 
Randomization computer 
generated 
Allocation concealment 
ITT analysis 
Blinded assessors 
No adverse events 
Tx included 
behavioral/lifestyle advice. 
Ferreira 
2014 (5) 
Summary of 
PFMR education 
program via 
pamphlet 
N=32  
Tx: 16  
CG: 16 
Nulliparous, female 
volleyball athletes with 
SUI (13-30 years) 
 
3 months of PFMR; “educational 
action,” awareness of PFM, and 
informational pamphlet; weekly visits; 
home exercise - 30 sustained 
contractions and 4 quick contractions 
daily; daily bladder diary for awareness 
7-day BD and pad test (15 min 
during practice).  
Tx group showed greater 
reductions on IEF (p<0.001) and 
pad test (P<0.001). 
Randomization by lottery 
(participant drawing paper 
from a box) 
Small N 
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Karger 
2015 (6) 
No Tx N=50 
Tx: 25 
CG: 25 
Elderly women with 
SUI (60-74 years) 
Two months; eight 45-min group 
training classes taught by a nurse; 8-
12 contractions in each of 3 positions, 
6-8 second contractions with 3-4 fast 
contractions added; home exercise: 8-
12 high intensity contractions, X3 daily. 
Strength, awareness, and relaxation 
training for other muscle groups. 
ICIQ-UI and self-esteem.  
Group differences observed on 
ICIQ-UI (p=0.001), and on 
individual items of frequency, 
amount of leakage, and QoL.  
Tx included other types of 
exercise. 
Kim 2011 
(7) 
General health 
class monthly for 3 
months 
N=127  
Tx: 63  
CG :64 
Elderly Japanese 
women with SUI, UUI, 
or MUI 
(70+ years) 
 
3 months, multi-dimensional exercise 
Tx; twice weekly group classes, PFM 
and general strength exercise. 
PFMT: 10 fast contractions (3 sec), 10 
sustained contractions (8-10 sec); 
lying, sitting, and standing positions. 
One-hour class X1/month during 7-
month follow-up. Home exercise: 2-3 
sets as learned in class, at least 
X3/week for 30 min/day 
Primary outcome was cure based 
on 7-day BD and ratings on 5-point 
scale (in BD); ICIQ  
Tx group showed greater change 
in urine leak score (p=0.007) and 
cure.  
Tx group 44.1% cure rate post-Tx 
and 39.3% at 7-month follow up vs 
1.6% and 1.6% in CG (p<0.001).  
Not ITT 
Computer generated 
randomization  
Randomization procedure 
blinded 
Blinded assessors 
Leong 
2015 (8) 
Advice and 
pamphlet on 
management of UI 
N=56 
Tx: 27  
CG: 28 
Older Chinese women 
with SUI, UUI, or MUI 
(55+ years) 
 
12-week PT program, 30-min individual 
training sessions, 8 sessions taught 
with manual palpation and verbal 
feedback; progressive exercise 
program starting with 10 slow 
submaximal contractions (5 sec) 
increasing to 25 per session; urge 
suppression + bladder training (BT). 
7-day BD, IIQ-SF-7, 11-point VAS 
for perception of improvement and 
satisfaction. 
Tx group showed greater 
improvement in IEF (p<0.001) and 
IIQ-7 (p=0.001) and greater 
perception of improvement 
(p=0.004) and satisfaction 
(p=0.001). Reductions significant in 
Tx group only.  
Computer generated 
randomization and 
allocation concealment 
Tx accompanied by urge 
suppression and bladder 
training 
McLean 
2013 (9) 
No treatment N=40 
Tx: 20  
CG: 20 
Women with 
predominant SUI 
(18+ years) 
 
12-week individualized PFMT program 
with weekly 30-min sessions; PFMT 
taught by manual palpation; home 
exercise: 3 sets of 12 PFM 
contractions daily 
3-day BD, pad test, IIQ-7, UDI-6. 
Tx group showed greater changes 
on IEF (intragroup p=0.007) and 
IIQ-7 (intragroup p=0.0003); 
Neither group had significant 
change on pad test or UDI-6 
Randomization by 
automated computer 
algorithm. 
Primary purpose of the 
study was to examine 
urethral morphology and 
mobility. Measures of UI 
were secondary outcomes. 
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Pereira 
2011 (10) 
No treatment N=49 
Group: 
17 
Individ: 
17 CG:15 
Women with SUI only 
(18+ years) 
 
6 weeks PFMT in group or individual 
sessions; two 1-hour sessions weekly 
(12 sessions); taught by vaginal 
palpation in both Tx groups; 3 s and 5-
10 s contractions; repetitions and 
duration progressed; average of 100 
contractions per session. 
Primary outcome: pad test; 
secondary King’s questionnaire 
and satisfaction.  
Both Tx groups showed greater 
improvement on pad test than CG 
(p<0.0001). Improvements shown 
in both Tx groups but not CG. 
Randomization was by 
participants drawing 
envelope from a box; 
assessments not blinded; 
not ITT 
Purpose of the study was to 
examine group vs individual. 
No adverse events. Small N 
Rutledge 
2014 (11) 
Usual care 
(no handout) 
N=40 
Tx: 20 
CG: 20 
Gyn cancer survivors 
with UI 
(37-79 years) 
 
12 weeks; single 15-min training 
session; taught using levator ani 
palpation; 10 contractions 5 s duration; 
handout on behavioral management 
tips: fluid intake, reduction of caffeine 
and bladder irritants; constipation 
management; Home exercise: 3 sets of 
exercises daily for 12 weeks. 
PGI-I and UDI-6 
PGII: 80% in Tx group vs 40% in 
CG were “much better” or “very 
much better” (p=0.02).  
UDI-6: Groups not significantly 
different: Tx 70% vs CG 50% 
reported lack of bother (p=0.62). 
Randomization generated 
by random number table. 
Allocation concealment 
Not ITT analysis 
Treatment included 
behavioral/lifestyle advice. 
1. Abdulaziz K, Hasan T. Role of pelvic floor muscle therapy in obese perimenopausal females with stress incontinence: A randomized control trial. The Internet 
Journal of Gynecology and Obstetrics. 2012;16(2):34-42. 
2. Asklund I, editor Treatment of stress urinary incontinence via a smartphone application. Report from an ongoing randomised controlled study. Medicine 20 Confer-
ence; 2014: JMIR Publications Inc., Toronto, Canada. 
3. Tosun OC, Mutlu EK, Ergenoglu A, Yeniel A, Tosun G, Malkoc M, et al. Does pelvic floor muscle training abolish symptoms of urinary incontinence? A randomized 
controlled trial. Clinical rehabilitation. 2015;29(6):525-37. 
4. Dumoulin C, Sran M, Lieblich P, Wilson P. Physiotherapy significantly reduces leakage in postmenopausal women with osteoporosis and urinary incontinence: 
result of a parallel randomised controlled trial. Neurology & Urodynamics. 2011;30(6):985. 
5. Ferreira S, Ferreira M, Carvalhais A, Santos PC, Rocha P, Brochado G. Reeducation of pelvic floor muscles in volleyball athletes. Revista da Associação Médica 
Brasileira. 2014;60(5):428-33. 
6. Jahromi MK, Talebizadeh M, Mirzaei M. The Effect of Pelvic Muscle Exercises on Urinary Incontinency and Self-Esteem of Elderly Females With Stress Urinary 
Incontinency, 2013. Global journal of health science. 2015;7(2):71. 
7. Kim H, Yoshida H, Suzuki T. The effects of multidimensional exercise treatment on community-dwelling elderly Japanese women with stress, urge, and mixed 
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Table 8 Studies comparing different PFMT programs included in the previous review (5th ICI) and current update (6th ICI) 
 
Studies included in the previous 
review (5th ICI) 
New studies identified in this update 
(6th ICI) 
Total 
1. Supervision of training: amount of contact with health professionals 6 4 10 
2. Supervision of training: individual versus group supervision 6 2 8 
3. Exercise program: direct versus indirect exercises 6 2 8 
4. Exercise program: generic versus individualized exercises 1 0 1 
5. Exercise program: submaximal versus near maximal contractions 1 
 
0 1 
6. Exercise program: daily versus three times per week 1 0 1 
7. Exercise program: addition of upright exercise position 1 0 1 
8. Exercise program: addition of strength training to motor learning 1 1 2 
9. Exercise program: addition of abdominal or hip muscle exercises 1 3 4 
10. Exercise program: addition of intravaginal resistance device 3 2 5 
11. Exercise program: addition of adherence strategy 2 0 2 
12. Exercise program: addition of biofeedback 9 6 15 
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Table 9 Summary of data on different PFMT programs comparisons  
Author, year Comparator N Study population Modality details or parameters Outcomes/Results Follow-up Notes 
Cruz et al. 
2014 (1) -
Abstract 
Supervised PFMT 
(43) 
vs 
Unsupervised (36) 
79 Primigravidas with UI 
at 21-26 weeks of 
pregnancy 
Supervised group – 5-6 biweekly 
sessions supervised by a 
physiotherapist 
 
Unsupervised group: same 
treatment protocol 
Self-reported cure: 
Non- sign. difference btw groups in 
cure rate (p=0.052) 
Supervised 16/20 (74%) 
Unsupervised 10/21 (48%) 
ICIQ-SF :  
Supervised group pre-Tx8.1±3.7 to 
post-Tx1.2±2.5 
Unsupervised PFMT group pre-
Tx7.7±5.0 to post-Tx 4.7±5.6 
Sign. difference btw treatments 
(p=0.016) 
3 weeks Large dropout 
rate: 
23/43 
supervised 
PFMT 
15/36 
unsupervised 
PFMT 
 
Delgado et al. 
2013 (2) 
 
Abstract was 
included in the 
ICI 5th edition 
PFMT (24) 
vs 
PFMT + resistance 
device (28) 
52 Women with SUI or 
MUI (stress 
predominant) 
PFMT: As below without device  
PFMT +resistance; 5 quick and 5 
slow (sustained), high-intensity 
contractions daily. Advised to hold 
contractions as long as possible, 
relaxing their PFM for an 
equivalent time before repeating 
the process. Intravaginal 
resistance: instructions to use the 
Pelvic-Toner Device concurrently 
whilst exercising. Two clinic visits 
and one phone call 
Reported cure (based on the Q11 of 
the ICIQFluts) 
PFMT 0/13 
PFMT+resistance 1/15 
Non-sign. difference btw groups 
(p=0.429) 
Improvement (post-Tx) 
PFMT 10/19 
PFMT+resistance 11/21 
Non-sign. difference btw groups 
 
16 weeks of 
treatment, 
outcomes 
assessed at 
post-Tx and at 
6 month 
follow-up 
Dropouts (at 6 
month) 
PFMT 9/24 
PFMT + 
resistance 
15/28 
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Donahoe-
Filmore et al. 
2011 (3) 
PFMT (5) 
vs 
PFMT + hip 
muscle training (6) 
 
11 11 women with SUI 
(urodynamic 
diagnosis) 
PFMT: 10 repetitions of 10s PFM 
contraction/5-10s rest, 10 
repetitions of 1-2s contraction 10s 
contraction, PFM and transverse 
abdominis contraction 
PFMT + hip muscle training:  
PFMT training while performing 
resisted hip contraction with a ball 
/elastic band, 10 repetitions of 5s 
(PFM contraction+TrA+squeezing 
a ball) and 10 repetitions of 5s 
(PFM contraction+TrA+hip 
external rotation resisted with an 
elastic band) 
Both groups were instructed to 
perform the exercises twice a day, 
7 days/week for 12 weeks. Both 
also had 3 sessions supervised 
with a physiotherapist 
ICIQ-IU-SF 
Delta between treatments -5.0±4.7 
(p=0.35) 
UDI-6 
Delta between treatments 10.25±3.5 
(p=0.043) in favor of combined 
treatment 
Incontinence severity index 
Delta between treatments -5.25±2.48 
(p=0.139) 
12 weeks of 
treatment, 
outcomes 
assessed 
post-Tx 
Dropouts: 
PFMT (1/5) 
PFMT + hip 
muscle 
training (4/6) 
 
Results should 
be interpreted 
with caution 
(n=11) 
 
Ferreira et al. 
2012(4) 
(pilot RCT) 
Supervised PFMT 
(20) 
vs 
Unsupervised 
(home) PFMT (18) 
38 Women with mild to 
moderate SUI 
(urodynamic 
diagnosis) 
Both groups received a leaflet and 
attended a 1h educational session 
including verification of adequate 
PFM contraction 
Supervised PFMT:  
Same as home program + weekly 
45 min session 
Unsupervised (Home) PFMT:  
8-10 PFM contraction, 10s 
contraction followed by four quick 
contractions/5-10s rest, three 
times a day, in different positions 
for 6 months with monthly 
motivational phone call 
Self-reported cure/improvement:  
The rate of women who thought they 
were cured, almost cured, or feeling 
better was 100% in supervised PFMT 
and 64.7% in home PFMT (p=.018) 
7-day bladder diary:  
Supervised PFMT pre-Tx 11.3±5.1 to 
post-Tx 4.5±5.1 (p<.05) 
Unsupervised PFMT pre-Tx 11.3±5.7 to 
post-Tx 6.4±7.5 (p<0.05) 
Similar reductions on pad test were 
registered in both groups (p=0.125) 
Pad test: 
Supervised PFMT pre-Tx 3.6±1.9 to 
post-Tx 1.90±1.5 (p<0.05) 
Unsupervised PFMT pre-Tx 3.8±3.0 to 
post-Tx 2.0±2.0 (p<0.05) 
Similar reductions on pad test were 
registered in both groups (p=0.530) 
6 month of 
treatment, 
outcomes 
assessed 
post-Tx 
Dropout 
Supervised 
PFMT 3/20 
Unsupervised 
PFMT 1/18 
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Fitz et al. 2015 
(5)- abstract 
Supervised (25) 
vs 
Unsupervised (25) 
63 Women with 
predominance of SUI 
and more than 2 g of 
leakage (pad test) 
Supervised: 24 sessions, twice 
weekly. 3 sets of 30 contractions 
followed by 3 fast-twitch 
contractions 
 
Unsupervised: Same exercise 
protocol, appointment once a 
month for exercise adjustment 
Bladder diary: 
Post-Tx score in supervised 0.6±0.9 
and unsupervised group 0.9±1.4 
Non-sign. difference btw groups 
(p=0.944) 
Pad test 
Supervised 3.8±6.6 and unsupervised 
16.0±28.2 
Sign. difference btw groups (p=0.026) 
QoL 
Non sign. difference btw groups (0.661) 
3 months of 
treatment, 
outcome 
assessed at 
post-Tx 
13 dropouts 
(on is not 
mentioned in 
which group) 
 
Galea et al. 
2013 (6) 
PFMT (11) 
vs 
PFMT+BF (clinic) 
(12) 
23 Women with SUI or 
UUI 
 
(over 60 years old) 
PFMT: correct PFM contraction 
was verified through vaginal 
palpation at the first visit 
 
PFMT+BF: Ultrasound imaging 
was used as a visual BF. The 
visual feedback was progressively 
reduced throughout sessions 
King’s health questionnaire 
Non-sign. difference btw groups 
7-day bladder diary 
PFMT pre-Tx 2(5) to post-Tx 2(3)  
PFMT+BF pre-Tx 8(8) to post-Tx 3(5) 
Non-sign. difference btw groups 
(p=0.868) 
Pad test 
PFMT pre-Tx 2.1(11.3) to post-Tx 
0.2(4.2) 
PFMT+BF pre-Tx 6(54) to post-Tx 
0(4.8) 
Non-sign. difference btw groups 
(p=0.428) 
10 weeks of 
treatment, 
outcomes 
assessed at 3 
month post-Tx 
PFMT 0/11 
PFMT+BF 
1/12 
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Hirakawa et al. 
2013 (7) 
PFMT (23) 
vs 
PFMT +BF (home 
and clinic) (23) 
46 Women with SUI  
(more than 1 
episode per week) 
PFMT: 5 individually supervised 
sessions over 12 weeks of 
treatment. PFM contraction taught 
with palpation of the perineal 
body.10 repetitions of 5s 
contraction/10s rest, 10 repetitions 
of 2s contraction/4s rest, Knack, 
twice daily 
 
PFMT +EMG biofeedback: same 
as above but with EMG BF at 
home and at the clinic 
ICIQ-UI-SF: 
PFMT pre-Tx 12.0±3.5 to post-Tx 
8.3±3.5 (p<0.001) 
PFMT+BF: pre-Tx 11.2±3.9 to post-Tx 
7.8±3.3 (p=0.002) 
Non-sign. difference btw groups 
King’s health questionnaire 
Non-sign. difference btw groups 
Bladder diary 
PFMT pre-Tx 1.9±1.8 to post-Tx 
1.2±1.4 (p=0.028) 
PFMT+BF: pre-Tx 1.2±0.7 to post-Tx 
0.8±1.2 (non-sign.) 
Non-sign. difference btw groups 
Pad test: 
PFMT pre-Tx 11.7±18.9 to post-Tx 
7.7±15.4 (non-sign.) 
PFMT+BF: pre-Tx 21.3±38.2 to post-Tx 
9.9±15.1 (non-sign.) 
Non-sign. difference btw groups 
12 weeks of 
treatment, 
outcomes 
assessed 
post-Tx 
Dropouts: 
PFMT 3/23 
vs 
PFMT +BF 
4/23 
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Jordre et al. 
2014 (8) 
Resisted hip 
rotation training 
(14) 
vs 
PFMT (16) 
30 30 SUI women (with 
at least 2 SUI 
episodes per month) 
Resisted hip rotation: 
-10 hip external/internal rotation 
during breathing 
-10 repetitions each of hip external 
rotation (resistance band) and 
internal rotation (with a ball) 
No PFM contraction 
PFMT: 
20 5s contraction and 20 quick 
flicks 
Vaginal palpation was performed 
only when required 
 
 
Both programs were performed 
twice daily. 
Weekly recheck were scheduled 
(in person or over the phone) 
Subjective improvement 
Hip training 69.6±21.4 post-Tx 
PFMT 52.8±32.2 post-Tx 
Non-sign. difference btw groups 
(p=0.24) 
UDI 
Hip training: pre-Tx 142.3±69.8 to post-
Tx 79.8±56.6 (p=0.02) 
PFMT: pre-Tx 145.2±54.0 to post-Tx 
77.7±60.4 (p<0.01) 
Non-sign. difference btw groups 
(p=0.90) 
IIQ 
Hip training: pre-Tx 151.3±77.2 to post-
Tx 122.5±68.2 (p=0.03) 
PFMT: pre-Tx 140.7±39.4 to post-Tx 
119.8±59.6 (p<0.01) 
Non-sign. difference btw groups 
(p=0.70) 
Bladder diary  
Hip training: pre-Tx 5.2±6.2 to post-Tx 
0.1±0.1 (p<0.01) 
PFMT: pre-Tx 3.3±3.5 to post-Tx 
1.1±3.4 (p<0.01) 
Women received hip training had sign. 
more reduction of UI episodes (p=0.03) 
6 weeks of 
treatment, 
outcomes 
assessed 
post-Tx 
Dropout 
Resisted hip 
rotation 2/14 
vs 
PFMT1/16 
 
Jungin et al. 
2014 (9) 
PFMT with bladder 
neck effective 
relearning (42) 
vs 
PFMT (38) 
 
80 Women with SUI or 
MUI 
PFMT with bladder neck effective 
relearning: PFM contraction and 
Knack taught with ultrasound 
biofeedback 
3 sessions supervised over 3 
months of treatment 
PFMT: PFMT with EMG 
biofeedback - 3 supervised 
sessions. 
PFM contractions (80% of the 
maximum, 8s contraction/10 s rest, 
for 10 min) 
Improvement: 
PFMT with bladder neck effective 
10(28%) had some improvement and 
15 (42%) reported great improvement 
PFMT 12 (46%) and 8 (31%) had some 
and great improvement, respectively 
Non-sign. difference btw the two 
groups (p=0.365) 
There were 14 women in the PFMT 
group who switch group after trial 
completion 
3 months of 
treatment, 
outcomes 
assessed 
post-Tx 
Dropouts: 
PFMT with 
bladder neck 
effective 
relearning 
6/42 
PFMT 7/38 
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Kashanian et 
al. 2011 (10) 
PFMT (50) 
vs 
PFMT + resistance 
device (41) 
91 Women with SUI or 
MUI 
PFMT: 6-8s contraction/6s rest 
Twice daily for 15 min 
 
PFMT + resistance device: twice 
daily for 15 min 
Number of UI (self-reported) 
The data were categorized in ranges of 
different frequencies. 
Sign. changes in both groups 
(p<0.0001) 
Non-sign. difference btw groups 
UDI 
PFMT pre-Tx 45.1±15.5 to post-Tx 
71.8±11.2 (p<0.0001) 
PFMT + resistance pre-Tx 39.9±13.5 to 
post-Tx 69.9±10.1 (p<0.0001) 
Non-sign. difference btw groups 
(p=0.418) 
IIQ 
PFMT pre-Tx 44.7±23.0 to post-Tx 
67.7±20.20 
(p<0.0001) 
PFMT+resistance pre-Tx 37.2±12.10 to 
post-Tx 62.52±12.13 
(p<0.0001) 
Non-sign. difference btw groups 
(p=0.162) 
12 weeks of 
treatment, 
outcomes 
assessed 3 
month post-Tx 
Dropouts: 
PFMT 4/50 
PFMT + 
resistance 
device 2/41 
 
Kim et al. 2012 
(11) 
Supervised PFMT 
+ trunk 
stabilization (10) 
vs 
Unsupervised 
PFMT + trunk 
stabilization (10) 
 
20 Women with 
postpartum UI 
Supervised PFMT and trunk 
stabilization: 23 1-h sessions, 3x/ 
week, for eight weeks; PFM 
contractions in different positions 
 
Unsupervised: same protocol but 
only one demonstration session 
Bristol Female Lower Urinary Tract 
Symptom questionnaire – 
Urinary symptoms  
(changes) 
Supervised –27.22±6.20 
Unsupervised–18.22±5.49 
Quality of life 
Supervised–5.33±2.96 
Unsupervised –1.78±3.93) 
Total score 
Supervised –32.56±8.17 
Unsupervised –20.00±6.67) 
All outcomes favored the supervised 
group (P<0.05) 
8 weeks of 
treatment, 
outcomes 
assessed 
post-Tx 
Dropout: 
Supervised 
1/10 
Unsupervised 
1/10 
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Konstantinidou 
et al. 2013 
(12)- abstract 
 
 
Results were 
also presented 
in two other 
abstracts 
(13, 14) 
It should be 
underlined that 
lower sample 
size were 
reported in the 
2011 abstract. 
PFMT (25) 
vs 
PFMT + transverse 
abdominis 
exercises (21) 
 
46 Women with SUI or 
MUI (stress 
predominant) 
 
(minimum of 7 
episodes per week 
and a 3-4 score at 
the Oxford scale) 
PFMT monotherapy 
 
Transverse abdominis exercises 
combined with PFMT 
 
Limited information was provided 
about the training protocol 
KHQ 
PFMT: pre-Tx 342.9±28.2 to post-Tx 
198.3±18.4 (p<0.0001) 
PFMT+TrA : pre-Tx 327.1±38.4 to post-
Tx 193.1±24.7 (p=0.0003) 
Non-sign. difference btw the two 
groups (p=0.76) 
Bladder diary 
PFMT: pre-Tx 4.36±0.6 to post-Tx 
1.8±0.3, (p<0.0001) 
PFMT+TrA : pre-Tx 3.4±0.4 to post-Tx 
1.2±0.2 (p<0.0001) 
Non-sign. difference btw groups 
3 months of 
treatment, 
outcomes 
assessed 
post-Tx 
Dropouts are 
not reported 
 
Lamb et al. 
2009 (15) 
Group PFMT (111) 
vs 
Individual PFMT 
(63) 
174 Women with SUI 
and/or UUI 
Group PFMT: Three 1h session for 
3 weeks, 
average of 10 women per class, 
individual assessment with PFM 
examination if required 
 
Individual PFMT: Same as group 
intervention but individually 
supervised 
Symptoms severity index 
Group changes from baseline 
2.34±0.44 
Individual changes from baseline 
1.71±0.57 
Non-sign. difference btw groups 
(p=0.38) 
Self-rated assessment of treatment 
benefit 
Group changes from baseline 
5.37±0.29 
Individual changes from baseline -
6.34±0.38 
Higher perceived benefit for individual 
treatment (p=.0462) 
Incontinence related QoL 
Group changes from baseline -
14.40±1.75 
Individual changes from baseline -
14.81±2.50 
Non-sign. difference btw groups (p=.89) 
3 weeks of 
treatment, 
outcomes 
assessed 6 
months after 
randomisation 
Dropout: 
Group PFMT 
13/111 
Individual 
PFMT 3/63 
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Liebergall-
Wischnitzer et 
al. 2013 (16) 
 
(This is a 
follow-up of the 
2009 study) 
Paula method 
(119) 
vs 
PFMT (126) 
245 Women with SUI Paula : 12 individual 45-min 
session 
 
PFMT : 6 group sessions over 12 
weeks 
 
Frequency of UI 
(low or high) 
No sign. deterioration of UI in 6 months 
in both groups 
Paula method: 25 (39.7%)  
reported a low frequency rate of 
UI episodes  
PFMT: 18 (22.8%) in the PFMT group 
reported a low frequency 
Sign. difference btw groups (p=0.03) 
 
 
12 weeks of 
treatment, 
follow-up at 6-
month post-Tx 
Dropout 
Paula 55/119 
PFMT 47/126 
 
The two 
groups 
differed 
according to 
the amount of 
supervision 
received 
(PFMT had 
group 
supervision 
and less 
sessions). 
Manonai 2013 
(17) -abstract 
PFMT  
vs 
PFMT +BF (home) 
 
(sample size in 
each group not 
specified) 
61 Women with SUI PFMT: verbal instruction about 
PFM contraction, 15 min of PFM 
exercises, three times a day for 16 
weeks 
 
PFMT+BF: same as above but 
with pressure BF 
Incontinence related QoL 
PFMT pre-Tx 51.1±15.9 to post-Tx 
70.6±15.5 (sign.) 
PFMT+BF: pre-Tx 53.9±18.3 to post-Tx 
72.6±10.81 (sign.) 
Non-sign. difference btw groups 
16 weeks of 
treatment, 
outcomes 
assessed 
post-Tx 
Dropouts: one 
in each groups 
 
Marques et al. 
2014 (18)- 
abstract 
 
(19) protocol 
PFMT (15) 
vs 
PFMT + hip 
muscle training 
(20) 
35 Women with SUI 
(urodynamic 
diagnosis) 
Both groups received 20 
individually supervised sessions, 
twice a week 
 
PFMT:  
PFM contraction verified by 
vaginal palpation in the first 8 
sessions 
 
PFMT: same PFMT program with 
the addition of hip muscle 
strengthening (with progressive 
increases in loads) 
 
 
Bladder diary (5 days) 
Non-sign difference btw the two groups 
(p=0.172) 
10 weeks of 
treatment, 
outcomes 
assessed 
post-Tx 
Dropout not 
reported 
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Author, year Comparator N Study population Modality details or parameters Outcomes/Results Follow-up Notes 
Pereira et al. 
2011 (20) 
Group PFMT (17) 
vs 
Individual PFMT 
(17) 
vs 
Control (15) 
 
49 Women with SUI Group PFMT: Two 1h weekly 
sessions for 6 weeks. 
Approximately 100 contractions 
(3s contraction/6s rest and 5-10 s 
contraction/10-20 rest). 
Contraction taught individually at 
baseline 
 
Individual PFMT 
Same as above but individually 
supervised 
 
Control (15) 
No treatment 
1-h pad test: 
Group: pre-Tx 1.88±2.85 to post-Tx 
0.46±0.45 (p=0.05) 
Individual: pre-Tx 4.22±5.21 to post-Tx 
0.45±0.90 (p=.0006) 
Non-sign. difference btw groups 
King health questionnaire 
Only the personal relationships and 
emotion differed btw the two groups 
and favored individual PFMT (p.043) 
6 weeks of 
treatment, 
outcomes 
assessed 
post-Tx 
Dropout: 
Group PFMT 
2/17 
Individual 
PFMT 2/17 
Control 0/15 
 
No adverse 
effects 
reported 
 
Ong et al. 2015 
(21) 
 
Results also 
presented in 
the following 
abstracts (22, 
23) 
PFMT (19) 
vs 
PFMT+ BF (home 
and clinic) (21) 
40 Women with SUI PFMT: 4 sessions individually 
supervised (20-min), 3-5 sets of 10 
repetitions (3-10s contraction/ 3-
10s rest). 3-5 sets of 10 repetitions 
(2s contraction/2s rest) 
 
PFMT + biofeedback: 
Same as above but with use of the 
Vibrance device at home and in 
the clinic  
Subjective cure (based on the Q6 of 
the Australian pelvic floor 
questionnaire) 
PFMT 10/16 
PFMT+BF 12/21 
Non-sign. difference btw groups 
(p=.742) 
 
Australian pelvic floor questionnaire 
(total score) 
PFMT post-Tx 7.8±5.1 
PFMT+BF post-Tx 11.3±8.3 
Non-sign. difference btw groups 
(p=0.157) 
16 weeks of 
treatment, 
outcomes 
assessed at 4 
weeks of 
treatment and 
post-Tx 
Dropouts: 
PFMT 3/19 
PFMT+ 
biofeedback 
0/21 
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Author, year Comparator N Study population Modality details or parameters Outcomes/Results Follow-up Notes 
Prudencio 
2014 
(24) abstract 
PFMT (51) 
Vs 
PFMT+VC (55) 
Vs 
PFMT+BF (clinic) 
(50) 
156 SUI women The 3 groups received 20 sessions 
of 45 min (twice a week for 3 
months). 
PFMT included isolated rapid and 
sustained contractions of the PFM 
and at the end functional exercises 
with contraction of the same 
muscle group by differentiating just 
the use or not of associated 
instruments. 
 
(No further information was 
provided on treatment in the 
abstract) 
Cure of SUI 
Non-sign. difference btw groups 
(p=0.267) 
PFMT 39.2% (20/51continent) 
PFMT+BF 44% (22/50continent) 
KHQ: 
The 3 groups significantly improved 
from baseline (p<0.001) 
PFMT preTx74±18 to postTx43±17 
(p<0.001) 
PFMT+BF preTx70±21 to postTx50±15 
Sign. Difference btw groups (p<0.001). 
It is not specified which groups differ 
 
3 months Dropout not 
specified 
 
Shin et al. 
2012 (25) 
 
Results also 
presented in 
the following 
abstracts  
(26, 27) 
PFMT (30) 
vs 
PFMT+BF (home) 
(30) 
60 Women with UI (type 
not specified) 
PFMT: 20 min, twice a day, 
5x/week for 6 months 
 
PFMT +BF: same as above but 
with the pressure device 
ICIQ-SF: 
PFMT pre-Tx 8.8±4.7 to post-Tx 
8.2±5.1 (non-sign.) 
PFMT+BF: pre-Tx 9.0±3.9 to post-Tx 
7.0±2.7 (p<0.05) 
KHQ 
PFMT pre-Tx 6.84±15.9 to post-Tx 
59.2±19.2 (non-sign.) 
PFMT+BF: pre-Tx 69.5±14.2 to post-Tx 
48.7±12.3 (p<0.001) 
Bladder diary 
PFMT pre-Tx 9.7±3.3 to post-Tx 
8.0±3.2 (non-sign.) 
PFMT+BF: pre-Tx 8.6±4.0 to post-Tx 
5.1±4.6 (p<0.001) 
Comparison btw groups not reported. 
Sign. reduction of leakage frequency, 
KHQ and ICIQ occurred in BF group 
but not in PFMT group 
6 months of 
treatment, 
outcomes 
assessed at 6 
weeks and 6 
months 
Dropouts : 
PFMT 6/30 
vs 
PFMT+BF 
(home) 0/30 
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Quality of data 
Of the 20 RCTs, 12 provided sufficient detail support-
ing adequate randomisation and allocation conceal-
ment methods (34, 50, 65-74). Of these, seven RCTs 
stated that the outcome assessors were blinded (34, 
65-70). Pereira et al. (50) reported adequate random-
isation and concealment but the evaluators were not 
blinded. Of the remaining eight RCTs, seven did not 
report sufficient information on allocation conceal-
ment methods and had unblinded assessors (75-81). 
None of the included trials was large and half (10/20) 
included only 20 to 51 participants per group (65, 68, 
69, 72, 74, 75, 77, 79-81). Eight had fewer than 20 
participants per comparison group (34, 50, 70, 71, 73, 
76, 78, 82). Six of the eight were reported as a pilot 
study (70-73, 76, 78). Only two RCTs had a larger 
sample size involving a total of 174 (66) and 245 
women (67). 
In four RCTs, a dropout rate of more than 46% in one 
study arm was reported. For instance, Dohanhoe et 
al. (78) reported 60% dropout in the PFMT combined 
with hip training and 20% in the PFMT group. 
Delgado et al. (72) had 37% and 57% in the PFMT 
group and PFMT combined with resistance, 
respectively. Liebergall-Wischnitzer et al. (67) 
reported a 46% and 37% dropout rate in the paula 
and PFMT group, respectively while Cruz et al. (65) 
had 42-53% dropout in the supervised and 
unsupervised PFMT group. The results of these 
RCTs should therefore be interpreted with extreme 
caution (65, 67, 72, 78). 
Ongoing RCTs 
Based on a research on protocol registry database, 
there is currently one ongoing large non-inferiority 
RCT comparing group versus individual supervised 
PFMT (83) (comparison 2). Involving 364 elderly 
women with SUI or MUI, this study is expected to be 
completed by March 2017. Moreover, the study of 
Buen et al. (84) is also ongoing and will compare the 
efficacy of PFMT and Pilates in preventing and 
treating UI (N=80) (comparison 3). The study of 
Navarro et al. (85) will evaluate the efficacy of 
hypopressive exercises in 78 women with various 
pelvic floor disorders including UI (comparison 3). 
Expected in July 2017, the study of Radlinger et al. 
(51) will assess the benefit of adding motor learning 
to PFMT in 96 women suffering from SUI or MUI 
(Comparison 8). Rao et al. (86) undertook a study 
comparing the addition of abdominal muscle training 
to PFMT in 300 women (Comparison 9). Three 
upcoming RCTs will assess the benefit of adding 
clinic-based BF to PFMT (87-89).  
Results 
 Comparison 1. Supervision of training: amount of 
contact with health professionals? 
Subgroup 1.1: additional group supervision 
No further studies investigated the effect of adding an 
additional supervised group exercise session. 
Subgroup 1.2: additional phone calls 
No new studies investigated the effect of adding su-
pervisory phone calls to PFMT programmes. 
Subgroup 1.3: individual supervision versus no su-
pervision 
Four new RCTs were included in this comparison (34, 
65, 71, 75). The PFMT programmes evaluated dif-
fered with regard to the amount of health-professional 
contact but were similar in type and quantity of PFM 
exercises. 
Self-reported cure: Women in the supervised group 
were more likely to report cure in comparison with 
women following unsupervised PFMT (71). Although 
non-statistically significant, Cruz et al. (65) also re-
ported a higher cure rate in the supervised group. 
Improvement: Two RCTs reported improvement in UI 
symptoms as assessed with validated questionnaires 
(34, 65). Both showed that women receiving super-
vised treatment reduced their UI symptoms signifi-
cantly more than women in the unsupervised arm (34, 
65). 
Leakage episodes: There was no statistically signifi-
cant difference in the number of leakage episodes 
when comparing supervised and unsupervised PFMT 
in women (71, 75). 
Pad tests: Two of the four RCTs measured UI severity 
with pad testing (71, 75). Fitz et al. (13) showed that 
supervised treatment resulted in a more significant 
reduction of leakage than unsupervised PFMT while 
Ferreira et al. (71)  reported a non-significant differ-
ence. 
 Comparison 2. Supervision of training: individual 
versus group  
Two new RCTs were included in this comparison; 
both studies used the same PFMT program and dif-
fered only according to the type of supervision (group 
vs individual). It should also be underlined that Pe-
reira et al. (50) conducted an individual assessment 
of the PFM to teach active PFM contraction to all 
women prior to class training while Lamb al. (66) in-
cluded this assessment only when required. 
Self-reported cure: No data were reported. 
Improvement: Non-significant differences in the 
symptom severity index were found between group 
and individual PFMT in the study of Lamb et al. (66) 
However, both Lamb et al. (66) and Pereira et al. (50) 
favoured individual treatment with regard to self-rated 
treatment benefits and the impact of UI (personal re-
lationships and emotion domains), respectively. The 
study of Pereira et al. (50) involving 17 women per 
group, may be insufficiently powered to detect signif-
icant difference between groups. In the study of Lamb 
et al. (66), a large sample was included (n=174). 
However, the information was limited in regard to 
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whether this sample was sufficient to conclude treat-
ment equivalence (as per sample size calculation in 
non-inferiority design). 
Leakage episodes: No data were reported. 
Pad test: Only the study of Pereira et al. (50) used the 
pad test and reported a non-significant difference be-
tween the two groups. 
 Comparison 3. Exercise programme: direct ver-
sus indirect exercises 
This comparison encompassed six subgroups evalu-
ating direct versus indirect training. In “direct” PFMT, 
women specifically performed voluntary contractions 
of the pelvic floor muscles while in the “indirect” 
PFMT, women focused on other muscle groups in or-
der to facilitate or stimulate pelvic floor muscle con-
tractions. 
Subgroup 3.1: PFMT versus sham/imitation 
No new studies were found comparing PFMT to sham 
or imitation PFMT treatments (e.g. crossing the an-
kles and pulling the legs apart). 
Subgroup 3.2: PFMT versus the 'Paula method' 
The previous ICI chapter on conservative manage-
ment included the study of Liebergall-Wischnitzer et 
al. (90) comparing PFMT to the Paula method. The 6-
month follow-up of this study was included in the cur-
rent review (67). It should be emphasized that the two 
groups did not receive the same amount of supervi-
sion by a health professional because the Paula 
group was individually supervised and the PFMT 
group had group teaching. 
Subgroup 3.3: PFMT versus the 'Sapsford' approach 
Our search revealed no new RCTs evaluating incon-
tinence outcomes for this subgroup. 
Subgroup 3.4: PFMT versus Pilates 
No new RCT were found evaluating Pilates treatment 
in comparison to PFMT. 
Subgroup 3.5: PFMT versus hip rotator training 
One RCT was included in this subgroup evaluating 
the effectiveness of hip external and internal rotator 
training compared to PFMT (76). 
Subgroup 3.6: PFMT versus hypopressive training 
Our search revealed no RCT including hypopressive 
training conducted in women with UI. 
Self-reported cure: No data were reported in the dif-
ferent sub-groups. 
Improvement: Liebergall-Wischnitzer et al. (67) in 
subgroup 3.2 showed that UI results were maintained 
at the 6-month follow-up in both the Paula method 
and the PFMT groups. Women who received the 
Paula method intervention were more likely to report 
a lower rate of UI than women after PFMT. In sub-
group 3.5, non-significant differences were found be-
tween hip rotator training and PFMT with regard to 
subjective UI improvement and UI symptoms and re-
lated impact (76). 
Leakage episodes: Jordre et al. (76), subgroup 3.5, 
reported that women who received hip training had 
significantly fewer UI episodes than women in the 
PFMT group. 
Pad test: Neither of the two new RCTs used pad-test-
ing measurements. 
 Comparison 4. Exercise programme: generic 
versus individualized exercises 
No further evidence was available. 
 Comparison 5. Exercise programme: submaxi-
mal versus near maximal contractions  
No further evidence was available. 
 Comparison 6. Exercise programme: daily ver-
sus three times per week. 
No further evidence was available. 
 Comparison 7. Exercise programme: addition of 
upright exercise position.  
No further evidence was available. 
 Comparison 8. Exercise programme: addition of 
strength training to motor learning. 
Junginger et al. (68) evaluated PFMT and motor re-
learning taught with ultrasound imaging in compari-
son to regular PFMT using EMG biofeedback in 
women with SUI or MUI. Both groups had the same 
amount of contact with health professionals. 
Self-reported cure: No data were reported. 
Improvement: There was no difference between the 
two groups in the number who reported ‘some’ or 
‘great’ improvement. However, women in the PFMT 
group were more likely to switch to the motor relearn-
ing group at RCT completion. 
Leakage episodes: No data reported. 
Pad tests: The pad-testing measure was not included 
(68). 
 Comparison 9. Exercise programme: addition of 
abdominal or hip muscle exercises. 
This comparison encompassed two subgroups eval-
uating the addition of either abdominal muscle (sub-
group 9.1) or hip muscle (subgroup 9.2) training to 
PFMT. 
Subgroup 9.1: PFMT vs PFMT+ abdominal muscle 
exercises 
One new RCT evaluates the effectiveness of adding 
transverse abdominis exercises to PFMT (77). Lim-
ited information was available about the training pro-
tocol in this abstract report. 
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Subgroup 9.2: PFMT vs PFMT+ hip muscle exercises 
Two RCTs investigated the addition of hip muscle ex-
ercises to PFMT in women with SUI (78, 82). The 
same amount of health-professional supervision was 
given to each group (78, 82). 
Self-reported cure: No trial reported this outcome. 
Improvement: There was no significant benefit of 
adding abdominal muscle exercises to PFMT in the 
study of Konstantinidou et al. (77) (subgroup 9.1). 
Likewise, Donahoe-Fillmore et al. (78) showed a non-
significant difference between adding hip muscle ex-
ercises to PFMT training as assessed with the King’s 
health question and the Incontinence Severity Index 
(sub-group 9.2). Results from the UDI-6 question-
naire, favoured the combined treatment (78). These 
findings should be interpreted with caution given the 
small sample size of Donahoe-Fillmore et al.’s study 
(78) (n=11).  
Leakage episodes: Non-significant differences in 
leakage episodes were found when adding ab-
dominal muscle (77) or hip muscle exercises (82). 
Pad and paper towel tests: No data were reported. 
 Comparison 10. Exercise programme: addition 
of intravaginal resistance device 
The study of Delgado et al. (2009) (91), presented as 
an abstract, was included in the previous ICI edition. 
The complete published manuscript has now been in-
cluded in the current review (72) along with a new 
study evaluating the addition of an intravaginal re-
sistance device to PFMT in women with SUI or MUI 
(69). Both RCTs were the same in all aspects except 
that one group used an intravaginal device designed 
to increase resistance to the PFM contraction. In both 
RCTs, the resistance device was composed of a 
spring-loaded device with two limbs (69, 72). 
Self-reported cure: There was no statistically signifi-
cant difference between the groups in terms of the 
number of women who indicated they were ‘cured’ 
(72). 
Improvement: There was no statistically significant 
difference between the groups in terms of self-re-
ported improvement and reduction of symptoms as 
assessed with standardised questionnaires (69, 72). 
Leakage episodes: No data were reported for this 
outcome. 
Pad and paper towel tests: No data reported. 
 Comparison 11. Exercise programme: addition 
of adherence strategy 
No new RCTs investigated the efficacy of adding ad-
herence strategies to PFMT. 
 Comparison 12 Teaching programme: Addition 
of biofeedback (BF)  
Six new RCTs compared PFMT alone to PFMT as-
sisted with BF (70, 73, 74, 79-81). In these RCTs, the 
comparison groups were similar according to the 
amount of supervision and the intensity of training; 
they differed only with regard to the addition of bio-
feedback. 
Two RCTs investigated clinic-based BF using pres-
sure perineometry (79) and ultrasound imaging (70). 
Prudencio et al. (79) included women with SUI while 
Galea et al. (70) also evaluated women with UUI. Du-
ration of treatment varied from 10 weeks (70) to 3 
months (79). 
Four RCTs evaluated home-based biofeedback using 
a Vibrance device (73), EMG BF (74) and pressure 
BF (80, 81). Of these, three were conducted in 
women with SUI (73, 74, 81) and one did not specify 
the type of UI of women included (80). In all RCTs, 
the same PFMT program was used in the comparison 
groups and differed only with regards to the addition 
of BF. Treatment duration varied from 12 weeks (74), 
16 weeks (73, 81) and 6 months (80). 
Self-reported cure: There was no statistically signifi-
cant difference in terms of the number of women who 
indicated they were ‘cured’ between PFMT alone or 
combined with home-based (73) or clinic-based BF 
(79).  
Improvement: Galea et al. (70) reported a non-signif-
icant benefit of adding clinic-based BF as assessed 
with the King’s health questionnaire. Using the same 
questionnaire, Prudencio et al. (79) conversely re-
ported a significant difference between groups but did 
not reveal which of the three treatment arms differed. 
With regard to home-based BF, three of the four 
RCTs reported a non-significant difference between 
PFMT combined or not with BF. Shin et al. (44) did 
not conduct any inter-group comparisons but re-
ported a significant reduction of incontinence only in 
the group which received BF. 
Leakage episodes: Galea et al. (70) found a non-sig-
nificant difference in leakage episodes in women re-
ceiving or not clinic-based BF. Likewise, non-signifi-
cant benefits were found when adding home-based 
BF to PFMT (74). 
Pad and paper towel tests: Galea et al. (70) reported 
a non-significant benefit of adding clinic-based BF to 
PFMT as assessed with pad-testing measurements. 
Also, Hirakawa et al. (74) found a non-significant dif-
ference between women receiving or not home-
based BF. 
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Summary 
Based on current evidence, PFMT with regular (e.g. 
weekly) supervision is better than PFMT with little or 
no supervision (Level of Evidence: 1). However, 
data were unclear as to whether supervision was 
more effective in individual or group settings. Suffi-
ciently powered studies using appropriate design 
should be undertaken to investigate this comparison. 
Based on limited evidence (6 previous RCTs and 2 
new RCTs), 'indirect' methods of PFMT (e.g. the 
'Paula method' or 'Sapsford' approach) are not better 
than direct PFMT, However, some data were con-
founded by differences in the amount of contact time 
with health professionals or the small sample size, 
which made it difficult to detect clinically significant 
differences (Level of Evidence 2: unchanged). 
No robust recommendation can be made with regard 
to the type or specification of training (i.e. generic ver-
sus individualized exercises, submaximal versus 
near maximal contractions, daily versus three times 
per week, addition of upright exercise position).  
There remains insufficient evidence as to whether the 
combination of PFMT with other treatment modalities 
(i.e. motor learning, abdominal- or hip-muscle train-
ing, intra-vaginal resistance device) could increase its 
efficacy.  
With regard to clinic-based BF, new evidence (2 stud-
ies) reported no statistically significant differences be-
tween BF-assisted and non-BF groups for self-re-
ported cure, improvement, or frequency of leakage 
episodes (Level  of Evidence: 1).  
Likewise, there is no statistically significant differ-
ences between home BF and non-BF groups for self-
reported cure, improvement, frequency of leakage 
episodes and pad-test measures in women with SUI 
(Level of Evidence:  2). 
Recommendations 
Clinicians should offer and provide the most intensive 
health professional-led PFMT programme possible 
within service constraints. (Grade of Recommenda-
tion: A).  
Although studies are limited, there does not appear to 
be clear benefit for adding other modalities (i.e. motor 
learning, abdominal- or hip-muscle training, intra-vag-
inal resistance device) to PFMT (Grade of Recom-
mendation: B) 
There is no clear benefit from adding clinic- (Grade 
of Recommendation: A) or home-based BF (Grade 
of Recommendation: B) to a PFMT program. 
Implications for research 
Comparisons of PFMT approaches are, de facto, 
comparisons of two active treatments. It is therefore 
difficult to determine which approach is best unless 
(a) the differences in outcome are large or (b) the 
RCTs are designed with sufficient sample size to find 
small to moderate differences. Finding the best ap-
proach to PFMT remains among the highest research 
priorities. Future studies should be sufficiently pow-
ered to detect clinically important differences. 
2.3.3 Is PFMT Better than Other Treatments? 
Trials were considered for inclusion in this section if 
they compared PFMT with another stand-alone inter-
vention, e.g. vaginal cones, bladder training, drug 
therapy. The 2013 ICI review concluded that PFMT is 
better than EStim, BT, or vaginal cones for women 
with SUI and better than duloxetine because of its 
side-effects. PFMT and surgery were both effective, 
but PFMT was recommended as first-line therapy be-
cause it is less invasive. For women with UUI or MUI, 
PFMT and BT were both deemed effective, with some 
evidence to suggest an advantage for PFMT. Evi-
dence was sparse for a comparison between PFMT 
and drug therapies  
Seven new trials were found that compared PFMT to 
another stand-alone treatment.  
PFMT was compared to vaginal cones (92-94), sur-
gery (95), continence pessary, (96, 97), drug therapy 
(98), and bladder training (98). One trial was a head-
to-head comparison of PFMT to surgery (95). The 
other trials had more than two arms. They included 
PFMT alone and another treatment alone, but were 
also designed to evaluate combinations of treatments 
(See Tables 10 and 13). 
Trials addressed the following comparisons: 
i) PFMT versus vaginal cones (VC):  
One recent Cochrane review compared PFMT to VC 
(92). This review considered the eleven studies in-
cluded in this consultation along with two other RCTs 
(93, 94). Moreover, our literature search revealed the 
study of Golmakani et al. (60). Details of these new 
trials are presented in Table 13.  
ii) PFMT versus EStim:  
No new trials have been published.  
iii) PFMT versus Bladder training (BT):  
The Kafri trial examined the effects of PFMT alone 
and BT alone in the context of its 4-arm design (98). 
All groups had significant improvement at 3 and 12 
months on all parameters, including UUI episodes. 
But, no significant time X group interactions were 
found that would indicate a difference between PFMT 
and BT (Table 10). 
iv) PFMT versus drug therapy:  
The trial by Kafri and colleagues examined the effects 
of PFMT alone compared to anticholinergic drug ther-
apy alone in the context of a 4-arm design (98). All 
groups had significant improvement at 3 and 12 
months on all parameters, including UUI episodes 
but, no significant time X group interactions were 
found that would indicate a difference between PFMT 
and drug therapy (Table 10).  
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v) PFMT versus surgery:  
The single trial of surgery compared PFMT to mid-
urethral sling in women with stress predominant UI 
(95). It was a multi-site trial involving 23 medical cen-
tres and 83 physiotherapists (Table 10).  
vi) PFMT vs continence pessary:  
A single new trial compared PFMT to continence pes-
sary in women with stress predominant UI (96, 97). It 
was a multi-site trial conducted by the Pelvic Floor 
Disorders Network of the National Institute on Child 
Health and Human Development (NICHD) (Table 10). 
Quality of data 
i) PFMT versus VC:  
Randomization and adequate allocation concealment 
were reported in the three new RCTs (93, 94, 99). Of 
these, two indicated that outcome assessors were 
blinded (93, 99). In the third study, the evaluator was 
unblinded (94). Sample sizes were small ranging 
from 15 to 30 women with SUI per group (93, 94, 99). 
Dropout rates were higher in the VC groups in two 
studies (93, 99); no loss to follow up was reported in 
the study of Pereira et al. (94). Substantial attrition 
occurred in the study of Harvey et al. (93) with drop-
outs reaching 41% in the PFMT group and 72% in the 
VC group. Follow-up beyond the post-treatment eval-
uation was reported by Pereira et al. (94) in a subse-
quent publication with a 12-month post-treatment as-
sessment (100). 
ii) PFMT versus EStim: Not applicable.   
iii) PFMT versus BT:  
Risk of Bias - This trial was not a head-to-head com-
parison of PFMT and drug therapy, but rather a com-
parison of four treatment approaches including BT 
and combined therapy. Randomization method and 
allocation concealment were described. Analysis was 
conducted by ITT. It was not clear whether assessors 
were blinded. 
iv) PFMT versus drug therapy:  
This trial was not a head-to-head comparison of 
PFMT and drug therapy, but rather a comparison of 
four treatment approaches including BT and com-
bined therapy. Randomization method and allocation 
concealment were described. Analysis was con-
ducted by ITT. It was not clear whether assessors 
were blinded. 
v) PFMT versus surgery:  
Randomization method and allocation concealment 
were reported. Analysis included ITT and other ap-
proaches. It was not clear whether assessors were 
blinded. Fifteen women in the surgery group and 28 
in the PFMT group did not start treatment after ran-
domization. The ITT analyses did not include these 
individuals. Nineteen women in the surgery group 
and 28 in the PFMT group were lost to follow-up after 
starting treatment. 
vi) PFMT vs continence pessary: 
Randomization method and allocation concealment 
were reported. Analyses were performed by ITT. 
Results and Summary 
i) PFMT versus VCs:  
As underlined in Herbison et al.’s meta-analysis (92)  
comprising 13 RCTs, most studies had a small sam-
ple size and differed according to the PFMT regimen 
(92). There was also limited overlap between out-
comes. No statistically significant differences be-
tween PFMT and VC were found in subjective im-
provement or cure (reported in six RCTs) (Risk ratio 
(RR) for failure 0.97, 95% CI 0.75 to 1.24) (92). There 
were no significant differences in subjective cure (re-
ported in five RCTs) (RR for failure 1.01, 95% CI 0.91 
to 1.13) (92). Pooled data from these RCTs showed 
substantial heterogeneity. Likewise, inconsistency 
between RCTs was noted in relation to leakage epi-
sodes whereas a non-significant difference between 
treatments was observed (mean difference 0.00, 95% 
CI -0.20 to 0.20) (92). With regard to improvement in 
pad test, non-significant differences were found in the 
meta-analysis based on six RCTs (RR for failure 1.00, 
95% CI 0.76 to 1.31). However, the new study of 
Golmakani et al. (60) favoured PFMT when using the 
1-h pad test and the leakage index. With regard to 
quality of life improvement, the three new RCTs found 
a non-significant difference between PFMT and VC 
treatments (93, 94, 99). Three RCTs included in the 
Herbison review as well as the study of Golmakani et 
al. (60) reported the inability for some women to use 
VCs and adverse effects such as pain, vaginitis, 
bleeding and a sense of unpleasantness or inconven-
ience.  
In the 14 RCTs (13 from the new Cochrane review, 
11 of which were discussed in the previous ICI chap-
ter edition and 1 additional RCT) that compared 
PFMT with VC in women with SUI, limited evidence 
suggests that VC appear to have similar effects or are 
not superior to PFMT (Level of Evidence: 1). There 
were no statistically significant differences between 
interventions in subjective improvement or cure (re-
ported in six RCTs), subjective cure (reported in five 
RCTs), or leakage episodes per day (reported in four 
RCTs), and no improvement in the pad test (reported 
in six RCTs). The additional RCT favoured PFMT us-
ing both the 1-h pad test and the leakage index. VC 
treatment may be inappropriate in some cases due to 
the inability to use and potential side effects as re-
ported in four RCTs (i.e. pain, vaginitis, bleeding and 
a sense of unpleasantness or inconvenience). 
ii) PFMT versus EStim:  
No new trials were found. Previous pooled data 
demonstrated that self-reported cure and cure/im-
provement were more likely in PFMT than in EStim 
groups (Level of Evidence: 1). 
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iii) PFMT versus BT:  
There is evidence for an advantage of PFMT over BT 
for women with SUI (Level of Evidence: 2). 
There does not appear to be a significant difference 
between PFMT and BT in UUI and MUI women 
(Level of Evidence: 2). 
iv) PFMT versus drug therapy:  
There is weak evidence that PFMT is more beneficial 
than drug therapy, but not enough evidence to 
change previous recommendations (Level of Evi-
dence: 2). 
v) PFMT versus surgery:  
On the primary outcome, PGI-I at 12 months, per-
ceived improvement was significantly greater in the 
surgery group compared to the PFMT group: 90.8% 
of women in the surgery group reported being “much 
better” or “very much better” compared to 64.6% in 
the PFMT group. Change in the UDI UI domain and 
OAB domain were also significantly greater with sur-
gery and a higher proportion of women in the surgery 
group had subjective and objective cure. 
The one new trial of PFMT compared to surgery ap-
peared well-designed and adequately powered, 
providing evidence that mid-urethral sling may be 
more effective than PFMT for treatment of SUI in 
women (Level of Evidence: 2). 
vi) PFMT vs continence pessary: 
The PFMT/behavioural group had better outcomes 
on the PFDI SUI subscale and greater patient satis-
faction. The groups were not significantly different on 
the PGI-I, UI episode frequency, or outcome 
measures, including domains of the PFDI and PFIQ. 
There may be some benefit for PFMT over conti-
nence pessary alone, the evidence is not strong 
enough to recommend one treatment over the other 
(Level of Evidence: 2; Grade of Recommendation:  
D). 
Recommendations 
For women with SUI: 
 PFMT and VC are both effective as conservative 
therapy, although PFMT is better because inabil-
ity of use and side effects are experienced with 
VC in some women (Grade of Recommenda-
tion: B). 
 PFMT is better than EStim as first line conserva-
tive therapy (Grade of Recommendation: B). 
 PFMT is better than BT as first line conservative 
therapy (Grade of Recommendation: B). 
 PFMT and drug therapy are both effective as first 
line therapy, although PFMT is better because of 
side effects experienced with drug therapy 
(Grade of Recommendation: B). 
 Surgery is more effective than PFMT, but poten-
tial benefit should be weighed against potential 
adverse events. PFMT should be offered as first 
line therapy due to its being less invasive. 
(Grade of Recommendation: B New).  
 PFMT and continence pessary are both effective 
in first line conservative therapy (Grade of Rec-
ommendation: B New). 
For women with SUI or MUI: 
 VC do not appear to be better than PFMT in the 
treatment of UI. PFMT should be recommended 
as first-line conservative therapy (Grade of Rec-
ommendation: B).  
VC with supervised training sessions by a trained 
health professional can be offered to women who can 
and are prepared to use them (Grade of Recommen-
dation: B). 
VC may be inappropriate for some women due to in-
ability to insert or retain the cone or because of side 
effects and discomfort.  
For women with UUI or MUI: 
 PFMT and BT are effective first-line conservative 
therapy (Grade of Recommendation: B). 
 PFMT is better than oxybutynin as first line ther-
apy (Grade of Recommendation: B). 
For women with UUI 
 PFMT and BT are effective first line conservative 
therapy (Grade of Recommendation: B). 
Research recommendation 
Larger, good quality trials are needed to address 
each of the above comparisons if these are of interest 
to women. In planning comparisons researchers 
should consider carefully the potential impact of dif-
ferent levels of supervisory intensity between groups, 
particularly in comparisons of conservative therapies.  
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Table 10 Summary of data on PFMT vs other treatments 
Author, 
year 
Comparator N 
Study 
Population 
Intervention Outcomes/Results Notes 
Kafri 
2013 (1) 
 
Drug therapy 
(anticholinergic) 
BT 
 
 
N=164 
DT: 42 
BT: 41 
PFMT: 40 
Conbined: 41 
Women with 
UUI, No SUI 
(45-75 years) 
 
 
PFMT based on National 
Institute for Health and Clinical 
Excellence (NICE) 
recommendations.  
Included behavioral guidance 
3 sets of 8-12 slow maximal 
contractions sustained for 6-8 
s in different positons.  
Daily home-based exercise 
prescribed.  
Number of voids and UUI episodes, 
QOL-ruI, Urogyn VAS. 
All groups had significant improvement at 
3 and 12 months on all parameters 
(p<0.001). 
No significant timeXgroup interactions 
(except favoring combination group) 
Comparison was in the context of 
4-arm trial, including arm for 
combined Tx. 
Randomization method and 
allocation concealment described.  
ITT analysis  
Not clear whether assessors were 
blinded 
 
Richter 
2010 (2) 
Kenton 
2012 (3) 
Intravaginal 
pessary 
N=446 
PFMT: 146 
Pessary: 149 
Combined: 
151 
Women with 
predominant 
SUI 
(18+ years) 
12 weeks of supervised PFMT 
and behavioral strategies 
(PFM pre-contraction for SUI; 
urge suppression for 
concomitant UUI). 
Implemented in 4 visits at 2-
week intervals. Home exercise: 
written prescriptions X3 daily 
exercise between visits. 
Primary: PGI-I and SUI subscale of the 
PFDI at 3 months (FU 6 & 12 months) 
Secondary: Satisfaction, PFDI, PFIQ  
PFMT/behavioral group had better 
outcomes on the PFDI SUI subscale 
(49% vs 33% reporting no bothersome 
SUI symptoms, p=0.006) and greater 
satisfaction (75% vs 63%, p=0.02). 
Groups not significantly different on the 
PGI-I (49% vs 40% “much better” or 
“very much better,” (p=0.09), UI episodes 
on bladder diary, or other outcome 
measures including other domains of the 
PFDI and PFIQ. 
Comparison was in context of 3-
arm trial, including arm for 
combined Tx 
Multi-site trial 
Randomization method and 
allocation concealment reported  
ITT analysis  
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Author, 
year 
Comparator N 
Study 
Population 
Intervention Outcomes/Results Notes 
Labrie 
2013 (4) 
Mid-urethral sling N=460 
PFMT: 230 
Surgery: 230 
Women with 
predominant 
SUI 
(35-80 years) 
 
Supervised, somewhat 
individualized program 
conducted by 83 PTs 
according to Dutch guidelines. 
Treatments given at 1-week or 
2-week intervals with an 
intended 9 sessions in 9-18 
weeks. Goal to build up to 8 to 
12 maximal contractions X3 
per day. Use of touch, tapping, 
massage, BF, or functional 
electrical stimulation allowed to 
increase muscle awareness as 
needed. 
Assessed at 12 months 
Primary: PGI-I, 90.8% in surgery group 
were “much better” or “very much better” 
vs 64.4% in PFMT. 
Secondary: UDI, IIQ, PGI-S 
Both groups had significant improvement 
in UDI and IIQ domain scores. Change in 
UDI greater for surgery than PFMT on UI 
and OAB domains (P<0.001, .02) 
Subjective cure: (single question) 85.2% 
in surgery vs 53.4% in PFMT 
Objective cure: (cough test) 76.5% in 
surgery vs 58.8% in PFMT 
After 12 months, 99 women (49.0%) had 
crossed over to surgery after a mean 
31.7 weeks. 
Multi-site trial (23) 
Randomization computerized on 
central server 
Allocation not concealed 
Not clear whether assessors were 
blinded. 
65 adverse events reported - all in 
surgery group. 
Analysis included modified ITT and 
other approaches. 
15 in surgery group and 28 in 
PFMT group did not start treatment 
after randomization. 
19 in surgery group and 28 in 
PFMT group were lost to follow-up 
after starting Tx. 
 
1. Kafri R, Deutscher D, Shames J, Golombp J, Melzer I. Randomized trial of a comparison of rehabilitation or drug therapy for urgency urinary incontinence: 1-year 
follow-up. Int Urogynecol J. 2013;24(7):1181-9. 
2. Richter HE, Burgio KL, Brubaker L, Nygaard IE, Ye W, Weidner A, et al. Continence pessary compared with behavioral therapy or combined therapy for stress 
incontinence: a randomized controlled trial. Obstet Gynecol. 2010;115(3):609-17. 
3. Kenton K, Barber M, Wang L, Hsu Y, Rahn D, Whitcomb E, et al. Pelvic floor symptoms improve similarly after pessary and behavioral treatment for stress inconti-
nence. Female Pelvic Med Reconstr Surg. 2012;18(2):118-21. 
4. Labrie J, Berghmans BL, Fischer K, Milani AL, van der Wijk I, Smalbraak DJ, et al. Surgery versus physiotherapy for stress urinary incontinence. N Engl J Med. 
2013;369(12):1124-33. 
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2.3.4 Does the Addition of PFMT to Other 
Treatments Add Benefit? 
Six trials addressed the following comparisons (Table 
11): 
i) PFMT+VC vs VC: Both the Herbison et al. meta-
analysis (92)  and the ICI 5th edition (2) included two 
studies comparing combined PFMT∕ VC versus VC. 
No new RCTs with the same comparators were iden-
tified. 
ii) PFMT + EStim vs EStim: A single trial examined 
the effects of adding PFMT to vaginal EStim in 48 
women with SUI (101). No significant differences 
were found between the groups. 
iii) PFMT+ BT vs BT: Two trials examined the effects 
of adding PFMT to BT, one in 108 women with SUI, 
UUI, or MUI (102), the other in 164 women with UUI 
(no SUI) (98). In the first, significantly more patients 
in the combined therapy group reported cure or im-
provement and greater improvements on several sec-
ondary outcomes. In the second trial, all groups had 
significant improvement, but there were no significant 
interactions indicating differential group effects.  
iv) PFMT + drug therapy vs drug therapy alone: A sin-
gle trial examined the effects of adding PFMT to in-
travaginal oestriol in 206 postmenopausal women 
with SUI and vaginal atrophy (103). Combined ther-
apy resulted in significantly greater improvement than 
oestriol only. 
v) PFMT + continence pessary vs continence pes-
sary:  
A single trial examined combined pessary + PFMT to 
pessary alone in 446 women with stress predominant 
UI (97). The combined therapy group had significantly 
better outcomes on the PGI-I and the PFDI and re-
ported greater satisfaction with treatment.  
vi) PFMT + surgery vs surgery: 
A single, multi-centre trial examined the effects of 
perioperative behavioural and pelvic floor muscle 
training (BPMT) in 374 women undergoing surgery to 
treat both apical prolapse and SUI (104). The group 
receiving BPMT resulted in no greater improvements 
in urinary symptoms compared to usual peri-opera-
tive care at 6 or 24-month follow up. 
Summary 
The literature on the effect of adding PFMT to another 
stand-alone therapy remains relatively small.  
There is no evidence of benefit in adding PFMT to VC 
in women with SUI (Level of Evidence: 2).  
There may be some benefit for adding PFMT when 
using a continence pessary (Level of Evidence: 2).  
PFMT may add benefit in terms of reducing SUI over 
intravaginal estrogen alone when treating women 
with vaginal atrophy (Level of Evidence: 2).  
There is some evidence that there may be benefit in 
adding PFMT to BT (Level of Evidence: 2).  
There is no evidence of improved outcomes with peri-
operative PFMT for women undergoing surgery for 
apical prolapse and SUI, or for adding PFMT to EStim 
in women with SUI (Level of Evidence: 2).  
Recommendation 
In women using VC, it does not appear to help to add 
PFMT (Grade of Recommendation: C).  
For the treatment of SUI, UUI, or MUI in women, con-
sider a combination of PFMT and BT rather then BT 
alone (Grade of Recommendation: C).  
For treatment of UUI (tolterodine) but not for SUI (du-
loxetine), consider adding PFMT to drug therapy 
(Grade of Recommendation: B),  
When treating women with SUI and vaginal atrophy, 
consider combining PFMT and intravaginal oestrogen 
over estrogen alone (Grade of Recommendation: C 
New).  
Note, many of these recommendations are based on 
single RCTs of variable quality. Larger, good-quality 
RCTs are needed to address each of the above com-
parisons. Furthermore, these studies examine the ef-
fects of combining therapies as an initial approach. 
Less is known about the effects of combining thera-
pies in a stepped fashion when women do not 
achieve the desired outcomes with a single therapy 
(i.e. active PFMT than resisted PFMT with cones 
such as in progressive muscle training overload). 
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Table 11 Summary of data on PFMT + another treatment vs the other treatment  
Study Comparator N Study Population Intervention Outcomes/Results Notes 
Richter 2010 
(1) 
 
 
 
 
 
 
Continence 
pessary alone 
N=446 
  
Women with stress 
predominant UI 
Pessary + behavioral 
training  
Behavioral training program 
- supervised PFMT + 
behavioral strategies: PFMT 
pre-contraction for SUI and 
urge suppression for 
concomitant UUI. Treatment 
implemented in 4 visits at 2-
week intervals and included 
written prescriptions for 
home exercise X3 daily 
between visits. 
 
Primary: PGI-I and SUI subscale of 
UDI at 3 months 
Results - Combined therapy group 
had significantly better outcomes on 
the PGI-I (53.3% vs 39.6% reporting 
“much better” or “very much better,” 
p=.02) and the PFDI (44.0% vs 
32.9% reporting no bothersome SUI 
symptoms (p=.05). Combined group 
also reported greater satisfaction 
with treatment (78.7% vs 63.1%, 
p=.003). The groups were not 
significantly different on number of 
UI episodes on bladder diary. Group 
differences not sustained to the 12-
month follow up. 
Multi-site trial conducted by the 
NICHD Pelvic Floor Disorders 
Network with randomization to 
3 arms: pessary alone, 
behavioral training alone, 
combined Tx 
Data quality – Randomization 
method and allocation 
concealment were reported. 
Analysis conducted by ITT 
 
Barber 2014 (2)  
 
 
 
 
 
Surgery alone 
for prolapse 
and SUI 
 
 
 
N=374 Women undergoing 
surgery to treat both 
apical vaginal prolapse 
and SUI 
Surgery + perioperative 
behavioral and pelvic floor 
muscle training (BPMT) 
PFMT program - Single 
session 2-4 weeks prior to 
surgery; 4 postoperative 
visits (2, 4-6, 8, & 12 weeks) 
Individualized, supervised 
program of progressive 
home PFME, education on 
healthy bladder and bowel 
habits, and behavioral 
strategies to reduce UI 
episodes (PFM pre-
contraction for SUI, urge 
suppression for UUI) Home 
PFME prescribed for X3 
daily with duration 
increasing to 10 sec. 
Primary: UDI at 6 months 
Results – Perioperative BPMT not 
associated with greater 
improvements in urinary symptoms 
at 6 months or 24-month follow-up 
Multi-center 2X2 factorial trial 
with 2 distinct randomizations: 
First: to perioperative BPMT or 
usual care 
Second: to one of 2 surgical 
approaches for prolapse, each 
with concomitant retropubic 
midurethral sling for SUI. 
Data quality – Randomization 
method and allocation 
concealment reported. 
 
Capobianco 2012 (3) 
 
Intravaginal 
estrogen alone  
N=206 
 
Postmenopausal 
women with SUI and 
Estrogen + PFMT with 
EStim (per Castro, 25) 
Outcome based on change in 
patient rating of SUI as none, mild, 
Data quality - Randomization 
method not described.  
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Study Comparator N Study Population Intervention Outcomes/Results Notes 
 
 
 
 
(estriol ovules, 
1m daily for 2 
wks, then 2.wk 
for 6 months) 
vaginal atrophy, no 
DO 
PFMT was for 6 months and 
included EStim. Further 
details lacking, but per 
reference to a previous 
article, PFMT was 
conducted in 45-minute 
group sessions X3 per week 
under the supervision of a 
physiotherapist. 
moderate, or severe before and after 
6 months of treatment.  
Results - Combined therapy resulted 
in significantly greater improvement 
than estriol only. 73.5% (61/83) of 
treated and 9.7% (10/103) showed 
improvement in UI (p<.01) 
  
Group allocation was 
concealed. 
Analysis was by ITT 
AEs were reported 
Not clear all women actually 
had SUI.  
Kafri 2013 (4) 
 
 
 
 
BT alone N=164 Women with UUI, no 
SUI 
(ages 45-75) 
Bladder training + PF rehab 
and behavioral. 
PFMT program based on the 
National Institute for Health 
and Clinical Excellence 
(NICE) recommendations. 
Women practiced 3 sets of 
8-12 slow maximal 
contractions sustained for 6-
8 s in different positons. 
Daily home-based exercise 
was prescribed, and urge 
suppression using PFM 
contraction was taught. 
Number of voids and UUI episodes, 
voids/24 hours, QoL-rUI, Urogyn 
VAS, number of pads 
Results - analysis was by repeated 
measures ANOVA with all four 
groups, including tests for main 
effects and group X time 
interactions. However, statistical 
analysis did not include comparisons 
between individual groups.  
All groups had significant 
improvement at 3 and 12 months on 
all parameters, (p<.001) but there 
were no significant interactions. UI 
episodes decreased by 1.7/day in 
BT and 4.0/day in combined 
therapy, but a test of this difference 
was not conducted. Only CPFR 
showed significant reduction in 
voids/24 hours. 
Comparison was in context of 
4-arm trial: BT alone, PFMT 
alone, drug therapy alone, and 
combined Tx. 
Data quality –Randomization 
method and allocation 
concealment described. 
Analysis conducted by ITT.  
Not clear whether assessors 
were blinded. 
 
Kaya 2015 
(5)   
 
 
 
 
 
 
BT alone N=108 
 
Women with SUI, UUI, 
MUI 
BT + PFMT for 6 weeks 
High-intensity PFMT 
program conducted in 4 
visits across 6 weeks by an 
experienced physical 
therapist. Home-based 
exercise regimen initiated 
with 5 sets of exercises per 
day and progressed to 30 
Primary: global rating of 
improvement on a 4-point scale 
(worse, unchanged, improved, 
cured). Secondary: UI severity, 
symptom distress, QOL, UI 
episodes, voids/day.  
Results – Significantly more patients 
in the combined therapy group 
reported cure or improvement 
(100% vs 82.7%, p=.001). Greater 
Data quality –Randomization 
method and allocation 
concealment described. 
Analysis conducted by ITT.  
Not clear whether assessors 
were blinded. 
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Study Comparator N Study Population Intervention Outcomes/Results Notes 
sets per day (600 PFM 
contractions).  
 
improvements observed for 
combined therapy on secondary 
outcomes, including severity of UI 
(ISI; p=.001), UDI-6 (p=.001), IIQ-7 
(p=.005), and incontinent episode 
frequency per bladder diary 
(p=.024). 
Furst 2014 
(6) 
EStim alone 
Vaginal probe; 
two 30-min 
sessions per 
week; 
frequencies of 
4Hz and 50Hz; 
fixed intensity 
(20mA); 4 s 
stimulation/rest 
cycles 
N=48 Women with SUI 
(Mean age 49.6) 
EStim + PFMT for 3 months 
PFMT program – individually 
designed by PT, 2 30-min 
sessions per week. 
PFMT and EStim conducted 
on alternate days. 
No home PFME program 
Improvements in urinary symptoms, 
IEF per bladder diary, satisfaction 
(perception of need or not to repeat 
or change Tx); assessments at 3, 12 
and 96 months. 
Results – Both groups showed 
improvement in leakage episodes 
and voiding intervals. 
No significant between group 
differences. 
Data quality – Randomization 
method described; allocation 
concealed. 
Analysis not conducted by ITT 
(only included patients who had 
not received any additional 
therapy) 
1. Richter HE, Burgio KL, Brubaker L, Nygaard IE, Ye W, Weidner A, et al. Continence pessary compared with behavioral therapy or combined therapy for stress 
incontinence: a randomized controlled trial. Obstet Gynecol. 2010;115(3):609-17. 
2. Barber MD, Brubaker L, Burgio KL, Richter HE, Nygaard I, Weidner AC, et al. Comparison of 2 transvaginal surgical approaches and perioperative behavioral therapy 
for apical vaginal prolapse: the OPTIMAL randomized trial. JAMA. 2014;311(10):1023-34. 
3. Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmen-
opausal women. Archives of gynecology and obstetrics. 2012;285(2):397-403. 
4. Kafri R, Deutscher D, Shames J, Golombp J, Melzer I. Randomized trial of a comparison of rehabilitation or drug therapy for urgency urinary incontinence: 1-year 
follow-up. Int Urogynecol J. 2013;24(7):1181-9. 
5. Kaya S, Akbayrak T, Gursen C, Beksac S. Short-term effect of adding pelvic floor muscle training to bladder training for female urinary incontinence: a randomized 
controlled trial. International Urogynecology Journal. 2015;26(2):285-93. 
6. Furst MC, Mendonca RR, Rodrigues AO, Matos LL, Pompeo AC, Bezerra CA. Long-term results of a clinical trial comparing isolated vaginal stimulation with combined 
treatment for women with stress incontinence. Einstein. 2014;12(2):168-74. 
52 
3. WEIGHTED VAGINAL CONES (VC) 
Weighted vaginal cones (VC) were developed as a 
method for testing PFM function and to provide pro-
gressive muscular overload during PFM strengthen-
ing exercises (105). In theory, when a cone is inserted 
into the vagina, the sensation of ‘losing the cone’ pro-
vides strong sensory feedback that prompts the PFM 
to contract to prevent the cone from slipping out. 
Women start in a standing position with a weighted 
cone held inside the vagina for at least one minute, 
incrementally adding time and increased cone weight 
whilst standing or walking. The goal is to walk around 
for 20 minutes without losing the cone; the gradual 
increase in cone weight maintains muscle overload 
over the course of the exercise programme.  
There are various cone weights and sizes (Figure 1). 
However, the effectiveness of the VC training method 
is unclear. Because orientation of the vagina is not 
completely vertical, some women can retain the cone 
without actually contracting the pelvic floor. Radiology 
has also demonstrated that the cones can rest in a 
transverse position (106). Depending on the axis of 
the vagina, women need to produce different force in-
tensities to retain the cone. Thus, using VC as a 
measure of PFM function may not be a valid method. 
Finally, some women may find it impossible to insert 
the cones due to a narrowed vaginal opening or, con-
versely, to retain it due to an enlarged vaginal open-
ing, prolapse, or an insufficient PFM contraction, one 
incapable of holding even the lightest cone. 
This section examines the evidence for VC in the pre-
vention and treatment of UI in women. Questions ad-
dressed: 
 Are VC better than no treatment, placebo or con-
trol for the prevention of UI? 
 Are VC better than no treatment, placebo or con-
trol for the treatment of UI? 
 Are VC as effective as other treatments for the 
treatment of UI? 
 Are VC combined with PFMT better than PFMT 
alone for the treatment of UI? 
3.1. Prevention 
No previous (prior to last Consultation) or new RCT 
investigating either the primary or secondary preven-
tion effects of training with VC for women with UI were 
found. 
3.2. Treatment 
A Cochrane review specifically addressing the effec-
tiveness of VC in the treatment of UI was updated in 
March 2013 (92) This meta-analysis and four new 
studies form the basis of this subsection (79, 99, 107, 
108). Table 12 illustrates the number of studies in-
cluded in the 5th ICI and in the Cochrane review of 
Herbison et al. (92)  as well as the new studies iden-
tified in the current update. Characteristics of each 
RCT not included in the previous ICI are presented in 
Table 13. 
 
 
 
Figure 1 Weighted vaginal cones 
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Table 12 Studies of VC included in the previous review (5th ICI), in the Cochrane meta-analysis of Herbison et al. and current update (6th ICI) 
 Studies included in the previous 
review (5th ICI) 
Studies included in the Cochrane 
review of Herbison et al. 
New studies identified in this update 
(6th ICI) 
PFMT vs VCs 
(section II.2.3.3i) 
11 13 1 
PFMT/VCs vs VCs 
(section II.2.3.4i) 
2 2 0 
VCs vs no treatment, placebo or control 
treatments 
4 5 0 
VCs vs EStim 5 6 0 
PFMT/VCs vs PFMT 2 2 3 
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Table 13 Summary of data on VC 
Author, 
year 
Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/Results Follow-up Notes 
Golmakani 
2014 (1) 
 
 
PFMT (30) 
vs 
VCs (30) 
60 Women with SUI 
(at least 3 
episodes per 
week) 
Behavioral Intervention 
including PFMT: 10 to 40 
repetitions daily, 
Knack and urge, suppression 
technique, 
Bladder training 
 
VCs:  
6 cones (20 to 70 g) 
Cone held passively (without 
PFM contraction) for 15 min 
twice a day 
Active PFM contractions with 
the cone inserted (30 x 5-s 
contractions) 
Supervision included weekly 
phone call and in-person 
assessment every 2 weeks 
Detection SUI severity questionnaire 
(mild/moderate/severe): 
Sign. reduction in both groups (p≤0.04) 
Non-sign. difference btw treatments 
(p=0.52) 
Leakage index: 
Sign. reduction in both groups 
PFMT pre-Tx 16.2±4.5 to post-Tx 3.2±0.15 
(p<0.001) 
VCs pre-Tx 16.6±4.8 to post-Tx 6.1±2.5 
(p<0.001) 
Greater changes in PFMT than VCs 
(p=0.001) 
7-day diary 
Sign. reduction in both groups 
PFMT pre-Tx 1.2±1.3 to post-Tx 0.5±0.5 
(p=0.001) 
VC pre-Tx 1.0±1.0 to post-Tx 0.8±0.7 
(p=0.001) 
Non-sign. difference btw treatments 
(p=0.52) 
1-h pad test  
Sign. reduction in both groups 
PFMT pre-Tx 35.8±6.8 to post-Tx 12.8±3.8 
(p<0.001) 
VC pre-Tx 36.1±7.1 to post-Tx 19.5±5.2 
(p<0.001) 
Greater change in PFMT than VC 
(p=0.008) 
Incontinence QoL and King’s Health 
questionnaires: 
Sign. improvement in both groups. 
Non-sign. difference btw treatments 
12 weeks of 
treatment, 
treatment, 
outcomes 
assessed post-
Tx 
Dropouts: 
VCs 5/30 
PFMT 4/30 
 
 
Side effects reported 
for VCs: Candida 
vaginitis and difficulty 
with the device 
reported in 5 women 
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Author, 
year 
Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/Results Follow-up Notes 
Harvey 
2006 
(2) -  
abstract 
PFMT (19) 
vs 
VCs (25) 
44 Women with 
urodynamically 
proven SUI 
PFMT: 10 weekly sessions of 
biofeedback with trained nurse 
VCs: Hold for 15 min daily 
Cure (based on pad test): 
PFMT 2/19 
VCs 2/25 
Women from both groups decreased their 
pad weight, but 
the difference btw groups was non-sign. 
(p=.39) 
PFMT:6.0 g, 95% CI −2.3 to 14.3 
VCs: 3.0 g 95% IC 0.3 to 5.7 
UDI-6: All women 
had reduced scores, but the changes were 
neither clinically nor statistically significant 
I-QoL: Subjects in both arms showed an 
improvement on I-QoL, with no difference 
btw 
groups (p=0.86) 
10 weeks, 
outcomes 
assessed at 6 
months post-Tx 
Dropout 
PFMT: 12/29 
VCs 18/25 
 
High dropout rate- No 
potential explanations 
provided 
56 
Author, 
year 
Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/Results Follow-up Notes 
Pereira 
2012 
(3) 
VCs (15) 
vs 
PFMT (15) 
vs 
Control (15) 
45 Postmenopausal 
women with SUI 
(at least 1 
episode of 
urinary leakage 
in the previous 
month) 
VCs: 12 sessions, 2x 40 
min/week, 5 cones 20-100 g, it 
is reported that the same 
exercises as the PFMT group 
were achieved with the cone 
inserted 
PFMT: 100 
contractions/session, 6 weeks 
with twice-weekly sessions of 
40 min, 3s contraction/6s rest 
and some help for 5-10s/ 10-
20s rest 
Control: no treatment for 6 
weeks, after which they 
received physiotherapy 
1-h pad test: 
VCs pre-Tx7.36±8.76 to FU 0.36±0.38 
(p<.001) 
PFMT pre-Tx3.70±4.35 to FU 0.19±0.27 
(p<.001) 
Control pre-Tx3.87±5.56 to post Tx 
3.65±4.94 (p=.19) 
Non-significant difference btw the VC and 
PFMT groups (p=.10) 
Significant difference btw the VCs and 
control group (p<.001) 
King’s Health Questionnaire (quality of life 
- incontinence impact) 
VCs pre-Tx75.56±32.0 to FU 17.78±17.2 
(p<.001) 
PFMT pre-Tx55.82±39.32 to post-Tx 
7.69±14.6 (p<.001) 
Control pre-Tx59.98±33.81 to post Tx 
57.84±29.48 (p=.39) 
Non-significant difference btw the VC and 
PFMT groups (p=.32) 
Significant difference btw the VC and 
control groups (p<.001) 
6 weeks of 
treatment, 
outcomes 
assessed 6 
weeks after 
treatment 
 
Dropout 
VCs: 0/15 
PFMT:2/15 
Control: 2/15 
 
No adverse effects 
reported in the three 
groups 
57 
Author, 
year 
Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/Results Follow-up Notes 
Porta Roda 
2013 
(4) abstract 
and poster 
VC+PFMT (37) 
vs 
PFMT (33) 
70 SUI or stress 
predominant 
MUI in parous 
women 
VCs (vaginal sphere, pelvic 
gym) and PFMT twice/day, 5 
days/week 
PFMT same as above 
Both treatment arms were 
supervised (5 sessions) 
Subjective cure/improvement 
VC+PFMT 24/30  
PFMT 26/35 
RR 1.08 95% CI 0.83 to 1.40 (non-sign. 
difference btw groups) 
ICIQ-UI-SF: 
Sign. improvement in both groups 
(improvement occurred earlier in the 
PFMT+VC group) 
VC+PFMT pre-Tx 8.6±2.6 to post-Tx 
4.8±3.5 (p<0.01) 
PFMT pre-Tx 8.9±2.3 to post-Tx 5.7±3.5 
(p<0.01) 
PFMT+VCs showed higher improvement 
than PFMT at the 3-month visit (p<0.05) 
(non-sign. for the 6-month visit) 
1-hour pad-test: 
Sign. improvement in the PFMT+VC group 
pre-Tx3.3±4.8 to post-Tx 1.9±3.7 (p<0.01) 
Non-sign. improvement in the PFMT group 
PFMT pre- Tx 1.5±3.0 to post-Tx 1.9±3.3 
(non-sign.) 
Non-sign. difference btw treatments 
King’s Health Questionnaire (KHQ): 
Non-sign. difference from baseline and btw 
treatment 
PFMT+VC showed higher adherence to 
treatment than PFMT alone 
6 months of 
treatment, 
outcomes 
assessed at 
each visit as well 
as post-Tx 
Dropouts:  
PFMT +VCs: 2/37 
PFMT: 3/33 
 
 
Mild adverse events at 
the beginning of 
treatment (i.e. second 
treatment visit). 4 in 
PFMT + VCs 
1 in PFMT 
No events were 
reported in the 
subsequent visits 
The nature of the 
events is not specified 
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Author, 
year 
Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/Results Follow-up Notes 
Prudencio 
2014 
(5) abstract 
PFMT (51) 
vs 
PFMT+VCs (55) 
vs 
PFMT+BF (50) 
156 SUI women 3 groups received: 20 sessions 
of 45 min (twice a week for 3 
months) 
PFMT included isolated rapid 
and sustained contractions and 
functional exercises 
(differentiating just the use or 
not of associated instruments) 
(no further information was 
provided on VCs in the 
abstract) 
Cure of SUI 
PFMT+VCs 30/55 
PFMT 20/51 
RR 1.39 95% CI .91 to 2.11 
KHQ: 
All groups significantly improved from 
baseline (p<0.001) 
PFMT pre-Tx74±18 to post-Tx 43±17  
PFMT+VCs pre-Tx62±17 to post-Tx31±8 
Difference btw groups (p<0.001). It is not 
specified which of the 3 groups differed 
3 months of 
treatment, 
outcomes 
assessed post-
Tx 
Dropout not specified  
 
 
Santos 2009 
(6) 
VCs (21) 
vs 
EStim (24) 
45 Women with SUI 
(urodynamic 
diagnosis) 
VCs: Participants attended 2 
sessions of 45 min per week. 
Cones 20-100 g 
EStim: 2x 20-min weekly 
session for 4 months 
supervised by a 
physiotherapist. Intravaginal 
EStim, Frequency 50 Hz, 
Intensity10-100 mA and pulse 
duration 1 ms  
Subjective cure or improvement: 
VCs 13/21 vs EStim 14/24 
RR: 1.06 (0.66-1.71) 
Leakage episodes per day: 
VCs 0.21 (0.24) vs EStim 0.33 (0.79) 
Mean difference -0.12 (-0.45 to 0.21) 
Improvement on pad test: 
VCs 10/21 vs EStim 12/24 
RR 0.95 (0.52- 1.73) 
4 months of 
treatment with 
outcomes 
assessed post-
Tx 
No loss to follow-up 
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Author, 
year 
Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/Results Follow-up Notes 
Stupp 2011 
(7) abstract 
PFMT (22) 
 
vs 
 
PFMT+ 
proprioception 
and awareness 
training 
(including VC) 
(22) 
44 Women with SUI 
or MUI 
PFMT (3 sets of 8 contractions. 
6s contraction: 8s rest and 3 
fast contractions) verbal 
commands given by a 
physiotherapist 
PFMT + proprioception and 
awareness training, including 3 
additional sessions with a 
physiotherapist 
a) session 1: education 
(anatomy and function of the 
PFM), diaphragmatic 
breathing, visualization with a 
mirror 
b) session 2: proprioceptive 
technique with a VC 
c) session 3: PFMT contraction 
during increases in intra-
abdominal pressure (Knack) 
Subjective cure (SUI during cough): 
Combined treatment group 12/21 
PFMT alone 7/21 
RR 1.71 95% CI 0.84 to 3.48 
KHQ: 
Sign. improvement in several domains of 
the KHQ in women in the combined 
treatment. Non- sign. improvement in the 
PFMT group 
Statistical comparisons btw group are not 
reported 
 
12 weeks of 
treatment 
outcomes 
assessed post-
Tx 
Dropouts 
PFMT: 1/22 
 
PFMT + proprioception 
and awareness training 
1/22 
 
1. Golmakani  N, Khadem N, Arabipoor A, Kerigh BF, Esmaily H. Behavioral Intervention Program versus Vaginal Cones on Stress Urinary Incontinence and Related 
Quality of Life: A Randomized Clinical Trial. Oman Med J. 2014;29(1):32-8. 
2. Harvey MA, Johnston SL. A randomized, single-blind, prospective trial comparing pelvic floor physiotherapy with biofeedback versus weighted vaginal cones in the 
treatment  of female genuine stress urinary incontinence: a pilot study. Int J Urogyn J. 2006;17(Suppl 2):S235-S6. 
3. Pereira VS, de Melo MV, Correia GN, Driusso P. Vaginal cone for postmenopausal women with stress urinary incontinence: randomized, controlled trial. Climacteric. 
2012;15(1):45-51. 
4. Porta Roda O, Simo Gonzalez M, Reula Blasco MC, Diaz Lopez MA, Diaz Bellido P, Vara Paniagua J. Use of a vaginal spheres device in the conservative treatment 
of stress urinary incontinence: a randomized controlled trial Neurourol Urodyn. 2013;32(6):661-3. 
5. Prudencio C, Barbosa A, Derobio AL, Anezio A, Vesentini G, Almeida AP, editors. Comparison of three physiotherapy methods for treatment of stress urinary 
incontinence: impact in quality of life and muscle function. Proceedings of the 44th Annual Meeting of the International Continence Society (ICS), 2014 Oct 20-24, 
2014; 2014; Rio de Janeiro, Brazil. 
6. Santos PF, Oliveira E, Zanetti MR, Arruda RM, Sartori MG, Girao MJ, et al. [Electrical stimulation of the pelvic floor versus vaginal cone therapy for the treatment of 
stress urinary incontinence]. Rev Bras Ginecol Obstet. 2009;31(9):447-52. 
7. Stupp L, Yamamoto D, Fonseca T, Resende AM, Ploger C, Oliveira E. Proprioception and awareness training prior pelvic floor muscle exercises for treatment of 
urinary incontinence: randomized controlled trial. Int Urogyn J. 2011;22(Supp 1):S162-S4. 
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3.2.1 Are VC Better than No Treatment, Pla-
cebo or Control Treatments? 
The meta-analysis published by Herbison et al. (92)  
comprised 5 RCTs comparing VC to a control treat-
ment. Except for Pereira et al. (94) (presented in Ta-
ble 13), these studies were part of the ICI previous 
edition. Our literature search identified no further 
RCT. 
Quality of data 
In the study of Pereira et al. (94), adequate allocation 
concealment and randomisation was reported. The 
evaluator was however not blinded to patient assig-
nation. No attrition was reported in the VC group while 
13% dropped out from the control group. No adverse 
effects were reported in this RCT. 
Results 
As discussed in Herbison et al.’s meta-analysis (92), 
women in the VC groups were more likely to report 
they were cured than the controls (RR for failure 0.84, 
95%CI 0.76 to 0.94). VCs were also better than con-
trol treatment in the subjective reporting of cure or im-
provement (RR for failure 0.72, 95%CI 0.52 to 0.99). 
Further, Pereira et al. (94) reported better inconti-
nence-related QOL and a significant reduction in the 
1-h pad test for women in the VC group compared to 
the control treatment. 
Summary 
VCs with supervised training sessions by a trained 
health professional are better than control treatments 
for subjective reporting of cure or cure/improvement 
and the QOL impact on the treatment of SUI (Level 
of Evidence: 1).  
However, VC treatment may be inappropriate in 
some cases due to potential reported side effects 
(92). 
Recommendations 
For women with SUI, VCs with supervised training 
sessions by a trained health professional may be of-
fered as a first-line conservative therapy to those who 
can and are prepared to use them (Grade of Recom-
mendation: B) 
Trained health professional assessment is recom-
mended. VC may be inappropriate in some cases due 
to inability to insert or retain the cone or because of 
side effects and discomfort. (Grade of Recommen-
dation: D). 
3.2.2 Are VC As Effective as Other Treat-
ments? 
VC have been compared with PFMT and EStim, but 
not with other therapies such as drug treatment, BT 
or surgery. 
i) VC versus PFMT 
This comparison is addressed in Section II.2.3.3. De-
tails of the VC and PFMT programs for each trial are 
presented in Table 13.  
ii) VC versus EStim 
Since the last ICI edition, a meta-analysis update was 
published. (92) It comprised the same trials as in the 
ICI 5th edition as well as the study of Santos et al. 
(109) (presented in Table 13). Our literature search 
revealed no further trials. 
Quality of data 
i) VC versus PFMT: See Section II.2.3.3.  
ii) VC versus EStim  
In the study of Santos et al. (109), participants were 
randomly assigned to treatments while blinding of as-
sessors and allocation concealment were not clearly 
reported. No losses to follow-up were reported (109). 
Results 
i) VC versus PFMT: See Section II.2.3.3. 
ii) VC versus EStim 
As reported in the Herbison et al. meta-analysis (92), 
there was no statistically significant difference be-
tween VC and EStim in the pooled data of three trials 
with regard to self-reported cure (RR for failure 1.26 
95% CI 0.85 to 1.87). Non-significant differences also 
emerged from the pooled data of three RCTs with re-
spect to improvement in pad test (RR 1.21 95%CI 
0.90 to 1.63) and leakage episodes (Mean difference 
-0.05 95% CI -0.27 to 0.17). Herbison et al. (92)  re-
ported discomfort or side effects associated to both 
EStim and VC (VC: abdominal pain, vaginitis, bleed-
ing, motivational problems and difficulties using the 
VC. EStim: tenderness and bleeding, discomfort or 
motivational and other difficulties in using the EStim).  
Summary 
The meta-analysis of Herbison et al. (92)  including 
six RCTs revealed no significant difference between 
VCs and EStim in terms of self-reported cure, 
cure/improvement, improvement in pad test or the 
number of leakage episodes; both the VC and EStim 
groups reported adverse events.  
VC and EStim seem equally effective in the treatment 
of SUI and MUI. (Level of Evidence: 1). Side effects 
and discomfort appear to limit their utility in clinical 
practice. (Grade of Recommendation: D). 
3.2.3 Are VC Combined with PFMT Better 
than PFMT Alone? 
Both Herbison et al.’s meta-analysis(92)  and the ICI 
5th edition relied on two RCTs comparing combined 
PFMT/VC to PFMT alone. Our search revealed three 
additional studies presented as published abstracts 
(79, 107, 108). Details of the PFMT/VC and PFMT are 
presented in Table 13. 
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Quality of data 
Limited information on method and results were avail-
able from these published abstracts (79, 107, 108). 
Although participants were randomly assigned, no in-
formation on allocation concealment and blinding of 
assessors was provided. The sample sizes were  rel-
atively small with no more than 39 patients per treat-
ment arm. Dropouts ranged from 0 (79) to 13% (108) 
in the PFMT group and 0% (79, 108) to 5% (107) in 
the combined treatment. 
Results 
Including two RCTs, Herbison’s meta-analysis re-
ported no significant differences between PFMT/VC 
and PFMT alone for either cure or cure/improvement. 
Likewise, the results from the three additional RCT 
failed to show any significant difference between 
treatments in terms of subjective cure (79, 108) and 
subjective cure/improvement (107). Porta Roda et al. 
reported that improvement occurred earlier in the 
combined group (after 3 months of treatment) but this 
was not maintained at the end of the treatment (6 
months of treatment) (107). 
Summary 
Limited evidence suggests no benefit from adding 
VCs to PFMT for women with SUI (Level of Evi-
dence: 2). 
Recommendations 
No recommendation is possible for combination inter-
vention. Adequately powered studies are needed to 
confirm or refute the advantages of adding VCs to 
PFMT (No Recommendation).   
3.3. Other Lower Urinary Tract Symptoms 
(LUTS) 
In the previous ICI, two RCTs reported data on the 
efficacy of VC on urgency and nocturia (Williams et 
al. 2006) and nocturia (Gameiro et al. 2010). Our 
search revealed no new RCTs on other lower urinary 
tract symptoms. 
3.4. Factors Affecting Outcome 
None of the RCTs above addressed the effect of age 
or other factors on the outcome of VC training. None-
theless, in the 22 RCTs included here, on average, 
22% of the women being treated with VCs (range 0 to 
63%) withdrew from the study or dropped out. Alt-
hough few RCTs examined the causes of attrition, 
among those that reported causal factors low compli-
ance, motivational problems, unpleasantness, aes-
thetic dislike, discomfort, and bleeding were impli-
cated although no one reason predominated. 
4. ELECTRICAL STIMULATION 
(ESTIM) 
The theoretical basis of neuromuscular electrical 
stimulation (EStim) interventions has emerged with 
increasing understanding of the neuroanatomy and 
physiology of the central and peripheral nervous sys-
tems. The mechanisms of action vary depending on 
the cause(s) of UI and the structure(s) being targeted 
e.g. PFM or detrusor, peripheral or central nervous 
system. In general, the aim of EStim for SUI appears 
to be to increase proprioception and/or to improve the 
muscle function of an atrophied or weak PFM, while 
for UUI the objective seems to be to inhibit detrusor 
overactivity (DO) (1).  
EStim is provided by clinic-based mains powered ma-
chines or portable battery powered stimulators (Fig-
ure 2) with a seemingly infinite combination of current 
types, waveforms, frequencies, intensities, electrode 
types and placements (Figure 3). Without a clear bio-
logical rationale, it is difficult to make choices about 
different ways of delivering EStim. Additional confu-
sion is created by the relatively rapid developments 
in the area of EStim, and a wide variety of stimulation 
devices and protocols that have been developed 
even for the same condition.  
Finally, the nomenclature used to describe EStim re-
mains inconsistent. EStim has not only been de-
scribed based on the type of current being used (e.g. 
faradic, interferential), but also on the structures tar-
geted (e.g. neuromuscular), the current intensity (e.g. 
 
Figure 2 Neuromuscular electrical stimulation equip-
ment 
 
Figure 3 Neuromuscular electrical stimulation elec-
trodes 
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low-intensity, or maximal stimulation), and the pro-
posed mechanism of action (e.g. neuromodulation). 
In this section, EStim type and parameters are re-
ported in line with International Continence Society 
definitions (1). 
This section presents the evidence for the use of ES-
tim in the prevention and treatment of UI in women. 
Questions addressed are:  
 Is EStim effective in the prevention of UI? 
 Is EStim better than no active treatment (pla-
cebo, sham, control or no treatment) for treat-
ment of UI? 
 Is one type of EStim better than another in the 
treatment of UI? 
 Is EStim better than other treatments in the treat-
ment of UI? 
 Does the addition of EStim to other treatments 
add any benefit in the treatment of UI? 
 What is the effect of EStim on other LUTS? 
 What factors might affect the outcome of EStim 
in the treatment of UI? 
Eligible interventions were non-invasive EStim with-
out implanted electrodes. (Magnetic stimulation and 
posterior tibial nerve stimulation are described in Sec-
tions II.5 and II.6). Other criteria for inclusion were (1) 
randomised or quasi-randomised (alternate alloca-
tion) trial design, (2) women with UI or other LUTS, 
(3) no participants with incontinence due to neurolog-
ical or cognitive impairment and (4) no pregnant or 
postpartum women (within 12 months of childbirth). 
Trial data reported in conference abstracts as well as 
full-text papers were included. EStim compared with 
PFMT and vaginal cones are covered in previous sec-
tions (sections II.2.3.3 and II.3.2.2). This section fo-
cuses on EStim compared with no active treatment or 
other conservative treatments.  
The primary outcomes were cure rates (the number 
of women with no urinary incontinence episode at 
time of assessment) and improvement rates (the 
number of women improved, including cure). There 
was considerable variability in the way these out-
comes were measured. Women’s self-report was 
given priority but for studies in which it was not re-
ported, the rate based on diaries was used as a 
proxy; where diary data were also not reported, the 
rate based on pad tests or any other definitions cho-
sen by the trialists was used (110). Data on health-
related quality of life and adverse effects were also 
extracted. Data at the end of the prescribed treatment 
phase, or at the first outcome measurement, if later, 
were used in the analysis. Any treatment effects 
shown are likely to reflect maximum effect of each in-
tervention. Data from further follow-up were also rec-
orded.  
Due to the small number of available studies per in-
tervention, data were sub-grouped by dominant type 
or pattern of incontinence: (1) studies with all or at 
least 50% of participants having SUI alone or a pre-
dominant symptom of SUI (as defined by trial investi-
gators), (2) studies with all or >50% of participants 
having UUI alone or a predominant symptom of UUI 
(as defined by trial investigators), (3) other studies of 
participants with UI in which neither stress- or ur-
gency-UI represented a predominant symptom in the 
study population (‘UI all types’ hereafter), and (4) 
studies of overactive bladder (OAB) or DO in which it 
was unclear whether all participants had UI.  
Single EStimates with 95% confidence intervals (CI) 
were derived for each study comparison using odds 
ratios (OR) for dichotomous variables or mean differ-
ence (MD) for continuous variables. Summary ESti-
mates were calculated using random effects models 
if there was more than one study reporting the same 
outcome (meta-analysis).  
‘Risk of bias’ in the included studies was assessed for 
allocation concealment (selection bias) and com-
pleteness of outcome data (attrition bias), using rele-
vant items in a standard tool developed by the 
Cochrane Urinary Incontinence Group (111). Risk of 
bias regarding blinding to the allocated intervention 
was high in most included studies: blinding of partici-
pants and care providers is not always feasible (other 
than the use of sham EStim), and blinding of outcome 
assessors is equally difficult for self-reported out-
comes such as cure, improvement and quality of life.  
Description of intervention in included studies of 
EStim 
Nine new trials were identified for this update, making 
a total of 42 trials included in this section. All new tri-
als targeted women with SUI or predominant SUI. No 
new studies for predominant UUI, DO or OAB (incon-
tinent or not) were found for this update. Findings for 
UUI, UI all types, DO and OAB are therefore un-
changed from 5th ICI. The number of included studies 
by dominant type or pattern of incontinence is sum-
marised in Table 14. 
In addition, there was one study, published in Portu-
guese, which was a three-arm trial comparing EStim 
and PFMT (N = 24), PFMT (N = 25) and control (N = 
22) (112). This trial could not be incorporated here, 
as an English translation was not available.  
The EStim parameters and protocols in this section 
are summarised in Table 15. Some approaches to 
treatment are now less common, such as the use of 
interferential current or external electrodes. There 
was considerable variation in the intervention proto-
col. Although the biological rationale and purpose of 
EStim might be different depending on diagnosis, 
there was no consistency in the EStim protocols used 
for women with SUI, UUI, UI all types, or DO.  
4.1. Prevention 
No published trials were found. 
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Table 14 Studies of EStim included in the previous review (5th ICI) and current update (6th ICI) 
 
Studies included in the previous 
review (5th ICI) 
New studies identified in this 
update (6th ICI) 
Total 
EStim vs No active treatment 
    SUI or predominant SUI 
    UUI or predominant UUI 
    UI all types 
    DO/OAB (dry or wet) 
 
9 
3 
2 
3 
 
4 
0 
0 
0 
 
13 
3 
2 
3 
One type of EStim vs another 
    SUI or predominant SUI 
    UUI or predominant UUI 
    DO/OAB (dry or wet) 
 
2 
0 
2 
 
4 
0 
0 
 
6 
0 
2 
EStim vs other treatment 
    SUI or predominant SUI 
    UUI or predominant UUI 
    DO/OAB (wet or dry) 
 
1 
1 
4 
 
No study found 
 
 
1 
1 
4 
EStim+PFMT vs PFMT 
    SUI or predominant SUI 
 
    UUI or predominant UUI 
    UI all types 
 
8 (no BF) 
2 (with BF) 
0 
2 (no BF) 
 
2 (no BF) 
1 (with BF) 
0 
0 
 
10 
3 
0 
2 
BF = biofeedback 
Table 15 Summary of EStim protocols 
Author, year Current 
Current 
Intensity 
Pulse Shape & 
Duration 
Frequency (Hz) Duty Cycle Electrodes 
Treatment 
Duration 
Target UI 
Alves 2011 (1) Biphasic Max tolerable 
intensity 
Study arm 1: 
100ms; 
Study arm 2: 
700ms 
Study arm 1: 
medium frequency 
2000Hz; 
Study arm 2: low 
frequency 50Hz 
Single ratio: 1:2 (4s on, 
8s off) 
Single vaginal electrode 20min session, 2x 
a week: 6wks 
SUI 
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Author, year Current 
Current 
Intensity 
Pulse Shape & 
Duration 
Frequency (Hz) Duty Cycle Electrodes 
Treatment 
Duration 
Target UI 
Correia 2014 (2) 
 
Biphasic  Max tolerable 
intensity 
Duration: 
700µsec 
Single freq: 50Hz Single ratio: 1:2 (4s on, 
8s off) + 2s rise, 2s fall 
Study arm 1: 4 electrodes 
(2 in the suprapubic 
region and 2 medial to 
the ischial tuberosity); 
Study arm 2: Single 
vaginal electrode 
20min session, 2x 
a week, by 
physiotherapist: 
6wks 
SUI 
Huebner 2011 (3) 
 
NR Range 20-
80mA 
NR Single freq: 50Hz Study arm 1: Active 
contracting of PFM 8s. 
After reaching the 
maximum contraction, 
electrical stimulation was 
added for 8s. Resting 
15s; 
Study arm 2: Stimulation 
8s. Resting 15s. Active 
contracting of PFM 8s. 
Resting 15s. 
Single vaginal electrode 15min session, 2x 
a day, home 
treatment with 5 
clinic visits: 12wks 
SUI 
Jeyaseelan 2003* 
(4) 
NR NR NR Range not defined A longer duty cycle than 
is traditionally used 
NR NR SUI 
Lopès 2014 (5) Rectangular 
biphasic 
NR Duration: 
400µsec 
3 frequencies 
available: 50Hz for 
SUI, 20Hz for MUI, 
12.5Hz for pure 
urgency 
NR Vaginal electrode 20min session, 3x 
a day, home 
treatment: 6mths 
SUI 
Maher 2009* (6) NR NR NR NR NR Study arm 1: external 
electrodes; Study arm 2: 
single vaginal electrode 
30min session, 4x 
a week, home 
treatment: 8wks 
(outcome 
reported at 4wks) 
SUI 
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Author, year Current 
Current 
Intensity 
Pulse Shape & 
Duration 
Frequency (Hz) Duty Cycle Electrodes 
Treatment 
Duration 
Target UI 
Patil 2010 (7) 
 
Interferential Max tolerable 
intensity 
NR Freq range: 0-
100Hz 
NR 4 electrodes (2 flat 
electrodes placed 
anteriorly over the 
obturator foramen, and 2 
electrodes placed 
posteriorly medial to 
ischial tuberosity on 
either side of the anus) 
First session 
15min, other 
sessions 30min, 
3x a week, by 
physiotherapist: 
4wks. 
SUI 
Pereira 2012 (8) 
 
NR Max tolerable 
intensity 
Duration: 
700µsec 
Single freq: 50Hz Single ratio: 1:2 (4s on, 
8s off) 
4 electrodes (2 in the 
suprapubic region and 2 
medial to the ischial 
tuberosity) 
20min session, 2x 
a week, by 
physiotherapist: 
6wks 
SUI 
Terlikowski 2013 
(9) 
NR NR 200 to 250µsec Freq range: 10-
40Hz 
Single ratio: 1:2 (15s on, 
30s off) 
Single vaginal electrode 20min session, 2x 
a day, home 
treatment: 8 
weeks..  
SUI 
* abstract only. 
Footnotes: EStim = electrical stimulation, freq= current frequency, PFM = Pelvic floor muscle, PFMC= Pelvic floor muscle contraction, VPFMC= voluntary Pelvic floor 
muscle contraction 
1. Alves PG, Nunes FR, Guirro EC. Comparison between two different neuromuscular electrical stimulation protocols for the treatment of female stress urinary inconti-
nence: a randomized controlled trial. Revista Brasileira de Fisioterapia. 2011;15(5):393-8. 
2. Correia GN, Pereira VS, Hirakawa HS, Driusso P. Effects of surface and intravaginal electrical stimulation in the treatment of women with stress urinary incontinence: 
randomized controlled trial. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2014;173(1):113-8. 
3. Huebner M, Riegel K, Hinninghofen H, Wallwiener D, Tunn R, Reisenauer C. Pelvic floor muscle training for stress urinary incontinence: a randomized, controlled 
trial comparing different conservative therapies. Physiother Res Int. 2011;16(3):133-40. 
4. Jeyaseelan S, Oldham JA. Can the effects of pelvic floor muscle exercises be enhanced with a new pattern of electrical stimulation in women with stress incontinence 
(Abstract). Proceedings of the World Confederation for Physical Therapy (WCPT), 14th International Congress, 7-12 June, Barcelona. 2003. 
5. Lopès P, Rimbault F, Scheffler M, Andre C, Cappelletti MC, Mares P. [Multicentric prospective randomized and controlled study assessing effectiveness of intravaginal 
electrostimulation at home compared to usual care in female patients with urinary incontinence and prior perineal reeducation]. [French]. Gynecologie, Obstetrique & 
Fertilite. 2014;42(11):779-86. 
6. Maher RM, Crowe L, Caulfield B. Comparison of two methods of electrical muscle stimulation training of pelvic floor musculature in the treatment of stress urinary 
incontinence (Abstract). Journal of Women's Health Physical Therapy. 2009;33(1):24. 
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7. Patil SP, Nagrale AV, Ganvir SD. Additive effect of interferential therapy over pelvic floor exercises. International Journal of Therapy & Rehabilitation. 2010;17(11):596-
602. 
8. Pereira VS, Bonioti L, Correia GN, Driusso P. [Effects of surface electrical stimulation in older women with stress urinary incontinence: a randomized controlled pilot 
study]. [Spanish]. Actas Urologicas Espanolas. 2012;36(8):491-6. 
9. Terlikowski R, Dobrzycka B, Kinalski M, Kuryliszyn-Moskal A, Terlikowski SJ. Transvaginal electrical stimulation with surface-EMG biofeedback in managing stress 
urinary incontinence in women of premenopausal age: a double-blind, placebo-controlled, randomized clinical trial. International Urogynecology Journal. 
2013;24(10):1631-8. 
Table 16 Summary of data on EStim vs no active treatment 
Author, year Comparator 
N 
randomised 
Study population 
Duration 
(months) 
Outcome** 
SUI or predominantly SUI 
Correia 2014 (1) ES (31)  
vs  
No treatment (17)  
48 SUI alone 1.5 Cure: NR Improvement: NR 
QoL via KHQ 
Surface ES vs no treatment, N = 32, mean difference 54.45 lower, 95% 
CI 73.44 to 35.46 lower; 
Vaginal ES vs no treatment, N = 32, mean difference 56.67 points 
lower, 95% CI 75.30 to 38.04 lower 
Adverse effects: NR 
Lopès 2014 (2) ES (78)  
vs  
No treatment (86) 
164 SUI or SUI-
predominant MUI 
6 Cure: NR 
Self-reported improvement: 63/76 vs 58/85 
QoL via ICIQ: N = 161, mean difference in change from baseline 3.10 
lower, 95% CI 4.39 to 1.81 lower 
Adverse effects: reported with no detail  
Pereira 2012 (3) ES (7)  
vs  
No treatment (7) 
14 SUI alone 1.5 Cure: NR Improvement: NR 
QoL via KHQ: N = 14, mean difference 42.95 lower, 95% CI 70.74 to 
15.16 lower 
Adverse effects: no events noted 
Terlikowski 2013 (4) ES + BF† (68)  
vs  
Sham ES + BF† (34) 
102 USI alone 2 Self-reported cure: 29/64 vs. 2/29 
Self-reported improvement: 41/64 vs 6/29 
QoL via I-QoL: N = 93 at 8 weeks (end of treatment), mean difference 
22.3 higher, 95% CI 15.52 to 29.08 higher; N = 93 at 16 weeks (8 8 
weeks after treatment), mean difference 30.20 higher, 95% CI 22.18 to 
38.22 higher 
Adverse effects: smarting and discomfort 
Note: For modality details or parameters, see Table 14. 
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NR = not reported; ICIQ = International Consultation of Incontinence Questionnaire (higher scores indicate greater impact on QoL, i.e. a higher score indicates a lower 
QoL); I-QoL = Incontinence Quality of Life Questionnaire (higher scores indicate higher QoL); KHQ = King’s Health Questionnaire (higher scores indicate greater impair-
ment);  
**Source of cure and improvement outcome: women’s self-report was given priority but for studies in which it was not reported, quantification of outcomes based on 
diaries, pad tests or any other definitions chosen by trialists were used as a proxy.  
† Electromyography-assisted biofeedback 
1. Correia GN, Pereira VS, Hirakawa HS, Driusso P. Effects of surface and intravaginal electrical stimulation in the treatment of women with stress urinary incontinence: 
randomized controlled trial. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2014;173(1):113-8. 
2. Lopès P, Rimbault F, Scheffler M, Andre C, Cappelletti MC, Mares P. [Multicentric prospective randomized and controlled study assessing effectiveness of intravaginal 
electrostimulation at home compared to usual care in female patients with urinary incontinence and prior perineal reeducation]. [French]. Gynecologie, Obstetrique & 
Fertilite. 2014;42(11):779-86. 
3. Pereira VS, Bonioti L, Correia GN, Driusso P. [Effects of surface electrical stimulation in older women with stress urinary incontinence: a randomized controlled pilot 
study]. [Spanish]. Actas Urologicas Espanolas. 2012;36(8):491-6. 
4. Terlikowski R, Dobrzycka B, Kinalski M, Kuryliszyn-Moskal A, Terlikowski SJ. Transvaginal electrical stimulation with surface-EMG biofeedback in managing stress 
urinary incontinence in women of premenopausal age: a double-blind, placebo-controlled, randomized clinical trial. International Urogynecology Journal. 
2013;24(10):1631-8. 
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4.2. Treatment 
4.2.1 Is EStim Better than No Active Treat-
ment (Placebo, Sham, Control or No 
Treatment) for Treatment of UI? 
Four new studies including 267 women with SUI or 
predominant SUI (113-116). Participants in one of 
these studies were women who had responded posi-
tively to physiotherapy treatment for their UI (10-15 
sessions), with EStim used to maintain the benefit of 
initial physiotherapy (114). One study (115) was a pi-
lot study for a newly identified study (113).  
Characteristics of the new studies comparing EStim 
with no active treatment are presented in Table 16. 
No active treatment consisted of no treatment (113, 
115), sham EStim (116) or usual care (114). One 
study was a three-arm trial. Two of the arms using 
surface and intravaginal EStim (N = 31) were com-
bined and compared with the ‘no treatment’ arm (N = 
17) (113). 
Quality of data 
Three studies reported adequate methods of alloca-
tion concealment, namely third party involvement 
(113, 116) or opaque (and sealed) envelopes with 
third party involvement (115) in the allocation proce-
dure. One study did not describe methods used for 
allocation concealment (116). Trial results were re-
ported for everyone who entered the trial in one study 
(115) but this was not done in the others. One study 
is funded by the manufacturer of the study stimulator 
(114).  
Results 
SUI or predominant SUI. When adding new studies 
to those previously reported, pooled data suggest 
that cure rates were, on average, higher for EStim 
compared with no active treatment but the difference 
was not statistically significant (N = 434, 22% vs 5%, 
OR 2.43, 95% CI 0.89 to 6.60) (116-123). Improve-
ment rates were statistically significantly higher for 
EStim compared with no active treatment (N = 613, 
53% vs 30%, OR 3.64, 95% CI 1.82 to 7.27) (114, 
116-118, 120-124), although there was some evi-
dence of statistical heterogeneity for the improvement 
rate (I-squared = 45%). The result of this meta-anal-
ysis using additional data from newly identified stud-
ies remains similar to the analysis performed in the 
5th ICI, except that effect size was larger and confi-
dence interval for cure was wider, and effect size was 
smaller and confidence interval was narrower for im-
provement.  
Quality of life was reported in seven studies, using di-
verse measures. Six studies, including 4 new studies, 
found statistically significant differences favouring 
EStim compared with no active treatment (113-116, 
118, 119), and one previous study found no signifi-
cant differences between the groups (125). All new 
studies that reported this outcome favoured EStim: 
one (114) used the International Consultation on In-
continence Questionnaire (ICIQ), one (116) used the 
Incontinence Quality of life (I-QoL) questionnaire, and 
two used the King’s Health Questionnaire (KHQ) 
(113, 115).  
Adverse effects appeared uncommon. One new 
study reported bleeding in one and discomfort in 
three of 64 participants using the active EStim device 
and none of 29 participants in the sham EStim device 
(116). This is in line with two previous studies that re-
ported tenderness and bleeding (118), and vaginal ir-
ritation, pain or infection (123) associated with the de-
vice. Another study reported that one participant each 
in the treatment (N = 78) and control (usual care; N = 
86) groups was lost to follow-up due to adverse ef-
fects (no further detail was provided) (114). 
Summary 
A total of 21 studies assessed the effect of EStim 
compared with no active treatment, including 13 in 
women with SUI or predominant SUI, three in UUI or 
predominant UUI, two in all types of UI, and three in 
DO/OAB (incontinent or no). 
Findings from update analysis using the additional 
data from newly identified studies were broadly simi-
lar to those from the 5th ICI. Included studies were 
generally assessed as having a high risk of bias.  
EStim might be more effective than no treatment in 
improving symptoms and quality of life in women with 
SUI and improving symptoms in women with UUI, alt-
hough this may not result in cure (Level of Evidence: 
2).  
Information on quality of life was sparsely reported 
particularly for UUI or DO, and the limited data that 
were available were not consistent. Adverse effects 
appear uncommon but some women experienced 
discomfort with the treatment device. Scant data were 
available on long-term performance.  
Recommendations 
EStim might be better than no treatment to improve 
symptoms and quality of life in SUI women (Grade of 
Recommendation: B).  
EStim may be considered for treatment to improve 
symptoms for UUI (Grade of Recommendation: B).  
However, this recommendation should be viewed 
with caution until the findings are supported or refuted 
in further trials; it would be particularly useful if further 
trials used validated and reliable quality life measures 
as a primary outcome indicator particularly for UUI. 
4.2.2 Is One Type of EStim Better than An-
other in the Treatment of UI? 
Four new studies including 145 women with SUI and 
predominant SUI (113, 126-128) were found. The 
characteristics of the new studies comparing one type 
of EStim with another are presented in Table 17. Dif-
ferent variants of EStim were assessed, either alone 
(113, 126, 128) or as an adjunct to PFMT and bio-
feedback (127).
69 
Table 17 Summary of data on different types of EStim comparisons  
Author, 
year 
Comparator 
N 
randomised 
Study 
population 
Duration 
(months) 
Outcome** 
SUI or predominantly SUI 
Alves 2011 
(1) 
Medium 
frequency ES 
vs 
Low frequency 
ES (number 
per group not 
reported) 
24 SUI alone 1.5 Cure based on pad test: 10/10 vs 
10/10 
Improvement: NR 
QoL: NR 
Adverse effects: NR 
Correia 
2014 (2) 
Surface ES 
(15) 
vs  
Vaginal ES 
(16) 
31 SUI alone 1.5 Cure: NR 
Improvement: NR 
QoL via KHQ: N = 30, mean 
difference 2.22 higher, 95% 6.95 
lower to 11.39 higher 
Adverse effects: NR 
Huebner 
2011 (3) 
Dynamic ES +  
PFMT + BF† 
(36) 
vs  
Conventional 
ES + PFMT + 
BF† (36) 
72 SUI or SUI-
predominant 
MUI 
3 Cure: NR 
Improvement: NR 
QoL via KHQ: N = 61, mean 
difference in change from baseline 
4.10 lower, 95% CI 6.77 to 1.43 
lower 
Adverse effects: allergic reaction to 
lubricant 
Maher 
2009* (4) 
(ongoing) 
External ES  
vs  
Vaginal ES  
(number per 
group not 
reported) 
18 SUI alone 2 (outcome 
measured 
at 1 month) 
Cure: NR 
Improvement: NR 
QoL: NR 
Adverse effects: NR 
Note: For modality details or parameters, see Table 14. 
NR = not reported; KHQ = King’s Health Questionnaire (higher scores indicate greater impairment); 
* abstract only;  
**Source of cure and improvement outcomes: women’s self-report was given priority but for studies in which it 
was not reported, quantification of outcomes based on diaries, pad tests or any other definitions chosen by 
trialists was used as a proxy.  
† Electromyography-assisted biofeedback 
1. Alves PG, Nunes FR, Guirro EC. Comparison between two different neuromuscular electrical stimulation 
protocols for the treatment of female stress urinary incontinence: a randomized controlled trial. Revista 
Brasileira de Fisioterapia. 2011;15(5):393-8. 
2. Correia GN, Pereira VS, Hirakawa HS, Driusso P. Effects of surface and intravaginal electrical stimulation 
in the treatment of women with stress urinary incontinence: randomized controlled trial. European Journal 
of Obstetrics and Gynecology and Reproductive Biology. 2014;173(1):113-8. 
3. Huebner M, Riegel K, Hinninghofen H, Wallwiener D, Tunn R, Reisenauer C. Pelvic floor muscle training 
for stress urinary incontinence: a randomized, controlled trial comparing different conservative therapies. 
Physiother Res Int. 2011;16(3):133-40. 
4. Maher RM, Crowe L, Caulfield B. Comparison of two methods of electrical muscle stimulation training of 
pelvic floor musculature in the treatment of stress urinary incontinence (Abstract). Journal of Women's 
Health Physical Therapy. 2009;33(1):24. 
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One study comparing external and vaginal EStim for 
women with SUI, available only as an abstract, did 
not report any of the specified outcomes and thus did 
not contribute to the analysis (128). Since there is lit-
tle duplication of EStim interventions, it was not 
thought appropriate to combine study findings.  
Quality of data  
Allocation concealment was adequate in one study 
which involved a third party in the allocation proce-
dure (113). The other three studies did not mention 
allocation concealment (126-128). Data were re-
ported only for those who completed the trial in two 
studies (126, 127) but it was unclear in the other two 
studies if trial results were reported for everyone who 
entered the trial (113, 128).  
Results 
SUI or predominant SUI. One new small study com-
paring medium and low frequency EStim found no dif-
ference for cure rates (126). The results for improve-
ment rates are as reported in two previous studies 
(129, 130).  
While no information was available on quality of life 
and adverse effects in the 5th ICI, two new studies re-
ported quality of life using the KHQ. The first study 
comparing ‘dynamic’ EStim (contract pelvic floor 
muscles, and then add stimulation at maximal con-
traction) with ‘conventional’ EStim (perform stimula-
tion, rest, and contract pelvic floor muscles) found a 
statistically significant difference favouring ‘dynamic’ 
ES, although study authors considered the difference 
to be small and not clinically important (127). The sec-
ond study comparing surface and vaginal EStim 
found no statistically significant difference between 
the groups (113).  
One new study in which EStim was performed as an 
adjunct to PFMT and biofeedback reported that one 
of 72 participants had an allergic reaction to biofeed-
back lubricant and withdrew from the study, although 
it was unclear in which group these adverse effects 
occurred (127).  
Summary 
A total of eight studies assessed the effect of one ap-
proach of EStim compared with another, with six in 
women with SUI and predominant SUI and two in 
women with DO. No study focusing on UUI or pre-
dominant UUI was identified.  
Findings from an updated analysis using the addi-
tional data from newly identified studies were broadly 
similar to those from the 5th ICI. Included studies gen-
erally had a high risk of bias. There were eight small 
trials comparing different EStim protocols; the clinical 
heterogeneity between studies meant it was not ap-
propriate to pool the data.  
Based on a single trial (130) for women with SUI, 
maximal clinic-based stimulation may be more effec-
tive than low-intensity home-based stimulation in im-
proving symptoms, although no data were available 
on cure rates, quality of life and adverse effects 
(Level of Evidence: 2).  
The other studies did not find clinically important dif-
ferences between stimulation groups for the specified 
outcomes; the studies were small and may have been 
underpowered. Further comparisons of EStim proto-
cols are needed. 
Recommendations  
For women with SUI maximal clinic-based EStim 
might be better than daily low-intensity home-based 
EStim in improving symptoms (Grade of Recom-
mendation: B).  
There is a need for studies to elucidate the purpose 
and biological rationale for EStim in different diagnos-
tic groups, so these can then be tested and compared 
in clinical trials. 
4.2.3 Is EStim Better than Other Treatments 
for UI? 
No new study was found that investigated whether 
EStim is better than other treatments for UI. The level 
of evidence and recommendations remains un-
changed from the previous review (5th ICI) formed on 
the basis of six studies (124, 131-135).  
Summary 
The 5th ICI included six studies, including one in 
women with SUI, one in women with predominant 
UUI, and four in women with OAB/DO (wet or dry).  
Included studies were generally assessed as having 
a high risk of bias. With small numbers per compari-
son group available, there is insufficient evidence to 
determine if EStim is better than vaginal oestrogens 
in women with SUI, propantheline bromide in women 
with UUI, or oxybutynin and tolterodine for DO (Level 
of Evidence: 2).  
Recommendation 
Based on current limited evidence, EStim could be 
considered as an alternative to medical treatment. 
Medical treatments (drugs) appear to be no more ef-
fective than EStim (Grade of Recommendation: B). 
These findings need to be investigated further with 
high quality trials, if it is a clinical question of interest 
to women.  
4.2.4 Does the Addition of EStim to Other 
Treatments Add Any Benefit in the 
Treatment of UI? 
Three new studies including 52 women including 
women with SUI and predominant SUI were found 
(127, 136, 137). The characteristics of these new 
studies are presented in Table 18. Two studies (136, 
137) combined EStim with PFMT (EStim + PFMT vs 
PFMT), while the other (127) combined EStim with 
PFMT and biofeedback (EStim + PFMT + BF vs 
PFMT + BF).. 
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Table 18 Summary of data on EStim + another treatment vs the other treatment 
Author Comparator N randomised 
Study 
population 
Duration 
(months) 
Outcome** 
SUI or predominantly SUI 
Jeyaseelan 
2003* (1) 
ES + PFMT 
(6?)  
vs  
PFMT (7?) 
13? SUI alone 2 Cure: NR 
Improvement: NR 
QoL via IIQ (% change from 
baseline): N = 6, median -27%, 
range -63 to 0, vs. N = 7, median 
0%, range -67 to 200 
QoL via UDI (% change from 
baseline): N = 6, median -32%, 
range -50 to -18, vs. N = 7, 
median 0%, range -43 to 180 
Adverse effects: NR 
Patil 2010 (2) ES + PFMT 
(55) 
vs  
PFMT (55) 
13 USI alone 1 Cure: NR 
Improvement: NR 
QoL via IIQ: N = 102, mean 
difference 12.53 lower, 95% CI 
19.45 to 5.61 lower 
Adverse effects: NR 
Huebner 2011 
(3) 
ES + PFMT + 
BF† (72) 
vs  
PFMT + BF† 
(36) 
26 SUI or SUI-
predominant 
MUI 
3 Cure: NR 
Improvement: NR 
QoL via KHQ  
Dynamic ES+PFMT+BF vs 
PFMT+BF: N = 55, mean 
difference in change from baseline 
4.60 lower, 95% CI 7.43 to 1.77 
lower;  
Conventional ES+PFMT+BF vs 
PFMT+BF: N = 60, mean 
difference in change from baseline 
0.50 lower, 95% CI 3.22 lower to 
2.22 higher 
Adverse effects: allergic reaction 
to lubricant  
Note: For modality details or parameters, see Table 14. 
NR = not reported; IIQ = Incontinence Impact Questionnaire (lower scores indicate better QoL); KHQ = King’s 
Health Questionnaire (higher scores indicate greater impairment); UDI = Urogenital Distress Inventory (higher 
scores indicate greater discomfort);  
**Source of cure and improvement outcome: women’s self-report was given priority but for studies in which it 
was not reported, quantification of outcomes based on diaries, pad tests or any other definitions chosen by 
trialists were used as a proxy.  
† Electromyography-assisted biofeedback 
1. Jeyaseelan S, Oldham JA. Can the effects of pelvic floor muscle exercises be enhanced with a new pattern 
of electrical stimulation in women with stress incontinence (Abstract). Proceedings of the World Confed-
eration for Physical Therapy (WCPT), 14th International Congress, 7-12 June, Barcelona. 2003. 
2. Patil SP, Nagrale AV, Ganvir SD. Additive effect of interferential therapy over pelvic floor exercises. Inter-
national Journal of Therapy & Rehabilitation. 2010;17(11):596-602. 
3. Huebner M, Riegel K, Hinninghofen H, Wallwiener D, Tunn R, Reisenauer C. Pelvic floor muscle training 
for stress urinary incontinence: a randomized, controlled trial comparing different conservative therapies. 
Physiother Res Int. 2011;16(3):133-40. 
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One study was a three-arm trial that included both 
‘dynamic’ EStim (stimulation added at maximum con-
traction of pelvic floor muscles) and ‘conventional’ 
EStim (stimulation followed by rest and pelvic floor 
muscle contraction) as two of the study arms (127). 
These arms were combined in the analysis. One 
study is a pilot study, available only as abstract, with 
limited information (136). 
Quality of data  
Allocation concealment was inadequate in one study 
which used opaque sealed envelopes but with no in-
dication of third party involvement in the allocation 
procedure (137). The other two studies did not men-
tion allocation concealment (127, 136). In two stud-
ies, data were reported only for those who completed 
the trial (127, 137) and it was unclear in the other 
study if trial results were reported for everyone who 
entered the trial (136). 
Results 
i) EStim + PFMT vs PFMT 
SUI or predominant SUI. Two new studies assessing 
EStim as an adjunct to PFMT compared with PFMT 
alone, contributed no additional data in terms of cure, 
improvement and adverse effects. The 5th ICI previ-
ous analysis  for these outcomes therefore remains 
unchanged.  
Three studies reported data on quality of life with in-
consistent results. One previous study found no sta-
tistically significant differences between the group 
(138), whereas one new study using the Incontinence 
Impact Questionnaire (IIQ) found a statistically signif-
icant difference favouring the group which combined 
EStim with PFMT (137). The results from another new 
study based on either the IIQ or the Urogenital Dis-
tress Inventory were inconclusive, due to the pilot na-
ture of the study and small sample size (N = 13) (136). 
ii) EStim + PFMT with biofeedback vs PFMT with bi-
ofeedback 
SUI. One new study assessed EStim as an adjunct to 
PFMT and biofeedback compared with PFMT and bi-
ofeedback alone. This was a three-arm trial, as-
sessing a combination of either ‘dynamic’ or ‘conven-
tional’ EStim with PFMT and biofeedback, compared 
with PFMT and biofeedback alone (127).  
This study did not provide any data on cure and im-
provement rates (127). Thus, the 5th ICI analysis of 
improvement rates based on two studies (129, 130) 
remains unchanged, with no available information on 
cure rates.  
While no information was available on quality of life 
and adverse effects for this comparison in the 5th ICI, 
the new study (127) reported that quality of life scores 
based on the King’s Health Questionnaire improved 
statistically significantly for the group which combined 
‘dynamic’ EStim with PFMT and biofeedback, com-
pared with PFMT and biofeedback alone, although 
study authors did not consider the difference to be 
clinically important. No significant difference was 
found for the group combining ‘conventional’ EStim 
with PFMT and biofeedback, compared with PFMT 
and biofeedback alone.  
In the same study (127), one of 72 participants had 
an allergic reaction to biofeedback lubricant and with-
drew from the study, although it was unclear in which 
group this occurred.  
Summary 
A total of 15 studies assessed the effect of EStim as 
an adjunct to another treatment, compared with the 
other treatment alone. All but two studies included 
women with SUI or predominant SUI. No study focus-
ing on UUI or predominant UUI was identified.  
Findings from update analysis using the additional 
data from newly identified studies were broadly simi-
lar to those from the 5th ICI. For comparisons of EStim 
with PFMT versus PFMT alone, there was no clear 
evidence of a difference between the groups in 
women with SUI or predominantly SUI in terms of 
cure and improvement. Evidence for quality of life out-
comes was not consistent across studies (Level of 
Evidence: 2). There was also no evidence to suggest 
that the addition of EStim to a BF-assisted PFMT was 
more effective than BF-assisted PFMT in women with 
SUI (Level of Evidence: 2). A few women experi-
enced adverse effects with EStim. There is no evi-
dence to draw any conclusion about the effect of add-
ing EStim to PFMT for women with UUI.  
Recommendations  
The addition of EStim to PFMT or BF-assisted PFMT 
programmes does not appear to add benefit (Grade 
of Recommendation: B); combinations of tech-
niques need to be investigated further with high qual-
ity trials if this is a clinical/research question of inter-
est to women. 
4.3. Other LUTS 
In the 5th ICI, there were no trials that analysed the 
effect of EStim in women with other LUTS alone.No 
new published trials were found. 
4.4. Factors Affecting Outcome 
None of the included trials addressed the effect of 
age, or any other factor, on outcomes of EStim. There 
was no clear indication from the included trials that 
EStim could not be tolerated by elderly. There is no 
reason, therefore, to either exclude older women from 
studies of EStim, or not to offer EStim as part of a 
conservative management programme, except where 
recognised precaution with use of intra-vaginal elec-
trodes in women with vaginal atrophy and contraindi-
cations such as a cardiac pacemaker are present. 
One newly identified study including elderly women 
(over 60 years old) highlighted the potential embar-
rassment perceived by the elderly with regard to con-
ventional intra-vaginal stimulation and suggested that 
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surface EStim may be a more acceptable method for 
this population (115).  
Of note, in a prospective cohort of 3,198 women 
treated with home-managed EStim in Norway during 
1992-1994, there was no association between self-
reported improvement and age (139). In the same co-
hort, success rates as defined by clinicians were 
higher in younger individuals but this effect was not 
significant after controlling for other factors.  
Aside from age, other factors may have the potential 
to mitigate treatment outcome. On the basis of trial 
reports to date, it appeared that there was considera-
ble variation in EStim protocols with no consistent 
pattern emerging. EStim protocols are also often 
poorly reported, lacking detail of stimulation parame-
ters, devices and methods of delivery. The wide 
range of protocols that have been tested may have 
affected the effect EStimates reported in this section. 
ICS/IUGA has produced a physiotherapy interven-
tions terminology paper in the last year, and authors 
are encouraged to refer to this paper when reporting 
EStim parameters in a publication (1). 
It is not clear whether one diagnostic group may ben-
efit more than another from EStim. It has been hy-
pothesised that, in women with SUI who cannot vol-
untarily contract the PFM to begin a PFMT pro-
gramme, EStim might help initiate or substitute for a 
voluntary contraction. However, most studies focus-
ing on the efficacy of EStim do use EStim to initiate 
or substitute for a voluntary PFM contraction (140). 
To date, there has been no trial addressing this hy-
pothesis.  
As with all conservative therapy modalities, one of the 
key factors to the success or failure of EStim is treat-
ment adherence. Some authors commented on ad-
herence or reported adherence data. Of the new 
studies identified for this 6th ICI update, one study re-
ported that adherence to EStim was satisfactory 
(116) and another reported that the EStim regimen 
was adhered to by over >75% of participants (114). 
However, adherence measures were highly variable, 
making comparison across studies difficult. 
5. POSTERIOR TIBIAL NERVE 
STIMULATION (PTNS) 
Posterior tibial nerve stimulation (PTNS) is a form of 
peripheral neurostimulation targeted towards symp-
tom relief of OAB and UUI (141). Indirect access to 
the sacral plexus is achieved by intermittent, electri-
cal stimulation of the posterior tibial nerve, which lies 
behind the medial malleolus. PTNS may be minimally 
invasive, involving insertion of a fine needle close to 
the nerve (Percutaneous PTNS), or non-invasive, us-
ing skin surface electrodes applied to the medial mal-
leolar area (Transcutaneous PTNS)(141). 
PTNS aims to stimulate the sacral nerve plexus 
through the afferent fibres of the posterior tibial nerve, 
a mixed nerve containing L5-S3 fibres (142). The S3 
nerve root contains sensory fibres from the pelvic 
floor and parasympathetic motor efferent fibres to the 
detrusor as well as the pelvic sphincters and the pel-
vic floor muscles. Afferent nerve stimulation can 
therefore lead to activation of inhibitory sympathetic 
neurons and suppression of detrusor contraction 
through a direct sacral route. Urodynamic studies 
have shown that electrical stimulation of the posterior 
tibial nerve increases cystometric capacity and sup-
presses detrusor contraction (143-145). The full 
mechanism of action of treatment effect for PTNS is 
not yet understood, however it is thought that the ob-
served effects may be related to a neuroplastic reor-
ganisation of sacral spinal reflexes and regulation of 
cortical excitability (146, 147). 
Percutaneous PTNS is performed as an outpatient 
procedure. It involves inserting a 34-gauge needle 3–
5 cm cephalad to the medial malleolus. The needle is 
connected to a low-voltage stimulator device, and a 
grounding pad is placed on the bottom of the foot just 
below the smallest toe. Transcutaneous PTNS may 
be delivered either in clinic or self-administered at 
home. Self-adhesive electrodes are placed behind 
the medial malleolus and 10cm proximal to this. The 
positive lead is connected to the proximal electrode 
and the negative to the distal electrode and both are 
connected to a portable battery-powered stimulator. 
The intensity level of the stimulation current for per-
cutaneous PTNS and transcutaneous PTNS is deter-
mined once correct positioning has been established 
by noting sensory and motor (hallux) reaction (Figure 
4). 
This section presents the evidence for the use of 
PTNS in the prevention and treatment of UI in 
women. Since this is a new section for the Conserva-
tive Management chapter, the same search strategy 
as EStim section was used although no date re-
strictions have been applied to the literature search.   
 
 
Figure 4 PTNS equipment 
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Table 19 Summary of PTNS protocols 
Author, year Current Current Intensity 
Pulse Shape & 
Duration 
Frequency 
(Hz) 
Duty Cycle Electrodes 
Treatment 
Duration 
Target UI 
Bellette 2009 (1) NR NR NR NR NR NR 2 months OAB 
Finazzi-Agrò 
2010 (2) 
NR 0 – 10 mA; increased 
until flexion of big toe 
or fanning of all toes 
become noticeable 
200 
microseconds 
20 Hz NR One surface electrode on 
the medial aspect of the 
calcaneous 
3 months UUI 
Manriquez 2013* 
(3) 
NR NR NR 
 
 
 
NR NR NR 3 months OAB 
Marques 2008* 
(4) 
Biphasic VIF (variation of 
intensity and 
frequency) 
200 
microseconds 
10 Hz NR Two transcutaneous 
electrodes 
1 month OAB 
Peters 2010* (5) NR NR NR NR NR NR 3 months OAB 
Preyer 2007* (6) NR NR NR NR NR NR 3 months UUI 
Preyer 2015 (7) NR NR NR NR NR NR 3 months OAB 
Sancaktar 2010 
(8) 
NR 0.5 – 10Ma; adjusted in 
accordance to patient’s 
tolerance 
0.2 milliseconds 20 Hz NR NR 3 months OAB 
Schreiner 2010 
(9) 
Continuou
s mode 
10 – 50mA; according 
to sensitivity and hallux 
mobilisation 
200 milliseconds 10 Hz NR Negative electrode on 
medial malleolus and the 
positive electrode was 
10cm proximal to this on 
the right leg along the nerve 
path 
3 months UUI 
Souto 2014 (10) NR NR 250 
microseconds 
10 Hz NR Negative surface electrode 
placed behind medial 
malleolus and positive 
electrode placed 10cm 
above it 
3 months OAB 
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Author, year Current Current Intensity 
Pulse Shape & 
Duration 
Frequency 
(Hz) 
Duty Cycle Electrodes 
Treatment 
Duration 
Target UI 
Vecchioli-
Scaldazza 2013 
(11) 
NR NR NR NR NR NR 1.5 months OAB 
* abstract only. 
NR = not reported 
1. Bellette PO, Rodrigues-Palma PC, Hermann V, Riccetto C, Bigozzi M, Olivares JM. [Posterior tibial nerve stimulation in the management of overactive bladder: a 
prospective and controlled study]. [Spanish]. Actas Urologicas Espanolas. 2009;33(1):58-63. 
2. Finazzi-Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due 
to a placebo effect: a randomized, double-blind, placebo controlled trial. Journal of Urology. 2010;184(5):2001-6. 
3. Manriquez VI, Naser ME, Gomez M, Guzman R, Valdevenito R, Lecannelier J, et al. Transcutaneal tibial nerve stimulation versus long release oxibutinin in the 
treatment of patients with overactive bladder. A randomize control trial (Abstract number 013). International Urogynecology Journal and Pelvic Floor Dysfunction. 
2013;24(Suppl 1):S14. 
4. Marques A, Herrmann V, Ferreira N, Bellette P. Transcutaneous posterior tibial nerve stimulation in overactive bladder (Abstract number 471). Proceedings of the 
38th Annual Meeting of the International Continence Society (ICS), 2008 Oct 20-24, Cairo, Egypt. 2008. 
5. Peters K, Carrico D, Perez-Marrero R, Khan A, Wooldridge L, Davis G, et al. 12 week results from the SUMIT trial: percutaneous tibial nerve stimulation vs validated 
sham in those exposed to pharmacologic therapy (Abstract number 125). Neurourology and Urodynamics. 2010;29(6):988-9. 
6. Preyer O, Gabriel B, Mailath-Pokorny M, Doerfler D, Laml T, Umek W, et al. Peripheral tibial neurostimulation (PTNS) versus tolterodine in the treatment of women 
with urge urinary incontinence and urge symptoms (Abstract number 246). International Urogynecology Journal and Pelvic Floor Dysfunction. 2007;18(Suppl 1):S139-
S40. 
7. Preyer O, Umek W, Laml T, Bjelic-Radisic V, Gabriel B, Mittlboeck M, et al. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: 
a randomised controlled trial. European Journal of Obstetrics, Gynecology, & Reproductive Biology. 2015;191:51-6. 
8. Sancaktar M, Ceyhan ST, Akyol I, Muhcu M, Alanbay I, Mutlu EC, et al. The outcome of adding peripheral neuromodulation (stoller afferent neuro-stimulation) to anti-
muscarinic therapy in women with severe overactive bladder. Gynecological Endocrinology. 2010;26(10):729-32. 
9. Schreiner L, dos Santos TG, Knorst MR, da Silva Filho IG. Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older 
women. International Urogynecology Journal. 2010;21(9):1065-70. 
10. Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and randomized comparison of electrical stimulation of the posterior tibial nerve versus oxybutynin 
versus their combination for treatment of women with overactive bladder syndrome. World Journal of Urology. 2014;32(1):179-84. 
11. Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin Succinate versus Percutaneous Tibial Nerve Stimulation in Women with Over-
active Bladder Syndrome: Results of a Randomized Controlled Crossover Study. Gynecologic & Obstetric Investigation. 2013;75(4):230-4. 
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Table 20 Summary of data on PTNS vs no active treatment 
Author, year Intervention 
N 
randomised 
Study population 
Duration 
(months) 
Outcome** 
UUI 
Finazzi-Agrò 2010 
(1) 
Percutaneous PTNS (18) vs Sham 
percutaneous PTNS (17) 
35 UUI 3 Cure: NR 
Improvement based on diary: 12/17 vs. 0/15 
QoL via I-QoL (mean): N = 17, change from pre 69.6 to 
post 81.3, p = 0.025 vs. N = 15, change from pre 69.5 
to post 70.6, p = 0.619 
Adverse effects: no serious events  
DO/OAB 
Bellette 2009† (2) Transcutaneous  PTNS (21) vs Sham 
transcutaneous PTNS (16) 
37 OAB 2 Not available† 
Marques 2008* (3) Transcutaneous   PTNS 
vs Sham transcutaneous PTNS  
(number per group not reported) 
43 OAB (some had SUI 
and UUI) 
1 Cure: NR 
Improvement: NR 
QoL: NR 
Adverse effects: NR 
Note: For modality details or parameters, see Table 19. 
NR = Not reported; I-QoL = Incontinence Quality of Life Questionnaire (higher scores indicate higher QoL); OAB-q = Overactive Bladder Questionnaire (higher scores 
indicating worse condition); 
* abstract only  
**Source of cure and improvement outcome: women’s self-report was given priority but for studies in which it was not reported, quantification of outcomes based on 
diaries, pad tests or any other definitions chosen by trialists were used as a proxy.  
† Publication in Spanish with English abstract. English translation of the main text was not available at the time of writing.  
1. Finazzi-Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due 
to a placebo effect: a randomized, double-blind, placebo controlled trial. Journal of Urology. 2010;184(5):2001-6. 
2. Bellette PO, Rodrigues-Palma PC, Hermann V, Riccetto C, Bigozzi M, Olivares JM. [Posterior tibial nerve stimulation in the management of overactive bladder: a 
prospective and controlled study]. [Spanish]. Actas Urologicas Espanolas. 2009;33(1):58-63. 
3. Marques A, Herrmann V, Ferreira N, Bellette P. Transcutaneous posterior tibial nerve stimulation in overactive bladder (Abstract number 471). Proceedings of the 
38th Annual Meeting of the International Continence Society (ICS), 2008 Oct 20-24, Cairo, Egypt. 2008. 
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Questions addressed are:  
 Is PTNS effective in the prevention of UI? 
 Is PTNS better than no active treatment (pla-
cebo, sham, control or no treatment) for treat-
ment of UI? 
 Is one type of PTNS better than another in the 
treatment of UI? 
 Is PTNS better than other treatments in the treat-
ment of UI? 
 Does the addition of PTNS to other treatments 
add any benefit in the treatment of UI? 
 What is the effect of PTNS on other LUTS? 
 What factors might affect the outcome of PTNS 
in the treatment of UI? 
Eligible interventions were PTNS/neurostimulation/ 
neuromodulation, percutaneous or transcutaneous. 
Eligibility criteria for study participants and outcomes, 
as well as criteria used to assess ‘risk of bias’ in the 
included studies, were identical to those used in the 
previous section on EStim (Section II.4). 
Description of intervention in included studies of 
PTNS 
A total of 11 studies were eligible and are summa-
rised in Table 19 (148-158). 
5.1. Prevention 
No studies that investigated either primary or second-
ary prevention of UI or LUTS were identified.  
5.2. Treatment 
5.2.1 Is PTNS Better than No Active Treat-
ment (Placebo, Sham, Control or No 
Treatment) for Treatment of UI? 
Three studies compared PTNS with no active treat-
ment (Table 20) (148, 149, 151). One study included 
women with UUI (149) and two included women with 
OAB where some but not all participants had UI. No 
study focusing on SUI or predominant SUI was found. 
A placebo or a sham procedure was employed as a 
comparator in all three studies. In two studies, the 
sham procedure was described as having electrodes 
placed without turning on the electrical generator 
(148, 151). In another study (149), the electrical gen-
erator was turned on only for a few seconds to allow 
the patient to experience a mild sensation; prior to 
treatment, patients in both groups had been coun-
selled that the subsequent absence of the sensation 
was due to adaptation. The choice of a different nee-
dle position in the sham group was to eliminate any 
presumed response that could arise from the acu-
puncture effect from piercing the skin cephalad to the 
medial malleolus (149).  
Quality of data  
One study described using a computer generated 
randomisation list (149); other studies did not report 
randomisation techniques (148, 151). No study re-
ported information on allocation concealment. Re-
sults were reported for everyone who entered the trial 
in one study (148), and another study reported 5% 
attrition rate from PTNS group and 13% from the 
sham group and that the reasons for drop out from 
each group were unrelated to the treatment (149), 
however it was unclear whether the other study had 
missing data (151).  
Results 
(a) UUI. No included studies reported information on 
cure rates. One study (149) reported that improve-
ment rates were significantly higher for PTNS com-
pared with no active treatment (reported p value 
<0.001). I-Qol scores found a significant difference 
between the groups which was due to a lack of signif-
icant change after the sham procedure and to the sig-
nificant increase (improved quality of life) after PTNS 
(149). No serious adverse effects were reported in ei-
ther group but patients in both groups reported occa-
sional transient pain at the stimulation site (149).  
(b) DO/OAB. There was no information on cure rates.  
Summary 
The three included studies were small (35-43 partici-
pants). All were generally assessed as having a high 
risk of bias. Data pooling was not possible. Data avail-
able from two studies on women with UUI or OAB 
suggests PTNS may be more effective than no active 
treatment in improving symptoms and quality of life, 
although no data were available on cure (Level of 
Evidence: 2). The included studies reported no seri-
ous adverse effects associated with either active or 
sham treatment (Level of Evidence: 2). No evidence 
was available for women with SUI or predominant 
SUI.  
Recommendations 
For women with UUI or OAB, PTNS may be more ef-
fective than no active treatment in symptom control 
(Grade of Recommendation: C New).  
More studies with larger sample sizes and consistent 
and clear reporting of core outcomes would be bene-
ficial in reaching a conclusion on the effectiveness of 
PTNS over no active treatment.  
5.2.2 Is One Type of PTNS Better than An-
other in the Treatment of UI? 
No study was found for this comparison. 
5.2.3 Is PTNS Better than Other Treatments 
for Treatment of UI? 
Five studies compared PTNS with drug treatment 
(Table 21).  
 
78 
Table 21 Summary of data on PTNS vs other treatments 
Author, 
year 
Comparator 
N 
random-
ised 
Study 
popula-
tion 
Duration 
(months) 
Source of outcome** 
UUI 
Preyer 
2007* (1) 
Percutaneous 
PTNS (16) 
vs 
Tolterodine (15) 
31 UUI 3 Cure: NR 
Improvement: NR 
QoL via unspecified tool (higher scores 
indicate improvement): mean 4.4 higher, 
95% CI 1.7 to 7.1 higher vs mean 4.6 
higher, 95% CI 2.1 to 7.0 higher, 
reported p value = 0.93  
Adverse effects: unspecified events 
noted 
DO/OAB 
Manriquez 
2013* (2) 
Transcutaneous 
PTNS 
vs 
Oxybutynin 
(number per group 
not reported) 
56 OAB 3 Cure: NR 
Improvement: NR 
QoL via OAB-q: no significant difference, 
no data 
Adverse effects: NR 
Preyer 
2015 (3) 
Percutaneous 
PTNS (18) 
vs 
Tolterodine (18) 
36 OAB 
(wet or 
dry) 
3 Cure: NR 
Improvement: NR 
QoL via VAS, change from baseline, 
median [range]: N = 18, 1.9 [0 to 8] vs N 
= 18, 2.7 [0 to 8.5], reported p-value = 
0.07 
Adverse effects: pain, dry mouth, 
dizziness 
Souto 
2014 (4) 
Transcutaneous 
PTNS (25) 
vs 
Oxybutynin (25) 
50 OAB 3 Cure: NR 
Improvement: NR 
QoL via ICIQ-SF, mean [range]: 7.2 [0 to 
18] vs 9.8 [0 to 18] at 3 months 
(treatment end), 8.3 [0 to 20] vs 13.3 [8 
to 20] at 6 months (i.e. 3 month after 
treatment) 
QoL via ICIQ-OAB, mean [range]: 5.9 [1 
to 11] vs 4.6 [0 to 10] at 3 months, 6.1 [1 
to 20] vs 9.2 [4 to 13] at 6 months 
Adverse effects: NR 
Vecchioli-
Scaldazza 
2013† (5) 
Percutaneous 
PTNS (20) 
vs 
Solifenacin 
Succinate (SS) 
(20) 
40 OAB 
(some 
had 
UUI) 
1.5 Cure: NR 
Improvement: NR 
QoL via PGI-I (Wilcoxon test for paired 
sample, mean, SD): 
Group A (SSPTNS): post SS 2.9 (1.1), 
post PTNS 2.1 (0.7);  
Group B (PTNSSS): post SS 3.1 (1.0), 
post PTNS 2.3 (0.7) 
QoL via OAB-q: significant improvement 
in all groups both with SS and PTNS 
Adverse effects: NR 
Note: For modality details or parameters, see Table 19. 
NR = not reported; ICIQ-SF = International Consultation on Incontinence-Short Form (higher scores indicate 
increased severity); ICIQ-OAB = International Consultation on Incontinence-OAB (higher scores indicate in-
creased severity); OAB-q = Overactive Bladder Questionnaire (higher scores indicating worse condition); PGI-
I = Patient Global Impression of Improvement Questionnaire (lower scores indicate greater improvement); VAS 
= Global response assessment on visual analogue scale (higher scores indicate greater impact on QoL); 
* abstract only  
**Source of outcome: women’s self-report was given priority but for studies in which it was not reported, quan-
tification of outcomes based on diaries, pad tests or any other definitions chosen by trialists was used as a 
proxy.  
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† Crossover study with a three-month washout period for both groups.  
1. Preyer O, Gabriel B, Mailath-Pokorny M, Doerfler D, Laml T, Umek W, et al. Peripheral tibial neurostimu-
lation (PTNS) versus tolterodine in the treatment of women with urge urinary incontinence and urge symp-
toms (Abstract number 246). International Urogynecology Journal and Pelvic Floor Dysfunction. 
2007;18(Suppl 1):S139-S40. 
2. Manriquez VI, Naser ME, Gomez M, Guzman R, Valdevenito R, Lecannelier J, et al. Transcutaneal tibial 
nerve stimulation versus long release oxibutinin in the treatment of patients with overactive bladder. A 
randomize control trial (Abstract number 013). International Urogynecology Journal and Pelvic Floor Dys-
function. 2013;24(Suppl 1):S14. 
3. Preyer O, Umek W, Laml T, Bjelic-Radisic V, Gabriel B, Mittlboeck M, et al. Percutaneous tibial nerve 
stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial. European 
Journal of Obstetrics, Gynecology, & Reproductive Biology. 2015;191:51-6. 
4. Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and randomized comparison of electrical 
stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of women 
with overactive bladder syndrome. World Journal of Urology. 2014;32(1):179-84. 
5. Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin Succinate versus 
Percutaneous Tibial Nerve Stimulation in Women with Overactive Bladder Syndrome: Results of a Ran-
domized Controlled Crossover Study. Gynecologic & Obstetric Investigation. 2013;75(4):230-4. 
 
PTNS was compared with solifenacin succinate in 
one (158), tolterodine in two (153, 154) and oxy-
butynin in two (150, 157). The target population had 
OAB (with UI in some but not all of the participants) 
except for one study (153) where it was UUI. No study 
focusing on SUI or predominant SUI was found. One 
study used a cross-over design (158). Another study 
was a three-arm trial comparing PTNS versus oxy-
butynin versus PTNS and oxybutynin; only the find-
ings for PTNS vs oxybutynin are reported here (157).  
Quality of data  
One study described using a computer generated se-
quence using adaptive randomisation, where alloca-
tion was centralised using telephone (154). Permu-
tated blocks were used in one study but it was unclear 
whether there was allocation concealment (150). 
Other studies did not report such information on allo-
cation concealment nor provided details on the ran-
domisation process (153, 157, 158). In one study 
there was a dropout rate of 11% in both groups (154). 
In another study (158), a two-arm crossover trial of 
PTNS and Solifenacin where group A had Solifenacin 
then PTNS after a washout period and group B had 
PTNS then Solifenacin, there was a dropout rate of 
30% from the group A and 20% from group B; the 
reasons were refusal of further treatment (10% vs 
5%), no indication for starting treatment (10% vs 
15%). A further 10% dropped out from group A as a 
result of adverse effects of treatment. Twenty-six per-
cent of participants were excluded from analysis in 
one study (157) because they failed to comply with 12 
weeks of treatment and/or did not attend follow up at 
six months; the reasons for non-compliance or miss-
ing data were not reported. In one study (150), it was 
unclear whether results were reported for everyone 
who entered the trial, while in another (153) the au-
thors did not account for all drop-outs. 
Results 
(a) UUI. There was no information on cure and im-
provement (153). Quality of life outcomes, measured 
using an unspecified tool, improved in both groups, 
although there was no statistically significant differ-
ence between them (153). One study reported un-
specified adverse events in one of 16  participants 
and six of 15 participants  in the PTNS and Toltero-
dine groups respectively; authors did not specify the 
nature of these adverse events (153). 
(b) OAB. Data on cure or improvement were not re-
ported. Quality of life outcomes were reported in four 
studies. Three of these found no significant difference 
between the groups, based on the Overactive Blad-
der Questionnaire in one study (150), OAB-q and the 
Patient Global Impression of Improvement (PGI-I) in 
another (158) and a visual analogue scale in the third 
(154). One study using ICIQ-SF and ICIQ-OAB re-
ported that post-treatment scores decreased (indicat-
ing symptom reduction) in both groups at 12 weeks of 
treatment, although the score increased (indicating 
symptoms worsened) significantly for the oxybutynin 
group in contrast to the PTNS group. The PTNS 
group maintained their scores at 6 months follow-up 
(12 weeks after the cessation of treatment) (157). 
One study reported that adverse events were ob-
served in three of 18 (17%) participants in the PTNS 
group (mainly pain at the puncture site) and nine of 
18 (50%) participants in the tolterodine group (mainly 
dry mouth and dizziness) (154).  
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Summary  
Five studies were included. These were small (36-56 
participants) and generally assessed as having a high 
risk of bias. There were limited and widely heteroge-
neous data. Two studies (one for UUI, one for OAB) 
reported that quality of life improved over time for both 
PTNS and drug treatment groups with no significant 
difference between them, while two other studies (for 
OAB) found no significant difference in quality of life 
between PTNS and drug treatment post-intervention 
(Level of Evidence: 2). However, one study on 
women with OAB found that the improvement in qual-
ity of life was longer lasting following the cessation of 
treatment with PTNS than after tolterodine (Level of 
Evidence: 2). Data available from two studies on 
women with UUI or OAB suggests that PTNS is as-
sociated with a lower rate of adverse events than 
tolterodine and when they occurred, there were not 
as bothersome as those associated with tolterodine 
(Level of Evidence: 2). No evidence was available 
for women with SUI or predominant SUI. 
Recommendations  
There is no significant difference between PTNS and 
tolterodine in terms of quality of life, however PTNS 
may be considered as both may improve quality of life 
(Grade of Recommendation: B New).  
PTNS may considered for women as it is associated 
with fewer and less bothersome adverse effects than 
those from drug treatment (Grade of Recommenda-
tion: B New).  
Recommendations  
More randomised controlled trials with large sample 
sizes and clear and consistent reporting of core out-
come data would be beneficial in reaching a firm con-
clusion on the effectiveness of PTNS over other treat-
ments. 
5.2.4 Does the Addition of PTNS to Other 
Treatments Add Any Benefit in the 
Treatment of UI? 
Three studies assessed the effect of PTNS as an ad-
junct to another treatment, compared with the other 
treatment alone or with PTNS alone (Table 22). One 
study included women with UUI (reported as OAB in-
continent) and combined PTNS with PFMT and blad-
der training (PTNS plus PFMT plus bladder training 
vs PFMT plus bladder training) (156). Two other stud-
ies included women with OAB (where some but not 
all participants had UI) and combined PTNS with a 
drug. One study combined PTNS using the Stoller af-
ferent neuro-stimulation (SANS) protocol with Tolter-
odine (PTNS plus Tolterodine vs Tolterodine) (155). 
The other study was a three-arm trial of PTNS versus 
Oxybutynin versus PTNS plus Oxybutynin; only the 
findings for PTNS plus Oxybutynin versus Oxybutynin 
are reported here (157). No study focusing on SUI or 
predominant SUI was found. 
Quality of data 
All studies reported adequate methods of randomisa-
tion, including the use of a list of random numbers 
(155), simple random number generator (156) and 
online randomisation (157). Allocation concealment 
was not mentioned in any of the study reports. In one 
study, there was 10% missing data from the group 
who had tolterodine alone, while there were no miss-
ing data in the combination therapy group (155). In 
another study, there was 5% missing data from the 
PTNS group only; the reported reason for the attrition 
was due to health problems unrelated to therapy 
(156). In the third study, 24% dropped out of the oxy-
butynin group while 16% were excluded from the 
analysis in the combination therapy group. The rea-
sons patients failed to complete the trial were not re-
ported and it is unclear whether they were related to 
treatment (157).  
Results 
(a) UUI. No information was available on cure rates. 
One study reported that improvement rates were sta-
tistically significantly higher for the group combining 
PTNS with PFMT and bladder training compared with 
PFMT and bladder training alone (156). None of the 
participants reported significant adverse effects 
(156). ICIQ-SF scores improved for both groups but 
the combination treatment group had a significantly 
greater improvement (156). Similar results were 
found for KHQ; the combination treatment group 
showed a significantly greater improvement (156).  
(b) OAB. No information was available on cure and 
improvement. Two studies reported quality of life out-
comes. One study using the short form of Inconti-
nence Impact Questionnaire (IIQ-7) reported that 
post-treatment scores decreased (indicating less im-
pact of UI on daily living) in both groups but this de-
crease in the group combining PTNS and drug was 
greater that the group using drug alone (155). An-
other study reported that ICIQ-SF scores decreased 
(indicating symptom reduction) in both groups at 12 
weeks of treatment, although the score increased (in-
dicating symptoms worsened) significantly for the 
group using drug alone compared with the group 
combining PTNS and drug at 6 month follow-up (12 
weeks after the cessation of treatment) (157). ICIQ-
OAB results from the same study found that the com-
bination treatment group had a greater improvement 
in OAB symptoms compared with the group using 
drug alone at 12 weeks of treatment; ICIQ-OAB 
scores increased (worsening in symptoms) for the 
group using drug alone in contrast to the other group 
that maintained their scores at 6-month follow-up 
(157). No information was available on cure and im-
provement.  
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Table 22 Summary of data on PTNS + another treatment vs the other treatment 
Author, 
year 
Comparator 
N 
randomised 
Study 
population 
Duration 
(months) 
Outcome** 
UUI 
Schreiner 
2010 (1) 
Transcutaneous 
PTNS + PFMT + 
bladder training 
(26) 
vs  
PFMT + bladder 
training (26) 
52 UUI 3 Cure: NR 
Improvement based on diary: 19/25 vs 7/26 
QoL via ICIQ-SF, change from baseline, 
mean (SD): 7.2 (4.3) vs. 2.6 (3.3), reported 
p-value <0.001 
QoL via KHQ: reported p-value <0.05 
favouring the combination treatment group; 
no data  
Adverse effects: no events noted 
OAB 
Sancaktar 
2010 (2) 
SANS 
(Percutaneous) + 
Tolterodine (20) 
vs 
Tolterodine (20) 
40 OAB 
(some had 
UUI) 
3 Cure: NR 
Improvement: NR 
QoL via IIQ-7, mean (SD):  
SANS + Tolterodine, change from pre 19.0 
(2.0) to post 9.0 (0.8), p <0.001;  
Tolterodine, change from pre 18.1 (2.5) to 
post 11.2 (2.7), p <0.001 
Adverse effects: dry mouth, constipation, 
headache, local irritation of puncture site 
Souto 
2014 (3) 
TENS 
(Transcutaneous) 
+ Oxybutynin 
(25) 
vs 
Oxybutynin (25) 
50 OAB 3 Cure: NR 
Improvement: NR 
QoL via ICIQ-SF, mean [range]: 7.9 [0 to 
14] vs 9.8 [0 to 18] at 3 months (treatment 
end), 7.4 [0 to 14] vs 13.3 [8 to 20] at 6 
months (i.e. 3 month after treatment) 
QoL via ICIQ-OAB, mean [range]: 2.9 [0 to 
5] vs 4.6 [0 to 10] at 3 months, 3.0 [0 to 5] 
vs 9.2 [4 to 13] at 6 months 
Adverse effects: NR 
Note: For modality details or parameters, see Table 19. 
NR = not reported; ICIQ-SF = International Consultation on Incontinence-Short Form (higher scores indicate 
increased severity); ICIQ-OAB = International Consultation on Incontinence-OAB (higher scores indicate in-
creased severity); IIQ-7 = short form of Incontinence Impact Questionnaire (lower scores indicate better QoL); 
KHQ = King’s Health Questionnaire (higher scores indicate greater impairment); 
SANS = Stoller Afferent Nerve Stimulation of the posterior tibial nerve;  
TENS = Transcutaneous Electrical Nerve Stimulation of the posterior tibial nerve;  
TTNS = Transcutaneous Tibial Nerve Stimulation;  
**Source of cure and improvement outcome: women’s self-report was given priority but for studies in which it 
was not reported, quantification of outcomes based on diaries, pad tests or any other definitions chosen by 
trialists was used as a proxy.  
1. Schreiner L, dos Santos TG, Knorst MR, da Silva Filho IG. Randomized trial of transcutaneous tibial 
nerve stimulation to treat urge urinary incontinence in older women. International Urogynecology Journal. 
2010;21(9):1065-70. 
2. Sancaktar M, Ceyhan ST, Akyol I, Muhcu M, Alanbay I, Mutlu EC, et al. The outcome of adding peripheral 
neuromodulation (stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe 
overactive bladder. Gynecological Endocrinology. 2010;26(10):729-32. 
3. Souto SC, Reis LO, Palma T, Palma P, Denardi F. Prospective and randomized comparison of electrical 
stimulation of the posterior tibial nerve versus oxybutynin versus their combination for treatment of 
women with overactive bladder syndrome. World Journal of Urology. 2014;32(1):179-84. 
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Adverse events were reported by one study compar-
ing PTNS plus tolterodine with tolterodine alone 
(155). In this study, severe dry mouth, severe consti-
pation, headache and local irritation at puncture site 
were reported in both treatment groups, and skin irri-
tation for the group using PTNS. Two of 18 partici-
pants (11%) experienced more than one adverse 
event in the tolterodine group compared with one of 
20 participants (5%) in the group combining PTNS 
with tolterodine.  
Summary  
Three small studies were included (40-52 partici-
pants). The included studies were assessed as hav-
ing a high risk of bias. No data were available on cure 
and improvement rates for this comparison. Data 
from one study suggests that the addition of PTNS to 
PFMT and bladder training was more effective in im-
proving symptoms and quality of life than PFMT and 
bladder training alone in women with UUI (Level of 
Evidence: 2).  
Data from two studies suggest that adding PTNS to 
drug treatment resulted in a greater improvement in 
quality of life than the drug treatment alone in women 
with OAB, and this effect was sustained for a longer 
term (6 months) for the treatment with PTNS than the 
treatment without PTNS (Level of Evidence: 2). Ad-
verse events appear uncommon for either group in 
the same study. No evidence was available for 
women with SUI or predominant SUI.  
Recommendations  
PTNS may be considered for symptom control when 
chosen in combination interventions by women with 
UUI or OAB (Grade of Recommendation: B New).  
This recommendation should be viewed with caution 
until these findings are supported or refuted in further 
trials.  
5.3. Other LUTS 
No trials were identified that analysed the effect of 
PTNS in women with other LUTS alone, e.g. fre-
quency of voiding, urgency and/or nocturia.  
5.4. Factors Affecting Outcome 
The included studies did not address the effect of fac-
tors that could potentially affect the response to treat-
ment with PTNS. A greater discussion of the factors 
that affect outcome is provided in the section on uri-
nary incontinence in men and women (see section 
V.1.4). 
6. MAGNETIC STIMULATION (MSTIM) 
MStim has been developed for “non-invasive” stimu-
lation of both central and peripheral nervous systems 
(159). MStim for the treatment of UI was reported for 
the first time in 1999 by Galloway (160). In contrast 
to EStim, extracorporeal magnetic innervation (more 
commonly called magnetic stimulation) stimulates 
the PFM and sacral nerve roots without insertion of 
an anal or vaginal probe (161). For treatment, the in-
dividual is positioned in a chair. Within the seat is a 
magnetic field generator (therapy head) that is pow-
ered and controlled by an external power unit (Figure 
5). A concentrated steep gradient magnetic field is di-
rected vertically through the seat of the chair. When 
seated, the individual’s perineum is centred in the 
middle of the seat, which places the PFM and sphinc-
ters directly on the primary axis of the pulsing mag-
netic field (Figure 6). Because of their anatomical lo-
cation, it is thought that all tissues of the perineum 
can be penetrated by the magnetic field. According to 
Galloway (1999) no electricity, but only magnetic flux 
enters the body from the device. Goldberg (2000) has 
suggested that, in contrast to electrical current, the 
conduction of magnetic energy is unaffected by tissue 
impedance, creating a theoretical advantage in its 
 
Figure 5 MStim machine 
 
Figure 6 Pulsing magnetic field 
83 
clinical application compared to EStim. Conventional 
magnetic stimulators deliver, at frequencies of 10 to 
50 Hz, repetitive pulses of current lasting less than 
100 μsec (161) and 275 s (160) in duration. Size 
and strength of the magnetic field is determined by 
adjustments of this amplitude by the therapist (160). 
Possible advantages of MStim are that it is performed 
through clothing, needs no probes, skin preparation, 
or contact with the skin surface. On the other hand, 
the need for repeated clinic based treatment sessions 
is a potential disadvantage. In contrast to EStim, 
MStim lacks portability, although a study by But in 
2003 (162) reported the development of a portable 
small electromagnetic device (Pulsegen) for home 
use that fit into the underwear and was designed for 
continuous use for up to 8 weeks.  
The mechanism of action of MStim is not fully under-
stood (163). Some authors have suggested that in 
SUI stimulation of the PFM causes external sphincter 
contraction (164), acts as a passive PFMT exercise 
(165), and increases maximal urethral closure pres-
sure (162). In UUI, MStim might suppress DO through 
activation of pudendal nerve afferents blocking para-
sympathetic detrusor motor fibres at the spinal reflex 
arc, activation of inhibitory hypogastric sympathetic 
neurons, or a combination of both mechanisms (166). 
Stimulation of sympathetic fibres maintaining smooth 
muscle tone within the intrinsic urethral sphincter and 
modulation of pudendal nerve afferent branches stim-
ulating an inhibitory spinal reflex at the S3 nerve root, 
are also suggested to play a role in this mechanism 
of action (166). 
In this section the evidence is considered for the use 
of MStim for the prevention and treatment of UI in 
women. Questions addressed are: 
 Is MStim effective in the prevention of UI? 
 Is MStim better than no active treatment (pla-
cebo, sham, control or no treatment) for the 
treatment of UI? 
 Is one type of MStim better than another in the 
treatment of UI? 
 Is MStim better than other treatments in the treat-
ment of UI? 
 Does the addition of MStim to other treatments 
add any benefit in the treatment of UI? 
 What is the effect of MStim on other LUTS? 
 What factors might affect the outcome of MStim 
in the treatment of UI? 
Eligible interventions were non-invasive magnetic 
stimulations. Eligibility criteria for study participants 
and outcomes, as well as criteria used to assess ‘risk 
of bias’ in the included studies, were identical to those 
described in the previous sections on EStim and 
PTNS (Sections II.4 and II.5).  
Description of intervention  
In addition to eleven studies included in the 5th ICI, 
two new trials were identified for this update. The 
number of included studies by dominant type or pat-
tern of incontinence is summarised in Table 23. Table 
24 illustrates the intervention characteristics of the 
two new trials.  
6.1. Prevention 
In the last ICI chapter, there were no trials on preven-
tion of UI or LUTS. No new published trials were 
found.  
6.2. Treatment  
6.2.1 Is MStim Better Than no Active Treat-
ment (Placebo, Control or no Treat-
ment)? 
Two new studies including 162 women were identi-
fied (167, 168). In one study the majority of female 
participants had SUI (refractory to first-line manage-
ment) (167). The other study included all types of UI 
(168).  
Characteristics of the two new studies comparing 
magnetic stimulation with no active treatment are pre-
sented in Table 25. In both studies the no active treat-
ment consisted of sham treatment.One study as-
sessed the efficacy of a magnetic stimulator devel-
oped for home use (168), whereas in the other study 
treatment was provided in the outpatient clinic setting 
(167). Since there was little duplication of MStim in-
terventions, or sample populations, in the eleven tri-
als, it was inappropriate to combine study findings. 
Quality of data  
Allocation concealment was considered to be ade-
quate in one study that used an independent re-
search assistant in the randomisation process (168). 
The other study did not describe methods used for 
allocation concealment (167). In both studies, data 
were reported only for those participants who com-
pleted the study (167, 168). In particular, in the study 
by Wallis (2012), 19% (12/62) of participants from the 
intervention group and 15% (9/60) in the control 
group withdrew from the study (168).  
Results 
i) SUI. No additional data on cure and improvement 
were available for this update. The results for cure 
and improvement rates are as reported in two previ-
ous studies (169, 170).  
Information on quality of life was provided in three 
studies, including one new study (167), but the results 
were not consistent. Two previously reported studies 
found no significant differences between the groups 
(169, 170), whereas the new study reported better 
quality of life at 18 weeks after active treatment com-
pared with sham treatment, based on the Urge-Uri-
nary Distress Inventory and the Overactive Bladder 
Questionnaire (167).  
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Table 23 Studies of MStim included in the previous review (5th ICI) and current update (6th ICI) 
 
Studies included in the 
previous review (5th ICI) 
New studies identified in 
this update (6th ICI) 
Total 
MStim vs No active treatment 
    SUI or predominant SUI 
    UUI or predominant UUI 
    MUI 
    UI all types 
    DO/OAB (wet or dry) 
 
3  
1  
1  
1  
3  
 
1 
0 
0 
1 
0 
 
4 
1 
1 
2 
3 
One type of MStim vs another 
    SUI or predominant SUI 
    UUI or predominant UUI 
    UI all types 
 
0 
0 
1 
 
No study found 
 
0 
0 
1 
MStim vs other treatment No study found No study found 0 
MStim+PFMT vs PFMT 
    SUI or predominant SUI 
    UUI or predominant UUI 
 
1 
0 
 
No study found 
 
1 
0 
Table 24 Summary of data on MStim 
Study Intervention description 
Tsai 2014 (1) A Magstim Rapid2 with a 70-mm figure-8 coil. Treatment administered over the 
bilateral third sacral roots, with the maximal tolerable intensity, which was typically 
70% to 80% of the maximal stimulator output, for 20 minutes each day for 12 
consecutive weekdays. The stimulation frequency and the stimulation-on time and -
off time were fixed at 5Hz, 10 seconds, and 20 seconds, respectively. 
Wallis 2012 (2) 
 
A commercially available undergarment incorporating 15 static magnets of 800-1200 
Gauss arranged anterior, posterior, and inferior to the pelvis. Women were asked to 
wear it for a minimum of 6 consecutive hours during the day and at least 6 hours 
overnight for 3 months. 
1. Tsai PY, Wang CP, Hsieh CY, Tsai YA, Yeh SC, Chuang TY. Long-term sacral magnetic stimulation for 
refractory stress urinary incontinence. Archives of Physical Medicine & Rehabilitation. 2014;95(12):2231-
8. 
2. Wallis MC, Davies EA, Thalib L, Griffiths S. Pelvic static magnetic stimulation to control urinary inconti-
nence in older women: a randomized controlled trial. Clinical Medicine & Research. 2012;10(1):7-14 
Two studies (one new) reported no adverse effects 
(167, 169).  
ii) All types of UI. One new study that provided stimu-
lation using an undergarment with embedded mag-
nets reported that improvement rates were statisti-
cally significantly higher for active compared with no 
treatment, although the result did not hold in sensitiv-
ity analysis (168). No information was available re-
garding cure rates.  
With respect to quality of life measures, no statisti-
cally significant difference was found based on the 
Bristol Female Lower Urinary Tract Symptoms 
(BFLUTS) questionnaire (168).  
In the same study, participants reported problems 
with comfort and wearability of the garment, which 
were considered by study authors to have contributed 
to a relatively high attrition rate of 20%. Commonly 
cited problems include the attraction to metal objects; 
embedded magnets sticking to each other and mak-
ing it difficult to put on; and also the garment being 
bulky and very warm to wear, especially in the sub-
tropical climate of the study area (168).  
Summary 
A total of 11 studies assessed the effect of MStim 
compared with no active treatment, including four fo-
cusing on SUI or predominant SUI, one on UUI, one 
on MUI, two on all types of UI, and three on OAB/DO 
(where only some but not all had UI).  
Findings, using the additional data from newly identi-
fied studies were broadly similar to those in the 5th 
ICI.  
For women with SUI, MStim might be more effective 
than sham in improving (not necessarily curing) 
symptoms (Level of Evidence: 2),  
Data from two small trials of MStim (12 and 6 ses-
sions) examining the effect on quality of life were con-
flicting (Level of Evidence: 2).  
For women with UUI, evidence from a small trial (171) 
suggests that active MStim might result in better qual-
ity of life than sham (Level of Evidence: 2), although 
there is some uncertainty surrounding this, as data 
was limited and no statistical test was performed.  
85 
Active MStim was associated with higher cure rates 
than sham in a small trial (172) with women with MUI 
(Level of Evidence: 2), and also higher cure and im-
provement rates in another small trial (162) with 
women with all types of UI (Level of Evidence: 2) but 
no such difference was observed for women with DO 
(wet or dry) (Level of Evidence: 2). In general, ad-
verse effects appear uncommon.  
Recommendations 
No recommendation is possible based on current 
conflicting evidence (Grade of recommendation D).  
6.2.2 Is One Approach to MStim Better than 
Another? 
No new study comparing one approach of MStim with 
another was found for this update. The level of evi-
dence and recommendations remains unchanged 
from the 5th ICI.  
Summary and Recommendation 
The 5th ICI included one study with women presenting 
UI symptoms (173). There is insufficient evidence to 
determine if one type of MStim is better than another 
(Level of Evidence: 2). No recommendation is pos-
sible (Grade of Recommendation: D).  
6.2.3 Is MStim Better than Other Treatments? 
There were no trials for this comparison in the 5th ICI 
chapter. No new published trials were found for this 
update.  
6.2.4 Does the Addition of MStim to Other 
Treatments Add Any Benefit in the 
Treatment of UI? 
No new study was found investigating the effect of 
adding MStim to other treatments compared with the 
other treatments alone. The level of evidence and 
recommendations remains unchanged. 
Summary and Recommendation 
The previous 5th ICI included one study in women with 
SUI (174). The addition of MStim to PFMT does not 
appear to be beneficial (Level of Evidence: 2). 
Adding MStim to PFMT does not appear to be bene-
ficial (Grade of Recommendation: C). This hypoth-
esis needs to be investigated further with high quality 
trials, if it is a clinical question of interest to women.  
6.3. Other LUTS 
No trials were identified that analysed the effect of 
MStim in women with other LUTS alone, i.e., fre-
quency of voiding, urgency and/or nocturia. 
6.4. Factors Affecting Outcome 
None of the included trials addressed the effect of 
age, or any other factor, on outcome of MStim. In one 
early prospective multi-centre study, factors predict-
ing success of MStim were included (160). Treatment 
success was associated with no prior hysterectomy, 
no prior anti-incontinence operations, UI symptoms 
for fewer than 10 years, and no use of medications 
known to cause UI. Brodak has suggested that detru-
sor response to MStim might be better in ‘thin’ indi-
viduals (presumably due to a shorter distance be-
tween the stimulating coil and the sacral nerve roots) 
and at low bladder volumes (175). Overall, little is 
known about the factors affecting the outcome of 
MStim. 
 
7. SCHEDULED VOIDING REGIMENS 
Scheduled voiding regimens 
This section examines the evidence on use of sched-
uled voiding regimens in cognitively intact, non-insti-
tutionalized women with UUI, SUI, and MUI and pro-
vides recommendations for their use in clinical prac-
tice. A summary of the search strategy and inclu-
sion/exclusion criteria for selecting studies for review 
is provided (see section I). The chapters on the Frail 
Elderly and Neurogenic Incontinence provide detailed 
review of scheduled voiding regimens that are used 
in those with cognitive impairment, or UI secondary to 
central nervous system or spinal cord disease (see 
chapter 11).  
Types of Scheduled Voiding Regimens  
Bladder training is a broad term often used to de-
scribe any type of a scheduled toileting intervention. 
This has created conceptual confusion in interpreting 
research reports where few details are provided other 
than the statement that bladder training was used. 
The types of scheduled voiding regimens can be cat-
egorised as: bladder training, timed voiding, habit 
training, and prompted voiding (176). Although these 
regimens share a common feature of a toileting 
schedule, they differ on the basis of adjustments to 
the voiding schedule, the active or passive involve-
ment of the patient, the nature of patient education 
including the teaching of strategies to control urgency 
and prevent stress leakage, the use of reinforcement 
techniques, and the nature of the interactions be-
tween clinicians and patients. In practice, however, 
scheduled voiding regimens may share aspects of 
one or more of these features. 
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Table 25 Summary of data on MStim vs no active treatment 
Author Comparator 
N 
random-
ised 
Study 
population 
Duration 
(months) 
Outcome** 
Predominantly SUI 
Tsai 2014 (1) MStim (20) 
vs 
Sham MStim 
(20) 
40 >50% of 
study 
sample 
had SUI 
alone 
 outcome 
measured 
at 4.5 
months 
Cure: NR 
Improvement: NR 
QoL: OQB-q: N = 30, mean difference 
23.80 lower, 95% CI 36.28 to 11.32 
lower 
QoL via Urge-UDI: N = 30, mean 
difference 1.80 lower, 95% CI 2.64 to 
0.96 lowerAdverse effects: no events 
observed 
All types of UI 
Wallis 2012 
(2) 
MStim (62) 
vs 
Sham MStim 
(60) 
122 SUI, UUI or 
MUI 
3 Cure: NR 
Self-reported improvement: 26/46 vs 
18/50 
QoL via BFLUTS (median change in 
score, IQR): UI symptoms, N = 101, 
1.5 (3.0) vs 1.5 (3.0), p = 0.80; Sexual 
function, N = 101, 0 (0.75) vs 0 (0), p 
= 0.80; Quality of life, N = 101, 1.0 
(5.0) vs 0 (5.0), p = 0.28 
Adverse effects: discomfort of the 
garment 
Note: For modality details or parameters, see Table 24. 
NR = not reported; BFLUTS = Bristol Female Lower Urinary Tract Symptoms (higher scores indicate more 
severe comlaints); OAB-q = Overactive Bladder Questionnaire (higher scores indicating worse condition); 
Urge-UDI = Urge-Urinary Distress Inventory (higher scores indicate worse condition);  
**Source of cure and improvement outcome: women’s self-report was given priority but for studies in which it 
was not reported, quantification of outcomes based on diaries, pad tests or any other definitions chosen by 
trialists was used as a proxy.  
1. Tsai PY, Wang CP, Hsieh CY, Tsai YA, Yeh SC, Chuang TY. Long-term sacral magnetic stimulation for 
refractory stress urinary incontinence. Archives of Physical Medicine & Rehabilitation. 2014;95(12):2231-
8. 
2. Wallis MC, Davies EA, Thalib L, Griffiths S. Pelvic static magnetic stimulation to control urinary inconti-
nence in older women: a randomized controlled trial. Clinical Medicine & Research. 2012;10(1):7-14. 
 
Bladder training 
Bladder training (also referred to as bladder drill, blad-
der discipline, bladder re-education, and bladder re-
training) involves a programme of patient education 
along with a scheduled voiding regimen with gradu-
ally progressive voiding intervals. Specific goals of 
bladder training are to correct faulty habit patterns of 
frequent urination (if present), improve control over 
bladder urgency, prolong voiding intervals, increase 
bladder capacity, reduce incontinent episodes, and 
restore patient confidence in controlling bladder func-
tion. The underlying mechanism of how bladder train-
ing achieves its effect is poorly understood. Several 
hypotheses have been proposed including improved 
cortical inhibition over detrusor contractions; im-
proved cortical facilitation over urethral closure during 
bladder filling; improved central modulation of affer-
ent sensory impulses; altered behaviour resulting 
from better individual awareness of the lower urinary 
tract function and circumstances that cause UI, and 
increasing the “reserve capacity” of the lower urinary 
tract system (177-179).  
Timed voiding 
Timed voiding is a fixed voiding schedule that re-
mains unchanged over the course of treatment (176). 
The goal is to prevent UI by providing regular oppor-
tunities for bladder emptying prior to exceeding blad-
der capacity. Timed voiding has been recommended 
for patients who cannot participate in independent toi-
leting (180). It also has applicability for use in outpa-
tient settings with incontinent women who have infre-
quent or irregular voiding patterns (181) and men who 
are independent in their voiding function (182).  
Habit training 
Habit training is a toileting schedule matched to the 
individual’s voiding pattern based on their voiding di-
ary. The toileting schedule is assigned to fit a time in-
terval that is shorter than the person’s normal voiding 
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pattern and precedes the time when incontinent epi-
sodes are expected. Thus, the voiding interval may 
be lengthened or shortened throughout the day de-
pending on the patient’s voiding pattern with the goal 
to pre-empt UI. Habit training is usually implemented 
by caregivers in institutional settings with cognitively 
and/or physically impaired adults, but it has also been 
tested in homebound older adults (183). It is poten-
tially useful for adults without cognitive or physical im-
pairment, who have a consistent pattern of UI (181).  
Prompted voiding 
Prompted voiding refers to a caregiver education pro-
gramme in combination with a scheduled voiding reg-
imen, typically every two hours. It is used to teach 
people with or without cognitive impairment to initiate 
their own toileting through requests for help and pos-
itive reinforcement from caregivers when they do so 
(184). It has been used primarily in institutionalized 
settings with cognitively and physically impaired older 
adults.  
Section Overview 
This section examines evidence for the use of blad-
der training and timed voiding for the prevention and 
treatment of UI in non-institutionalised women of all 
ages without cognitive or mobility impairment. How-
ever, the majority of evidence available pertains to the 
effects of bladder training, thus this is the focus of this 
section.  
Previously, no trials were identified that tested habit 
training or prompted voiding for UI in independent-liv-
ing women without cognitive or physical impairment, 
and no new trials meeting these criteria were identi-
fied in this update. Therefore, evidence for use of 
habit training and prompted voiding is not included in 
this section. 
Questions addressed in this section include: 
 Can scheduled voiding regimens prevent UI? 
 What is the most appropriate bladder training 
protocol? 
 Is bladder training better than no treatment, pla-
cebo or control treatments? 
 Is bladder training better than other treatments? 
 Can any other treatment be added to bladder 
training to add benefit? 
 Does the addition of bladder training to other 
treatments add any benefit? 
 Is timed voiding effective at treating UI? 
 What is the effect of bladder training on other 
LUTS? 
 What factors might affect the outcome of bladder 
training? 
7.1. Prevention 
Previously no trials had examined scheduled voiding 
regimens as a sole intervention in the prevention of 
UI. In this update, no further trial was identified.  
7.2. Treatment  
Previous recommendations related to bladder train-
ing as treatment for UI were based on review of indi-
vidual published trials and three systematic reviews 
that provided descriptive synthesis with evidence 
grading (180, 185, 186), including a published 
Cochrane review last updated in 2006 (185). In this 
ICI update, 5 additional trials were identified and are 
described in the relevant sections below (98, 102, 
156, 187, 188). 
7.2.1 What Is the Most Appropriate Bladder 
Training (BT) Protocol? 
Previously no trials were identified that compared two 
or more methods of bladder training (BT), and none 
were identified for this update. In the absence of trials 
comparing two or more approaches, a content analy-
sis was performed looking at the protocols used in tri-
als investigating the effects of BT. It has been up-
dated for this edition. Twenty-two trials on BT involv-
ing a total of 3194 women have been identified, in-
cluding 5 trials involving 732 women added since the 
last update (98, 102, 156, 187, 188). Several of the 
trials previously reviewed (189-194) and 2 of the new 
trials identified for this update (156, 187) provided no 
or minimal details regarding the specific BT protocol 
used. In trials that did provide some description, BT 
protocols were implemented in differing ways. In the 
following review of BT protocols, information from 
studies added in this update are integrated with infor-
mation from previously reviewed studies.  
All protocols involved some type of patient education, 
namely: 
 Brief verbal (191, 192) or written instructions 
(195, 196) 
 Verbal, written, and audio-visual instruction (177, 
179, 197) 
 Introduction to an individual who successfully 
completed BT (193)  
If specified, the education was provided by nurses 
(177, 179, 189, 190, 198, 199), general practitioners 
(200), or physiotherapists (98, 102, 188). 
Scheduling of voids varied in the following ways: 
 Assignment of the initial voiding interval varied 
from 30 minutes to two hours, with one hour be-
ing the most common interval based upon the 
participant’s voiding pattern or 30 minutes be-
yond the participant’s average (195, 201) or 
longest (102) voiding interval. 
 Adjustments to the voiding interval varied from 
15 to 30 minutes, with 30 minutes the most com-
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mon interval. Increases were made daily for in-
patient regimens (193), after 48 hours of dryness 
(202), every four to five days (201), or weekly if 
schedule was well-tolerated (102, 177, 179). 
 Goals for optimal voiding interval varied from 
three to four hours. 
 Voiding was ‘mandatory’ with restriction of void-
ing in between assigned toileting times even if UI 
occurred (193), a scheduled voiding regimen 
that allowed interruptions in the schedule if ur-
gency became unbearable (177, 179, 199), or 
self-scheduling of voiding with a target goal to 
reach (195). 
 Voids were not scheduled (allowed) during 
sleeping hours (193); none of the other protocols 
identified how voids were handled during sleep-
ing hours. 
In some protocols the scheduled voiding regimen was 
supplemented by specific strategies to control ur-
gency and/or stress leakage, including distraction 
and relaxation (102, 177, 179, 188, 195, 199), and 
pelvic floor muscle contraction (102, 177, 190, 196). 
In other studies there was encouragement to sup-
press urge but it was not clear what strategies were 
used (192, 200, 203). Feedback techniques included 
self-monitoring (177, 179, 191, 194, 199), goal setting 
with feedback of progress (198), and positive rein-
forcement (177, 179, 201). 
Several protocols included use of adjunctive treat-
ments: 
 Fluid and caffeine adjustments (197, 199, 203) 
 Fluids allowed up to a certain level (1,500 ml) 
(202) 
 No fluid modifications (102, 177, 179, 195, 200) 
 Advice on constipation prevention (199) 
Both in and outpatient BT programmes have been 
used. Early inpatient BT programmes involved five to 
13 days of hospitalisation to ensure strict protocol ad-
herence (193). Outpatient programmes are more 
commonly described and the amount of health pro-
fessional contact ranged from weekly visits for six 
weeks with fortnightly telephone calls for six addi-
tional weeks (177), to weekly visits (179, 188, 189), 
fortnightly visits (102, 201), and monthly visits (202). 
A “simplified” BT treatment with minimal to no health 
professional contact (instructions given to patients on 
a one page instruction sheet) has also been tested 
(195, 196). 
Overall, there is a lack of consistency in BT protocols. 
Based on the protocols described, a reasonable out-
patient BT protocol, based on expert opinion is shown 
in Figure 7.  
Typical Bladder Training Regimen 
 An initial voiding interval typically beginning at 
one hour during waking hours, which is in-
creased by 15 to 30 minutes per week depending 
on tolerance of the schedule (such as fewer in-
continent episodes than the previous week, min-
imal interruptions to the schedule, and the pa-
tient’s feeling of control over urgency and confi-
dence to expand the voiding interval), until a two 
to three hour voiding interval is achieved. A 
shorter initial voiding interval, e.g. 30 minutes or 
less, may be necessary for patient whose base-
line micturition patterns reveal an average day-
time voiding interval of less than one hour. 
 Education about normal bladder control and 
methods to control urgency such as distraction 
and relaxation techniques and PFM contraction.  
 Self-monitoring of voiding behaviour using dia-
ries or logs in order to determine adherence to 
the schedule, enhance self-awareness, evaluate 
progress, and determine whether the voiding in-
terval should be changed (for example, see Fig-
ure 7). 
 A supervising health care professional to monitor 
progress, suggest adjustments to the voiding in-
terval, and provide positive reinforcement to pa-
tient undergoing BT at least weekly during the 
training period. 
 If there is no improvement after three weeks of 
BT, re-evaluation is warranted and other treat-
ment options would be considered. Inpatient BT 
programmes may follow a more rigid scheduling 
regimen with progression of the voiding interval 
on a daily basis. 
Summary 
There is still no trial evidence to suggest the most ef-
fective method or specific BT parameters. For those 
undertaking BT it is likely that more health profes-
sional contact will be better than less, based on the 
developing evidence for PFMT, which like BT, re-
quires behavioural change (Level of Evidence: 4). 
The literature suggests several areas that could be 
investigated in future trials, including the instructional 
approach, supervisory intensity, strategies for con-
trolling urgency, scheduling parameters, frequency of 
schedule adjustments, length of treatment, and use 
of adjunctive treatments. 
Recommendations  
Clinicians and researchers are advised to refer to the 
operant conditioning and educational literature to pro-
vide a rationale for their choice of their approach to 
BT. The ICS Consensus statement and review pa-
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pers on Adherence and PFMT could be useful to cli-
nicians and researchers (24-27). (Grade of Recom-
mendation: D).  
Clinicians should provide the most intensive BT su-
pervision that is possible within service constraints 
(Grade of Recommendation: D).  
More research is needed to investigate which BT pa-
rameters, supervisory intensity, and adjunctive treat-
ments are most effective. Future trials should include 
outcomes that matter to patients, including the length 
and frequency of supervisory contact. 
7.2.2 Is BT Better than No Treatment, Pla-
cebo or Control Treatments? 
BT as sole therapy has been used in the treatment of 
DO, urodynamic SUI, MUI, UUI, UUI with a stable 
bladder, and OAB (also called urgency-frequency 
syndrome).  
No new trials were identified that addressed this 
question. Previously 5 RCTs reporting on 515 women 
were identified that compared the effect of BT to no 
treatment or control (179, 189, 194, 199, 200). Of 4 
trials with relevant analysable data (179, 189, 194, 
200), 3 reported improvements in the BT group com-
pared to the control group (179, 194, 200). The trial 
quality and detailed results were presented in previ-
ous editions of this chapter. 
Summary 
The few available trials (reviewed previously) were 
small and of variable quality. No new trials were iden-
tified in this update.  
There is  limited Level 1 evidence that BT may be an 
effective treatment for women with UUI, SUI, and MUI 
(Level of Evidence: 1). 
Recommendations  
BT should be recommended as first line conservative 
therapy for UI in women (Grade of Recommenda-
tion: A).  
Additional high quality studies are needed that exam-
ine the effect of BT versus no treatment in treatment 
of women with UUI, SUI, and MUI. 
7.2.3 Is BT Better than Other Treatments? 
This section, considered trials which compared BT 
alone versus another active therapy.  
For the comparison of BT versus PFMT see II.2.3.3. 
The only other comparison for which trials were found 
was BT versus drug therapy. One additional trial was 
identified for this update (98). Previously, two small 
trials were identified that randomized 131 women with 
UUI to BT or drug treatment (193, 201).  
Kafri et al. (98) randomized 184 women with UUI to 
one of four groups: BT, PFMT, tolterodine extended 
release 4 mg or combined behavioural therapy (BT 
and PFMT). Results from the BT and drug treatment 
group comparison are included here, while results of 
   
Figure 7 Bladder diary 
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the BT vs PFMT comparison are included in section 
II.2.3.3. 
Quality of data 
Kafri et al. (98, 201) was a single-blinded trial in which 
83 women were randomized to drug treatment or BT 
and followed up for 12 months. A power calculation 
and adequate random allocation concealment were 
reported. Drug tolerability and adverse events were 
assessed, but side effects were reported in a compo-
site outcome only. Intent-to-treat principles were fol-
lowed. Drop out at 3 months was higher in the drug 
treatment compared to BT group (36% vs 5%) (98).  
Results 
In Kafri (98), the number of self-reported UUI epi-
sodes in the past week significantly decreased at 3 
and 12 months in both the BT and drug treatment 
groups. Between group comparisons suggested no 
difference in outcomes. Differential dropout sug-
gested drug treatment was associated with more ad-
verse effects, but this was not clearly reported. These 
results were similar to one previously reviewed trial in 
short-term outcomes (201), but in that trial symptoms 
recurred more often after drug treatment than after BT 
at 6 months follow-up. Another older trial found BT 
superior to drug treatment at 3 months follow-up 
(193). Both previously reviewed trials found adverse 
effects common in the drug treatment groups, but not 
in BT groups. 
Summary 
Despite an additional trial, it remains unclear whether 
BT or drug therapy is more effective for women with 
DO or UUI (Level of Evidence: 1).  
This result is consistent with the findings of the 
Cochrane review (185), which concluded that there 
was not enough evidence to determine whether first 
line therapy should be BT or anticholinergic drugs. 
Recommendations  
When considering BT and anticholinergic drug for 
women with DO or UUI, either may be effective 
(Grade of Recommendation: B).  
BT may be preferred by women and clinicians be-
cause it is not associated with the drug related side 
effects (Grade of Recommendation: D). 
7.2.4 Can Any Other Treatment Be Added to 
BT to Add Benefit? 
To be included here, trials needed to investigate the 
effects of BT versus BT plus therapy A to address the 
additive benefit of therapy Three new trials were iden-
tified that tested the additional benefit of PFMT, drug 
therapy and tibial nerve transcutaneous electrical 
stimulation when added to BT (102, 156, 187). One 
trial addressed the added benefit of PFMT to BT (102) 
and is considered in the section on PFMT (II.2.3.4). A 
2010 randomized trial tested the additive effects of 
tibial nerve transcutaneous electrical stimulation in 51 
older women undergoing “routines of care” which in-
cluded BT and Kegel exercises (156). As BT was 
combined with pelvic floor exercise treatment in both 
groups and no details were provided about the BT 
protocol, it was not possible to determine the effects 
of BT alone, and it is not considered further here. The 
third trial tested the addition of oxybutynin, imipra-
mine or placebo to BT in 282 men and women with 
DO who had failed at least 8 weeks treatment of BT 
alone (187). However, very limited information is 
available on the methods and results (abstract only). 
This trial was also not considered further.  
Prior editions of this chapter identified trials address-
ing the additional benefit of caffeine reduction, PFMT, 
and drug therapy when combined with BT. The caf-
feine reduction trial was included in the Lifestyle In-
terventions (II.1) section (203), and the trial address-
ing additional benefit of PFMT when added to BT was 
included in the PFMT section (II.2.3.4) (177). Three 
trials previously identified tested the added benefit of 
drug therapy to BT treatment. One of these tested a 
drug that is no longer available (terodiline), and is not 
considered further (192). The remaining trials in-
cluded one that randomized 34 women and men with 
DO to BT or BT plus imipramine therapy (202), and 
another that randomized 60 women and men to BT 
and placebo or BT plus immediate release oxybutynin 
(191). No difference was seen in incontinence out-
comes between the groups in either trial, although 
subjective improvement was greater with addition of 
a drug in one (191). Data quality and detailed results 
from these trials were reviewed in past editions of this 
chapter.  
Summary 
No new trials contributed evidence in this area. In two 
small trials (reviewed in previous editions) comparing 
BT (or BT plus placebo) versus BT plus drug in DO, 
there was a suggestion that the effect of BT might be 
enhanced by active drug (Level of Evidence: 2). 
However, both trials were small, conducted in gen-
der-mixed sample populations, and outcomes were 
not common to both trials. Thus, there is insufficient 
evidence to derive a conclusion related to the effec-
tiveness of augmenting BT with drug therapy. 
Recommendations  
Direct comparisons of BT versus BT with drug for UI 
treatment are needed to address the question of 
whether the effect of BT can be augmented by drug 
therapy. No recommendation is possible (Grade of 
recommendation D). 
7.2.5 Does the Addition of BT to Other Treat-
ment Add Benefit? 
To be included here, trials needed to investigate the 
effects of Therapy A versus Therapy A plus BT to as-
sess the added benefit of BT over Therapy A alone. 
A search for trials that investigated the effects of 
PFMT alone versus PFMT plus BT, and drug therapy 
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alone versus drug therapy plus BT was performed. 
No new trials focused on this question were identified.  
Three trials were reviewed in previous editions of this 
chapter, including one older study that compared BT, 
PFMT and combination therapy in 204 community-
dwelling women with SUI and/or DO (177). Two larger 
RCTs compared a “simplified” BT (administered by 
providing participants with a 1 page written instruc-
tions on BT) plus drug therapy (tolterodine (2mg twice 
daily) (190, 195) and solifenacin (5/10mg daily)(195)) 
to drug therapy alone in women and men with OAB 
with or without UUI. UI outcomes were secondary 
endpoints in these trials. 
Summary 
A single trial found combining BT with PFMT im-
proved short-term outcomes compared to PFMT 
alone, but the added benefit did not persist three 
months later (Level of Evidence: 2).  
There is no evidence for an added benefit of combin-
ing brief written BT instructions with tolterodine (2mg 
twice daily) or solifenacin (5/10mg daily) compared to 
drug therapy alone for urgency incontinence (Level 
of Evidence: 2), although these trials were likely un-
derpowered to study UI outcomes.  
Recommendations  
With no new trials contributing evidence in this up-
date, the available evidence (single trial) supports the 
use of BT as a supplement to PFMT in improving 
short-term outcomes, but not longer-term results 
(Grade of Recommendation: C). 
Limited evidence suggests the addition of written in-
formation on BT for women with OAB taking an anti-
muscarinic drug does not further improve UI (Grade 
of Recommendation: B).  
More research is needed using an appropriately su-
pervised BT programme combined with drug therapy 
versus drug alone. 
7.2.6 Is Timed Voiding Effective at Treating 
UI? 
The Cochrane review on timed voiding for manage-
ment of UI in adults was last updated in 2010 (204). 
Ostaszkiewicz (2010) considered randomized and 
quasi-randomised trials only and identified two trials 
comparing timed voiding combined with additional in-
terventions (including medications) to usual care. 
Both trials were conducted in nursing homes and 
most participants were elderly women with cognitive 
impairment. Neither study recruited participants that 
met criteria for inclusion here. 
No new trials were identified that tested timed voiding 
for UI in women without cognitive or physical disabil-
ity. Previously, two older non-randomised studies, ex-
cluded from the Cochrane review, reported findings 
on the effects of timed voiding in women with UUI, 
stable bladders with UUI, and MUI (205, 206). One of 
these, a small, double-blind crossover study com-
pared timed voiding plus anticholinergic drug therapy 
(terodiline) to timed voiding plus placebo (205). As 
terodiline is no longer available, this study was not 
considered further. The second study was a small 
case series of 20 women with mild UI treated with 
timed voiding and followed from 6 weeks to 8 months 
after treatment (206). A successful outcome (not ob-
jectively quantified) was reported in 79% of partici-
pants.  
Summary 
There are no RCTs, or high quality observational 
studies, providing evidence on the effects of timed 
voiding for UI in cognitively intact, community-dwell-
ing women, and no new trials considering this were 
identified. Based upon the data from one small un-
controlled study, it seems a two-hour timed voiding 
schedule may be beneficial in treating women with 
mild UI, infrequent voiding patterns, and stable blad-
der function (Level of Evidence: 3). 
Recommendations  
Timed voiding with a two-hour voiding interval may be 
considered as a sole intervention for women with mild 
UI or infrequent voiding patterns (Grade of Recom-
mendation: C) Timed voiding may also be consid-
ered as an adjunct to other treatment.  
7.3. Other LUTS 
Two new trials were identified that reported frequency 
outcomes. Kafri et al. (98) compared BT to drug treat-
ment and reported on frequency outcomes (others re-
viewed in section II.7.2 above). A second trial ad-
dressed the added benefit of PFMT to BT (102) and 
reported frequency as a secondary outcome. This 
trial is considered in the section on PFMT (II.2.3.4).  
Older trials (from past editions of this chapter), which 
also contributed evidence related to other LUTS out-
comes, compared BT to drug therapy (190, 193, 201), 
BT to no treatment (179, 189, 194), BT plus placebo 
to BT and drug treatment (191), and additive effects 
of a simplified BT program to drug treatment (195, 
196).  
Quality of data 
The quality of data in the new trial that tested BT vs 
drug treatment was described earlier (II.VII.2c). 
Results  
i) Urgency: No new trials reported on urgency out-
comes. In previously reviewed trials, urgency results 
were conflicting. An older trial suggested BT was su-
perior to drug treatment (193), but another reported 
greater improvement in urgency after drug treatment 
or combined drug and BT treatment compared to BT 
alone (190). Two larger trials found no additional im-
provement in urgency when a simplified BT treatment 
was added to drug treatment for OAB (195, 196).  
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ii) Daytime (diurnal) frequency:  
A newly identified trial found frequency improved at 3 
and 12 months after treatment with BT, drug treat-
ment (tolterodine extended release 4 mg), or a com-
bined BT and PFMT group (98). On average, subjects 
reported 2 to 4 fewer voids per 24 hours after treat-
ment. Between group differences were not reported. 
In previously reviewed trials, frequency improved to a 
greater extent in BT groups compared to no treatment 
(179, 189, 194). In trials testing BT compared to drug 
treatment, frequency improved in both groups simi-
larly (190, 201), or to a greater extent in the BT group 
(193). In one trial testing the additive effect of drug 
treatment to BT, a greater reduction in frequency was 
reported in the BT plus drug treatment group com-
pared to BT plus placebo group (191). Lastly, two tri-
als found that “simplified” BT significantly augmented 
the effect of drug alone. BT with tolterodine had 
greater improvement in voiding frequency compared 
to drug alone (33% versus 25% improvement, re-
spectively; p<0.001) and BT with solifenacin reduced 
the number of voids in 24 hours to a greater extent 
compared to drug alone (2.8 versus 2.1 fewer voids 
in 24 hours; p<0.001) (195, 196). 
iii) Nocturia: No new trials were identified reporting on 
nocturia. Three previously reviewed trials reported 
data in comparisons of BT with no treatment, and 
found reductions in nocturia after BT but not in the 
control group (179, 189, 194). Four previously re-
viewed trials compared BT with drug therapy. Two 
smaller trials found BT superior compared to drug 
treatment in treating nocturia (193, 201). Another trial 
compared BT plus placebo versus BT plus drug (191) 
and found no difference in nocturnal micturition fre-
quency. Song (2006) reported that nocturia improved 
similarly in women with OAB treated with BT (56.1%), 
tolterodine (65.4%), and combined treatment (66.3%) 
(190).  
Summary 
No trials were identified which tested the effective-
ness of BT compared to no treatment or a control for 
urgency. It remains unclear whether BT or drug treat-
ment is more effective in treating urgency (Level of 
Evidence: 2).  
Several trials, including one newer study, suggest BT 
is effective at improving frequency, (Level of Evi-
dence: 1), but it is unclear whether BT or drug treat-
ment is more effective (Level of Evidence: 2). Two 
larger, higher quality trials show that the addition of 
“simplified” BT to drug treatment does not provide ad-
ditional benefit in treating urgency, but does improve 
frequency (Level of Evidence: 1). A few small, ran-
domized trials of variable quality suggest BT is effec-
tive at treating nocturia (Level of Evidence: 2). Addi-
tional small trials do not find that BT (or BT added to 
drug treatment) is more effective at treatment of noc-
turia than drug treatment, but evidence is limited 
(Level of Evidence: 2).  
Recommendations  
Insufficient evidence exists to support either the use 
of BT to treat urgency in women with UI and/or OAB, 
or to guide the choice of BT vs drug treatment as ini-
tial treatment aimed at urgency (Grade of Recom-
mendation: D).  
Routine addition of a “simplified” BT to drug therapy 
does not provide additional improvement in urgency, 
but should be considered in treatment of voiding fre-
quency in women with UI and OAB (Grade of Rec-
ommendation: B).  
BT should be offered as treatment for urinary fre-
quency and nocturia (Grade of recommendation: 
B), but in choosing between BT and an anticholiner-
gic drug for women with frequency, either may be ef-
fective (Grade of Recommendation: B). 
7.4. Factors Affecting Outcome 
Few trials on BT have examined predictors of treat-
ment response. New trials reviewed for this update 
did not contribute additional information related to 
predictors of timed voiding or BT treatment response. 
8. COMPLEMENTARY AND 
ALTERNATIVE MEDICINES 
There is limited, but growing evidence that comple-
mentary and alternative medicines (CAMs) may influ-
ence physiological function and/or health outcomes. 
CAMs include those therapies that are not part of the 
traditional biomedical model, such as meditation, im-
agery, hypnosis, acupuncture and naturopathic and 
herbal remedies.  
This section reviews the current evidence for the ef-
fects of CAMs on UI in cognitively intact, community-
dwelling women. Studies focused on UI in women 
with neurogenic aetiologies (for example, UI associ-
ated with stroke or multiple sclerosis) have been ex-
cluded. A summary of the search strategy used for 
selecting studies for review is provided in section I.  
In the 5th ICI, a single RCT focused on hand acupunc-
ture therapy was reviewed here. Given the lack of ev-
idence, no recommendations related to CAMs were 
made for women with UI. Since then, additional RCTs 
and a Cochrane review have been published. Many 
of these trials tested various acupuncture techniques 
for UI; these are reviewed and summarized below.  
Small individual trials testing other types of CAM ther-
apy (for example, meditation and relaxation therapies 
and natural supplements) for UI were identified in the 
current search, many labelled as pilot trials. As rec-
ommendations cannot be made based on the minimal 
evidence available for any individual type of CAM 
therapy, these are not formally reviewed here. As in-
terest in CAM therapies grows and more evidence ac-
crues, additional types of non-traditional therapies 
may be reviewed in future editions. 
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Acupuncture and UI 
Acupuncture and related techniques have been per-
formed as part of Eastern medicine for thousands of 
years. Related therapies may include body acupunc-
ture, hand acupuncture, electroacupuncture and acu-
pressure, amongst others. Their mechanisms of ac-
tion are not fully understood, but discussions of these 
mechanisms related to treatment of UI from tradi-
tional Chinese medicine and other perspectives are 
available (207, 208).  
8.1. Prevention 
In the 5th ICI, no trials examined acupuncture for the 
prevention of UI. In this update, no new trials were 
identified. 
8.2. Treatment 
8.2.1 Acupuncture for Treatment of SUI 
Previously, one low-quality RCT that studied the ef-
fect of hand acupuncture vs control (no treatment) for 
female SUI in 52 women (209) was identified. In this 
update, a recently-published Cochrane review of ac-
upuncture and SUI was reviewed (207), which in-
cluded one trial of acupuncture vs drug treatment for 
SUI (210). An additional trial of acupressure for the 
treatment of is included in this update (211).    
The 2013 Cochrane review considered evidence for 
acupuncture interventions from traditional Chinese 
medicine (body acupuncture, scalp acupuncture, 
electroacupuncture, warm acupuncture, fire needle 
and elongated needle), and did not consider trials of 
other interventions, such as hand acupuncture and 
acupressure (207). The authors searched and re-
viewed English and Chinese language publications. 
Only 1 trial was included (many were excluded be-
cause they combined acupuncture with other treat-
ments or compared different types of acupuncture). 
The single eligible trial randomized 60 women to ac-
upuncture vs a drug treatment (midrodine) and re-
ported subjective improvement and cure and adverse 
effects at 6 to 12 weeks (207).  
Chang et al. completed an RCT of 81 women with 
urodynamic SUI, randomized to 3 groups including 
acupressure, sham acupressure and “usual care” in-
cluding PFMT (taught at baseline) (211). The treat-
ment and sham groups underwent 3 weekly treat-
ment sessions for 10 weeks. No information was pro-
vided on performance of PMFT (or other treatments) 
in the “usual care” group (or the other treatment 
groups). Outcomes were assessed after the 10-week 
treatment period. The primary outcome was pelvic 
floor muscle strength. Numbers of urine leak epi-
sodes from a 4-day diary and a subjective assess-
ment of urine incontinence severity were also as-
sessed.  
Quality of data 
Randomization concealment was inadequate in both 
trials (207, 211). No blinding or partial blinding was 
performed. Few participants withdrew from the trials 
(<5%). Adverse effects were reported in 1 reviewed 
trial (207). 
Results  
More women reported improvement in the acupunc-
ture group (73% vs 33%; risk ratio 2.2 (95% CI 1.3-
3.8)) compared to drug treatment (207). Cure rates 
were low and not different between the groups (13% 
vs 7%; risk ratio 2.0 (95% CI 0.4, 10.1)). Adverse ef-
fects were reported in the drug group only (including 
headache, dizziness, and thirst).  
In the trial comparing acupressure, sham acupres-
sure vs PFMT alone, numbers of incontinence epi-
sodes were unchanged and did not differ between 
groups, although self-reported severity of leakage im-
proved to a greater extent in the acupressure com-
pared to the sham acupressure group (p=0.04) and 
to PFMT alone (p=0.01) (211).  Adverse effects were 
not reported. 
Summary 
A single trial suggests acupuncture may be better 
than drug treatment in SUI (Level of Evidence: 2), 
but the low quality and atypical comparator group lim-
its the impact of these results.   
A single trial suggests mixed results for acupressure 
compared to sham treatment or usual care in treat-
ment of SUI (Level of Evidence: 2), but the low qual-
ity and small numbers limit these findings.  There is 
inadequate evidence to know if acupuncture or acu-
pressure treatments are effective for SUI in women. 
Recommendations 
No recommendations can be made regarding the use 
of acupuncture or acupressure for SUI in women. 
High-quality RCTs are needed. 
8.2.2 Acupuncture for Treatment of OAB, UUI 
and Mixed UI 
In this update, two recently-published reviews were 
identified which focused on acupuncture for women 
with OAB, UUI or Mixed UI, as well as an additional 
trial (not included in the reviews) (208, 212, 213).  
Paik et al. (208) performed a systematic review of 
RCTs published in English or Korean language jour-
nals testing acupuncture and acupressure treatments 
for UI. Four small RCTs were found eligible for that 
review. One of these studied acupressure for SUI and 
is discussed in the section above (211), but 3 are con-
sidered in this section, all published before 2010 
(214-216). A second review focused on acupuncture 
and OAB in non-comparative and comparative trials 
(212).  This review identified 4 RCTs relevant to this 
section (comparative trials of acupuncture for women 
with UI), 3 of which were also included in the review 
by Paik et al. (214-217). Thus, in total 5 RCTs (four 
included in the recently published reviews and 1 ad-
ditional trial) are included in this edition. Study popu-
lations included  women with OAB and UUI (214, 
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215), OAB with or without UUI (217), MUI and UUI 
(216) and MUI (213). 
Two trials compared acupuncture to sham or placebo 
acupuncture (215, 216). One was a pilot RCT which 
tested acupuncture vs sham acupuncture (sham nee-
dles which did’nt puncture the skin were used) in 9 
women with mixed or urgency UI (216). The second 
trial randomised 74 women with OAB including UUI 
to acupuncture vs acupuncture performed at relaxa-
tion points (215). Two trials compared acupuncture to 
drug treatment, including an older trial that tested ac-
upuncture vs oxybutynin 5 mg twice daily in 39 
women with OAB with UUI (214). A recent, larger trial 
randomized 272 women with OAB with or without UUI 
to acupuncture or tolterodine 2 mg twice daily (217). 
Last, Jin et al. studied combination therapy with elec-
troacupuncture plus tolterodine 2 mg twice daily ver-
sus electroacupuncture alone in 71 women with MUI 
(213). 
Acupuncture techniques and regimens differed 
widely among the studies, including different acu-
puncture points treated. Treatments occurred 1 to 3 
times weekly, lasted 4 to 8 weeks and outcomes were 
assessed immediately after treatment or 2 to 12 
weeks later.  
Quality of data 
Randomization concealment was considered ade-
quate in 2 of 5 trials (215, 217), one testing acupunc-
ture vs placebo acupuncture and one comparing ac-
upuncture to drug treatment (tolterodine). Blinding of 
participants and assessors was done in the trials test-
ing acupuncture with a sham or placebo treatment 
(215, 216). Participants were not blinded in the 3 trials 
involving acupuncture and drug treatments (213, 214, 
217), and assessors were blinded in only 1 of these 
(217). Sample size calculations were reported in only 
one trial (215). Adverse effects were described in 4 of 
5 trials (214-217). 
Results  
Overall, no differences were seen in primary out-
comes when comparing acupuncture with sham or 
placebo treatment and when comparing acupuncture 
with drug treatment. One small trial comparing acu-
puncture vs sham acupuncture in women with MUI 
reported greater reductions in overall incontinence 
episodes and urgency incontinence episodes in the 
acupuncture group after 4 weeks of treatment (67.5% 
vs 16.7% and 75.2% vs 24.9%, respectively), but sta-
tistical significance was not reached (216). Another 
trial of acupuncture vs sham acupuncture (relaxation 
points) in women with OAB and with UUI found a non-
significant reduction in incontinence episodes (59 and 
40% in the treatment and placebo groups) (215). For 
acupuncture treatment compared to drug therapy (ox-
ybutynin or tolterodine) in women with OAB, no differ-
ence was seen in improvement in UUI episodes be-
tween treatment groups (214, 217). In one, frequency 
and urgency improved but UUI was unchanged and 
in the other, frequency, urgency and UUI improved, 
but no between group differences were reported 
(214). In the trial comparing combination treatment 
with electroacupuncture and tolterodine to electro-
acupuncture alone for MUI, both groups had signifi-
cant reductions in overall UI episodes and in urine 
leakage volume on pad test, but these outcomes did 
not differ between groups. Significantly more women 
in the combination treatment group had a more than 
50% improvement in number of UI episodes (76 vs 
59%, p<0.05) (213).   
No serious adverse effects occurred. Minor bruising 
and bleeding as well as some discomfort with needle 
placement were described (214-217). 
Summary 
Two trials (small to medium size) of varying quality 
found no or limited benefit in testing acupuncture to 
various sham treatments for MUI and OAB\UUI in 
women (Level of Evidence: 2).  
Several factors limit these results, including small 
sample size, risk of bias and heterogeneity of active 
and sham treatments. Two trials comparing acupunc-
ture to drug therapy in women with OAB, UUI and 
MUI found no difference between treatments (Level 
of Evidence: 2). One low quality trial suggested com-
bination therapy of electroacupuncture plus drug for 
MUI was superior to electroacupuncture alone (Level 
of Evidence: 2). 
Recommendations 
When choosing between acupuncture and anticholin-
ergic drug for women with OAB, UUI and MUI, either 
may be effective (Grade of Recommendation: B).  
There is insufficient evidence to make a recommen-
dation related to the effectiveness of augmenting 
electroacupuncture with drug therapy (Grade of rec-
ommendation: D). High-quality RCTs are needed, 
including standardized acupuncture treatment regi-
mens. 
Conclusions 
Limited evidence is available for the use of acupunc-
ture techniques for the treatment of UI in women. 
Challenges in this area (in performing research as 
well as in interpreting the literature) include a lack of 
consistency in acupuncture techniques and regimens 
and controversy regarding the best comparator 
(sham or placebo acupuncture) (218). Also, much of 
the literature is not published in English language 
journals. Given the limitations to the quality and the 
heterogeneous nature of evidence available, few for-
mal recommendations are possible related to use of 
acupuncture for SUI, UUI, MUI or overall UI in 
women. More rigorously-conducted RCTs are 
needed in this area. 
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9. FUTURE RESEARCH DIRECTIONS  
9.1. Summary 
Even with the number of reasonable trials on con-
servative management of UI in women, the standards 
of trial conduct and reporting varied considerably. It is 
strongly recommended that future RCTs on con-
servative management include power and sample 
size calculation, account for potential risk of bias, in-
tervention content and intensity, and choice of out-
come measures prior to conducting the trial. 
9.2. Recommendations for practice  
While some recommendations are underpinned by 
good and consistent evidence of effects, there re-
mains a need for further testing because of insuffi-
cient Level 1 and Level 2 evidence.  
9.2.1 Lifestyle Intervention 
Treatment:  
Nonsurgical weight loss should be considered a first 
line treatment to reduce UI in obese and overweight 
women (Grade of Recommendation: A).  
Moderate exercise may help in decreasing the inci-
dence of UI: this effect may be mediated by weight 
control (Grade of Recommendation: C). 
Caffeine reduction may help in improving inconti-
nence symptoms (Grade of Recommendation: B).  
Minor decrease of fluid intake (by 25%) may be rec-
ommended provided baseline consumption is not 
less than 30 ml/Kg a day (Grade of Recommenda-
tion: B). 
9.2.2 PFMT (Principal Recommendation) 
PFMT in the prevention of UI in childbearing 
women: Continent, pregnant women should be of-
fered a supervised (including regular health profes-
sional contact) and intensive strengthening antepar-
tum PFMT programme to prevent antepartum and 
postpartum UI (Grade of Recommendation: A). 
PFMT in the treatment of UI in childbearing 
women: PFMT should be offered as first line con-
servative therapy to women with persistent UI symp-
toms three months after delivery (Grade of Recom-
mendation: A). 
An ‘intensive’ PFMT programme (in terms of supervi-
sion and exercise content) is likely to increase the 
treatment effect (Grade of Recommendation: B). 
PFMT in the prevention/treatment of UI in 
childbearing women: Health providers should care-
fully consider the cost/benefit of population based ap-
proaches to health professional taught antepartum or 
postpartum PFMT, that is, health professional instruc-
tion to all pregnant or postpartum women regardless 
of their current or prior continence status (Grade of 
Recommendation antepartum PFMT: A). (Grade 
of Recommendation postpartum PFMT: B).  
Where a population approach is used, the ‘best’ evi-
dence to date suggests the following: (a) an interven-
tion comprising of a daily home PFMT and weekly 
physiotherapist-led exercise classes for 12 weeks, 
starting at 16-24 weeks’ gestation for pregnant 
women, and (b) an individually taught strengthening 
PFMT programme that incorporates adherence strat-
egies for postpartum women who have had a forceps 
delivery or a vaginal delivery of a large baby (4000g 
or more) (Grade of recommendation: C). 
i) Other women PFMT 
Prevention: 
There is preliminary evidence that PFMT may help 
prevent UI in older women.  (Grade of Recommen-
dation: C New). 
Treatment:  
Supervised PFMT should be offered as first line con-
servative therapy to women urinary incontinence 
(Grade of Recommendation: A). 
Clinicians should provide the most intensive health 
professional-led PFMT program possible within ser-
vice constraints because programs that are thaught 
and supervised by health-professionals are better 
than those with little or no supervision (Grade of Rec-
ommendation A).  
Although studies are limited, there does not appear to 
be clear benefit for adding other modalities (i.e. motor 
learning, abdominal- or hip-muscle training, intra-vag-
inal resistance device) to PFMT (Grade of Recom-
mendation: B) 
There is no clear benefit from adding clinic- (Grade 
of Recommendation B) or home-based BF (Grade 
of Recommendation B) to a PFMT program. The 
use of clinic or home-based BF should remain a ther-
apist/individual decision based on individual’s needs 
and service constraints. 
ii) Other women PFMT vs other intervention 
For women with SUI: 
 PFMT and VC are both effective as conservative 
therapy, although PFMT is superior (Grade of 
Recommendation: B). 
 PFMT is better than EStim as first line conserva-
tive therapy (Grade of Recommendation: B). 
 PFMT is better than BT as first line conservative 
therapy (Grade of Recommendation: B). 
 PFMT and drug therapy are both effective as first 
line therapy, PFMT avoids the adverse effects 
experienced with drug therapy (Grade of Rec-
ommendation: B). 
 Surgery is more effective than PFMT, but poten-
tial benefit should be weighed against potential 
adverse events. PFMT should be offered as first 
line conservative therapy (Grade of Recom-
mendation: B New).  
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 PFMT and continence pessary are both effective 
as first line conservative therapy (Grade of Rec-
ommendation: B New). 
For women with SUI or MUI: 
 VC does not appear to be better than PFMT in 
the treatment of UI. PFMT should be recom-
mended as first-line conservative therapy 
(Grade of Recommendation: B).  
VCs with supervised training sessions by a trained 
health professional can be offered to women who can 
and are prepared to use them (Grade of Recommen-
dation: B) 
VC may be inappropriate for some women due to in-
ability to insert or retain the cone or because of side 
effects and discomfort.  
For women with UUI or MUI: 
 PFMT and BT should be offered as effective first-
line conservative therapies (Grade of Recom-
mendation: B). 
 PFMT is better than oxybutynin as first line ther-
apy (Grade of Recommendation: B). 
For women with UUI 
PFMT and BT should be offered as effective first line 
conservative therapy (Grade of Recommendation: 
B). 
iii) Other women PFMT + other intervention vs PFMT 
In women using VC, it does not appear to help to add 
PFMT (Grade of Recommendation: C).  
For the treatment of SUI, UUI, or MUI in women, con-
sider a combination of PFMT and BT rather then BT 
alone (Grade of Recommendation: C).  
For treatment of UUI (tolterodine) but not for SUI (du-
loxetine), consider adding PFMT to drug therapy 
(Grade of Recommendation: B),  
When treating women with SUI and vaginal atrophy, 
consider combining PFMT and intravaginal oestrogen 
over estrogen alone may be better than estrogen 
alone (Grade of Recommendation: C New).  
9.2.3 Cones  
For women with SUI, VC with supervised training ses-
sions by a trained health professional may be offered 
as a first-line conservative therapy to those who can 
and are prepared to use them (Grade of Recommen-
dation: B).  
VC may be inappropriate in some cases due to ina-
bility to insert or retain the cone or because of side 
effects and discomfort. Trained health professional 
assessment is recommended (Grade of Recom-
mendation: D). 
VC and EStim seem equally effective in the treatment 
of SUI and MUI. Side effects and discomfort caused 
by both VC and EStim appears to limit their utility in 
clinical practice (Grade of Recommendation: B). 
If this combined intervention proves to be of interest 
to women, then adequately powered studies are 
needed to confirm or refute the advantages of adding 
VCs to PFMT (No Recommendation).   
9.2.4 EStim 
EStim might be better than no treatment to improve 
symptoms and quality of life in SUI women (Grade of 
Recommendation: B).  
EStim may be considered for treatment to improve 
symptoms for UUI (Grade of Recommendation: B).  
For women with SUI maximal clinic-based EStim 
might be better than daily low-intensity home-based 
EStim in improving symptoms (Grade of Recom-
mendation: B).  
Based on current limited evidence, EStim could be 
considered as an alternative to medical treatment. 
(Grade of Recommendation: B). 
The addition of EStim to PFMT or BF-assisted PFMT 
programmes does not appear to add benefit (Grade 
of Recommendation: B) 
9.2.5 PTNS 
For women with UUI or OAB, PTNS may be more ef-
fective than no active treatment in symptom control 
(Grade of Recommendation: C New).  
There is no significant difference between PTNS and 
tolterodine in terms of quality of life, however PTNS 
may be considered as both may improve quality of life 
and PTNS is less invasive (Grade of Recommenda-
tion: B New).  
PTNS may be considered for women as it is associ-
ated with fewer and less bothersome adverse effects 
than those from drug treatment (Grade of Recom-
mendation: B New).  
PTNS may be considered for symptom control when 
chosen in combination interventions such as with 
PFMT plus bladder training, or drug treatment by 
women with UUI or OAB (Grade of Recommenda-
tion: B New).  
9.2.6 Magnetic Stimulation 
No recommendation is possible based on current 
conflicting evidence (Grade of recommendation: 
D). 
No recommendation is possible regarding optimum 
type of MStim (Grade of Recommendation: D).  
The addition of MStim to PFMT in treatment of SUI 
does not appear to be beneficial (Grade of Recom-
mendation: C). 
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9.2.7 Bladder Training 
BT should be recommended as first line conservative 
therapy for UI in women (Grade of Recommenda-
tion: A).  
Clinicians should provide the most intensive BT su-
pervision that is possible within service constraints 
(Grade of Recommendation: D).  
Clinicians and researchers are advised to refer to the 
operant conditioning and educational literature to pro-
vide a rationale for their choice of their approach to 
BT. (Grade of Recommendation: D). 
When considering BT and anticholinergic drug for 
women with DO or UUI, either may be effective 
(Grade of Recommendation: B).  
BT may be preferred by women and clinicians be-
cause it is not associated with the drug related side 
effects (Grade of Recommendation: D). 
The available evidence (single trial) supports the use 
of BT as a supplement to PFMT in improving short-
term outcomes, but not longer-term results (Grade of 
Recommendation: C). 
Limited evidence suggests the addition of written in-
formation on BT for women with OAB taking an anti-
muscarinic drug does not further improve UI (Grade 
of Recommendation: B).  
Timed voiding with a two-hour voiding interval may be 
considered as a sole intervention for women with mild 
UI or infrequent voiding patterns (Grade of Recom-
mendation: C) Timed voiding may also be consid-
ered as an adjunct to other treatment. 
Insufficient evidence exists to support the use of BT 
to treat urgency in women with UI and/or OAB, or to 
guide the choice of BT vs, drug treatment as initial 
treatment aimed at urgency (Grade of Recommen-
dation: D).  
Routine addition of a “simplified” BT to drug therapy 
does not provide additional improvement in urgency, 
but should be considered in treatment of voiding fre-
quency in women with UI and OAB (Grade of Rec-
ommendation: B).  
BT should be offered as treatment for urinary fre-
quency and nocturia (Grade of recommendation: 
B), but in choosing between BT and an anticholiner-
gic drug for women with frequency, either may be ef-
fective (Grade of Recommendation: B). 
9.2.8 Complementary and Alternative Medi-
cine 
Acupuncture:  
The limited evidence available to date does not sup-
port the use of acupuncture when compared to sham 
or placebo treatment for women with OAB, UUI and 
MUI.  
When choosing between acupuncture and anticholin-
ergic drug for women with OAB, UUI and MUI, either 
may be effective (Grade of Recommendation: B).  
There is insufficient evidence to make a recommen-
dation related to the effectiveness of augmenting 
electroacupuncture with drug therapy (Grade of rec-
ommendation: D).  
High-quality RCTs are needed, including standard-
ized acupuncture treatment regimens. 
9.3. Future Research Direction 
All future trials must be designed, implemented and 
reported in ways that maximise their usefulness in 
practice; this includes being well powered, with longer 
term follow up, with evaluation of cost-effectiveness 
and planned secondary analysis of trial data to inves-
tigate predictors of effectiveness. Readers are re-
ferred to the revised CONSORT statement for guid-
ance (219). 
9.3.1 Lifestyle Modification Intervention  
Prevention should be an area for future research in-
vestment and comprise robust economic evaluation 
to determine the benefits of lifestyle modification 
strategies in women with UI. 
With limited new data on the effects of physical activ-
ity (moderate or strenuous), smoking cessation, diet 
modification and constipation, their association with 
UI development or symptom reduction should be in-
vestigated further. 
Separate investigation of the impact of lifestyle modi-
fication interventions on nocturia, diurnal frequency, 
urgency and UI should be undertaken. 
9.3.2 PFMT in Antenatal and Postnatal 
women  
 Additional trials with longer-term follow-up 
(greater than 12 months postnatal) are needed 
to determine long-term benefits of antenatal 
PFMT.  
 Large and good-quality RCTs are needed to in-
vestigate the effect of antepartum PFMT on pre-
venting postpartum UI in multiparous women. 
 Large and good-quality RCTs are needed to in-
vestigate the effect of intensive post-partum 
PFMT on preventing postpartum UI in women. 
Attention must be given to high risk subgroups. 
 There is a need for at least one large, pragmatic, 
well-conducted and explicitly reported trial with 
long term follow-up (five plus years) of postpar-
tum PFMT that investigates the long term effect 
of ‘intensive’ PFMT for persistent postnatal UI. 
9.3.3 PFMT in Women (Others) 
The effect of PFMT in the prevention of UI in women 
should be studied further.  
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Larger, good quality trials are needed to address 
comparisons between PFMT regimens, PFMT and 
other modalities or PFMT + another modality and 
PFMT alone, if these are of interest to women. In 
planning comparisons, researchers should consider 
carefully power calculation, intervention intensity and 
the potential impact of different levels of supervisory 
intensity between groups, particularly in comparisons 
of conservative therapies.  
9.3.4 Vaginal Cones  
Larger, good quality trials are needed to address 
comparisons between VC and other modalities, and 
VC+ other modalities compared to VC, if these are of 
interest to women. In planning comparisons re-
searchers should consider carefully power calcula-
tion, intervention intensity and the potential impact of 
different levels of supervisory intensity between 
groups, particularly in comparisons of conservative 
therapies. 
9.3.5 EStim/PTNS/MStim 
Larger, good quality trials are needed to address 
comparisons between EStim/PTNS/MStim and no 
treatment, EStim/PTNS/MStim and other modalities, 
EStim/PTNS/MStim + other modalities and ES-
tim/PTNS/MStim, if these are of interest to women. In 
planning comparisons researchers should consider 
carefully power calculation, intervention intensity and 
the potential impact of different levels of supervisory 
intensity between groups, particularly in comparisons 
of conservative therapies. 
9.3.6 Scheduled Voiding Regimen 
Larger, good quality trials are needed to address 
comparisons between BT and no treatment, BT and 
other modalities, BT + other modalities and BT, if 
these are of interest to women. In planning compari-
sons researchers should consider carefully power 
calculation, intervention intensity and the potential im-
pact of different levels of supervisory intensity be-
tween groups, particularly in comparisons of con-
servative therapies. 
 PELVIC ORGAN PROLAPSE 
(POP) 
Pelvic organ prolapse (POP) refers to the loss of sup-
port for the uterus, bladder, colon or rectum leading 
to prolapse of one or more of these organs into the 
vagina. Prolapse is characterised by a variety of pel-
vic floor symptoms (2), the most commonly reported 
being a sensation of bulging into the vagina. Treat-
ment depends on the severity of the prolapse and its 
symptoms, and the woman's general health (2). Con-
servative treatment is generally considered for those 
with a lesser degree of prolapse, those who wish to 
have more children, those with frailty or those unwill-
ing to undergo surgery. Conservative management, 
defined here as lifestyle modification interventions, 
PFMT and pessaries, was first reviewed in the 3rd ICI 
and in the 5th was recommended as first-line treat-
ment for prolapse. 
The aims of conservative treatment in the manage-
ment of POP include: 
 preventing the prolapse becoming worse; 
 decreasing the frequency or severity of symp-
toms caused by prolapse (pelvic pressure, vagi-
nal bulging, backache, urinary, bowel and sexual 
dysfunction); 
 aversion or delaying of the need for surgery. 
In this section the evidence is presented for the use 
of conservative management of POP, utilising infor-
mation from Cochrane systematic reviews (220-222), 
and literature identified via a search strategy summa-
rised in Section I. For included trials, risk of bias 
(RoB) was assessed using the Cochrane Collabora-
tions RoB tool (223). For other types of study, bias 
was assessed using the Critical Appraisal Skills Pro-
gramme (CASP) (224) checklist item relating to ad-
justment in analysis for potential confounding risk fac-
tors. 
1. LIFESTYLE MODIFICATION 
INTERVENTION 
Lifestyle modification interventions include weight 
loss, reducing exacerbating activities (e.g. lifting, 
coughing) and treating constipation, and are intended 
to avoid worsening of the prolapse by decreasing in-
tra-abdominal pressure. 
1.1. Prevention 
1.1.1 Quality of Data 
No trials of lifestyle modification interventions to pre-
vent prolapse were identified in this update. However, 
12 observational studies (retrospective reviews, pro-
spective surveys and case-control studies) that ex-
amined the association between modifiable lifestyle 
factors such as occupation (involving heavy lift-
ing/strenuous physical activity), bodyweight, smok-
ing, constipation, nutrition and the development of 
prolapse have been published since last review, 
which add to the 33 previously described (9 in 5th edi-
tion, 15 in 4th edition and 9 in 3rd edition). These are 
reported and summarised in Table 26. Studies often 
examined multiple risk factors and contribute evi-
dence to more than one section below. If modifiable 
lifestyle factors are established as risk factors for pro-
lapse these could be targeted with a view to preven-
tion. 
1.1.1.1 Association Between POP and Oc-
cupation and Physical Activity  
To date, the potential relationship between occupa-
tion and physical activity on prolapse has received 
scant attention (5 studies in 3rd edition (225), 5 in 4th 
edition(226), 3 in 5th edition(2)). A recent narrative lit-
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erature review (227) investigated the effect of physi-
cal activity and occupation on the development of 
prolapse. The review authors identified 10 studies, all 
of which have been reviewed in–depth in previous 
editions of this chapter. They concluded that the evi-
dence linking physical activity and occupation with an 
increased risk for POP was weak and inconclusive.  
Our systematic search identified a further 5 additional 
studies, included (228-232). The key characteristics 
of these studies are described in Table 26. 
Akmel et al. (2012) conducted a retrospective study 
of women in one Ethiopian hospital treated surgically 
for prolapse over three years (230). Medical interns 
extracted data from the women’s medical records on 
demographics, medical, surgical and obstetric his-
tory, symptoms and risk factors. Only univariate anal-
ysis was performed and therefore the study was 
judged to be at high risk of bias (Table 26). 
Bathla et al. 2014 (232) carried out a retrospective re-
view of case notes for women who presented with 
prolapse at mobile surgical camps in a remote village 
of Himachal Pradesh between 2009- 2013. Women 
underwent POP-Q assessment prior to surgery. The 
aim was to study the epidemiological risk factors for 
prolapse, including occupation and nutrition (see be-
low). The analysis was mainly descriptive although 
the authors report they did “correlation regression”, 
but it was not clear what this was, and therefore the 
results were difficult to interpret and at high risk of 
bias (Table 26). 
Gumanga et al. (2014) undertook a prospective study 
of women presenting with prolapse at gynaecological 
outpatients at a hospital in Ghana over two years 
(2010-2011), describing occupational, socio-cultural 
practices and obstetric characteristics and how they 
related to severity of prolapse (231). Data collected 
included demographics, reproductive history and pel-
vic examination findings. Women were included if 
they complained of a mass in the vagina and had de-
monstrable descent on pelvic examination. There 
was no control group so analysis of risk factors was 
not possible, thus the study was at high risk of bias 
(Table 26). 
Lonnée-Hoffmann et al. (2015) recently reported on a 
cross sectional study they undertook in women 30 
years or older in one Nordic county in the Nord-
Trøndelag Health Study (228). Outcome measures 
examined were self-reported prolapse surgery, age at 
survey, socio-demographic factors, and information 
on risk factors for prolapse (smoking, chronic obstruc-
tive pulmonary disease, asthma, constipation a dec-
ade previously, and measured body mass index) (see 
Table 26). Multivariable logistic regression was used 
for analysis thus the study was judged to be at low 
risk of bias. 
Nygaard et al. (2014) conducted a retrospective 
case-control study of women with prolapse (descent 
≥ 1 cm beyond the hymen) and without prolapse (de-
scent ≤ 1 cm above the hymen), age and site 
matched, to assess the impact of lifetime physical ac-
tivity on the risk of prolapse (229). Women were re-
cruited from primary care or community advertise-
ments, and were not seeking treatment for prolapse. 
Physical activity was measured using the Lifetime 
Physical Activity Questionnaire (LPAQ), which as-
sesses physical activity over four periods (start of 
menstruation to age 21, 22-34, 35-50, and 51-65 
years), and includes leisure activity, outdoor work, 
and housework. The Occupation Questionnaire (OQ), 
part of the LPAQ, was also used. Multivariable mod-
els were fitted to assess the effect of physical activity 
on prolapse indicating a low risk of bias for this study 
(Table 26). 
1.1.1.2 Association Between POP and Body 
Weight  
There has been little agreement on whether an in-
crease in weight (or increased waist circumference or 
higher BMI) is linked with an increased risk of POP. 
Seventeen studies have evaluated the effects of bod-
yweight on POP since the previous editions (4 in 5th 
edition, 5 in 4th edition, 6 in 3rd edition) (228, 233-248). 
In addition, two reviews have recently been published 
on this topic (249, 250) (Table 26). The former litera-
ture review included a study by Kudish and col-
leagues (2009) – which had not previously been in-
cluded in earlier editions of this chapter – it is there-
fore included here (251). 
1.1.1.3 Association Between POP and 
Smoking 
Three studies on the relationship between smoking 
and prolapse were identified (228, 232, 252). In addi-
tion, Kudish (2009) investigated smoking as a risk 
factor (251). 
Estanol and colleagues (252) studied female smok-
ers and non-smokers with and without prolapse in a 
cross-sectional study in one centre. Smokers and 
non-smokers without prolapse were age matched to 
smokers and non-smokers with prolapse. The aim 
was to examine the impact of smoking on collagen 
markers (MMP-9) and vitamin C, in those with and 
without prolapse. Women with prolapse had a bulge 
at or beyond the hymen on examination, and an-
swered positively to two Pelvic Floor Distress Inven-
tory (PFDI) questions on the feeling of a bulge or a 
visible bulge in the last 12 months. A univariate anal-
ysis of the associations was carried out, thus a high 
risk of bias was assumed (Table 26). 
A significant association between POP and smoking 
has also been reported in 2 studies above (228, 251). 
Bathla et al., (2014) also noted that 30-57% of their 
sample were smokers; collectively these studies sug-
gest that smoking is a risk factor for POP.  
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Table 26 Summary of data on lifestyle factors and POP 
Author, 
year 
Study design/ 
Comparator 
N Study population 
Modality details/methods 
employed 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
POP and Occupation/Physical activity 
Akmel 
2012 (1) 
Retrospective 
descriptive case note 
analysis 
129 Patients who were 
admitted and operated 
on in the gynaecology 
ward in one hospital in 
Ethopia. All the women 
with POP who were 
admitted and treated 
during the study period 
were included; no 
sampling technique was 
employed 
Demographic and medical 
characteristics were 
extracted based on the initial 
medical history and physical 
examination documentation 
in the case records 
Type of occupation was 
strongly associated with stage 
of prolapse. Housewives were 
more likely to have stage IV 
(vs stage III) prolapse 
compared to farmers. 
 
None Data was available for 
129 out of a possible 
143 women. No 
multivariate analysis to 
allow for other 
confounding variables. 
Bathla 
2014(2) 
Retrospective 
descriptive case note 
analysis  
157 157 women who had 
POP surgery conducted 
in 5 mobile surgical 
camps in Shillai, 
Himachal Pradesh from 
2009 to 2013 (“Project 
Prolapse”).  
Epidemiological data and 
POP-Q data were collected. 
 
Factors contributing to POP 
believed to be “poor nutritional 
status (mean weight 41.1 kg), 
multiparity (mean 3.5), early 
marriage (mean age 18.2 
years), unassisted home 
deliveries (100%), premature 
bearing down (23.8%), early 
postpartum resumption of 
strenuous activity (54.7%) and 
smoking (33%)” This was not 
based on statistical analysis. 
None “Statistical analysis was 
performed using 
correlation regression 
analysis”, but limited 
data presented. No 
multivariable analysis 
performed. 
 
Gumanga 
2014 (3) 
Prospective 
observational study 
118 POP cases, out-patients 
seen over 2-year study 
period at a teaching 
hospital in Ghana.  
 
Questionnaires and physical 
exam in patients whose 
main complaints included “a 
mass falling from the vagina” 
or “bulging mass” or 
“sensation of mass in the 
vagina”. 
Main occupations were 
trading of produce 66/118 
(55.9%) and farming 44/118 
(37.3%) 
None Authors report that 
occupational factors 
might contribute to the 
severity of POP in this 
sample. Analysis 
undertaken is unclear 
but appears not to be 
multivariable analysis. 
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Author, 
year 
Study design/ 
Comparator 
N Study population 
Modality details/methods 
employed 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
Lonnee-
Hoffmann 
2015 (4) 
Cross-sectional 
survey 
 
20,285 All women aged ≥ 30 
years in one Nordic 
county invited to take 
part 
 
Women were sent 
questionnaires and attended 
screening stations. Risk 
factors assessed: smoking, 
chronic obstructive 
pulmonary disease, asthma, 
constipation a decade 
previously, and measured 
BMI 
POP surgery was reported by 
1,123 (5.3 %). Only women 
reporting more lifting in 
addition to walking had 
significantly higher odds of 
reporting POP surgery 
compared with women with 
sedentary occupation in the 
age-adjusted model 
None Authors also report that 
constipation reported a 
decade prior, above-
normal BMI, and COPD 
were significant non-
obstetric risks for 
prolapse surgery. 
Multivariable analysis 
performed. 
Nygaard 
2014 (5) 
Retrospective case-
control study 
382 191 POP cases and 191 
age and recruitment-site 
matched controls, aged 
between 39-65 years, not 
seeking prolapse 
treatment  
Women were asked to 
complete Lifetime Physical 
Activity and Occupation 
Questionnaires based on 
self-reported activities 
No associations between 
odds of POP and overall 
lifetime physical activity, 
lifetime leisure activity, or 
lifetime strenuous activity 
None Authors suggest that 
strenuous activity 
during teenage years 
may have an 
association with POP, 
and recommend further 
prospective research in 
this area 
Multivariable analysis?? 
POP and Smoking (see also entries for Bathla 2014, Kudish 2009 and Lonnee-Hoffmann 2015) 
Estanol 
2015 (6) 
Cross-sectional 
study 
96 4 groups of women: 
smokers with POP 
(n=16), non-smokers 
with POP (n=16), 
smokers without POP 
(n=32) and non-smokers 
without POP (n=32) 
Fasting blood panel, 
including plasma 
procollagen 1-N propeptide 
(P1NP), matrix 
metalloproteinase 9 (MMP-
9), and vitamin C. These are 
markers of collagen 
metabolism. Smokers were 
defined as smoking 1 pack 
or more a day for at least 1 
year; non-smokers were 
defined as not having 
smoked for at least 7 years 
Comparing women with POP 
and without, there were no 
significant differences in 
vitamin C, P1NP and MMP-9 
levels, independent of 
smoking status. 
MMP-9 levels were higher and 
vitamin C lower in smokers 
compared to non-smokers.  
None Small sample size; was 
not sufficiently large to 
detect a true difference, 
particularly in those 
with prolapse. 
No multivariable 
analysis 
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Author, year 
Study design/ 
Comparator 
N Study population 
Modality details/methods 
employed 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
POP and Bowel function (see also entries for Kudish 2009 and Lonnee-Hoffmann 2015) 
Bezerra 2014 
(7) 
Cross-sectional 
survey 
 
172 
Participants referred to 
one tertiary 
urogynecology outpatient 
clinic with self-reported 
symptoms of PFD: POP 
[POP-Q ≥ stage II and/or 
UI] 
Medical history, series of 
questionnaires (ICIQ-SF; 
KHQ; PISQ-12), Cleveland 
Constipation Scale and 
physical exam using the 
PERFECT scheme.  
No differences in 
prolapse status between 
patients with and without 
anal incontinence and/or 
bowel disorders. 
 
None  No multivariable 
analysis 
Elbiss 2015 (8) 
 
Cross-sectional 429 
Women attending family 
development centres in 
United Arab Emirates, 
29.6% reported POP 
symptoms 
Questionnaire included 
items for details of socio-
demographic, obstetrics, 
medical and surgical history. 
Presence of a lump in/out of 
vagina was taken as 
presence of POP. 
Chronic constipation and 
chest disease, level of 
education, occupation 
birth weight and BMI 
were independent risk 
factors for having POP 
symptoms. 
 
None 
Multivariable analysis 
was performed. Authors 
recommended 
additional healthcare 
campaigns to raise 
awareness about risk 
factors for POP 
POP and Nutrition (see also entries for Estanol, 2015) 
Navaneethan 
2015 (9) 
Prospective case-
control study 
120 Women with (n=51) or 
without (n=69) PFD on 
examination when 
attending outpatient clinic 
at one tertiary care 
centre in South India 
Medical history and clinical 
examination (POP-Q) were 
performed. Serum 25-
hydroxy vitamin D levels 
were measured in all 
participants 
 
23/51 had POP alone, 
9/51 had POP+SUI; 
vitamin D levels were not 
significantly associated 
with POP 
None Multivariable analysis 
performed to adjust for 
age. 
 
Parker-Autrey 
2012 (10) 
Retrospective chart 
review 
394 Women over 19 years 
old attending a 
Urogynecology Care 
Clinic from 2008 to 2010 
who had vitamin D 
measured. 
Diagnosis categorized as 
PDF (SUI, UUI, FI, POP) 
(n=268) or general GYN 
(n=126). Demographic and 
medical characteristics were 
extracted. PFDI-SF 20, IIQ-
7, Medical, Epidemiologic, 
and Social Aspects of Aging 
(MESA) questionnaire.  
Only higher IIQ-7 scores 
were significantly related 
to having insufficient 
vitamin D. 
 
None Multivariable logistic 
regression model used 
to adjust for age, BMI, 
ethnicity, and use of vit. 
D supplementation 
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Author, year 
Study design/ 
Comparator 
N Study population 
Modality details/methods 
employed 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
POP and body weight  
Myers et al., 
2012(11) 
Secondary data 
analysis of RCT 
338 Overweight and obese 
women with UI  
Women were randomised 
either into an intensive 6-
month weight loss or to the 
control group (educational 
program) 
Symptomatic prolapse was 
defined as a positive 
response to at least 1 
prolapse subscale question 
of the UDI. "Bother" was 
defined as responses of 
slight, moderate, or great. 
Increasing BMI was 
associated with only 
"feeling" a vaginal bulge. 
(13% of obese women 
reported feeling vaginal 
bulging compared with 
overweight women (0%). 
Evaluated for 
prolapse 
symptoms at 
baseline and 6 
months 
At 6 months, there were 
no significant 
differences in 
improvement of self-
reported bothersome 
prolapse symptoms in 
women in the weight 
loss or the control 
group 
Multivariable analysis 
was performed.  
Kudish 2009 
(12) 
Secondary analysis 
of a 5-yr clinical trial 
16608 Post-menopausal women 
aged 50-79 yrs 
Degree of prolapse 
assessed using the WHI 
Prolapse 
Classification System 
Prolapse risk in 
overweight and obese 
women (compared with 
the women with healthy 
BMI) increased by 32% 
and 48% for 
cystocele, by 37% and 
58% for rectocele, and by 
43% and 69% for uterine 
prolapse, respectively 
Annual pelvic 
exam over a 5 
year interval 
Being overweight or 
obese is associated 
with progression of 
POP. Authors reported 
that “weight loss was 
not significantly 
associated with 
regression of POP”, 
and argued that pelvic 
floor damage related to 
weight gain could be 
irreversible 
Multivariable analysis 
was performed. 
Abbreviations: PFDI-20: pelvic floor distress inventory short form 20, PFIQ-7: pelvic floor impact questionnaire short form; PFM: pelvic floor muscles; PFMT: pelvic floor 
muscle training; POP-Q; Pelvic Organ Prolapse Quantification system; PISQ-12: Pelvic organ prolapse/urinary incontinence sexual questionnaire’ POP-SS: pelvic organ 
prolapse symptom score; QoL: quality of life; RCT: randomized controlled trial; sEMG: surface electromyography; SR: systematic review; UI: urinary incontinence 
1. Akmel M, Segni H. Pelvic organ prolapse in jimma university specialized hospital, southwest ethiopia. Ethiop J Health Sci. 2012;22(2):85-92. 
2. Bathla S, Verghese G, Kalla V, Sharma TC, Dam S, Agarwal N, et al. Reaching the unreached: Mobile surgical camps in a remote village of Himachal Pradesh. J 
Midlife Health. 2014;5(3):139-42. 
3. Gumanga SK, Munkaila A, Malechi H. Social demographic characteristics of women with pelvic organ prolapse at the Tamale Teaching Hospital, Ghana. Ghana 
Med J. 2014;48(4):208-13. 
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4. Lonnee-Hoffmann RA, Salvesen O, Morkved S, Schei B. Self-reported pelvic organ prolapse surgery, prevalence, and nonobstetric risk factors: findings from the 
Nord Trondelag Health Study. Int Urogynecol J. 2015;26(3):407-14. 
5. Nygaard IE, Shaw JM, Bardsley T, Egger MJ. Lifetime physical activity and pelvic organ prolapse in middle-aged women. Am J Obstet Gynecol. 2014;210(5):477 
e1-12. 
6. Estanol MV, Crisp CC, Oakley SH, Kleeman SD, Fellner AN, Pauls RN. Systemic markers of collagen metabolism and vitamin C in smokers and non-smokers with 
pelvic organ prolapse. Eur J Obstet Gynecol Reprod Biol. 2015;184:58-64. 
7. Bezerra LRPS, Vasconcelos Neto JA, Vasconcelos CTM, Karbage SAL, Lima AC, Frota IPR, et al. Prevalence of unreported bowel symptoms in women with pelvic 
floor dysfunction and the impact on their quality of life. International Urogynecology Journal and Pelvic Floor Dysfunction. 2014;25(7):927-33. 
8. Elbiss HM, Osman N, Hammad FT. Prevalence, risk factors and severity of symptoms of pelvic organ prolapse among Emirati women. BMC Urology. 2015;15(1):no 
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9. Navaneethan PR, Kekre A, Jacob KS, Varghese L. Vitamin D deficiency in postmenopausal women with pelvic floor disorders. J Midlife Health. 2015;6(2):66-9. 
10. Parker-Autry CY, Markland AD, Ballard AC, Downs-Gunn D, Richter HE. Vitamin D status in women with pelvic floor disorder symptoms. Int Urogynecol J. 
2012;23(12):1699-705. 
11. Myers DL, Sung VW, Richter HE, Creasman J, Subak LL. Prolapse symptoms in overweight and obese women before and after weight loss. Female pelvic medicine 
& reconstructive surgery. 2012;18(1):55-9. 
12. Kudish BI, Iglesia CB, Sokol RJ, Cochrane B, Richter HE, Larson J, et al. Effect of weight change on natural history of pelvic organ prolapse. Obstet Gynecol. 
2009;113(1):81-8. 
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1.1.1.4 Association Between POP and 
Bowel Function 
Previously there were 8 studies that had examined 
the potential impact of bowel disorders/ or bowel dys-
function on prolapse (4 in 5th edition, 4 in 4th edition). 
This update adds a further 4 studies. Two are de-
scribed below; two have been described above (Lon-
nee-Hoffman et al., 2012; Kudish et al., 2009).  
Bezerra et al. (2014) undertook a cross-sectional 
study of women with pelvic floor disorders (POP-Q ≥ 
stage II and/or urinary incontinence) presenting at a 
tertiary urogynaecology clinic in Brazil (253). The aim 
was to report the prevalence, bother, and impact on 
quality of life (QoL) of unreported bowel symptoms, to 
improve the patient care. Those with and without def-
aecatory or anal continence problems were com-
pared. A number of measures were used depending 
on the presence/absence of bowel and urinary incon-
tinence symptoms: ICIQ-SF, King’s Health Question-
naire, PISQ-12, the Wexner score, Cleveland Clinic 
Florida Incontinence Scale, Cleveland Clinic Florida 
Constipation Scale (mild, moderate or severe). All 
women completed the SF-36 and had their pelvic 
floor assessed by a physiotherapist using the 
PERFECT scheme. Only univariate analysis was per-
formed, putting the study at a high risk of bias (Table 
26). 
Elbiss and colleagues (238) carried out a cross-sec-
tional study of parous Emirati women 30 years or 
older attending three family development centres in 
Al-Ain in one year. The objective was to EStimate the 
prevalence of prolapse and its risk factors. The study 
used a self-developed questionnaire, which was pi-
loted and revised before use. The questionnaire cov-
ered demographic, obstetrics, and medical history, 
prolapse symptoms (lump coming down in the 
vagina, lump coming out of vagina or lump felt or seen 
outside vagina), other vaginal symptoms and the 
need to digitate to empty bladder or bowel. Following 
univariate analysis, multivariable binary logistic re-
gression analysis (prolapse symptoms versus no pro-
lapse symptoms) was performed including all signifi-
cant variables to determine which were independent 
risk factors for prolapse (Table 26). This study was 
judged as having a low risk of bias. 
1.1.1.5 Association Between POP and Nu-
trition 
Two studies were identified in previous editions of the 
chapter that examined the effects of anaemia (4th edi-
tion) and vitamin D (5th edition) on prolapse. A further 
2 studies relating to vitamin D are included in this up-
date (Table 26).  
Navaneethan et al (2015) conducted a case-control 
study of postmenopausal women with and without 
pelvic floor disorders, in particular, symptoms of uri-
nary incontinence or prolapse. It was not clear how 
the women were selected but the study took place in 
a department of obstetrics and gynaecology in South 
India. A clinical and obstetric history was taken, ex-
amination performed (POP-Q and stress test) and vit-
amin D measured in all women. A multivariable lo-
gistic regression analysis was undertaken to assess 
the relationship between vitamin D and PFD adjusting 
for other variables (254). A low risk of bias was as-
sumed (Table 26). 
Parker-Autry et al. (2012) in Alabama, US, undertook 
a retrospective review of women who were new 
urogynaecology outpatients presenting over a two-
year period (2008 to 2010) and who then had vitamin 
D measured within one year of that visit. 25(OH)D < 
15 ng/ml was defined as being deficient in vitamin D, 
and 15 to 29 ng/ml as having insufficient vitamin D. 
Women were classified into two groups, either PFD 
(having SUI, UUI, FI or POP) or general gynaecology 
(no PFD) (Table 26). Demographic, medical, and la-
boratory data were extracted from the initial history 
and physical examination notes. Questionnaire re-
sponses from the clinic visit were also available 
(PFDI-SF 20 (including the UDI, CRADI, POPDI) and 
IIQ-7). Multivariable logistic regression was used to 
examine the association between vitamin D status 
and pelvic floor disorder symptoms, with adjustment 
for age, BMI, race/ethnicity, and the use of vitamin D 
supplementation. This study was judged to be at low 
risk of bias. 
1.1.2 Results 
1.1.2.1 Association Between POP and Oc-
cupation and Physical Activity  
In the Akmel et al. (2012) study, 143 prolapse cases 
were examined and complete data retrieved for 129 
cases. The mean age of the women was 42 years 
(range 22 to 72 years), mean parity was 6.5 (range 1 
to 14) and all had stage III (56%) or IV (44%) pro-
lapse. Significant univariate associations were found 
between age, parity and rurality and stage of pro-
lapse. Occupation was significantly associated with 
prolapse stage in that farmers were more likely to 
have a lower stage and housewives a higher stage of 
prolapse (230). 
In the retrospective case analysis described by 
Bathla et al. (2014), 192/490 surgical case presenta-
tions were gynaecological and 82% of these were 
prolapse (99% involving the anterior compartment). 
These women were aged between 30 and 70 (mean 
47 years), had mean parity of 3.5, and all had unas-
sisted home deliveries. Premature bearing down dur-
ing delivery was reported for 24%. Women on aver-
age resumed strenuous physical work and sexual ac-
tivity 20 days after giving birth. 33% were smokers 
and 55% lifted heavy weights uphill. The authors re-
ported non-significant correlations between POP-Q 
stage and parity, resumption of physical activity and 
weight (232). 
Out of 4403 outpatients, 118 cases (2.7%) of pro-
lapse were seen over the study period in the 
Gumanga (2014) paper, with a mean age of 46 years 
(SD 15 years) and mean parity 4.4 (SD 1.7). For 57% 
106 
of women their deliveries had been exclusively at 
home. Women were predominantly farmers (37%) or 
traders (56%) (231). 
Of all women in the county 30 years or older, 20,285 
(50.3%) were included in the Lonnee-Hoffman (2012) 
study; of which 1,123 (5.5%) reported having under-
gone prolapse surgery. In the multivariable models, 
the odds of having prolapse surgery were shown to 
be significantly greater for women with BMI of 25 or 
greater, and for those who reported “marked” consti-
pation (as compared to no or mild constipation). 
There was no relationship with smoking, asthma or 
occupation (228). 
One hundred and ninety-one cases and an equal 
amount of matched controls were recruited in the Ny-
gaard et al. (2014) study. The mean age of women 
was 50 years (SD 7). Cases tended to have a higher 
BMI than controls, and had significantly greater parity 
and more vaginal deliveries. Vaginal bulge was more 
prevalent in the cases than controls, but there was no 
difference in other pelvic floor symptoms. The authors 
found no evidence that physical activity (lifetime over-
all activity, leisure or strenuous physical activity) was 
associated with risk of prolapse in multivariable mod-
els. The exception was that strenuous physical activ-
ity in the teenage years showed a significant relation-
ship with the odds of prolapse, indicating an in-
creased risk of prolapse for those reporting 21 
hours/week or more of strenuous physical activity 
when a teenager (229). 
Elbiss (2015) found nature of occupation to be a sig-
nificant predictor of prolapse symptoms (see below); 
women with non-physical jobs were more likely to re-
port symptoms. 
1.1.2.2 Association Between POP and Body 
Weight 
Vergeldt et al. (2015) systematically identified 8 stud-
ies that examined the association of higher BMI and 
POP and presented the results in a narrative synthe-
sis. The authors reported that 4/8 studies identified 
that higher BMI was a significant risk factor for POP; 
3/8 found no relationship between high BMI and the 
development of primary POP and 1/8 study found that 
a “higher BMI slightly protective”. The authors re-
ported that the relationship between weight and POP 
was inconsistent; thus no conclusions can be reliably 
drawn (250). This well-conducted review was judged 
to be at low risk of bias. 
Kudish and colleagues (2009) explored the relation-
ship between prolapse progression (or regression) 
and weight change in 16,608 post-menopausal 
women (Table 26). This secondary analysis study 
was based on longitudinal data from the WHI E+P 
trial; a double-blinded RCT. Women aged between 
50 and 79 years received annual pelvic examinations 
over a 5-year interval. The majority of women enrolled 
in the study gained weight, and the overall prolapse 
prevalence (stage I-III) increased from 40.9% at 
baseline to 43.8% by year 5. The risk of all types of 
prolapse increased in overweight and obese women 
compared to post-menopausal women with normal 
BMIs (Table 26). When the data was adjusted for 
women diagnosed with prolapse at baseline and 
baseline BMI, a 10% weight loss was associated with 
minimal change in overall POP (251). This study was 
judged to be at low risk of bias. 
1.1.2.3 Association Between POP and 
Smoking 
In the Estanol (2015) study, a total of 96 women were 
recruited: 32 with prolapse (16 smokers, 16 non-
smokers) and 64 without prolapse (32 smokers, 32 
non-smokers) (252). Smokers with prolapse had 
lower levels of vitamin C and higher levels of MMP-9, 
compared to non-smokers with prolapse, but this re-
lationship was not statistically significant. However, 
comparing smokers without prolapse to non-smokers 
without prolapse, there were significant differences in 
both vitamin C and MMP-9, suggesting an impact of 
smoking on these collagen markers. Ignoring smok-
ing status, vitamin C and MMP-9 levels in women with 
prolapse were similar to those without prolapse. The 
authors suggest that the damage to connective tissue 
that leads to prolapse may be different from the harm 
caused by cigarette smoking.  
Lonnee-Hoffman et al. (2015) found no association 
between smoking and whether a woman reported 
having had prolapse surgery or not (228). Bathla et 
al. (2104) commented that 33% of the women having 
prolapse surgery were smokers (232). 
1.1.2.4 Association Between POP and 
Bowel Function  
Bezerra and colleagues reported that a total of 172 
women with prolapse and/or urinary incontinence 
participated and initially none of them reported defe-
catory problems or anal incontinence, although 
54.6% reported one or both on interview. Those with 
AI/defecatory problems were no more likely to report 
prolapse (sensation of a ball in the vagina) than those 
without these problems (68% versus 65%). Stage of 
prolapse was not associated with AI/defecatory prob-
lems either (253). 
Of the 482 eligible women in the Elbiss (2015) study, 
429 (89%) participated, of which 127 (29.6%) re-
ported prolapse symptoms. Those women with and 
without prolapse symptoms did not differ in terms of 
age. Of the factors significantly associated with pro-
lapse in the univariate analysis (BMI, education level, 
nature of occupation, history of chronic chest dis-
ease, constipation, diabetes, previous instrumental 
delivery, maximum birth weight, history of urinary in-
continence and previous surgery for urinary inconti-
nence) six were independent risk factors in the multi-
variable analysis: history of constipation, education 
level, chronic chest disease, nature of occupation, 
maximum birth weight and BMI. Women were more 
likely to have prolapse symptoms if they had chronic 
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chest disease or constipation, higher BMI or maxi-
mum birth weight, lower education level, and were a 
housewife or had a non-physical job (238). 
Lonnee-Hoffman et al (2015) found that marked con-
stipation (as compared to no or mild constipation) was 
significantly associated with having prolapse surgery 
(228). 
1.1.2.5 Association Between POP and Nu-
trition  
Navaneethan et al (2015) reported that of the 120 
women who participated: 42.5% had PFD (54.9% 
prolapse alone, 27.4% SUI alone, 17.6% SUI and 
prolapse) and 57.5% had no PFD. Multivariable anal-
ysis showed that, after adjustment for age, having any 
PFD was associated with having lower vitamin D lev-
els and being five years or more post-menopausal. 
However having prolapse was only associated with 
the latter, and there was no significant relationship 
with vitamin D (254). 
Of 550 women potentially eligible to participate in the 
Parker-Autry (2012b) study, 394 were included (268 
in the PFD group and 126 in the no PFD group). The 
prevalence of vitamin D insufficiency was 51% in the 
PFD group. Vitamin D insufficiency was inde-
pendently associated only with IIQ-7 score. That is, 
there was no relationship with prolapse symptoms 
(255).  
Summary 
 There remain no trials of lifestyle modification in-
terventions to prevent prolapse. Some new ob-
servational studies have added to our knowledge 
of potentially helpful ways to modify lifestyle risk 
factors.  
 Two new good quality observational studies 
(228, 229) suggested occupation and physical 
activity are not risk factors for prolapse surgery 
or prolapse 1cm or more beyond the hymen on 
examination. A third study however found 
women who were housewives or in a non-physi-
cal occupation were more likely to report pro-
lapse symptoms (238). The vast majority of stud-
ies reported in previous editions supported an 
association between current heavy occupational 
lifting and prolapse, overall therefore the evi-
dence seems to be conflicting, and this may be 
due to different ways of defining prolapse (Level 
of Evidence: 3; Grade of Recommendation: D 
Conflicting therefore no recommendation).  
 Recent evidence on the relationship between 
prolapse and bodyweight is conflicting. (Level of 
Evidence: 3; Grade of Recommendation:  D 
Conflicting therefore no recommendation). 
 Smoking was found not to be associated with 
prolapse in two studies: a matched case control 
study (Estanol) (high risk) and large cross-sec-
tional survey with multivariable analysis (Lon-
nee-Hoffman) (low risk). No studies were found 
in earlier editions (Level of Evidence: 3; No rec-
ommendation). 
 Evidence from previous editions regarding the 
association between constipation or straining at 
stool and prolapse was conflicting. Two new, low 
risk studies, which adjusted for covariates, con-
cluded that constipation was associated with 
both prolapse symptoms and having prolapse 
surgery, contributing more evidence of an asso-
ciation (Level of Evidence: 3; Grade of Recom-
mendation: C New; Majority evidence of an 
association).  
 Two new, low risk studies on vitamin D supported 
previous findings (1 study, 5th Edition) of no as-
sociation with prolapse (Level of Evidence: 3; 
Grade of Recommendation: C Majority evi-
dence of no association). 
1.2. Treatment  
Previously no studies that evaluated the effective-
ness of lifestyle modification interventions in the treat-
ment of women with POP had been identified. Sub-
sequently we have identified one trial, which meas-
ured prolapse outcomes after weight loss pro-
grammes (243). Not all trial participants had prolapse 
however, which limits the usefulness of this evidence 
(see Table 26). 
Quality of data 
Myers and colleagues (2012) performed a secondary 
analysis of data from the PRIDE trial of an intensive 
weight loss programme versus an educational pro-
gramme for urinary incontinence in overweight and 
obese women (243). Prolapse symptoms were meas-
ured at baseline and six months (post-intervention) 
using the prolapse items from the UDI. Any positive 
response to any questionnaire items indicated the 
presence of prolapse symptoms. A subgroup of 
women agreed to have urodynamics and POP-Q as-
sessment before and after intervention. Women were 
classified as overweight, obese or severely obese ac-
cording to their BMI. Women who had prolapse symp-
toms at baseline were analysed at 6 months for dif-
ferences between the randomised groups. The risk of 
bias was judged as low in relation to selection, detec-
tion and attrition for the original PRIDE trial (6) in a 
recent Cochrane review (5). 
Results 
Myers et al., (2012) reported that 338 women were 
randomised and 110 had urodynamics and POP-Q 
(243). Of the women randomised, 16% were over-
weight, 58% obese and 26% severely obese. At 
baseline 53% reported at least one prolapse symp-
tom, but this did not differ across BMI groups. A sig-
nificantly greater proportion of obese women reported 
feeling vaginal bulge compared to overweight women 
(10% severely obese vs 14% obese vs 0% over-
weight), but the mean number of prolapse symptoms 
did not differ across the BMI groups. The proportion 
with prolapse beyond the hymen was 17% overall but 
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did not differ across the BMI groups (24% overweight 
group, 17% obese group, 13% severely obese 
group). Post-intervention the intensive weight loss 
group had lost significantly more weight than the con-
trol group (mean 7.8kg vs 1.5kg). Over 70% reported 
cure or improvement in prolapse symptoms, although 
this was no different between the intensive weight 
loss group and the educational group. There was also 
no significant difference in prolapse beyond the hy-
men between weight loss intervention and educa-
tional groups. The findings would suggest a lack of 
relationship between weight loss and improvements 
in prolapse. However, the trial was designed for 
women with urinary incontinence rather than pro-
lapse, and the post-intervention comparison was not 
randomised. 
Summary  
Currently, there is evidence from secondary analysis 
of one robust trial regarding the role of weight loss in 
the treatment of POP. The trial however was in over-
weight and obese women with UI, some of whom had 
prolapse. It would appear that weight loss in both 
groups led to an improvement in prolapse, however 
there was no relationship between degree of weight 
loss (intensive vs normal weight loss programme). 
Any weight loss may improve prolapse in overweight 
or obese women and UI. (Level of Evidence: 2; 
Grade of Recommendation:  D).  
 
2. PELVIC FLOOR MUSCLE 
TRAINING 
The pelvic floor muscles play a critical role in giving 
structural support to the pelvic organs and pelvic 
openings. It is hypothesized that improving pelvic 
floor muscle function may improve this structural sup-
port for the pelvic organs.  
A programme of supervised PFMT includes assess-
ment of the woman’s pelvic floor muscles and her 
ability to contract these muscles; education about the 
pelvic floor muscles and how they support the pelvic 
organs; instruction in how to correctly perform pelvic 
floor muscle exercises and “the Knack” (pelvic floor 
muscle bracing against increased intra-abdominal 
pressure, for example when coughing and sneezing) 
(256). An individualised exercise programme is pre-
scribed for the woman to follow. Adjuncts to PFMT 
(such as biofeedback) or other physical therapies 
(such as neuromuscular EStim) may be used. These 
therapies aim to improve PFM strength, endurance, 
coordination and function. Other forms of physical 
therapy involving diaphragmatic aspiration are 
emerging. 
2.1. Prevention 
Quality of data 
Previously there were no trials of PFMT for prevention 
of prolapse, only evidence from cross-sectional stud-
ies of a possible association between pelvic floor 
muscle function and risk of prolapse. Two RCTs have 
now been identified that evaluate the role of PFMT in 
prevention of prolapse (257, 258). A summary of the 
setting, design and study population of prevention tri-
als is presented in Table 27. Blinding of patients is 
generally not possible in trials of PFMT so this is not 
taken into consideration in the risk of bias analysis. 
Bo et al (2013) (258) carried out a trial in primiparous 
women after vaginal delivery of a singleton infant af-
ter 32 weeks gestation, comparing supervised PFMT 
with written advice to do PFMT (control), to prevent 
and treat prolapse. All women had received written 
recommendations to perform PFMT in the delivery 
ward. The PFMT group attended a weekly PFMT 
class for 4 months starting at 6-8 weeks postpartum, 
and performed home-based exercise. The control 
group had no further supervision or follow-up. Out-
comes measured at 6 weeks and 6 months post-par-
tum included POP-Q stage, bladder neck position 
(transperineal ultrasound) and symptom of vaginal 
bulge (ICIQ-VS). The trial was judged as low risk for 
selection bias, performance and detection bias, attri-
tion bias and reporting bias. However, the trial was 
judged as unclear for other types of bias (Table 27).  
The PREVPROL trial, undertaken by Hagen and col-
leagues, compared PFMT versus lifestyle advice leaf-
let as secondary prevention for women with pre-clini-
cal signs of prolapse (257). Participants were women 
originally enrolled in a longitudinal follow-up of post-
natal incontinence (at 3 months, 6 and 12 years) after 
giving birth in 1993/94. Those, who had not sought 
treatment for prolapse, but who showed early signs of 
prolapse (POP-Q stage I, II or III) were invited to take 
part. They were randomised to receive either a pro-
gramme of PFMT (individualised physiotherapy ap-
pointments, maintenance via Pilates-based classes 
(progressive Pilates-based exercises, pelvic floor 
muscle training as given in the one-to-one interven-
tion, core exercises from the “Pelvicore Technique 
with Kari Bo” DVD) and annual one-to-one check-
ups) or a prolapse prevention lifestyle advice leaflet. 
Women were followed up at 1 and 2 years in terms of 
their prolapse symptoms (POP-SS), prolapse-related 
QoL, uptake of prolapse treatment, symptoms of uri-
nary incontinence (ICIQ-UI SF), anorectal or sexual 
dysfunction (PISQ-12), perceived health benefit, and 
cost-effectiveness.  
The trial was judged as low risk for selection bias, per-
formance and detection bias, attrition bias, reporting 
bias and other types of bias (Table 27).  
Results 
One hundred and seventy-five primiparous women 
were randomised in the Bo (2013) study, 87 to PFMT 
and 88 to control, mean age 30. At 6 months post-
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partum there was no difference between groups in 
the prevalence of symptoms of bulging either inside 
or outside the vagina. There was no difference be-
tween groups in the prevalence of stage II prolapse 
at 6 months, or in any of the individual POP-Q meas-
urements, or the bladder neck position (258).  
In the PREVPROL trial 414 women were randomised, 
207 to PFMT and 207 to control, mean age 46 years 
(257). There was a significantly lower POP-SS score 
at 2 years in the PFMT group compared to the control 
group, indicating fewer symptoms. Women in the 
control group were significantly more likely to have 
sought treatment for prolapse symptoms by 2 years. 
No significant difference was found between the 
groups in the percentage who experienced any urine 
leakage at 2 years, although there was a significant 
difference in favour of the intervention group in the 
ICIQ-UI short form score. Faecal urgency and leak-
age, and sexual function were not significantly differ-
ent between the groups at 2 years. Women in the in-
tervention group were more likely to say they felt a 
health-related benefit from the study compared to the 
control women. 
Summary 
Currently, there is evidence from two robust trials re-
garding the role of PFMT in the prevention of POP. 
The trials were in different populations of women 
however (postnatal women, 13% of whom had stage 
II prolapse, and middle-aged women with mild pro-
lapse, 55% with stage II or greater, who had not 
sought treatment) and drew differing conclusions. It 
would appear that in younger post-natal women 
PFMT does not influence the development of pro-
lapse by 6 months, whereas in older women, more 
than 12 years after giving birth, there was a significant 
benefit of PFMT in terms of fewer prolapse symptoms 
after 2 years and less uptake of treatment. PFMT can 
prevent symptoms of prolapse which develop in the 
longer term after childbirth but not immediately after 
giving birth. 
Postnatal: Level of Evidence: 1; Grade of Recom-
mendation:  B New; majority evidence from RCT 
of no effect for postnatal.  
12 years post-childbirth: Level of Evidence 1; 
Grade of Recommendation: B New; Majority evi-
dence from RCT of effect in the long term after 
childbirth. 
2.2. Treatment 
Quality of data 
Evidence from trials now exists relating to the role of 
PFMT in the treatment of prolapse. The role of PFMT 
as an adjunct to surgery or pessary has also been the 
subject of randomised studies. A Cochrane review 
specifically addressing this question was first pub-
lished in 2004 (259), and updated in 2011 (220) and 
2016 (in preparation) (221).  
2.2.1 PFMT Alone 
Thirteen trials now exist in this area, six of which were 
previously reported in previous consultations. Key 
characteristics of the seven new trials, and new pub-
lished information about two earlier trials, are summa-
rised in Table 28. Narrative descriptions of these trials 
are reported below.  
Alves and colleagues carried out a trial in post-men-
opausal women in which they compared a general fit-
ness programme (control) with a PFMT programme 
(intervention) (47). Both groups performed a fitness 
programme twice weekly for 6 weeks including global 
muscle stretching, endurance and functional exer-
cises. In addition, the intervention group took part in 
a physiotherapist-supervised PFMT programme in 
groups of seven, 30 minutes twice weekly for 6 
weeks. The control group women were taught about 
pelvic floor muscles and how to contract them cor-
rectly, but without any training. Outcomes were as-
sessed after the intervention at 6 weeks. The trial was 
generally judged as low risk for performance and de-
tection bias, attrition bias, reporting bias and other 
types of bias. However it was unclear if opaque enve-
lopes were used in the allocation process, and an in-
tention to treat analysis was not performed (Table 
28). 
Culligan and colleagues compared a standardised 
PFMT programme with a standardised Pilates pro-
gramme in community women with POP-Q stage I 
prolapse to see if they provided similar improvements 
in PFM strength (260). The PFMT programme, made 
up of twice weekly 1-hour sessions for 12 weeks, in-
cluded computerized biofeedback, vaginal manipula-
tion, neuromuscular re-education, and manual ther-
apy. Participants completing 20 or more of the 24 
possible sessions were defined as “successful”. The 
control group attended a Pilates programme with the 
same pattern of sessions where they were taught full-
body exercises focusing on the “core muscles”, and 
the pelvic floor in particular. Women were assessed 
at baseline and after the intervention at 12 weeks in 
terms of PFM strength and pelvic floor symptoms and 
impact (PFDI-20), Short Form Pelvic Floor Impact 
Questionnaire (PFIQ-7). The trial was judged as low 
risk for selection bias, attrition bias, reporting bias and 
other types of bias. However, performance and de-
tection bias was judged as unclear risk of bias as it 
was unclear if outcome assessors were blinded (see 
Table 28). 
Due et al. (2016) undertook a trial in women with 
symptomatic prolapse of stage II or greater, compar-
ing a structured lifestyle advice programme plus 
PFMT (combined group) with lifestyle programme 
alone (lifestyle group) (261). The PFMT included both 
group PFMT (6 sessions over 12 weeks) and individ-
ual home training after an assessment and individual 
instruction. Women were assessed using the Patient 
Global Index of Improvement scale (PGI-I), POP-Q, 
PFDI-20, PFIQ-7 and PISQ-12 at baseline, immedi-
ately post-intervention (3 months) and at 6 months. 
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The trial was judged as low risk for selection bias, per-
formance and detection bias, attrition bias, reporting 
bias and other types of bias (261) (see Table 28). 
Frawley et al. (2012) carried out a trial in four Austral-
ian centres involving women with symptomatic pro-
lapse stage I to III, randomised to PFMT or a lifestyle 
advice leaflet (control) (262). This trial protocol was 
based on that of the UK POPPY trial (263) described 
below with some slight adjustments and additional 
measurements. Women were assessed at baseline, 
6 and 12-month follow-up for PFM function (mano-
metric and digitally-assessed strength and endurance 
(ICS scale)), prolapse symptoms (POP-SS) and se-
verity/type (POP-Q). The trial was judged as low risk 
for selection bias, performance and detection bias, 
reporting bias and other types of bias. However, the 
trial was considered to have high risk of attrition bias. 
Communication with the author provided explana-
tions about the dropout observed (Table 28). 
Giraudo et al’s (2011) trial compared PFMT plus neg-
ative pressure abdominal work (intervention group) 
with PFMT plus abdominal hollowing exercise (con-
trol group) in women with untreated stage I or II pro-
lapse (264). Both groups were taught correct contrac-
tion of the pelvic floor muscles and given tailored life-
style advice on ways of reducing intra-abdominal 
pressure, as well as a standardised lifestyle advice 
sheet. There was no description of 1) the negative 
pressure abdominal work or 2) abdominal hollowing 
exercises but they are described elsewhere as 1) hy-
popressive exercises, which are thought to result in 
negative pressure in the thoracic cavity and involun-
tary contraction of the pelvic floor and abdominal wall, 
and 2) pulling the belly button in towards the spine. 
The intervention duration was 24 weeks, with individ-
ual supervision twice weekly for one hour each ses-
sion during the first 3 months, followed by once a 
week for the last 3 months. Women were assessed at 
baseline and at 24 weeks for prolapse symptom se-
verity (P-QOL), prolapse severity (POP-Q) and PFM 
strength (Oxford scale). The trial was judged as low 
risk for selection bias (randomisation only), perfor-
mance and detection bias and reporting bias. The trial 
was judged as unclear risk of bias for selection bias 
(allocation concealment), attrition bias, and other 
types of bias (264) (Table 28).  
Hagen and colleagues carried out a multicentre trial 
(POPPY trial) comparing an individualised PFMT pro-
gramme (including lifestyle advice) with a lifestyle ad-
vice leaflet (control group) (263). Participants were 
outpatients attending with newly-diagnosed, sympto-
matic stage I, II, or III prolapse. The PFMT interven-
tion which was delivered by a specialist women’s 
health physiotherapist over 16 weeks in 5 sessions 
included teaching of anatomy and function of pelvic 
floor muscles, the correct exercise technique and 'the 
Knack', and a prescription of a home exercise pro-
gramme. A standardised lifestyle advice leaflet and 
tailored lifestyle advice were given. The control group 
received the lifestyle advice leaflet by post. Outcomes 
measured at 6 and 12 months were prolapse symp-
toms (POP-SS), prolapse-related QoL, need for fur-
ther prolapse treatment, bladder, bowel and sexual 
symptoms. POP-Q was measured at baseline and 6 
months. The trial was judged as low risk for selection 
bias, performance and detection bias, attrition bias, 
reporting bias and other types of bias (Table 28).  
Kashyap and colleagues reported a single-centre trial 
in parous women with stage I to III prolapse, which 
compared taught pelvic floor muscle training plus a 
self-instruction manual (SIM) with the SIM alone as 
the control intervention (265). One person delivered 
the training to all intervention women. This included 
explanation of anatomy and function of pelvic floor 
muscles, PFMT training, plus exercise practice and 
checking for correct PFM contractions by vaginal ex-
amination. Pressure manometry was included for bi-
ofeedback and motivation. A home exercise pro-
gramme was prescribed for 3 times daily. Women 
were instructed to perform the intervention for 24 
weeks. After the initial training session, there were 6 
follow up visits (at weeks 1, 3, 6, 12, 18 and 24). The 
content of the manual was not described and there-
fore what written instruction the control group re-
ceived is unclear. Women were assessed at baseline 
and at 1, 3, 6, 12, 18 and 24 weeks using the POP-
SS, a visual analogue scale and the PFIQ-7. The trial 
was judged as low risk for selection bias. However, 
the trial was judged as high risk for performance and 
detection bias, attrition bias, reporting bias and other 
types of bias (see Table 28). 
Stupp/Resende carried out a three-arm trial compar-
ing PFMT versus hypopressive exercises (diaphrag-
matic breathing) plus voluntary pelvic floor muscle 
contraction (PFMT+HE) versus lifestyle advice only 
(266, 267). Participating women were attending a 
urogynaecology service in Sao Paulo, Brazil, and had 
untreated stage II anterior or posterior prolapse. The 
PFMT intervention involved three physiotherapy ap-
pointments to learn how to perform PFMT correctly 
(weeks 0, 1, 2). Then a 12-week home exercise pro-
gramme was prescribed consisting of three sets of 
exercises daily. The PFMT+HE group had three ap-
pointments (weeks 0, 1, 2) during which they had in-
struction in correctly performing hypopressive exer-
cises and pelvic floor muscle contractions, and how 
to do these simultaneously. They practiced the exer-
cises for 12 weeks. Both of these groups completed 
an exercise diary, had a telephone call from the phys-
iotherapist every two weeks and a monthly appoint-
ment (weeks 6, 10, 14). The control group received 
one appointment, were given lifestyle advice and 
were instructed how to perform PFM contractions. 
However, it was unclear with whom the appointment 
was held, or whether the instruction was verbal or in-
cluded a digital assessment. A standardised lifestyle 
advice sheet was given to all women containing 
global stretching exercises and advice on weight loss, 
constipation, coughing and avoidance of heavy lifting.  
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Table 27 Summary of data on POP prevention 
Author, 
year 
Comparator N Study population Modality details or parameters Outcomes/results Follow up Notes (side effects, loss of follow 
up…) 
Bø 
2013 
(1) 
 
 
Parallel group 
RCT; 2 groups, 
PFMT vs control 
 
175 Primiparous 
women, vaginal 
delivery, singleton 
infant, ≥ 32 weeks 
All women: written advice in delivery 
ward to perform PFMT. 2 trained 
physiotherapists taught PFM 
contraction and assessed PFM 
function before randomisation by 
observation of the perineum and 
vaginal palpation.  
PFMT group: weekly PFMT classes 
delivered by trained 
physiotherapists for 4 months 
starting at 6-8 weeks postpartum. 
Performed home-based exercise, 3 
sets of 8-12 close to maximum PFM 
contractions per day.  
Control group: no further 
supervision or follow-up during the 
intervention period. 
Stage of POP and 
bladder neck position. 
Secondary outcomes: 
symptoms of POP 
(sensation of bulging) 
using International 
Consultation on 
Incontinence Vaginal 
Symptoms 
questionnaire 
 
Assessed at 6 
weeks (pre-
test) and 6 
months’ 
(post-test) 
postpartum 
 
Randomisation was computer 
generated and opaque sealed 
envelopes were used. Outcome 
assessors were blinded and the groups 
were comparable at baseline. Intention-
to-treat analysis was employed and 
dropouts were clearly reported. The trial 
was judged as potentially having an 
unclear risk of bias as the authors noted 
that "because of ethical reasons the 
control group was not discouraged from 
performing PFMT on their own, but they 
were asked to follow the prescription for 
the group they were randomised to." 
Hagen 
2014 
(2) 
 
Parallel group 
RCT; 2 groups, 
PFMT versus 
control (lifestyle 
advice leaflet) 
 
407 Primi and 
multiparous 
women assessed 
for pelvic floor 
dysfunction 12 
years after an 
index birth; women 
involved in the 
ProLong cohort 
study (3) who have 
POP-Q stage I, II 
or III); no previous 
treatment for 
prolapse (surgery, 
pessary, PFMT) 
 
Intervention: 1:1 PFMT taught using 
digital palpation delivered in 5 
physiotherapy appointments over 16 
weeks, followed by Pilates-based 
classes, including PFMT. Classes 
were carried out in 6-week block 
(one class per week) and each 
woman was offered two 6-week 
blocks. Exercise DVD was provided 
for home use. Women offered a 1:1 
physiotherapy annual review 
appointment at 1 and 2 years after 
randomisation. 
Control group: sent a lifestyle advice 
leaflet containing advice on weight 
loss, and avoidance of constipation, 
heavy lifting, coughing and high 
impact exercise. 
POP-SS, Prolapse-
related QoL, uptake of 
prolapse treatment, 
symptoms of urinary 
incontinence, 
anorectal or sexual 
dysfunction, women’s 
perceived health 
benefit, and cost-
effectiveness 
 
 
Data 
collected at 
baseline, 1 
and 2 years 
post 
randomisation 
 
 
Randomisation was generated using a 
computer program located at the Trial 
Office on a password-protected PC. 
Outcome assessors were blinded and 
the groups were comparable at 
baseline. Intention-to-treat analysis was 
employed and dropouts were 
adequately reported.  
Questionnaire response rate: 81% year 
1, 86% year 2 follow-up. 
Attendance at annual review 
appointments: 52% and 46% at year 1 
and year 2 respectively, and uptake of 
classes in the UK was 33% and 17% at 
1st and 2nd block respectively. By year 
2, 77% in the intervention group 
reported they had done PFM exercises 
in the last 4 weeks 
112 
Abbreviations: PFM: pelvic floor muscles; PFMT: pelvic floor muscle training; POP-SS: pelvic organ prolapse symptom score; QoL: quality of life; RCT: ran-domized 
controlled trial 
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Table 28 Summary of data on PFMT vs no active treatment for POP 
Author, year 
Study 
design/ 
Comparator 
N Study population Modality details or parameters Outcomes/results Follow up 
Notes (side effects, loss of 
follow up…) 
Alves 2015 (1) 
 
Parallel 
group RCT, 2 
groups, 
PFMT vs 
control 
 
 
30 Women ≥5 years 
postmenopausal, 
with 
urogynecological 
complaints  
 
Intervention: PFMT taught using digital 
palpation. Groups of 7 women; 12 
sessions, twice weekly for 30 minutes, 
over six weeks. Include pelvic mobility 
exercises, stretching, strengthening and 
relaxation in supine, sitting, on Gym 
Ball, squatting and standing, along with 
PFM contractions, consisting of 4 sets of 
10 fast contractions and 4 sets of 10 
sustained contractions, 8 seconds hold 
followed 16 seconds relaxation  
 
All women: performed a Fitness 
Program based on global muscle 
stretching, endurance and functional 
exercises for the elderly 
POP-Q, ICIQ-VS, 
ICIQ-UI SF, ICIQ-
OAB, PFM 
assessment (digital 
palpation, sEMG), 
treatment 
satisfaction (VAS, 
0-10) 
 
Assessed 
at baseline 
and post 
intervention 
(6 weeks). 
 
Generally low ROB. 
Randomisation by draw, with each 
participant blindly drawing a 
sealed envelope containing a pre-
printed card; however it was 
unclear whether opaque 
envelopes were used. Outcome 
assessors were blinded. Sample 
size calculation was reported and 
the groups were comparable at 
baseline. ITT not employed but 
dropouts were adequately 
reported. High attrition rate for the 
intervention group; 30/42 women 
completed the trial. 
 
Culligan 2010(2)  
 
Parallel 
group RCT; 2 
groups, 
standardised 
PFMT 
program vs 
standardised 
62 Non pregnant 
community women 
with POP-Q stage 
I, with or without 
complaint of pelvic 
floor dysfunction 
 
Intervention: 1:1 PFMT, 24 1-hour 
sessions, twice weekly for 12 weeks. 
Included computerized biofeedback, 
vaginal manipulation, neuromuscular re-
education, and manual therapy. Authors 
imply women taught contraction used 
digital palpation. 
PFDI-20; PFIQ-7, 
PFM strength 
(vaginal pressure) 
 
Assessed 
at baseline 
and post-
intervention 
at 12 weeks 
Generally low ROB. Randomised 
using blocked random assignment, 
and allocation concealment used 
sequentially numbered opaque 
sealed envelopes. Unclear 
whether participants and outcome 
assessors were blinded. Groups 
were comparable at baseline. 
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Author, year 
Study 
design/ 
Comparator 
N Study population Modality details or parameters Outcomes/results Follow up 
Notes (side effects, loss of 
follow up…) 
Pilates 
program  
 
Control: Pilates, 24 1-hour sessions, 
twice weekly for 12 weeks. Taught full-
body exercises designed to emphasize 
the “core muscles” and pelvic floor.  
Although intention-to-treat analysis 
was not employed, dropouts were 
adequately reported. Authors 
reported that seven of the eight 
participants who dropped out of 
the PFMT arm reported doing so 
because they found the treatments 
“unpleasant in some way”. 
All Pilates and PFMT sessions 
were free to the participants, who 
were also paid up to $75 for 
completion of the study protocol. 
Due 2016 (3) 
 
Parallel 
group RCT; 2 
groups, 
Combined 
group (PFMT 
plus 
structured 
lifestyle 
advice 
program) and 
lifestyle 
group 
(structured 
lifestyle 
advice 
program 
alone) 
 
109 Women ≥18 years 
with POP 
symptoms and a 
POP-Q ≥ stage II 
 
Intervention: group PFMT and home 
training after a digital assessment and 
individual instruction. 6 group sessions 
delivered over 12 weeks. Include the 
Knack, home exercise 5 days a week (3 
sets of up to 10, 10 second 
contractions). Plus lifestyle advice 
program as below. 
Control group: Lifestyle advice program, 
6 1-hour group teaching sessions 
including information on POP-promoting 
factors, reducing pelvic floor pressure, 
bladder and bowel function, diet, body 
image and physical activity. No PFMT. 
POP-Q; PFDI-20; 
PFIQ-7; PISQ-12; 
Patient Global 
Index of 
Improvement scale 
(PGI-I) 
 
Assessed 
at baseline, 
immediately 
post-
intervention 
(3 months) 
and 6 
months 
 
Low ROB for selection bias, 
performance and detection bias, 
attrition bias, reporting bias and 
other types of bias  
"Majority of the women in the 
lifestyle advice group (p≤0.001) 
had sought further treatment at six 
months follow-up, mainly as 
PFMT" 
 
Frawley 2012 (4) 
 
Parallel 
group RCT; 2 
groups, 
PFMT vs 
control 
(lifestyle 
168 Women with 
symptomatic POP 
of stage I, II or III 
 
This trial used the same protocol as the 
UK POPPY trial with some slight 
adjustments and additional 
measurements (see Hagen 2010 below) 
 
POP-Q; POP-SS; 
PFM manometric 
strength and 
endurance; digitally 
assessed PFM 
strength/endurance 
(ICS scale) 
Data 
collected at 
baseline 
and 6 and 
12 month 
follow up 
 
Generally low ROB. 
Randomisation was computer 
generated and participants were 
allocated to the trial using a 
remote randomisation service. 
Outcome assessors were blinded. 
Potentially high risk for attrition 
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design/ 
Comparator 
N Study population Modality details or parameters Outcomes/results Follow up 
Notes (side effects, loss of 
follow up…) 
advice 
leaflet) 
 
bias. Dropouts were accounted for 
but no explanations given for high 
attrition rates at 6 and 12 month 
follow up. Attrition was greater in 
the PFMT group at 6 months 
(14.3% vs 10.7%) but greater in 
the lifestyle group at 12 months 
(5.6% vs 21.3%). 
 
Giraudo 2011 (5) Parallel 
group RCT; 2 
groups, 
PFMT plus 
negative 
pressure 
abdominal 
work vs 
PFMT plus 
abdominal 
hollowing 
exercise 
 
44 Women with 
untreated stage I or 
II prolapse. No 
mention of whether 
women had 
symptoms. 
 
Both interventions: PFMT delivered over 
24 weeks, 1:1 supervised sessions 
twice-weekly for 1 hour for 3 months, 
once a week for last 3 months. Women 
taught to contract the PFMs correctly by 
vaginal palpation. Tailored lifestyle 
advice given on reducing intra-
abdominal pressure plus standardised 
lifestyle advice sheet (advice on weight 
loss, constipation, avoidance of heavy 
lifting, coughing and high-impact 
exercise). 
Groups: individualised PFM contraction 
with either abdominal hollowing 
exercises or negative pressure 
abdominal work.  
Prolapse symptom 
severity measured 
via P-QOL 
Questionnaire. 
Prolapse severity 
(POP-Q) and PFM 
strength (Oxford 
scale). ICIQ-UI SF 
also used but not 
reported. 
 
Assessed 
at baseline 
and at 24 
weeks 
 
ROB was judged as low or 
unclear. Randomisation was 
computer generated, but allocation 
concealment was not described. 
The physician involved in the trial 
was blinded to study group 
allocation, but there was 
insufficient information about the 
blinding of participants. The 
groups were comparable at 
baseline and all pre-specified 
outcomes were reported. However 
although dropouts were accounted 
for, it was not clear when the 
women were excluded, and which 
group they had originally been 
allocated to.  
 
Hagen 2014(6) Parallel 
group RCT; 2 
groups, 
individualised 
programme 
of PFMT vs 
prolapse 
lifestyle 
advice leaflet 
 
447 Female outpatients 
with newly-
diagnosed, 
symptomatic stage 
I, II, or III POP 
Intervention: Anatomy/function of PFMs 
explained, taught to correctly contract 
PFMs (vaginal palpation, PERFECT) 
and pre-contracting against increases in 
abdominal pressure. 5 physiotherapy 
appointments delivered over 16 week 
period (weeks 0, 2, 6, 11 & 16). Home 
exercise prescribed - 3 sets of exercises 
per day: 10 maximum voluntary 
contractions held for up to 10s, with 
POP-SS; POP-Q; 
women’s perceived 
change in prolapse; 
interference due to 
prolapse; days of 
symptoms; uptake 
of prolapse 
treatment; ICIQ UI-
SF; PISQ; SF-12 
 
Assessed 
at 12 
months, 
except 
POP-Q 
assessed at 
6 months 
 
Low ROB. Randomisation was 
computer generated, and 
university-based trial coordinator 
accessed the web-based 
application and then informed the 
woman, and the physiotherapist as 
necessary, of the allocated group. 
Outcome assessors and 
investigators (who were 
gynaecologists at trial sites), were 
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follow up…) 
4srest between; after 1 minute rest, up 
to 50 rapid contractions. Standardised 
lifestyle advice leaflet and tailored 
lifestyle advice given.  
Control group: received the same 
lifestyle advice leaflet by post.  
masked to group allocation; the 
statistician was masked until after 
data analysis. ITT analysis was 
employed and dropouts were 
adequately reported. 
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Notes (side effects, loss of 
follow up…) 
Kashyap 2013 (7) Parallel 
group RCT; 2 
groups, 
PFMT and a 
self-
instruction 
manual (SIM) 
vs SIM alone 
 
140 Parous women 
attending 
gynaecology 
outpatient 
department, aged 
20–70 years, who 
were willing to 
attend follow-up 
visits 
 
Intervention: anatomy/function of PFMs 
explained. 1:1 PFMT training, plus 
exercise practice and checking for 
correct contractions of PFM by vaginal 
examination. Pressure manometry for 
biofeedback and motivation. Given SIM. 
After training session, 6 follow up visits 
(weeks 1, 3, 6, 12, 18 and 24). Home 
exercise programme of 3 times/daily set 
of exercises comprising 10 voluntary 
contractions, held for 10s each with 10s 
rest in between. Participants performed 
the intervention as described for 24 
weeks.  
Control: SIM plus 3 follow-up visits 
(weeks 6, 18 and 24). Home exercise 
prescribed as above. 
POP-SS; 
symptoms 
measured by visual 
analog scale (VAS), 
PFIQ-7, POP-Q 
 
Assessed 
at baseline 
and at 1, 3, 
6, 12, 18 
and 24 
weeks 
 
Low risk for selection bias as the 
trialists had used a block 
randomisation method for 
randomisation, and a physician, 
who was not involved in the study, 
performed the patient allocation. 
Potential for high risk of bias, as 
“the study design did not include 
blinding”. There was a crossover 
of 4 participants from group B to 
group A after randomisation. 
Details of attrition were not well 
reported: it was indicated that 
analysis was performed on all 140 
participants however there was 
also reference to individuals 
“missing” and “lost to follow-up”. 
Self-completed exercise diary but 
unclear how well adherence was 
actually delivered as planned. 
Resende 2008/ 
Stupp 2011 
(8, 9) 
3-arm RCT; 
PFMT 
training vs 
hypopressive 
58 Women with stage 
II POP and not 
undergoing surgery 
to correct it during 
PFMT: Session 1 (week 0), anatomy/ 
function of PFMs explained, training on 
PFM contractions, observation on 
correct performance. Follow up sessions 
POP-Q; symptom 
severity (Prolapse 
Quality of Life (P-
QoL)); PFM 
Baseline 
evaluation 
and 
immediately 
Low or unclear ROB. 
Randomisation was computer 
generated, but allocation 
concealment was not described. 
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exercises 
plus PFMT 
vs lifestyle 
advice & 
instruction on 
PFM 
contraction 
(1 
appointment) 
 
 
the study. Not on 
hormonal 
treatment, not had 
previous PFMT or 
pelvic floor surgery. 
Recruited during 
routine 
consultation. 
 
at weeks 1 (vaginal palpation), 2, 6, 10 
and 14. 12 week home exercise 
programme of 3 sets of exercises daily: 
1 set of 8-12 maximum contractions held 
6-10s, double time rest between each 
contraction, then 3-5 fast contractions. 
Bi-weekly telephone calls. 
PFMT+HE: Hypopressive exercises plus 
PFMT (3 sessions). Monthly 
appointments, 12 week home exercise 
programme. Bi-weekly telephone calls. 
 
Control group: 1 appointment for lifestyle 
advice and instruction in PFM 
contraction. 
  
All: Standardized lifestyle advice sheet 
about weight loss, fluid intake, 
constipation and avoidance of heavy 
lifting.  
function 
assessment 
(strength and 
endurance), 
electrical activity 
measured (sEMG) 
after 
intervention 
(at 3 
months) 
 
The main investigator was blind to 
the study groups and not involved 
in delivering the intervention. 
Groups were comparable at 
baseline and dropouts were 
accounted for. Attrition was 
evident only in the control group 
where 16/21 (76%) were analysed.  
Single trial reported over multiple 
papers (confirmed by author). 
Reports do not agree about 
number of participants, age. 
Authors state: “The women who 
took part in the present study also 
participated in a randomized, 
controlled trial on PFMT to reduce 
POP, the results of which are not 
available yet. Therefore, in this 
study, we considered only the 
results regarding PFM function.” 
Wiegersma 2014 
(10) 
 
Two parallel 
RCTs.  
POPPS 1 
(described 
here) 2 
groups; 
PFMT vs 
watchful 
waiting 
 
287 Women aged at 
least 55 years with 
symptomatic mild 
POP identified via 
screening survey in 
15 GP practices 
 
Intervention: Explanation of the function 
of pelvis/pelvic floor/ pelvic floor 
dysfunctions, taught “the Knack”. 
Weekly visits to pelvic physiotherapist 
until able to correctly contract and relax 
PFMs (assessed by digital palpation), 
then 2-3 weeks intervals. Home exercise 
3-5 times a week, 2 or 3 times a day. 
Advice on lifestyle (diet, body weight) 
and toilet habits. 
Control: no treatment or 
recommendations 
Assessed 3 months 
from the start of 
treatment (or from 
randomisation for 
control group): 
PFDI-20, PFIQ-7, 
POP-Q, SF-12, 
PISQ-12, patients’ 
perceived change 
in symptoms (VAS) 
, PFM function (ICS 
method) 
 
Data 
collected at 
baseline 
and at 3, 
12, and 24 
months 
after the 
start of 
treatment 
 
Low ROB. Block randomisation; 
independent statistician generated 
the allocation sequence. Research 
physicians and pelvic 
physiotherapists were blinded to 
all answers on the participant 
completed questionnaires, and 
research physicians were blinded 
to the outcomes of the previous 
POP-Q measurements and 
previous evaluations of pelvic floor 
muscle function. ITT analysis 
employed; dropouts and missing 
data were accounted for. 
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Women were assessed at baseline and immediately 
after intervention (at 3 months) using POP-Q (blinded 
assessment); PFM strength and endurance (Oxford 
scale), electrical activity (sEMG) and symptom sever-
ity and impact (P-QoL). The trial was judged as low 
risk for selection bias (randomisation) and unclear 
risk for allocation concealment. The trial was also 
judged at low risk for performance and detection bias, 
attrition bias, reporting bias and other types of bias 
(266, 267) (Table 28). 
Wiegersma and team conducted a trial in primary 
care (POPP1) of women aged ≥55 years with symp-
tomatic mild prolapse (above the hymen) (268). 
Women in the trial were randomised to either PFMT 
or watchful waiting. Women in the PFMT group were 
given an explanation of pelvic floor anatomy and pel-
vic floor dysfunction, were taught “the Knack”, and 
given lifestyle advice. They had weekly visits with the 
pelvic physiotherapist initially. The intervals between 
appointments were extended when they could cor-
rectly contract and relax their PFMs. Home exercise 
was recommended three to five times a week, twice 
or three times each day. Data were collected at base-
line and at 3, 12, and 24 months after the start of 
treatment. The primary outcomes were change in 
bladder, bowel, and pelvic floor symptoms, as meas-
ured by the PFDI-20, assessed at three months. Sec-
ondary outcomes were condition specific and general 
quality of life, sexual functioning, and degree of pro-
lapse, PFM function, and patients’ perceived change 
in symptoms from the start of the study. The POPP1 
trial was judged as low risk for selection bias, perfor-
mance and detection bias, attrition bias, reporting 
bias and other types of bias (Table 28). 
Results 
In the Alves (2015) trial, 42 women were randomised, 
21 in each group, however there was high attrition 
and only data from 18 and 12 women in the interven-
tion and control group respectively were analysed. 
Two in the intervention group did not complete the 
treatment due to health or family problems, while 9 in 
the control group refused to complete the final physi-
cal exam: these women were excluded from the sam-
ple. There was a significant difference in favour of the 
intervention group in terms of decreased anterior pro-
lapse, but no difference in posterior prolapse or the 
ICIQ-VS score. There was a significant difference be-
tween the groups in the ICIQ-OAB and ICIQ-UI SF 
scores after treatment, with improvement occurring 
only in the intervention group. There was a greater 
increase in PFM contractility (measured both by digi-
tal palpation and sEMG) in the PFMT intervention 
group compared to the general fitness control group 
at 6 weeks. Satisfaction with the treatment was re-
ported to be greater in the intervention group (47). 
Sixty-two women were randomised in the Culligan 
(2010) trial; 32 to PFMT and 30 to Pilates (control), of 
which 8 and 2 withdrew respectively (260). Seven of 
the 8 who dropped out of the PFMT arm did so be-
cause they found the treatment unpleasant, while the 
2 in the Pilates arm withdrew for health reasons un-
related to the trial. All women could correctly contract 
their pelvic floor muscles (as assessed by perineom-
etry at baseline) and most did not have pelvic floor 
symptoms at baseline. Both groups demonstrated im-
proved PFDI-20 and PFIQ-7 scores and pelvic floor 
muscle strength, at 12 weeks, but these improve-
ments were not significantly different between the 
groups. The authors concluded that it is feasible for a 
Pilates exercise program to strengthen the pelvic 
floor muscles of women with stage I prolapse. 
In the Due (2016) trial, 109 women were randomised, 
56 to the combined group and 53 to the lifestyle group 
(261). Of these 43% had POP stage III and 57% had 
POP stage II. Follow-up at 3 and 6 months was 82% 
and 78% complete respectively. Significantly more 
women in the combined group indicated improvement 
in the PGI-I at 3 and 6 months. There was no differ-
ence between groups in any PFDI-20 or PFIQ-7 
scores at 3 months. Both groups improved signifi-
cantly in the total PFDI-20 score and its subscores by 
3 months, except the lifestyle group had no improve-
ment in the POPDI sub-score. Significant improve-
ment in PFIQ-7 could only be found in the lifestyle ad-
vice group. It was unclear if there were any differ-
ences between groups in PFDI/PFIQ at 6 months. 
The PISQ-12 and objective prolapse stage did not im-
prove significantly. Significantly more women (68% 
vs 28%) in the lifestyle advice group had sought fur-
ther treatment (mainly PFMT) at 6 months follow-up. 
The authors concluded that there was a small benefit 
of both lifestyle advices alone or combined with PFMT 
for women with stage II or III prolapse. There was a 
significant difference in the primary outcome (PGI-I) 
in favour of the combined group, but this was not re-
ally highlighted. 
In the Frawley (2012) trial, 168 women were random-
ised to either the PFMT group (n=84) or the control 
group (n=84), with 12 and 9 lost to follow-up by 6 
months and a further 4 and 16 by 12 months respec-
tively, 19% and 30% in total (262). 82% of women in 
the PFMT group attended 4 or 5 of the 5 physiother-
apist appointments. The POP-SS score was signifi-
cantly lower, indicating fewer symptoms, in the PFMT 
group compared to the control group at both 6 and 12 
months. There was no difference in POP-Q stage be-
tween groups at 6 or 12 months, although there was 
some evidence of a difference at 12 months between 
groups, in the posterior wall POP-Q measurements, 
Ap and Bp, in favour of the PFMT group. Digital mus-
cle strength was significantly stronger in the PFMT 
group compared to the control group at 6 months but 
not at 12 months. There were no significant differ-
ences between groups in manometry outcomes, ex-
cept total work performed was higher in the PFMT 
group at 6 months. The intervention was concluded 
to be beneficial immediately following the interven-
tion, and after a further 6 months. 
In a conference abstract, Giraudo and colleagues re-
ported 47 women were randomised but 3 were ex-
cluded because they could not contract their pelvic 
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floor muscles, leaving 44, 23 intervention (PFMT + 
negative pressure abdominal work) and 21 control 
(PFMT + abdominal hollowing) (264). Improvement in 
prolapse symptoms and POP-Q values from baseline 
to 24 weeks was significantly greater in the interven-
tion group compared with the control group. There 
was evidence of an improvement in PFM strength and 
endurance in both groups, but no significant differ-
ence between the groups. The authors concluded 
there may be benefit of adding negative pressure 
core exercises to PFMT for women with stage I and II 
prolapse. 
Of the 447 women enrolled in the POPPY trial, 225 
women were randomised to intervention and 222 to 
control (263). 84% and 66% of women completed 
questionnaires at 6 and 12 months respectively, with 
no differential drop-out. POP-Q re-assessments at 6 
months were obtained for 75% (168) and 77% (171) 
of women respectively. 80% in the intervention group 
attended 4 or 5 of the 5 appointments. Women in the 
intervention group had a significantly greater reduc-
tion in prolapse symptoms at 6 and 12 months than 
those in the control group, although they were no 
more likely than control women to have a reduced se-
verity of prolapse at 6 months. At 12 months, signifi-
cantly more women in the control group than the in-
tervention group had received further treatment. In 
particular significantly more women in the control 
group (27% vs 1%) had had a referral for PFMT. At 6 
months, all aspects of daily life, and sexual, bladder, 
and bowel function (except for faecal incontinence), 
were significantly better in the intervention group 
compared to the control group. This was not sus-
tained at 12 months. It was concluded that one-to-one 
PFMT is effective for improving symptoms in women 
with stage I to III prolapse in the medium term. 
In the Kashyap trial, 140 women were randomised, 
70 per group, although four women transferred from 
the control group to the training plus manual group 
and the group in which these women were analysed 
was unclear (265). Improvements were reported in 
POP-SS, VAS and PFIQ-7 scores in both groups from 
baseline to week 24. There were significant differ-
ences between groups in the change in POP-SS with 
the intervention group reporting greater symptom im-
provement. There was also significantly more im-
provement in the intervention group in terms of the 
VAS scores and the PFIQ-7 scores. Five women in 
the intervention group had an improved POP-Q stage 
compared to one woman in the control group. The au-
thors concluded that one-to-one PFMT plus the SIM 
led to more symptom improvement than the SIM 
alone. 
The Stuppe-Resende trial was reported over multiple 
publications (4 conference abstracts, 2 papers and a 
trial register entry) (confirmed by personal communi-
cation with an author), reporting on different compar-
isons amongst the three trial groups, and not all re-
ports agreed on participant details (e.g. the number 
of participants, age) making it difficult to interpret the 
findings. 63 women were randomised in the trial: 21 
to PFMT, 21 to PFMT plus hypopressive exercise, 21 
to lifestyle group. Five women in the lifestyle group 
discontinued leaving 58 women at follow-up. The 
PFMT group women were more likely than the control 
group to have an improvement in their POP-Q stage 
of prolapse, both anterior and posterior. The domains 
and symptoms scores from the P-QoL were com-
pared before and after in each group separately, but 
no between-group comparisons were made. How-
ever, the authors concluded erroneously that since 
the PFMT group scores improved significantly and 
the control groups did not, the PFMT group had ben-
efitted more. Pelvic floor muscle assessment out-
comes were compared between the three groups 
(266). Significant differences were found between the 
PFMT and PFMT+HE groups when compared to the 
control group, in favour of the PFMT groups, in terms 
of Oxford score, contraction endurance and muscle 
activity (SEMG). No significant difference was found 
between the PFMT and PFMT+HE groups in terms of 
Oxford score and muscle activity (SEMG), however 
PFMT group did significantly better than PFMT+HE in 
terms of contraction endurance.  
Wiegersma trialists screened 4,465 women to identify 
those with mild prolapse (n=365) (268). Of these, 287 
women were randomised, 145 to PFMT and 142 to 
watchful waiting, of which 250 (87%) completed the 
trial follow-up. Women in the intervention group im-
proved their PFDI-20 score significantly more than 
those in the watchful waiting group, and were also 
more likely to report overall symptom improvement 
(57% vs 13%). There were no other significant differ-
ences between the trial groups including improve-
ment in POP-Q stage. The authors concluded that the 
difference in PFDI-20 may not be clinically significant 
and that more studies are needed to examine the fac-
tors affecting success. 
Summary 
Results from an additional seven new trials are now 
available and more complete reports for two of the six 
earlier trials. 
There have been different types of control groups 
used in the trials to date: minimal intervention control 
e.g. lifestyle leaflet or watchful waiting; other type of 
exercise as control e.g. Pilates or general fitness; life-
style intervention as control; other form of delivery of 
PFMT as control e.g. self-instruction PFMT manual. 
One small trial compared PFMT of two different types 
(PFMT with negative pressure abdominal work and 
PFMT with abdominal hollowing).  
Most evidence (8 trials) exists for PFMT versus a min-
imal intervention control, and it can now be concluded 
more confidently that PFMT significantly reduces pel-
vic floor symptoms in women with stage I to III pro-
lapse. Evidence of effectiveness for PFMT relating to 
the specific symptom of a vaginal bulge or something 
coming down associated with prolapse was Level 1, 
but less consistent. 
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Six of these trials reported change in POP-Q stage, 
but a beneficial effect on the stage was reported in 
only 1 of these, and thus there was evidence of no 
effect of PFMT on prolapse stage.  
In the other categories, four out of six trials providing 
data were small and very likely underpowered alt-
hough they were otherwise at low risk of bias (Alves 
n=42, Culligan n=62, Giraudo n=47, Stupp n=63).  
Of the remaining two, Due (n=109) found PFMT plus 
lifestyle advice to be superior to a lifestyle advice pro-
gramme in terms of overall improvement on the Pa-
tient Global Index of Improvement Scale, but not pro-
lapse symptoms or POP-Q severity, where both 
groups improved [46]. Kashyap (n=140) found a 
taught course of PFMT plus self-instruction manual 
was better than a self-instruction manual alone in im-
proving prolapse symptoms [50]. The difference in 
findings might in part be due to different PFMT inter-
ventions: group PFMT delivered in the Due trial ver-
sus one-to-one PFMT in the Kashyap trial. 
Based on previous studies and new evidence there is 
now evidence of benefit that PFMT is effective in re-
ducing pelvic floor symptoms in women with prolapse 
(Consistent Level of Evidence: 1, Grade of recom-
mendation: A). There is some evidence of benefit 
showing that PFMT is effective in alleviating specific 
prolapse symptoms (e.g. vaginal bulge) (Majority 
Level of Evidence: 1, Grade of recommendation: 
C). There is no evidence that PFMT is effective in re-
ducing severity of prolapse based on POP-Q stage 
(Consistent Level of Evidence: 1, Grade of recom-
mendation: B).   
2.2.2 PFMT and Surgery 
Two trials have been reported in previous editions of 
this chapter (269, 270). There have been an addi-
tional 4 trials published since the last edition (104, 
271-274). Three trials compared surgery plus PFMT 
with surgery alone, and one trial compared surgery 
with PFMT (275). The latter did not report on prolapse 
outcomes and is therefore not discussed further. Sa-
lient features of each trial are described in Table 29. 
Quality of data 
Barber and colleagues carried out the OPTIMAL 2x2 
factorial trial of PFMT as an adjunct to vault prolapse 
surgery (104). This trial compared two methods of 
suspending the vaginal vault in women undergoing 
surgery for prolapse. Additionally, participants were 
randomised either to adjunctive post-operative PFMT 
or routine care, to assess whether such adjunct ther-
apy improves both anatomical and symptomatic out-
comes two years after surgery. 
The adjunct intervention consisted of one pre-opera-
tive visit and four post-operative visits with a behav-
ioural interventionist for PFMT and education in be-
havioural strategies. Routine care was usual peri-op-
erative teaching and post-operative instructions. The 
authors’ primary outcomes were urinary symptoms at 
6 months (PFDI-UDI), and prolapse symptoms 
(PFDI-POPDI) and anatomical failure (descent on the 
POP-Q or retreatment) at 24 months after surgery 
(Table 29).  
The OPTIMAL trial was judged as low risk for selec-
tion bias, performance and detection bias, attrition 
bias, reporting bias and other types of bias (104) (Ta-
ble 29). 
McClurg and colleagues undertook a pilot trial of pre-
and post-operative PFMT for women undergoing a 
primary prolapse repair (274). Women were random-
ised to either the intervention group receiving PFMT 
or the control group receiving usual care. Prior to sur-
gery all women were seen by a physiotherapist to 
complete baseline outcome measures. Those in the 
intervention group were also seen once pre-opera-
tively by another physiotherapist to be taught pelvic 
floor muscle exercises and the Knack. Women were 
advised to do three sets of exercise per day. After 6 
weeks the intervention group women were seen for 5 
visits over 16 weeks and an individualised home ex-
ercise programme was prescribed and advice given. 
Control group women received a lifestyle advice leaf-
let. Both groups completed outcome measures at 6 
and 12 months post-surgery: POP-SS (primary), 
ICIQ-UI SF, ICIQ-BS, PISQ-12, SF-12, and PFM as-
sessment (PERFECT and modified Oxford scale) 
(Table 29). The feasibility trial was generally judged 
as low risk for selection bias, attrition bias, reporting 
bias and other types of bias. However, there was po-
tential for performance and detection bias (see Table 
29) (274). 
Pauls et al. (2011) (271, 272) undertook a trial in 
women undergoing vaginal reconstruction, compar-
ing PFMT as an adjunct to surgery with standard 
care. Women were having planned surgical correc-
tion, including a native tissue vaginal repair with or 
without a vaginal hysterectomy or suburethral sling. 
PFMT consisted of one appointment 2 weeks before 
their scheduled surgery date, and five post-opera-
tively, each with a specialist pelvic floor physiothera-
pist. The control group attended appointments with 
physician assessment alone at all the same post-op-
erative intervals. There was a final follow-up assess-
ment at 24 weeks (Table 29). The primary outcome 
was quality of life measured using the WHOQOL-
Bref. Secondary outcomes included PFDI-20, PFIQ-
7, POP-Q assessment, the Female Sexual Function 
Index (FSFI), PISQ-12, a modified Oxford scale for 
pelvic floor strength and contraction, short form Gen-
eral Health Survey (SF-12), and a 24-hour voiding di-
ary (271, 272). The trial was judged as low risk for 
selection bias, performance and detection bias, attri-
tion bias, reporting bias and all other types of bias 
(Table 29). 
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Table 29 Summary of data on PFMT + surgery for POP 
Author, year Comparator N Study population Modality details or parameters Outcomes/results Follow up 
Notes (side effects, loss of 
follow up) 
Barber 2014 (1) 
 
2 x 2 factorial 
RCT: comparing 
to surgery types 
+/- PFMT  
 
374 Women having 
surgical repair for 
apical or uterine 
POP of stage II or 
greater, who also 
have SUI 
Women were randomised to 
both surgery type and PFMT. 
Surgery: 1) sacrospinous 
ligament fixation, or 2) 
uterosacral vaginal vault 
suspension 
Perioperative PFMT: 1) 1:1 
PFMT (1 pre-operative + 4 post-
operative visits for PFMT 
(2,4,6,8 and 12 weeks), 
examination at each visit, and 
exercise and education in 
behavioural strategies), or 2) 
usual care (usual peri-operative 
teaching and post-operative 
instructions) 
Outcomes for PFMT: 
long-term improvement 
in anatomic outcomes 
(POP-Q) and prolapse 
symptoms (POPDI 
subscale of the PFDI); 
short term (6 months) 
improvement in urinary 
symptoms (UDI subscale 
of PFDI). 
 
6, 12 and 24 
months 
 
Low ROB for selection bias, 
performance and detection 
bias, attrition bias, reporting 
bias and other types of bias 
McClurg 2010 (2) 
 
Parallel group 
RCT; 2 groups, 
treatment group 
(surgery and 
PFMT sessions) 
vs a control 
group (usual 
care) 
 
57 Women attending 
the 
gynaecological 
clinic and for 
whom primary 
surgery was 
recommended 
due to their POP 
symptoms 
 
Intervention: 1 pre-operative + 5 
post-operative appointments 
within a period of 12 weeks. 
Pre-operatively, anatomy and 
function of PFMs, types of 
prolapse and the surgical 
procedure discussed with 
information about 
recovery/return to normal 
activities. Women taught by 
digital palpation to contract 
PFMs and 'the Knack'. Home 
exercise, 3 sets per day of 10 
maximum contractions (up to 
10s hold) with 4s rest between, 
1-min rest followed by 10 fast 
contractions.  
 
Control: received the same  
lifestyle advice leaflet. 
POP-SS; ICIQ-UI SF; 
ICIQ-BS; PISQ-12; SF-
12; PFM assessment 
(PERFECT, modified 
Oxford scale). 
 
All outcomes 
were measured 
at baseline, 6 
and 12 months 
 
Generally judged as low ROB. 
Randomisation generation and 
allocation concealment were 
judged as adequate. Outcome 
assessors reported as being 
blinded but researchers 
involved in the trial were not 
blinded and it is unclear what 
direct involvement they may 
have had with each 
participant. Groups were 
comparable at baseline, but 
there were more complaints of 
bowel dysfunction in the 
treatment group. Dropouts 
were clearly accounted for and 
all pre-specified outcomes 
were adequately reported. 
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Author, year Comparator N Study population Modality details or parameters Outcomes/results Follow up 
Notes (side effects, loss of 
follow up) 
Pauls 2013  
(3) 
Parallel group 
RCT; 2 groups, 
PFMT vs 
standard care in 
women 
undergoing 
vaginal 
reconstruction 
 
49 Women aged > 18 
years having 
surgical correction 
to include a native 
tissue vaginal 
repair +/- a 
vaginal 
hysterectomy or 
suburethral sling 
 
Intervention: physiotherapy 
appointment 2 weeks before 
surgery, and 2, 4, 6, 8, and 12 
weeks postoperatively, in 
conjunction with a physician 
assessment. Sessions covered 
bladder and bowel function, pain 
management, breathing and 
relaxation, core exercises, scar 
tissue mobilization, increased 
strengthening and training over 
time.  
 
Control: attended appointments 
(biweekly until 12 weeks 
postoperatively) with physician 
assessment alone at intervals 
as above. 
 
PFDI-20, PFIQ-7, POP-
Q, Female Sexual 
Function Index (FSFI), 
PISQ-12, SF-12, WHO-
QOL Bref, modified 
Oxford scale for PFM 
strength and contraction, 
24-hour voiding diary 
 
Assessments 
undertaken at 
baseline (some 
limited 
assessment at 
appointments 
occurred at 2, 4, 
6, 8 weeks), and 
follow-up 
assessments at 
12 and 24 
weeks 
 
Low ROB. Randomisation 
generation and allocation 
concealment were judged as 
adequate. Outcome assessors 
were blinded appropriately. 
Groups were comparable at 
baseline, dropouts were all 
accounted for and all pre-
specified outcomes were 
reported. 
 
The trial is fully reported in two 
main papers. 
Abbreviations: PFM: pelvic floor muscles; PFMT: pelvic floor muscle training; POP: pelvic organ prolapse; POP-SS: pelvic organ prolapse symptom score; QoL: quality 
of life; RCT: randomized controlled trial; ROB: risk of bias; SUI: stress urinary incontinence; UI: urinary incontinence 
1. Barber MD, Brubaker L, Burgio KL, Richter HE, Nygaard I, Weidner AC, et al. Comparison of 2 transvaginal surgical approaches and perioperative behavioral 
therapy for apical vaginal prolapse: the OPTIMAL randomized trial. JAMA. 2014;311(10):1023-34. 
2. McClurg D. A two group, single-blind, randomised controlled study to assess the feasibility of physiotherapy following surgery for prolapse to avoid recurrence. 
http://isrctnorg/ISRCTN08203452010. 
3. Pauls RN, Crisp CC, Novicki K, Fellner AN, Kleeman SD. Impact of physical therapy on quality of life and function after vaginal reconstructive surgery. Female 
Pelvic Med Reconstr Surg. 2013;19(5):271-7. 
 
124 
Results 
In the OPTIMAL trial, 408 women were randomised, 
34 withdrew prior to surgery leaving 374 women ran-
domised to PFMT (n=186) or usual care (n=188). 
There was no significant difference at 6 months or 24 
months between the PFMT and usual care groups in 
the prolapse scores or POP-Q. The routine use of 
PFMT was concluded to be unnecessary (104). 
McClurg (2010) randomised 57 women from three 
sites, 28 to PFMT and 29 to control, with the majority 
of women (n=27, 47%) coming from one site. By 6 
months there was significant improvement in both 
groups on prolapse, bladder, bowel and general 
health measures, but no difference between groups. 
Analysing 12 month data from the highest recruiting 
site where longer follow-up was possible (there were 
significant recruitment and logistical issues at other 
sites which caused delays and limited the follow-up), 
there were significant differences between groups in 
POP-SS and SF-12: prolapse symptoms and general 
health were more improved in the PFMT groups 
(274). 
In Pauls (2013) trial, a total of 57 women were ran-
domised, 29 to physiotherapy and 28 to control, and 
49 completed the study (24 and 25 respectively). Im-
provement over baseline was found in both groups in 
quality of life, PFDI and PFIQ measures, but there 
were no differences between groups. The PFMT 
group had better muscle strength after 12 weeks, but 
at 24 weeks this was no longer evident. (271, 272). 
Summary 
Although there were three new randomised studies 
reporting prolapse outcomes, only one trial 
(OPTIMAL) was both at low risk of bias and of ade-
quate size (104). It found no evidence of an effect on 
prolapse symptoms or stage at 2 years of adding 
PFMT to surgery in women having vault prolapse re-
pair (Level of Evidence: 1). The other two small trials 
provided no evidence of an effect of PFMT. 
Peri-operative PFMT does not improve prolapse 
symptoms in women undergoing surgery for vault 
prolapse (Grade of Recommendation: B New). 
2.2.3 PFMT and Pessary  
Three RCTs have been published since the 5th Edi-
tion when previously there had been none. Details of 
the categories and treatment components of the ac-
tive interventions are provided in Table 30. 
i) Pessary + PFMT vs pessary 
Hagen and colleagues carried out a pilot trial in which 
women with stage I to IV prolapse of any type who 
had successfully been fitted with a pessary were ran-
domised to have PFMT or not. PFMT was delivered 
by a specialist women’s health physiotherapist in 5 
appointments over 16 weeks (276) (Table 30). The 
pessary was removed at 6 months and outcomes 
(POP-SS, prolapse-related quality of life, prolapse 
severity (POP-Q), and perceived change in prolapse 
since pessary fitted) measured at 7 months. The au-
thors aimed to randomise 50 women from 4 centres 
to inform the development of a larger trial. The 
PEPPY trial was judged as low risk for selection bias, 
performance and detection bias, attrition bias, report-
ing bias and all other types of bias (276, 277). 
ii) PFMT vs PFMT + pessary 
Cheung and colleagues carried out a trial in women 
with symptomatic stage I to III prolapse with no previ-
ous treatment for prolapse, who were randomised to 
either a vaginal ring pessary+ PFMT, or PFMT alone 
(278). Both groups were taught and encouraged to do 
PFMT standardized pelvic floor exercise training 
course which included a teaching session within 2 
weeks after the first consultation and three individual 
training sessions at 4, 8, and 16 weeks. Women were 
advised to practice daily with at least two sets of 8– 
12 preset exercise repetitions per day, with 8– 10 ex-
ercises per session at least two times per week. 
Change in urinary symptoms was measured using 
the PFDI (including PFDI-UDI) before, 6 months and 
12 months after the treatment. The PFIQ was also 
completed at 12 months. The trial was judged as low 
risk for selection bias, performance and detection 
bias, attrition bias, reporting bias and other types of 
bias (Table 30). 
iii) Colpexin sphere +PFMT vs PFMT  
Manonai and colleagues (2012) studied the use of the 
Colpexin sphere in women with Stage I or II prolapse 
(279). The Colpexin sphere is an intra-vaginal device 
similar to a pessary except it requires the woman to 
actively contract her pelvic floor muscles to keep the 
device in place. Women were randomised to either 
PFMT alone (control) or PFMT along with a Colpexin 
sphere (study group). All women were instructed to 
perform three sets of exercises daily. Those in the 
Colpexin group exercised with the device in situ. The 
intervention duration was 16 weeks. Pelvic floor mus-
cle strength was measured using the Colpexin pull 
test and digitally using the Brink scale, at baseline, 4, 
8, 12 and 16 weeks after treatment. There were no 
specific prolapse outcomes reported. Participants 
were excluded if compliance with the daily pelvic floor 
exercise was less than 80%. The trial was judged as 
low risk for selection bias, performance and detection 
bias, attrition bias, reporting bias and other types of 
bias (Table 30). 
Results 
Of the 31 eligible women recruited to the PEPPY trial, 
16 were randomised, eight to the pessary alone 
group and eight to the pessary plus PFMT group. The 
mean age of women was 63 years (SD 14); 25% had 
stage I prolapse, 50% stage II, and 25% stage III. 
Compliance with the intervention was good: 75% of 
intervention women attended 4 or 5 appointments. 
With such a small sample size statistical analysis was 
not carried out.   
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Table 30 Summary of data on PFMT + pessary / other medical devices for POP 
Author, 
year 
Comparator N Study 
population 
Modality details or 
parameters 
Outcomes/results Follow up Notes (side effects, loss of follow 
up…) 
Cheung 
2016(1)  
 
Parallel group 
RCT; 2 groups, 
Vaginal ring 
pessary + PFMT 
vs PFMT  
 
276 Women had 
symptomatic 
prolapse (Stage 
I- Stage III), 
had received no 
previous 
treatment 
Intervention: vaginal pessary, 
(ring pessary was used). 
Women also received regular 
PFMT. Home exercise 
performed at least 3 times a 
week and 2 times each day. 
Control: PFMT alone. 
Total scores on PFDI 
and PFIQ. Change of 
urinary symptoms 
measured by PFDI-
UDI and subscales 
(obstructive, irritative, 
stress).  
Data collected at baseline 
and 6 months (PFDI-UDI 
only) and 12 months after 
treatment. 
 
Low ROB for selection bias, 
performance and detection bias, 
attrition bias, reporting bias and other 
types of bias 
Hagen 
2010(2)  
Feasibility pilot 
RCT; 2 groups, 
PFMT in 
conjunction with 
pessary 
management vs 
pessary 
management 
alone  
 
16 Women with 
prolapse of any 
type, of stage I 
to IV, with a 
pessary newly 
successfully 
fitted (still in 
place after 2 
weeks) 
PFMT was delivered at 5 
appointments over 16 weeks (as 
per Hagen 2010 in Table 28) 
with the pessary in place. 
 
Control: pessary management 
alone. 
  
POP-SS, prolapse-
related quality of life, 
prolapse severity 
(POP-Q), and 
perceived change in 
prolapse since 
pessary fitted. 
 
Data collected at baseline 
(after pessary fitted but 
before randomization), 6 
months post-
randomization 
(with pessary in situ, then 
pessary removed), and 7 
months post-
randomization without 
pessary. 
Low ROB for performance and 
detection bias, attrition bias, 
reporting bias and all other types of 
bias.  
 
Poor recruitment was a key issue 
within the trial – target was to 
randomise 50 women 
 
Manonai 
2012(3)  
 
 
Parallel group 
RCT; 2 groups, 
Colpexin sphere 
with PFMT vs 
PFMT alone 
 
91 Women aged 
20 years+, 
prolapse stage I 
or II 
 
All participants: taught about 
home-based practice with 
booklet of PFM. Visual 
inspection of contraction. Home 
exercise involved tightening the 
PFMs, holding for 10s, relaxing 
10s and doing 10 repetitions 3 
times a day for a period of 16 
weeks. 
Colpexin+PFMT: exercised as 
above with the Colpexin sphere 
in situ. 
ICIQ-VS (Thai 
version), POP-Q, 
PFM strength 
(Colpexin pull test, 
digital test using 
Brink scale) 
 
POP-Q and ICIQ-VS at 
baseline and 16 weeks. 
PFM data collected at 
baseline, 4, 8, 12 and 16-
week after starting 
treatment. 
 
Low ROB. Random sequence 
generation was computer generated 
and information for decoding 
randomisation was kept secure and 
opaque sealed envelopes were used 
during the allocation process. 
Although ITT analysis was not 
employed, all dropouts were clearly 
accounted for. The groups were 
comparable at baseline and the 
authors reported a sample size 
calculation.  
Abbreviations: PFM: pelvic floor muscles; PFMT: pelvic floor muscle training; POP-SS: pelvic organ prolapse symptom score; RCT: randomized controlled trial 
1. Cheung RY, Lee JH, Lee LL, Chung TK, Chan SS. Vaginal Pessary in Women With Symptomatic Pelvic Organ Prolapse: A Randomized Controlled Trial. Obstet 
Gynecol. 2016. 
2. Hagen S. Pessary Plus Physiotherapy for Pelvic Organ Prolapse (PEPPY). http://ClinicalTrialsgov/show/NCT011368892010. 
3. Manonai J, Harnsomboon T, Sarit-apirak S, Wattanayingcharoenchai R, Chittacharoen A, Suthutvoravut S. Effect of Colpexin Sphere on pelvic floor muscle strength 
and quality of life in women with pelvic organ prolapse stage I/II: a randomized controlled trial. Int Urogynecol J. 2012;23(3):307-12. 
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However, from observing the mean scores it was ap-
parent that symptoms in both groups were worse a 
month after the pessary had been removed (month 7) 
compared to baseline (when the pessary had been in 
place for 2 weeks), and there was no indication of a 
symptom or objective benefit for those women who 
had received PFMT on any of the outcomes. In both 
groups 2 out of 7 women said their prolapse was the 
same or worse at 6 months after the pessary had 
been inserted. Recruitment was problematic in the 
trial, and it was concluded that this would need to be 
addressed before moving to a larger trial (276, 277). 
Of the initial 311 women recruited to the Cheung trial, 
276 were randomised, 137 to PFMT treatment and 
139 to vaginal pessary plus PFMT. Authors reported 
in one abstract an intention-to-treat analysis of the dif-
ference between the groups in PFDI-UDI and its sub-
scores, and on the prevalence of women with SUI, 
UUI and voiding difficulties (278). Prolapse outcomes 
were not reported. Although there was significant im-
provement on all outcomes at 12 months, there was 
no significant difference between the groups. In a 
second abstract the authors reported a non-random-
ised comparison of those women who continued suc-
cessfully with their pessary until 12 months (n=78) 
and those who continued successfully with pelvic 
floor exercises only (n=118) (278). At 12 months the 
pessary group had significantly better scores that the 
PFMT group on all the PFDI and PFIQ scores and 
subscores. This would seem to suggest that generally 
pessary and pelvic floor exercises are equally effec-
tive at improving urinary symptoms in women with 
prolapse, however in the select subgroup of women 
who adhere to treatment, the pessary provides extra 
benefit in reducing pelvic floor symptoms (278). 
A total of 91 women were randomised in the Manonai 
(2012) trial, 45 in the study group and 46 in the control 
group. Eighty-five women (93%, equal in both 
groups) completed the 16-week assessment with 
80% compliance to daily exercise. There was no sig-
nificant difference in improvement in pelvic floor mus-
cle strength between the groups at 16 weeks; either 
measured using the pull test or the digital assessment 
(279). 
Summary  
Three new trials were found, one comparing pessary 
alone versus pessary plus PFMT and two comparing 
pessary plus PFMT versus PFMT alone. The first was 
a pilot trial with recruitment difficulties and a very 
small sample, which did not contribute to the evi-
dence (276). The other two trials were larger and con-
cluded no difference between pessary plus PFMT 
and PFMT alone in terms of muscle strength at 4 
months (279) or prolapse symptoms at 12 months 
(non-randomised comparison) (278). Combined pes-
sary and PFMT and PFMT alone can be equally ef-
fective (Level of Evidence: 1)  
PFMT + pessary may be as effective as PFMT alone 
in reducing symptoms. (Grade of Recommenda-
tion: B New; however; some caution since the two 
trials considered two very different devices). 
 
3. PESSARIES 
A pessary is defined as a device that is inserted into 
the vagina to provide structural support to one or 
more of descending vaginal compartments, i.e., the 
uterus, anterior vaginal wall (and bladder), posterior 
vaginal wall (and rectum) and/or vaginal apex (with or 
without small intestine after a prior hysterectomy 
(280). They offer a non-surgical option for the treat-
ment of urinary incontinence and pelvic organ pro-
lapse (POP). This section, discusses evidences for 
use of pessary to prevent or treat POP; evidence for 
use of pessaries to prevent or treat UI will be covered 
in chapter 20.  
A range of vaginal pessaries (Figure 8) exist which 
can be broadly divided into two types: support and 
space-filling pessaries. Support pessaries lie along 
the vaginal axis, with the posterior component sitting 
in the posterior fornix and the anterior component 
coming to rest just under the symphysis pubis, thus 
providing a supportive shelf for the descending pelvic 
organs. As there is no evidence to support the use of 
a specific type of pessary, choice is based on clinical 
experience and trial and error. It is generally accepted 
that the ring pessary should be tried first because of 
ease of insertion and removal, and if this fails, other 
pessaries can be used (281). 
A recent review of data obtained from public use files 
from the Centres for Medicare and Medicaid Services 
in the United States over a 10-year period from 1999 
to 2009 showed that the rates of pessary insertion 
were consistent at 11-13% over the period (282). In 
the United Kingdom, a postal survey demonstrated 
that 87% of consultants use vaginal pessaries for 
management of POP (283). The likely candidates for 
vaginal pessaries are those with co-morbid medical 
conditions, those who still wish to bear children, as 
interim relief prior to surgery and for those who prefer 
 
Figure 8 Pessaries 
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non-surgical treatment (284). Other indications in-
clude vaginal laxity, neonatal prolapse mainly seen in 
association with neural tube defects such as spina bi-
fida and prolapse during pregnancy (285). 
Factors that predict the type of treatment chosen for 
POP have been evaluated in various studies. 
Younger women (286) and those with a higher inci-
dence of stress incontinence (286) are more likely to 
refuse pessary use. Age greater than 65 years at the 
time of pessary insertion and more severe prolapse 
(Stage III-IV) were more predictive for pessary dis-
continuation at one year (287-289). Ko et al. (2011) 
found that substantially older women or post meno-
pausal women opted for a pessary rather than sur-
gery, and more sexually active women expressed a 
significantly greater preference for surgery. In addi-
tion to opting for surgery over pessary use, younger 
sexually active women are more likely to change from 
conservative to surgical treatment over a one-year 
period (290). 
3.1. Prevention of POP with Pessaries 
Previously no trials had examined pessaries as an in-
tervention in the prevention of POP. In this update, no 
further trials were identified. 
3.2. Treatment of POP with Pessaries 
3.2.1 Pessary Alone 
Three new studies were included. Study details are 
presented in table 31. Ding et al. (291) evaluated 81 
women with stage 3 and 4 prolapse who were suc-
cessfully fitted with a ring pessary with support after 
3 months. Subjective evaluation was carried out us-
ing non-validated questions and prolapse was objec-
tively assessed using POP-Q. 
To evaluate if the cube pessary can be used as a first 
line treatment, Nemeth et al. (292) prospectively eval-
uated 78% of women who had a cube pessary in-
serted after one year. Subjective outcome was estab-
lished by using a non-validated questionnaire as a 
validated questionnaire was not available in Hungar-
ian. As one of the aims of the study was to evaluate 
if it was well tolerated, the authors rated the process 
of pessary insertion and general wellbeing on a nu-
meric rating scale and also on a patient global im-
provement scale.  
Brazell et al (293) reported findings from a secondary 
analysis of a study that sought to evaluate if pessary 
use was associated with improvement in bulge symp-
toms and improvement in body image (294). They fo-
cused on bowel symptoms using the Colorectal Anal 
Distress Inventory, a subscale of PFDI-20 and Colo-
rectal Anal Impact Questionnaire, a subscale of 
PFIQ-7. The study had a high attrition rate as only 43 
women of the initial 104 had complete data at 12 
months.  
Results 
The study by Ding et al. (295) found improvement in 
prolapse and bladder symptoms 3 months after use 
of a ring pessary with support in women with stage 3 
and 4 prolapse. Of the 74% who were initially suc-
cessfully fitted with the pessary, 10% failed to retain 
the pessary at 3 months. Their findings contradict the 
manufacturer’s recommendations regarding use of 
this type of pessary in early prolapse. Of interest, 
82.7% women who were of the median age of 70 
years were able to manage the pessary themselves 
indicating that with proper counselling and encour-
agement hospital care can be minimised.  
The cube pessary seemed to be a viable option for 
sexually active women to self-manage their pessary 
as Nemeth et al. (292), were able to demonstrate a 
significant improvement in general wellbeing in the 
78% women who were still using the pessary at 12 
months, 85% rated pessary care use as easy or very 
easy. 
Brazell et al. (293) demonstrated a significant im-
provement in both bowel related symptoms and qual-
ity of life. Patients who completed the 12-month fol-
low-up were significantly older and more likely to have 
stage 3 and 4 prolapse compared to stage 2. 
3.2.2 Pessary Versus no Treatment 
No new studies were identified.  
3.2.3 Pessary and PFMT 
 Pessary versus PFMT  
One new study was identified. A RCT comparing 
PFMT to pessary treatment in 160 women (PFMT 
n=79, pessary n=81) aged ≥55 years with advanced 
POP. A pessary was fitted successfully in 47/81 (58 
%)women (296). Only those women in whom a pes-
sary was fitted successfully, were compared. Risks 
of bias were high as both participant and evaluator 
were not blinded and an ITT analysis was not per-
formed.  
In women aged ≥55 years with an advanced symp-
tomatic POP, PFMT resulted in a significant but not 
clinically relevant improvement of pelvic floor symp-
toms after 3 months (PFDI-20). There was no differ-
ence between PFMT and pessary treatment. PFMT 
was more effective in improving anterior wall POP 
than pessary treatment on POP-Q (Table 31). 
 Pessary plus PFMT versus PFMT  
Refer to section III.2.3.2 
 Pessary plus PFMT versus Pessary  
Refer to section III.2.3.2 
3.2.4 Pessary Versus Surgery 
One new study was identified (297), making a total of 
three studies comparing pessary versus surgery (Ta-
ble 32). All were prospective, observational cohort 
case controlled. The new study by Lone et al. (297) 
evaluated 133 women who opted for surgery and 154 
who opted for surgery one year after pessary treat-
ment using the ICIQ-VS and ICIQ-UI (297). Women 
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who had surgery were older with no difference in 
characteristics like body mass index, parity, ethnicity, 
history of hysterectomy and prolapse surgery. 69% 
women who used pessary and 67% women who had 
surgery completed the questionnaire at one year. The 
non-randomised design of the study with approxi-
mately 30% attrition rate suggested a high risk of 
bias. 
Three studies (285, 297, 298) compared patient re-
lated outcomes after pessary use and surgery. 
Abdool demonstrated a significant improvement in 
prolapse, urinary, bowel and sexual function in both 
treatment arms but no difference between the two 
groups. Using the ICIQ-VS and ICIQ-UI, Lone et al. 
found a statistically significant vaginal, sex, QOL and 
urinary symptoms score improvement in both groups 
but no statistically significant difference was noted 
between the surgery and pessary groups. However, 
Barber (2006) found that subjects in the surgery 
group had significantly greater improvement in each 
of the scales of the PFDI and the prolapse and urinary 
scales of the PFIQ than did the pessary group. 
3.2.5 Comparison of One Pessary to Another 
No new trial was identified for this update, making a 
total of one trial included in this section comparing 
pessary to another device. Cundiff (299) conducted 
the largest multi-centre crossover trial, comparing a 
ring with support and a Gellhorn pessary for the treat-
ment of symptomatic stage II or greater symptomatic 
prolapse in 134 women. There were no significant dif-
ferences between groups in baseline characteristics. 
Participants were fitted with one of the pessaries for 
three months, and with the second for a further three 
months. During each three-month period, data was 
collected at one, six and twelve weeks from women 
who had a successful fit. Outcomes were measured 
at enrolment, three and 12 months, and included ob-
jective assessment using POP-Q and subjective as-
sessment using PFDI, PFIQ, and a sexual function 
questionnaire. Allocation was by computer-generated 
random numbers using permuted blocks of variable 
size. Opaque, sealed envelopes were used to store 
the random allocation. Participants and clinicians 
were not blind to the allocation, but data was coded 
such that the analysis was conducted blind. Those 
women who were successfully fitted were asked to 
wear the pessary for three months, but if they discon-
tinued prior to three months’ data collection was ac-
celerated. Attrition rates in the study were high with 
only 85 of the 134 women completing the study lead-
ing to high risk of bias. However, the trial was not un-
derpowered due to the cross over design. 
Cundiff et al. (299) found a statistically and clinically 
significant improvement in the majority of the PFDI 
scales and many of the PDIQ scales with both pessa-
ries but no difference between the ring or Gellhorn 
pessary. Approximately 60% of women offered a pes-
sary continued treatment in the long term irrespective 
of the type of device. 
Success rates 
There is no agreement as to what constitutes a suc-
cessful fitting of a pessary. Some consider success if 
a pessary was perceived comfortable by a patient 
when retained during Valsalva and voiding at the ini-
tial visit, while others consider it success if a patient 
continues to use the pessary until the following visit 
to the doctor. Thus quoted rates of successful fitting 
vary widely with differing follow-up times. (Table 33). 
Reasons for failure range from expulsion due to com-
plications such as vaginal discharge, erosion, de 
novo SUI, pain, voiding difficulty and constipation 
(Table 33). The risk factors for failure also vary, mak-
ing it difficult to draw conclusions. 
Complications 
Minor complications after pessary insertion range 
from vaginal discharge, erosion, de novo SUI, bleed-
ing, pain and constipation (Table 33). A recent study 
by Collins (300) has shown that women who have a 
pessary are more likely to be bothered by discharge 
(30.0% vs 2.1%, p < .001) and this develops early and 
may be due to an inflammatory process in the vagina 
(300). Using the cube pessary appears to be compli-
cation free, probably because it has to be removed 
on a regular basis. 
Rarely major complications may occur. Neglected 
pessaries present with more serious complications 
namely fistula formation and peritonitis. Erosion into 
the bowel or bladder and dense adhesions to other 
pelvic structures have been reported. Unusual com-
plications of cervical entrapment, small bowel incar-
ceration, and hydronephrosis have also been re-
ported (301).  
Conclusion 
As in the most recent Cochrane review (222) and 1 
recent RCT, there is no good quality evidence from 
randomised controlled trials on which to base the 
management of  POP using pessaries. 
Prospective case controlled cohort studies suggest 
that pessaries are a viable option for women who 
complain of symptomatic prolapse. (Level of Evi-
dence: 3). 
There appears to be no advantage of pessary use 
over PFMT, from one high risk of bias RCT (Level of 
Evidence: 3).  
One single randomised study, with a high attrition rate 
of 40% found no significant difference between ring 
pessaries with support and the Gellhorn pessary in 
PFDI and PFQI scores (Level of Evidence: 2).  
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Table 31 Summary of data on PFMT vs pessary for POP 
Author/ year Study 
design 
Comparison group Participants Type of pessary Subjective 
assessment 
Objective 
assessment 
Length of 
follow-up 
Improvement in 
symptoms 
Panman CM, 
2014 
 
 
RCT PFMT  (n=79): 
No standard protocol 
– individual 
adaptation in line 
with normal practice 
(included being able 
to use electrical 
stimulation) 
vs  
PESSARY (n 81): 
Fitting – opted for 2 
week try of pessary 
with refit at 2 weeks if 
necessary and max 
of 3 refits.Fitted by 
‘trained research 
physician’ 
160 women aged > 
55 years with self 
identified POP 
symptoms (on 
screening) 
POP at or beyond 
hymen (POPQ) 
 
First ring, then 
ring with support 
and then Shaatz 
or Gellhorn 
Primary outcome: 
PFDI-20  
 
 
 
 
Secondary: change 
in POP-Q stage 
3 months  No sign diff. in PFDI 
POP-Q Anterior 
compartment: 26.5% 
>=1 stage change in 
PFMT v 7.1% pessary 
p=0.013 
* No ITT, only 47 of 81 
(58%) with successful 
fitting included in 
analysis 
Foot notes: RCT- Randomised Controlled study, PFDI- Pelvic Floor Distress Inventory, PFMT- Pelvic floor muscle training, POP- pelvic organ prolapse 
Table 32 Summary of data on pessary for POP 
Author/ 
year 
Study design Comparison group Participants 
Type of 
pessary 
Subjective and 
Objective 
assessment 
Objective 
assessment 
Length of 
follow-up 
Improvement in symptoms 
Abdool et 
al. 2011 (1) 
 
Prospective 
observational 
cohort case 
controlled 
 
Pessary treatment 
compared to 
surgery  
 
359 Ring, 
Gellhorn, 
Cube, Donut 
 
Sheffield prolapse 
questionnaire 
 
Baden-Walker 12 months Awareness of lump, prolapse coming out 
of vagina, dragging pain in lower 
abdomen, low back pain, voiding difficulty, 
need to push prolapse to void, urinary 
urgency, fecal urgency, sexual 
satisfaction, interference with physical 
activity and quality of life 
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Author/ 
year 
Study design Comparison group Participants 
Type of 
pessary 
Subjective and 
Objective 
assessment 
Objective 
assessment 
Length of 
follow-up 
Improvement in symptoms 
Barber et 
al. 2006 (2) 
Prospective 
observational 
cohort case 
controlled 
 
 
Pessary treatment 
(3 months) 
compared to 
surgery (6 months) 
for pelvic organ 
prolapse 
Pessary (n= 
42) Surgery 
(n=64) 
 
Ring and 
Gellhorn 
 
PFDI and PFIQ 
 
POP-Q 3 months 
for pessary  
 
Significant improvement in prolapse and 
urinary scales of the PFDI. No change in 
the colorectal scale. No change in the 
PFIQ scales 
 
Brazell et 
al. 2014 (3) 
Prospective 
observational 
cohort 
N/A 43 Ring with 
support and 
Gellhorn 
PFDI-20 
PFIQ-7 
POP-Q 12 months CRADI-8 mean scores decreased by 6.9 
and CRAIQ-7 decreased by 8.1 
Clemons et 
al. 2004 (4) 
Prospective 
observational 
cohort 
N/A 100 Ring and 
Gellhorn 
Not validated POP-Q 2 months Bulge (90% to 3%) 
Pressure (49% to 3%) 
Discharge (12% to 0%) 
Splinting (14% to 0%) 
SUI 45% 
UI 46% 
Voiding difficulty 53% 
Cundiff et 
al. 2007 (5) 
Randomised 
cross-over 
 
Ring with support to 
Gellhorn 
 
134 Ring with 
support to 
Gellhorn 
 
PFDI,PFIQ, Sexual 
Function 
Questionnaire 
 
POP-Q 6 months Statistically and clinically significant 
improvements in majority of the PFDI and 
many PFIQ scales in both pessaries, but 
no clinically significant differences 
between the two pessaries 
Ding et al. 
2015 and 
2016 (6, 7) 
Prospective 
observational 
study 
N/A 81 with Stage 
III and IV 
Ring with 
support 
Not validated POP-Q 3 months Improved bulging (90.4% to 23.3%) 
Decreased pelvic pressure (64.4% to 
13.7%) 
Improved urinary symptoms as follows 
Voiding – 97.8% 
Splinting- 100% 
Urge urinary incontinence- 76.9% 
Stress urinary incontinence- 58.1% 
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Author/ 
year 
Study design Comparison group Participants 
Type of 
pessary 
Subjective and 
Objective 
assessment 
Objective 
assessment 
Length of 
follow-up 
Improvement in symptoms 
Fernando et 
al. 2006 (8) 
Prospective 
observational 
cohort 
 
N/A  203 Ring, 
Gellhorn, 
Cube, Donut 
 
Sheffield prolapse 
questionnaire 
 
Baden Walker 4 months Awareness of lump (71%), prolapse 
coming out of vagina (52%), vaginal 
soreness (21%), dragging sensation in 
lower abdomen 24%), lower back ache 
(30%), difficulty emptying bladder (40%), 
push prolapse to void (29%), urinary 
urgency (38%), urge urinary incontinence 
(29%), stress urinary incontinence (40%), 
incomplete emptying of bowels (28%), 
rectal digitation to empty bowels (12%), 
vaginal digitation to empty bowel (7%), 
faecal urgency (30%), urge faecal 
incontinence (20%), frequency of sexual 
intercourse (16%), sexual satisfaction 
(11%)  
 
Jones et al. 
2008 (9) 
Prospective 
observational 
cohort 
N/A 90 Ring, 
Incontinence 
ring, 
Gellhorn, 
Oval  
PFDI POP-Q 3 months Improvement in the overall PFDI scale 
and all subscales with the exception of 
colorectal distress inventory 
Komesu et 
al. 2007 
(10)  
 
Prospective 
observational 
cohort 
 
Compare PF 
symptoms in 
patients who 
continue and 
discontinue pessary 
use 
 
64 
 
 
 
Choice of 
pessary left 
to discretion 
of the 
provider 
 
PFDI-20 
 
POP-Q 6-12 
months 
In the continuation group final PFDI-20 
total, bladder and prolapse scale scores 
were better than the discontinuation 
group.  
 
Kuhn et al. 
2009 (11) 
Prospective 
observational 
cohort 
N/A 73 Cube Female Sexual 
Function Index, 
Sheffield 
questionnaire, 
Kings Health 
Questionnaire 
POP-Q 3 months Improvement in feeling of bulge, 
improvement in stool outlet problems, 
overactive bladder symptoms. 
Improvement in sexual desire, orgasm, 
lubrication and satisfaction after therapy 
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Author/ 
year 
Study design Comparison group Participants 
Type of 
pessary 
Subjective and 
Objective 
assessment 
Objective 
assessment 
Length of 
follow-up 
Improvement in symptoms 
Lone et al. 
2015 (12) 
Prospective 
observational 
study 
Pessary treatment 
versus surgery 
269 Ring, 
Gellhorn, 
Cube, Donut 
ICIQ-VS 
ICIQ-UI 
POP-Q 12 months Statistically significant vaginal, sex, QOL 
and urinary symptoms score improvement 
in both groups. There was no statistically 
significant difference was noted between 
the surgery and pessary groups. 
Nemeth et 
al. 2013 
(13) 
Prospective 
observational 
study 
N/A 78 Cube 
pessary 
Non-validated 
questionnaire 
(Hungarian) 
POP-Q 12 months Improved general wellbeing score 
Patel et al. 
2010 (14) 
Prospective 
observational 
cohort 
N/A 75 Ring, Ring 
with support, 
Gellhorn 
 
Body Image Scale 
(BIS) and PFDI-20, 
PFIQ, Prolapse 
subscale of PFIQ 
 
POP-Q 3 months Improvement in body image scale scores, 
PFDI-20 scores, PFIQ scores 
 
Foot notes: N/A-Not applicable, SUI- Stress Urinary Incontinence, UUI-Urge urinary incontinence, RCT- Randomised Controlled study, P- Prospective Observational 
study, PFDI- Pelvic Floor Distress Inventory, UDI -Urinary Distress Inventory, ICIQ-VS- International Consultation on Incontinence- Vaginal Symptoms, ICIQ- UI- Interna-
tional Consultation on Incontinence- Urinary Incontinence, CES-D – The center for Epidemiological Depression Measures, MOS Scores- Medical Outcome Study (MOS) 
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Table 33 Summary of data on pessary success rates and risk factors for failure  
Author/ year Number Types of pessaries Study design 
Follow-up 
period 
Success rate 
n (%) 
Reason for failure Risk factors 
Abdool et al. 2011 
(1) 
554 Ring, Gellhorn, 
Cube, Donut 
 
Prospective 
observational case 
controlled cohort 
12 months 243 (68%) N/A  N/A  
Brazell et al. 2014 
(2) 
104 Ring with  Prospective 
observational 
study 
12 months 34(41%) N/A N/A 
Ding et al. 2015 
and 2016 (3, 4) 
81 Ring with support Prospect 
observational cohort 
3 months 73 (67%) Feeling of discomfort and pressure, a 
desire for surgical correction, extrusion 
of pessary, bothersome de novo stress 
incontinence 
No specific risk factors 
like stage or type of 
prolapse identified 
Fernando et al. 
2006 (5) 
203 Ring, Gellhorn, 
Cube, Donut 
 
Prospective 
observational cohort 
2 weeks 153 (75%) Failure to retain pessary, pain/ 
bleeding/discomfort, worsening 
symptoms 
 
Increasing parity, previous 
hysterectomy 
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Author/ year Number Types of pessaries Study design 
Follow-up 
period 
Success rate 
n (%) 
Reason for failure Risk factors 
Handa et al. 2002 
(6)  
56 Ring, Donut, 
Gellhorn, Cube 
Prospective 
observational cohort 
3 months 36 (64.3%) Discomfort, expulsion - 
Jones et al. 2008 
(7) 
90 Ring, Incontinence 
ring, Gellhorn, Oval 
Prospective 
observational cohort 
3 months 42 (47%) Failure to retain, Inadequate relief of 
symptoms 
Large baseline 
measurement of the 
perineal body at rest 
Large levator hiatus 
Komesu et al. 2007 
(8) 
 
64* Choice of pessary 
left to discretion of 
the provider 
Prospective 
observational cohort 
6-12 
months 
64 (56%) failure to retain, uncomfortable Prolapse score decrease 
to 77% of baseline  
Kuhn et al. 2009 (9)  73 Cube Prospective 
observational cohort 
12 months 32 (44%) Pessary expulsion, desire for surgery, 
bothersome de novo SUI, inability to 
remove or insert pessary, pain or feeling 
of discomfort, unspecified 
N/A 
Lone et al. 2011 
(10) 
246 Ring, Gellhorn, 
Cube, Donut 
 
Prospective 
observational cohort 
5 years 53 (28.3%) Expulsion, excoriation/bleeding, 
pain/discomfort, constipation  
N/A  
Patel et al. 2010 
(11)  
75 Ring,  
Ring with support, 
Gellhorn 
 
Prospective 
observational cohort 
3 months 54 (79%) Failure to retain, ineffective N/A 
Nemeth et al. 2012 
(12) 
78 Cube Prospective 
observational cohort 
12 months 62 (79%) Stress incontinence 
Vaginal discomfort 
Parity, previous 
hysterectomy and/or 
colpoperineorrhaphy, 
Difficult insertion 
Wu et al. 1997 (13) 110 Ring with and 
without diaphragm, 
Cube 
Prospective 
observational cohort 
Initial visit 81 (74%) Failure to sustain support of the 
prolapse, intolerable urinary 
incontinence, vaginal discharge, pelvic 
pain, vaginal abrasions and erosions 
Younger women, previous 
pelvic surgery, history of 
stress incontinence prior 
to pessary insertion 
Foot notes: N/A = not applicable; N/R = not reported,*Includes patients with incontinence and/or prolapse 
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4. RECOMMENDATIONS 
There is growing attention being paid to the effective-
ness of conservative interventions for POP. There are 
encouraging signs of more rigorous research in the 
area. 
4.1. Recommendations for Practice 
4.1.1 Lifestyle Modification 
1. Constipation is associated with development of 
prolapse (Grade of Recommendation: C New). 
2. Smoking cessation, while generally recom-
mended, cannot be recommended specifically 
for the avoidance of prolapse development 
(Grade of Recommendation: D). 
3. Vitamin D deficiency is not associated with de-
velopment of prolapse (Grade of Recommen-
dation: C New). 
4.1.2 Pelvic Floor Muscle Training (PFMT) 
1. PFMT does not influence the development of 
prolapse post-natally (Grade of Recommenda-
tion: B New). 
2. PFMT intervention delivered 12 years+ after 
childbirth can reduce symptoms of prolapse 
which develop in the longer term (Grade of Rec-
ommendation: B New). 
3. There is evidence of benefit that PFMT is effec-
tive in reducing pelvic floor symptoms (Grade of 
recommendation: A New) 
4. There is some evidence of benefit showing that 
PFMT is effective in alleviating specific prolapse 
symptoms (e.g. vaginal bulge) (Grade of recom-
mendation: C New) 
5. There is no evidence that PFMT is effective in 
reducing severity of prolapse based on POP-Q 
stage (Grade of recommendation: B New).  
6. Peri-operative PFMT does not improve prolapse 
symptoms in women undergoing surgery for 
vault prolapse (Grade of Recommendation: B 
New). 
7. Combined pessary and PFMT and PFMT alone 
can be equally effective in reducing symptoms 
and increasing muscle strength and should be 
considered for treatment (Grade of Recommen-
dation: B New). 
4.1.3 Pessaries 
1. In a choice between the Gellhorn pessary and a 
ring with support, offer either to improve prolapse 
symptoms and reduce their impact (Grade of 
Recommendation: B). 
4.2. Future Research Directions 
4.2.1 Lifestyle Interventions 
1. Trials of interventions for constipation are 
needed to assess their effectiveness in prevent-
ing/treating prolapse. 
2. Studies to fully investigate the association be-
tween occupation/heavy lifting, and bodyweight 
and prolapse are needed as current evidence is 
conflicting. These studies should ensure that: 
i. Occupation, physical activity and diet are as-
sessed rigorously, using instruments with 
sound psychometric properties. 
ii. Potential confounding variables are consid-
ered. Attempts are made to overcome recall 
bias inherent in assessing lifetime occupational 
history, and healthy worker bias, which is a 
problem when attempting to compare prolapse 
in women currently employed in heavy labour 
type jobs versus others. 
iii. Outcome measures used are valid and relia-
ble, and are consistent across studies; pro-
lapse symptoms should be the primary out-
come within studies, followed by prolapse ana-
tomical severity. 
4.2.2 Pelvic Floor Muscle Training (PFMT) 
1. Further studies are needed to confirm the role of 
physical therapies in the prevention of POP.  
2. Further trials are needed to add to the evidence 
regarding: 
i) The effectiveness of PFMT for different stages 
and types of prolapse. 
ii) The role of PFMT as an adjunct to surgery for 
anterior and posterior prolapse.  
3. More trials needed to improve the evidence re-
lating to the following comparisons: 
i) Low versus high intensity supervision of PFMT 
(taught PFMT vs self-instruction manual already 
trialled) 
ii) Individual versus group PFMT (group PFMT vs 
group lifestyle already trialled) 
iii) PFMT versus surgery (anterior/posterior repair 
vs PFMT already trialled) 
iv) PFMT versus pessary. (PFMT vs PFMT plus 
pessary already trialled) 
The assessment and measurement of POP and the 
assessment of prolapse symptoms need to be made 
in a standardised fashion using a validated outcome 
measure (such as the POP-Q examination). A single 
validated symptom tool was not apparent in new stud-
ies, but the PFDI, PFIQ and POP-SS tools were most 
commonly used and may provide a useful basis for 
comparisons across trials in future. 
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4.2.3 Pessarie for Prolapse 
Although the use of pessaries has been common clin-
ical practice and has been used for many centuries 
robust evidence of their use is lacking. There is a 
pressing need for well-designed randomised studies 
using validated measures for subjective and objective 
assessment. Areas that need focus are: 
 Pessary versus no treatment 
 Pessary versus PFMT 
 Pessary versus surgery 
 Risk benefit of the use of local oestrogen in con-
junction with a pessary 
 Progression or regression of prolapse using in 
women using pessaries 
 Optimal management protocols for pessary us-
age e.g. indications, interval between pessary 
changes, complications and their treatment and 
which pessary is indicated for a specific type of 
prolapse. 
 URINARY INCONTINENCE IN 
MEN 
As in earlier consultations, UI in men remains under-
reported and under-studied in comparison to studies 
of women. Pooled prevalence of UI in community 
based men ranges from 4.81-32.17%. (302). UI and 
other LUTS in men increase with age, with variation 
in prevalence rates reflecting different study popula-
tions, definitions of incontinence and methods (303). 
Despite the prevalence of UI and LUTS in older men, 
the only aspect which continues to receive systematic 
consideration with respect to conservative manage-
ment is post-prostatectomy urinary incontinence after 
radical prostatectomy (RP). The primary conservative 
approach for prevention and treatment of UI after RP, 
or transurethral resection (TURP), remains PFMT, 
with or without some form of biofeedback (BF). 
PFMT, in combination with anal EStim, BF or 
transcutaneous electrical nerve stimulation (TENS), 
MStim, and novel therapies such as dyadic planning 
and concentration have been utilised for UI in men.  
The PFMT, EStim, MStim and PTNS interventions, 
and other combinations of PFMT with general exer-
cise and other approaches, in the current review were 
kept in the same organizational format as the previ-
ous consultation to reflect evolving evidence and 
emerging directions of research. All new studies of 
EStim and MStim in men undergoing or post prosta-
tectomy combined these modalities with PFMT and 
thus were included under the PFMT section. Penile 
vibratory stimulation (PVS) was added as a novel 
technology category. The study on PVS involved men 
incontinent after RP, but did not include PFMT, so 
was kept in a separate section, as were studies of 
EStim and MStim for non-prostatectomy related in-
continence or other LUTS. Studies on PTNS are pre-
sented in section V.1. 
A literature search of relevant systematic reviews and 
reports of RCTs and quasi-RCTs was updated. No 
other types of study designs were considered. One 
systematic review, an update of the Cochrane sys-
tematic review on conservative management of post-
prostatectomy incontinence, was identified (304). For 
this review, 14 new published trials (305-318) and 
eight abstracts (319-326) were identified. Table 34 
provides summary information on the 22 trials added 
in this review. One study previously included only as 
an abstract (327) is now included as a full publication 
(328). This study is included in the table as in the full 
publication with additional information that was not 
previously included in the abstract. The published 
peer reviewed journal publication (329) of a previ-
ously included report of two parallel trials (RP and 
TURP arms) was added to the references which pre-
viously included an abstract and health technology 
report (330, 331). One study previously excluded as 
it was a study in progress (332) was included this time 
as a peer reviewed publication of a completed trial 
(307). Nine ongoing trials were identified from trial 
registries, but not included in this review. 
1. LIFESTYLE 
Lifestyle recommendations such as smoking cessa-
tion, healthy eating, appropriate body weight, avoid-
ing excessive caffeine or alcohol are all part of a pri-
mary care approach and are intended to be preven-
tative in the onset of obesity, cardiovascular disease, 
diabetes. Up until the last ICI edition, no trial had ad-
dressed the topic of lifestyle interventions alone in 
men with UI. In this edition, a few new trials have 
been added.  
1.1. Weight Loss by Obese or Overweight 
Men 
One new trial was identified on weight loss in over-
weight/obese men (7, 333) and has been added in 
this update. This was the partner study to Phelan, Ka-
naya et al. (2012) conducted to determine the effect 
of an intensive weight loss programme over 4 years 
previously outlined in the look AHEAD trial - on a sub-
set of male participants (n=1910). Men were random-
ised to an intensive weight loss programme or diabe-
tes support and education group. Self-report of incon-
tinence, nocturia and daytime voiding frequency were 
recorded at baseline and 1 year. The odds of preva-
lent UI at one year were reduced by 38% in the inten-
sive lifestyle modification intervention group com-
pared to the support and education group, with UI de-
creasing from 11% to 9% in men. As reported for 
women there was uncertainty over the risk of selec-
tion bias for a number of key parameters including: 
random sequence generation and allocation conceal-
ment. Performance bias was unclear as the blinding 
of participants and staff was not undertaken. Both 
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studies did ensure the blinding of outcome assess-
ment but neither provided complete outcome data 
and both provided only selective reporting indicating 
possible reporting bias (Table 2).  
1.2. Smoking 
One new trial was found however data was not pre-
sented separately for women and men. (Refer to sec-
tion II.1.2.4 for more details) 
1.3. Dietary Modification in Men 
In a separate sample (from the study by Davis, 
Vaughan et al. 2013 presented in Lifestyle interven-
tion in women’s section II.1.2.5) 3960 men over 20 
were included (16).  
The authors found that the highest level of caffeine 
intake was associated with having moderate to se-
vere UI (1.72, 95% 1.18-2.49 and 2.08, 95% 1.15-
3.77) respectively. All parameters in terms of risk of 
bias reporting were unclear or high risk. The blinding 
of participants and personnel and blinding of outcome 
assessment were at high risk of bias and the likeli-
hood of incomplete outcome data and selective re-
porting was also high.  
A sample of 683 men aged 40-75 who completed a 
food frequency questionnaire and the Consultation on 
Incontinence short Form (ICI-SF) as part of the 
Hirayama study (18). The data showed a slight in-
crease in the risk of UI at the highest level of caffeine 
consumption (similar to the US data), but this was not 
significant after adjusting for confounding factors with 
OR: 95% CI, 1.36 (0.65-2.88) in the male participants. 
The risk of bias reporting was largely unclear in this 
study with blinding of participants and personnel and 
blinding of outcome assessment, incomplete out-
come data and selective reporting all of high risk. Re-
sults of sex stratified analysis of the data from the 
sample of Japanese men and women did not show 
an association between caffeine and UI, the authors 
suggest the need for further larger samples to explore 
any association further (Table 5).  
Summary 
Evidence from 1 RCT supports lifestyle modification 
interventions promoting weight loss as a tool to re-
duce urinary incontinence in men who are overweight 
or obese. (Level of Evidence: 2; 1 new RCT). 
Evidence from a small new RCT indicates that urinary 
frequency may be improved by smoking abstinence, 
(Level of Evidence: 3).  
Caffeine consumption is likely to play a role in exac-
erbating UI in men. New epidemiological evidence 
from a large cross sectional study supports this con-
clusion (Level of Evidence: 3). 
Recommendations 
Weight loss: Where weight loss through lifestyle 
changes should be recommended to obese and over-
weight men with UI, particularly those with type 2 di-
abetes. (Grade of Recommendation: B New) 
Smoking abstinence should be recommended for 
men with UI. (Grade of Recommendation: C New) 
A reduction in caffeine intake is recommended for 
those with incontinence symptoms; evidence suggest 
the equivalent of 2 cups of coffee a day (250mg) is 
associated with urinary incontinence in both men and 
women. (Grade of Recommendation: C) 
Larger RCTs to assess effect of lifestyle modification 
interventions are important.  
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Table 34 Summary of data on conservative management in male urinary incontinence  
Author, year Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
Pelvic Floor Muscle Training (PFMT) 
Ahmed et al. 
2012 (1) 
3 group 
comparison 
PFME vs PFMT 
plus EStim vs 
PFMT plus 
EStim plus 
biofeedback 
N= 90 men 
randomized, N=80 
completed trial 
Group 1 n= 26 
Group 2 n=26 
Group 3 n= 28 
Randomization by 
computer generated 
random number list in 
sealed envelopes. 
Surgeons blinded to 
randomization. Blinding 
of outcomes assessor 
not indicated. 
Men undergoing 
RP for clinically 
localized 
prostate cancer  
Treatments started one 
week after catheter 
removal, twice weekly 
for 12 weeks 
Group 1 PFME 
(control) 
Group 2 PFMT plus 
EStim starting one 
week after catheter 
removal, twice weekly 
for 12 weeks 
Group 3 PFMT plus 
EStim plus 
biofeedback starting 
one week after 
catheter removal, twice 
weekly for 12 weeks 
EStim – electrodes on 
skin over sacrum  
Biofeedback - surface 
electrodes on abdomin 
and perineum 
Primary outcome 24 hour 
pad test, secondary was 
quality of life assessed 
with IIQ-7.  
Mean leakage significantly 
lower in Group 3 (EStim 
plus biofeedback) at 6 
through 24 weeks (p < 
0.05)  
Significant differences in 
continence at weeks 12 
and 24 with Group 3 
having more continent 
patients, followed by 
Group 2. Concluded early 
EStim and biofeedback 
decrease duration and 
degree of 
postprostatectomy UI 
Continence 
assessed at 
baseline, 6, 12 
and 24 weeks 
Dropouts: none 
reported 
Sample size analysis 
reported (n=80)  
Dropouts  
Group 1= 4 (2 
radiotherapy, 2 
postoperative 
complications 
Group 2 = 2 (both 
radiotherapy) 
Group 3 = 4 (2 
radiotherapy, 2 
declined followup) 
No intention to treat 
analysis.  
Baroni et al. 
2013(2) 
 
Abstract only 
Intervention 
(individual 
PFMT and 
group 
treatment) vs 
control 
(individual 
PFMT) 
N= 40 men  
Divided into two groups 
(randomization not 
described).  
Intervention: n = 16 
patients mean age 61.8 
years  
Control n = 24 mean 
age 67.5 
Assessor blind to 
allocation until 
assignment.  
Men with SUI or 
mixed UI after 
RP (time after 
surgery not 
reported) 
Intervention: 5 
individual training 
sessions with a 
physical therapist 
followed by small 
groups sessions (total 
15 sessions at the 
rehabilitation centre), 
home exercises.  
Control: individual 
training sessions with 
physical therapist.  
Outcomes included 
adherence to training 
program (exercise at 
home), self report of 
change in continence 
using VAS scale and 
number of pads, quality of 
life ICIQ-SF, cost 
effectiveness (therapist 
time).  Non significant 
difference in home 
practice (intervention 69% 
vs 58% controls). No 
Initial briefing by 
therapist, final 
evaluation one 
month after 
rehabilitation.  
Dropouts: none 
reported.  
No sample size 
analysis reported.  
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Author, year Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
difference between groups 
on VAS or pads used per 
week. Authors conclude 
group treatment allows 
cost effective 
improvement.  
Burkert et al. 
2011(3) 
Intervention 
(dyadic PFME 
planning) vs 
one of three 
controls  
N = 112 prostatectomy 
patients and their 
partner (dyads).  
2x2 mixed design. 
Couples randomized in 
blocks of four to one of 
four groups Intervention 
n= 28,  
Controls n= 29, 29 and 
26  
Research assistants 
blinded to allocation  
Mean age of patients 
62.8 years, partners 
59.3 years.  
Men undergoing 
laprascopic RP 
who had a 
partner willing to 
participate 
All patients received 
standard care including 
written information on 
PFME 1 day post 
surgery (PFME 3x day 
for 10 minutes), 
physical therapist 
introduced PFME on 
day 3 or 4. Discharge 
day all participated in 
single 30 minute 
planning session 
intervention with 
completion of planning 
sheet for health 
behaviours (in dyad or 
individually).  
Intervention: dyad 
PFME planning  
Control: (dyadic 
nutrition planning, 
Control:  
individual PFME 
planning, Control:  
individual nutrition 
planning 
Main outcome: self 
reported dyadic planning 
and PFME. 
Self reported dyadic 
PFME planning increased 
with both the dyadic and 
individual PFME planning 
session. No effect on 
PFME was found.  
Continence was not an 
outcome. 
Questionnaires at 
2 days, 2 weeks, 
1, 3 and 6 months 
post-surgery. 
Dropouts 
Intervention n=5  
Control: dyadic 
nutrition planning n=2  
Control individual 
PFME planning n=7 
Control:  
individual nutrition 
planning n= 4 
Sample size analysis 
required 112 couples 
(dyads).  
Intention-to-treat 
analysis completed.  
Collado, Serra 
2013 (4) 
 
Abstract only 
Intervention 
PFMT plus BF 
pre-op vs 
Control PFME 
after RP 
N= 193 patients 
recruited 
Randomization and 
blinding detail not 
provided.  
Men with 
localized 
prostate cancer 
scheduled for 
RP 
Intervention: starting 3 
weeks before surgery 
included weekly 
assisted BF sessions 
(surface electrodes) 
with periodic, rapid, 
Primary outcome: Degree 
of continence 
improvement compared to 
week 1 during followup 
(continence not defined) 
No detailed 
description. Pad 
tests reported for 
week 1, week 6, 
month 3, month 6 
and 1 year.  
Dropouts –detail only 
for intervention group 
n=5 (2 perineal pain, 2 
post RP complication, 
1 left treatment.  
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Author, year Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
N= 179 included in final 
analysis 
Intervention = 87 
Control = 92 
intense and maximal 
strength contractions 
and transversus 
abdominis activation 
plus daily PFMT 
performed at home 
with written instruction 
(no detail on whether it 
was continued post-
operatively) 
Control: oral instruction 
on PFME post surgery, 
structured program of 
BF, transversus 
abdominis activation 
and PFMT 3 months 
post surgery 
Secondary outcomes 24 
hour pad test and ICIQ-UI 
SF score 
Significant difference in 
continence improvement 
reported for week 6, 
month 3, month 6 and 1 
year favouring intervention 
group. Difference in 24 
hour pad test significant 
only at 3rd month, 
favouring intervention 
group. 
No sample size 
calculation provided.  
No intention–to-treat 
analysis.  
Dijkstra-Eshuis 
et al. 2015 (5) 
Intervention 
PFMT plus 
biofeedback 
pre-op vs 
Contol PFME 
post-op 
N=122 patients 
recruited, N= 121 
randomized. Pre-
operatively. 
Mean age 63.7 years.  
Randomization by 
computer generated 
random numbers (block 
randomization, variable 
block size). Therapists 
and participants blinded 
to randomization until 
first visit.  
Intervention n= 65 
Control n= 56 
Men undergoing 
laparascopic RP 
(one surgeon), 
prostate cancer 
state T1 or T2.  
All participants 
assessed pre-op by 
physical therapist 
Intervention: once 
weekly 30 minute 
session of PFMT with 
biofeedback pre-op x 4 
weeks provided by 
physical therapist with 
twice daily practice at 
home. Told to restart 
immediately after 
catheter removal. 
Written instructions for 
2 sets of 30 
contractions.  
Control: standard care 
of written PFME 
instructions on catheter 
removal (7-10 days 
post surgery) 
Primary outcome: urinary 
continence defined as no 
leakage on 24 hour pad 
test and self report by 
KHQ, IPSS and PeLFI 
(pelvic floor inventories)  
20.8% of patients 
continent at 6 weeks, 
43.6% at 3 months, 61.5% 
at 6 months, 72.3 % at 9 
months, 77.2% at one 
year.  
No difference in SUI or 
QoL between intervention 
and control at any time 
points.  
Authors suggested that 
post-prostatectomy UI 
likely due to intrinsic 
sphincter deficiency that 
Questionaires, 24 
hour diary and 
pad test at 6 
weeks, 3, 6, 9 
and 12 months 
post-operatively.  
PeLFT and 
examination of 
the pelvic floor 
pre-operatively 
and 1 year post-
operatively.  
Dropouts 
Intervention: language 
barrier (1), lost to 
followup (4), 
discontinued 
intervention (4) 
Control: 
Lost to followup (4), 
discontinued 
intervention (6) 
Sample size analysis 
was 124 patients in 
each group (n=248), 
interim analysis 
planned at 122 
patients. Trial halted 
as interim analysis 
showed no benefit.  
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Author, year Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
cannot be treated with 
exercise.  
Geraerts et al. 
2013 (6) 
Intervention 
PFMT plus 
biofeedback 
pre-op vs 
Control PFMT 
post-op 
N= 180 men  
Computer generated 
randomization using 
permuted blocks for 
strata (age <65/≥65, 
surgical approach 
open/robot assisted 
laproscopic 
Intervention n= 91 
Control n=89  
Men undergoing 
open or robot 
assisted 
laproscopic RP 
(3 surgeons)  
Intervention: 30 minute 
session of therapist 
guided PFMT with 
biofeedback weekly 
starting 3 weeks prior 
to surgery plus home 
program of 60 
contractions per day. 
Restarted PFME day 4 
post-op with catheter in 
situ 
Control: PFMT after 
catheter removal  
Both groups: Post-op 
weekly session to 
discuss bladder diary 
and have guided 
session with digital or 
EMG biofeedback plus 
home program. PFMT 
continued until 
continent 
Primary outcome: 
incidence of contience and 
time to continence. 
Continence defined as 3 
consecutive days of 0gm 
urine loss on 24 hour pad 
test. Other measures 
were: 1 hour pad test, 
VAS, IPSS, KHQ (QoL).  
No difference between 
groups on duration of UI, 
pad test, VAS or IPSS. 
Median time continence 
was 30 (control) and 31 
(intervention) days. 
Intervention group scored 
better on impact of 
incontinence at 3 and 6 
months  
Pre-operative 
baseline and 1, 3, 
6 and 12 months 
post-operatively 
Dropouts:  
Intervention n=6 died 
(1), stroke (1), 
transport problems 
(3), refused further 
participation (1)  
Control n= 4 transport 
probems (2), refused 
further participation 
(2) 
Sample size analysis 
required 166 for 
power.  
Ghanem et al. 
2013 (7) 
Abstract only 
Intervention 
PFME pre-op vs 
Control PFME 
post-op 
N=100 men 
randomized. 
Randomization 
technique not 
described.  
Intervention N=50 
Control N=50 
Men with 
localized 
prostate cancer 
undergoing 
radical 
prostatectomy 
Intervention: 
PFME protocol for 2 
weeks prior to surgery 
(detail not provided) 
with post-operative 
PFME program. 
Control: postoperative 
PFME program only 
Continence defined as 
using 0-1 pads. Also 
completed the ICIQ SF 
male. 
More intervention patients 
continent at 14 weeks than 
controls (p< 0.05). 70% of 
patients in both groups 
continent at 18 weeks, 85 
% by 54 weeks.  
Timepoints for 
measurement not 
clear, last dated 
reported at 54 
weeks post-op.  
Dropouts: not 
described 
 
Sample size analysis 
not described.  
Hou et al 2013 
(8) 
Intervention 
post-op PFME 
vs control 
N= 66 randomized. 
Randomization 
Men undergoing 
TURP for benign 
Intervention: PFME 
after removal of 
catheter day 2 post-op. 
Outcome: early recovery 
of bladder function post 
TURP using the IPSS and 
Baseline and 1, 4 
and 12 weeks 
post-op 
Dropouts n= 5 (group 
assignment not 
identified) delay in 
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Author, year Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
technique not 
described.  
N= 61 completed study 
(intervention n= 32; 
control n= 29)  
prostatic 
hyperplasia.  
Instructed to contract 
PFM for 5 seconds, 
relax for 10 seconds. 
Surface EMG to 
confirm PFM 
contraction. Home 
program 5 minutes 
practice 3 x per day. 
Weekly telephone 
reminders.  
Control: not described 
SF-36. Q-max (maximum 
urinary flow), voided 
volume and PVR (post 
void residual volume).  
At 12 weeks, intervention 
group had significantly 
less severe LUTS 
compared to control 
(p<0.001), Qmax 
(p=0.026) and QoL 
physical (p=0.029) and 
mental health domains (p= 
0.005). No significant 
differences in voided 
volume or PVR.  
catheter removal prior 
to discharge (2), lost 
to followup (3).  
Sample size analysis 
not provided. No 
intention-to-treat 
analysis.  
Kakihara et al. 
2007 (9) 
Intervention 
(PFMT with 
EStim) vs 
PFME only 
N=20 men from a 
single urology clinic, 
mean age 64.3 years 
Randomly divided into 
two groups (detail on 
randomization 
technique not provided)  
Intervention group 
n=10, control n=10  
N=18 in final analysis 
for pad test and visual 
analogue data : 
intervention n=8, 
control n=10  
Men with urinary 
incontinence 
post RP 
(minimum of 6 
months post-op, 
had undergone 
urodynamic 
testing) 
Intervention:  
Physical therapy taught 
functional PFMT with 
EStim. 
PFME started with 2s 
contractions increasing 
daily by 1suntil 10s 
reached. Patients were 
instructed to do 90 
contractions/day at 
home (divided equally 
into 3 times per day). 
Also had EStim with 
endo-anal electrode 
weekly. UUI – 8 Hz 
increasing to 10 Hz 
after 3 months, for SUI 
35Hz increasing to 50 
Hz after 3 months.  
Control: Physical 
therapy taught 
functional PFMT only 
UI measured with 1 hour 
pad test (incontinence < 2 
gm), visual analogue 
scales for incontinence 
patient perception of the 
problem, and pad use  
Intervention group: 4 
patients UUI, 6 had SUI, 
mean time post surgery 
12.3 months. Control 
group: 5 had UUI, 5 SUI, 
meantime post surgery 
16.8 months 
Significant decrease in 
urine loss on pad test and 
self report baseline to 12 
months in both groups. No 
difference between groups 
Measures at 
baseline, visit 2, 
and 3, 6 and 12 
months.  
Dropouts 
Intervention n=2 
discharged at 3rd and 
6th months, reason 
not provided.  
Control n=3 
discharged at 3rd, 6th 
and 12th as regained 
continence  
Length of time EStim 
continued for the 
intervention group 
unclear.  
No sample size or 
intention-to-treat 
analysis reported.  
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Author, year Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
Kongtragul et 
al. 2014 (10) 
Intervention 
(PFME with 
concentration 
therapy) vs 
control (PFME 
only)  
N= 138 men recruited 
from a single hospital 
N= 135 cases in final 
analysis (n= 68 
intervention, n= 67 
control) 
Randomization 
technique not given. 
Sample stratified for 
time of catheter 
removal (prior to or 
after discharge) and 
type of surgery (no 
further detail provided).  
Men 17-80 
years of age 
with prostate 
cancer who had 
no incontinence 
prior to radical 
prostatectomy 
surgery  
Intervention: Starting 3 
weeks post-
operatively, PFME with 
concentration therapy 
(concentrating on the 
exercise and 
eliminating other 
issues or use of the 
rehabilitation health 
spa rock - not clearly 
described). PFME was 
practiced 240 times 
daily by holding and 
relaxing muscle 
tension around the 
anus.  
Control: PFME only 
Primary outcome was 
urinary incontinence 
(incontinence ≥ 2 gm urine 
on 1 hour pad test)  
65/68 in intervention group 
compared to 48/67 
controls achieved 
continence (p< 0.001 
More men in intervention 
group 66/68 practiced 
regularly than in control 
group 34/67 (p<0.001) 
Measurements at 
baseline (3 weeks 
post surgery) and 
weekly for up to 3 
months 
Dropouts 
Intervention n=1 
(refused treatment) 
Control n=2 (refused 
treatment)  
Needed 69 cases in 
each group for power.  
No intentiontotreat 
analysis.  
Laurienzo et al. 
2013 (11) 
3 groups  
Pre-op PFMT 
plus EStim vs 
pre-op PFMT vs 
control  
N= 58 men recruited.  
Randomization by 
computer generated 
list. All intervention 
provided by a single 
therapist 
N= 49 completed study 
(n= 17 PFME plus 
EStim, n= 17 PFME, n= 
15 control) 
Men with 
prostate cancer 
stage T2 waiting 
RP 
Intervention  
Group 1: 10 pre-op 
physiotherapy sessions 
of EStim using rectal 
probe. Tonic fibers – 
20HZ, 700 
microseconds, work 
time 6s, rest 6s. Phasic 
fibers – 65 HZ, 150 
microseconds, work 
time 6s, rest 18s. Five 
exercises for PFM 
contraction. 
Group 2: 10 pre-op 
physiotherapy sessions 
with only the PFME.  
Control  
Pre-op information on 
prostate anatomy only 
Primary outcome: 
continence assessed by 1 
hour pad test (> 2 gm 
incontinence). Secondary 
outcomes: ICIQ-SF, SF-36  
 
No significant differences 
between groups on pad 
test at any time points. No 
differences in QoL (SF-36) 
Measurements at 
1, 3 and 6 months 
post surgery.  
Dropouts 
N=9 (detail on group 
not provided). 
Desistance (sic)(2), 
adjuvant radiotherapy 
(1), urethral stenosis 
(1), urinary fistula (1), 
surgical risk (1), 
inadequate followup 
(1) 
No sample size 
analysis described. 
No intention-to-treat. 
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Author, year Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
No post-op PFM 
rehabilitation for any 
group  
Laurienzo et al 
2015 (12) 
Abstract only 
3 groups  
PFMT plus 
EStim vs PFMT 
vs control  
N=123 men incontinent 
after RP 
Randomization by 
computor, sealed 
envelopes.  
Group 1 n=40 control, 
no treatment 
Group 2 n=41 assisted 
PFMT 
Group 3 n=42 EStim 
with assisted PFME 
No details on blinding.  
Men with more 
than 3 gram loss 
of urine on a 1 
hour pad test 
one month after 
RP 
Assisted PFMT 
described as two 
series of ten exercises 
taught by verbal 
command 
EStim protocol was 20 
minute sessions twice 
weekly over 7 weeks. 
Frequency 35 HZ 
 
 
Outcomes Incontinence 
and quality of life using the 
ICQ-SF, erectile 
dysfunction by IIEF-5, 
IPSS, 1 hour pad test, 
evaluation of pelvic floor 
with perineometer. 
No differences between 
groups in quality of life, 
erectile dysfunction or 
PFM strength at any time 
point post-surgery. Pad 
test data not provided. 
Patients 
evaluated pre-
operatively and 
then at 1, 3, and 6 
months post RP 
Dropouts not 
discussed.  
Sample size analysis 
not provided.  
Martini et al 
2011 (13) 
Abstract only 
Intervention 
pre-op PFMT vs 
control 
N= 70 men recruited 
N= 49 with pelvic floor 
impairment identified 
on exam randomized to 
intervention or control.  
Intervention n=24 
Control n=25 
Randomization details 
not provided.  
Men undergoing 
laparoscopic RP 
for localised 
prostate cancer 
T1-T3 
Intervention: 5 
sessions of physical 
therapist guided PFMT 
2-3 weeks before 
surgery, PFME 
continued post-op 
Control: usual care – 
written instruction on 
PFME provided post-
operatively 
Outcome: focus on PFI as 
a potential factor in post 
RP UI. Continence defined 
by not wearing a pad. 
Other: 24 hour pad test, 
pad use, 7 day bladder 
diary, QoL.  
Patients with PFI used 
more pads and had more 
SUI episodes. PFI 
independent predictor of 
UI at 3 and 6 months. For 
those with PFI, UI on 
getting up and squating 
was significantly lower in 
intervention group at 1 
month (p=0.006) but not 
other time points.  
Measurement 
pre-op baseline, 
and 1, 3 and 6 
months post-op.  
Dropouts: not 
identified.  
Sample size analysis 
not provided.  
Morihoro et al 
2011 (14) 
Abstract only 
Intervention 
post-operative 
PFME with 
N= 34 men 
Randomized post-
operatively to 2 groups. 
Men who had 
undergone 
laparoscopic RP 
Intervention: PFME 
and EStim 2x daily for 
15 minutes for one 
Outcome UI, defined as 
not needing a pad to keep 
clothing dry.  
Measurement at 
1, 3, 6, and 12 
months.  
Dropouts: not 
described.  
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Author, year Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
EStim vs control 
PFME 
Randomization 
technique not 
described. 
Intervention n=20 
Control = 14 
month after catheter 
removal, starting on 
day 5 after surgery.  
Control: PFME alone 
Recovery of urinary 
continence significantly 
favored intervention group 
at 12 months (p = 0.007). 
Multivariate analysis 
showed EStim associated 
with continence recovery 
at 6 and 12 months.  
No sample size 
analysis based on 
multivariate or other 
analysis provided.  
Ng 2014 (15) 
Abstract only 
Intervention 
pre-op PFMT vs 
control 
N=66 men 
Randomization 
technique not given.  
Men undergoing 
radical 
prostatectomy 
Intervention: PFMT 
started 3 weeks pre-
operatively from 
advanced practice 
nurse.  
Control: Standard care 
(no detail provided).  
Primary outcome: urine 
loss on 24 hour pad test. 
Secondary outcomes: 
incontinence impact and 
potency satisfaction.  
Earlier return to 
continence in intervention 
group at 3 months 
compared to controls (p= 
0.002). Intervention group 
also had higher score on 
potency at 3 months (p = 
0.005).  
Measures at 1,2, 
3 and 6 months 
Dropouts: no 
information provided.  
Ocampo-Trujillo 
et al. 2014 (16) 
Intervention 
(pre-op PFMT 
with 
biofeedback)  
vs control 
(standard pre-
op teaching 
only)  
N=16 men, mean age 
58 years 
Randomized to 2 
groups 
Intervention n=8, 
control n=8 
Randomization –single 
blind, centralized. 
Researchers blind to 
group assignment prior 
to enrollment. 
 
Men > 40 years 
waiting RP for 
prostate cancer 
(T<3 N0M0 
PSA<20) 
Intervention: Intensive 
PFMT 3 times daily for 
4 weeks prior to 
surgery. Biofeedback 
audible and visual 
signals, anal pressure 
probe.  
Control: standard pre-
operative diet and 
general health teaching  
24 hour pad test for 
continence, histological 
analysis of muscle tissue 
from external sphincter of 
urethra. Health related 
quality of life assessed 
with UCLA-PCI and SF 12.  
Continence defined as 3 
consecutive days of no 
urine loss on 24 hour pad 
test, results not reported. 
6/8 intervention vs 4/8 of 
controls did not need pads 
at 8 weeks. Self report of 
symptoms favoured 
improvement in 
intervention group (no p 
Measurements 
(pad test, health 
related quality of 
life) at week 0 
prior to surgery 
and week 8 post-
op.  
Histology 
samples taken at 
the end of the 
intervention and 
on day of surgery.  
Dropouts: none 
 
 
No histiology samples 
taken prior to start of 
intervention.  
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Author, year Comparator N 
Study 
population 
Modality details or 
parameters 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
values provided except for 
erectile dysfunction).  
Intervention patients had 
higher values in cross 
sectional area of external 
sphincter muscle than 
controls (p=0.03) 
Park et al. 2012 
(17) 
Previously only 
in abstract form.  
Intervention 
(combined 
exercise with 
PFME vs 
control (PFME 
only) 
N= 66 men 65 years or 
older recruited. 
Random allocation by 
random number 
generator, sealed 
envelopes 
N= 39 completed study.  
(n= 26 in intervention 
group, n= 25 in control)  
Participants not 
blinded; surgeons and 
research assistant 
completing evaluation 
questionnaires not 
blinded. 
Men who had 
undergone 
laparoscopic 
RP.  
Intervention: Exercise 
(resistance, pelvic 
flexibility and Kegel 
exercises) initiated 
post-op week 3 for 12 
weeks (twice weekly).  
Control : Kegel 
exercises only 
Detail of Kegal (PFME) 
exercises not provided. 
Exercise program 
developed by sport 
science experts, detail 
of who supervised the 
intervention not 
provided.  
Continence a secondary 
outcome 
Measured by 24 hour pad 
test. Urinary continence 
was < 1 gm 
Significant improvement 
(p= 0.033) in favour of 
intervention group at time 
of last visit (15 weeks 
post-op).  
Concluded intervention 
group had an earlier return 
to continence.  
Measurements at 
1 week prior to 
surgery, 3 weeks 
post-op and after 
the intervention 
(15 weeks post-
op)  
Dropouts  
Intervention:  
n=7 (other unrelated 
surgery, TURP for 
urethral stricture, non 
compliance, new 
employment)  
Control: 
n=8 (other unrelated 
surgery, adjuvant 
radiotherapy, non 
compliance, new 
employment)  
No intention-to-treat.  
Pedriali et al. 
2014 (18) 
Abstract only 
Intervention 
post-op pilates 
vs control 
PFME plus 
EStim 
N= 69  
 
Randomization 
technique not 
described 
N=54 completed study 
( n=26 intervention, n= 
28 control)  
Men one month 
after RP 
Intervention: 
10 sessions mat 
Pilates exercises with 
certified Pilates 
physical therapist 
Control: 10 sessions of 
PFME plus EStim with 
physical therapist.  
Both: Written 
instructions for home 
exercises 
corresponding to 
treatment. 
Outcomes: continence on 
24 hour pad test, number 
of pads used, ICIQ-SF 
Significant reduction in 
urine loss/24 hours and 
pads used, improvement 
in QoL in both groups.  
58% of intervention and 
50% of controls achieved 
continence as measured 
by no pad use (p=0.57)  
Authors concluded Pilates 
as efficacious as control 
condition and may reduce 
health care costs.  
Time points of 
measurement not 
provided, 3 
months of 
treatment 
mentioned.  
Dropouts: no details 
provided.  
No information on 
sample size 
calculation provided.  
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Serda et al. 
2014 (19) 
Intervention 
post-op 
combined 
exercise with 
PFME vs 
control no 
intervention 
 
N= 69 men with 
prostate cancer (any 
stage) who had 
undergone 
prostatectomy +/- 
hormone or hormone 
and radiotherapy 
randomized to 2 
groups.  
n= 36 intervention 
n= 33 control 
Mean age 71 in both 
groups.  
N=66 completed 
Men with no 
prior 
incontinence 
recruited after 
treatment for 
prostate cancer 
(time period not 
identified).  
Details of 
randomization 
approach not 
provided.  
Intervention:  
Progressive strength 
program in 3 
consecutive stages: 
global posture re-
education, PFMT, 
exercises to radiate 
muscle strength. 
Duration 24 weeks, 16 
weeks of supervised 
work, 8 of autonomous 
exercise.  
PFMT performed with 
music, focus on 
biofeedback (sense of 
awareness). Slow 
twitch (≤1s) and fast 
twitch (5s) 
contractions.  
Control group: watchful 
waiting by telephone 
contact 
UI assessed by 20 
minutes pad test. Type of 
incontinence measured by 
UI-4, intensity and 
frequency of urine loss by 
Sandvik scale and VAS-UI 
and FACT-P (urinary 
related QoL). Also 
included data on obesity, 
muscle resistance, 
constipation andactivity.  
33.33% of intervention 
group had stress UI 
compared to 36.36% 
controls. The rest had 
urgency UI or mixed UI. 
Significant improvement 
on VAS-UI scale regarding 
intensity UI symptoms 
favouring intervention 
group. QoL improvement 
greater in those with 
greater improvement in UI. 
Pad test dated/number 
achieving continence not 
reported.  
Data collected at 
baseline and 24 
weeks.  
Calculated 
sample size 
achieved.  
Dropouts 
Intervention: n=3 
(medical reason, 
cognitive problem, 
metastasis) 
Control: None 
No intention-to-treat.  
Tienforti et al. 
2012 (20) 
Intervention 
(pre-operative 
and post-
operative PFMT 
with 
biofeedback)  
vs  
control group 
(post-op PFME 
only) 
N= 34 men screened 
and recruited pre-op, 
computer generated 
randomization 
schedule.  
N= 32 men in the final 
analysis (n= 16 in 
intervention, age 60-74; 
n= 16 in control age 52-
74).  
No significant 
differences between 
Men undergoing 
standard open 
retropubic RP 
for localized 
prostate cancer 
at one centre.  
Intervention: Pre-
operative biofeedback 
(anal probe, reference 
electrode on anterior 
superior iliac spine) 
with teaching on PFM 
the day prior to 
surgery. After catheter 
removal, oral and 
written  PFME with 
structured exercise 
program (3 daily 10 
Recovery of continence 
(self report on ICIQ-UI) 
primary outcome.  
Significant difference in 
achievement of continence 
favoring intervention group 
at 1, 3 and 6 month 
followups. 10/16 
intervention vs 1/16 
control patients continent 
at 6 months.  
Measurements at 
baseline, 1, 3 and 
6 months.  
Dropouts 
Intervention: n=1 
(intolerence to rectal 
probe insertion)  
Control: n=1 
(intraoperative 
surgical 
complications)  
No intention-to-treat.  
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Modality details or 
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Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
intervention and control 
groups in age, disease 
stage, intra or post-
operative features.  
minutes sets 5 second 
contractions followed 
by 5 seconds 
relaxation) lying/sitting/ 
standing, recorded in 
diary. Monthly 
supervised 
biofeedback and 
motivation sessions  
Control: oral and 
written instructions on 
home PFME post-op 
after catheter removal, 
no diary, monthly 
followup 
Pre-op session 
provided by a 
dedicated caregiver.  
Patients in intervention 
group reported higher QoL 
(IPSS QoL), difference not 
significant 
Concluded pre-operative 
biofeedback with PFME 
and monthly assisted 
sessions improves 
recovery to continence.  
Zopf et al. 2015 
(21) 
Intervention 
(combined 
exercise with 
PFME vs 
control (no 
intervention) 
N = 85 men who had 
undergone 
prostatectomy for 
prostate cancer.  
n= 56 in intervention 
group 
n= 29 in control group 
N= 70 (50 intervention, 
20 control) completed 
followup 
Men recruited 6-
12 weeks after 
prostatectomy 
+/- radiation. 
Multicentre, 
partially 
randomized 
controlled trial.  
Patients who 
consented to 
randomization 
were to be 
randomized, 
patients who 
refused 
randomization 
were to receive 
intervention of 
their choice. As 
all patients 
Intervention: 15 month 
supervised multimodal 
exercise program 
(aerobic, resistance 
and PFME) with one of 
4 community sports 
groups. Exercise 60 
minutes per week 
Details of PFME not 
provided.  
Control: No 
intervention 
Multiple secondary 
outcomes including urinary 
incontinence as measured 
by 20 minute pad test. 
Primary endpoint was 
physical fitness.  
Significant improvement in 
UI for intervention group 
between baseline and post 
testing (p= 0.005). No 
significant difference 
between intervention and 
control.  
Significant improvement of 
self reported urinary 
symptoms (EORTC-QLQ 
PR 25) in favour of 
intervention group.  
Measures for UI 
at 3 time points, 
detail not 
provided.  
 
Authors identify 
poor compliance 
with pad testing 
was a limitation.  
 
Calculated 
sample size not 
achieved, limited 
power to detect 
differences 
between groups.  
Dropouts  
 
Intervention: n=6, 
reasons not related to 
intervention  
 
Control: dropouts not 
described.  
 
Intention-to-treat 
analysis performed.  
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Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
indicated a 
group 
preference, trial 
was not 
randomized.  
Penile Vibratory Stimulation (PVS) 
Fode 2015 (22) Intervention 
PVS vs control 
delayed PVS 
N= 39 randomized by 
computer generated list 
1 :1 ratio 
N= 31 in analysis 
(Group 1 early 
intervention n= 19; 
Group 2 delayed 
intervention n=20  
 
 
Men with UI > 1 
year post RP. All 
patients had 
previously 
received PFMT 
with RP.  
12 week study. 
Intervention: PVS for 
first 6 weeks of study. 
Stimulation of ventral 
surface of glans once 
daily; 10 seconds of 
stimulation followed by 
10 second pause 
repeated 10 times.  
Control: delayed 
intervention – no 
intervention in first 6 
weeks, PVS in second 
6 weeks  
 
Primary outcome: 
difference in leakage 
measured by 24 hour pad 
test and 72 hour voiding 
diary. Subjective 
assessment by ICIQ-SF, 
IPSS and satisfaction 
questionnaire.  
Early intervention group:  
12/15 had reduction in 
leakage on pad test 
baseline to 6 weeks (p = 
0.021); maintained in 8/12 
at 12 weeks (p= 0.04)  
Delayed intervention 
group: reduction (not 
significant) with treatment 
weeks 6-12. No significant 
difference between groups 
at 6 weeks. Pooled 
analysis: Significant 
overall median decline in 
urine loss on 24 hour pad 
test (p= 0.07) Authors 
suggest sufficient 
evidence to move to larger 
trial.  
Measures at 
baseline prior to 
inclusion and 6 
and 12 weeks.  
Drop outs:  
Group 1 early 
intervention n=4 lung 
infection (1), pain on 
stimulation (2), non 
compliance (1)  
Group 2 delayed 
intervention n= 5 
untreated diabetes 
(1), urinary tract 
infection (2), change 
in drinking habit (1) 
discontinued after 6 
weeks non 
compliance (kept in 
analysis) (1) 
Sample size 
calculation was n=50, 
enrollment stopped 
early as sample size 
deemed adequate for 
purpose (pilot) 
Scheduled Voiding Regimes  
Burgio 2011 
(23) 
Combined 
behavioural 
N=143 men from 2 
sites.  
Men with 
continued OAB 
Intervention: 8 weeks 
(4 clinic visits) 
Primary outcome: post 
treatment 24 hour voiding 
Baseline 
assessment and 
Intention-to-treat 
analysis undertaken.  
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Modality details or 
parameters 
Outcomes/results Follow up 
Notes (side effects, 
loss of follow up…) 
treatment 
(PFME, urge 
suppression, 
delayed 
voiding) vs drug 
therapy 
Randomized using 
sealed envelopes after 
stratification for voiding 
frequency 
Behaviour treatment 
n=73 
Drug therapy n=70 
symptoms after 
treatment with 
an alpha blocker 
for prostatic 
obstruction.  
combined behavioural 
treatment composed of 
elements of bladder 
training (PFME, urge 
suppression 
techniques and 
delayed voiding). 
Verbal instruction by 
nurse practitioners, 
and PFME guided 
practice using verbal 
feedback based on 
anal palpation. Daily 
practice of 45 
exercises (3 sessions 
of 15 exercises). Also 
used fluid 
management.  
 
Control: drug therapy 
with oxybutynin 5-
30mg.   
 
frequency on 7 day 
bladder diary. Other OAB 
symptoms (nocturia, 
urgency, incontinence) 
also collected on bladder 
diary. Secondary 
outcomes: global 
perception of improvement 
and patient satisfaction.  
Results 
Frequency: both groups 
had statistically significant 
improvement from 
baseline to after treatment. 
Equivalence analysis 
showed post treatment 
voiding frequency 
equivalent between 
behaviour and drug 
therapy groups (p< 0.001)  
Behaviour therapy group 
had greater reduction of 
nocturia episodes, but 
urgency scores were lower 
in the drug therapy group. 
No difference in reduction 
in incontinence episodes.  
measure, post 
treatment 
measures.  
 
 
Dropouts reported: 
n=9 in behavioural 
therapy group, n= 10 
in drug therapy group.  
BF – biofeedback; RP – radical prostatectomy; TURP – transuretheral prostatectomy; PFME – pelvic floor muscle exercises; PFMT – Pelvic floor muscle training; PVS – 
Penile vibratory stimulation; ICIQ-SF – International Consultation on Incontinence Questionnaire Short Form; IPSS – International Prostate Symptom Score 
1. Ahmed MT, Mohammed AH, Mansour AA. Effect of pelvic floor electrical stimulation and biofeedback on the recovery of urinary continence after radical prostatec-
tomy. Turkish Journal of Physical Medicine and Rehabilitation. 2012;58(3):171-7. 
2. Baroni M, Lorenzetti R, Renzi C, Brizzi A, Branchini W, Altavilla MG, et al. Approach HTA (health technology assessment) to treat urinary incontinence after radical 
prostatectomy (Abstract number 23). Neurourology and urodynamics. 2013;32:S20. 
3. Burkert S, Scholz U, Gralla O, Roigas J, Knoll N. Dyadic planning of health behavior change after prostatectomy: a randomized controlled trial planning intervention. 
Social Science and Medicine. 2011;73:783-92. 
152 
4. Collado Serra A, Pellicer Cabo M, Ramirez Backhaus M, Dominguez-Escrig J, Rubio-Briones J, Gomez-Ferrer A, et al. Intensive preoperatory Pelvic Floor Muscle 
Training reduce duration and severity of stress urinary incontinence after radical prostatectomy: A randomized controlled trial (Abstract number 1007). European 
Urology Supplements. 2013;12(1):e1007-e8. 
5. Dijkstra-Eshuis J, Van den Bos TWL, Splinter R, Bevers RFM, Zonneveld WCG, Putter H, et al. Effect of preoperative pelvic floor muscle therapy with biofeedback 
versus standard care on stress urinary incontinence and quality of life in men undergoing laparascopic radical prostatectomy: a randomized control trial. Neurourol-
ogy and urodynamics. 2015;34:144-50. 
6. Geraerts I, Van Poppel H, Devoogdt N, Joniau S, Van Cleynenbreugel B, De Groef A, et al. Influence of preoperative and postoperative pelvic floor muscle training 
(PFMT)compared with postoperative PFMT on urinary incontinence after radical prostatectomy: a randomized controlled trial. European urology. 2013;64:766-72. 
7. Ghanem A, Khallaf M, Assem A, Hassan A. Does preoperative pelvic floor muscle exercise improve post prostatectomy urinary incontinence (Abstract 695)? . 
Conference: Annual Meeting of the International Continence Society ICS, Barcelona, Spain. 2013. 
8. Hou CP, Chen TY, Chang CC, Lin YH, Chang PL, Chen CL, et al. Use of the SF-36 quality of life scale to assess the effect of pelvic floor muscle exercise on aging 
males who received transurethral prostate surgery. Clinical Interventions in Aging. 2013;8:667-73. 
9. Kakihara C, Sens Y, Ferreira U. Effect of functional training for the pelvic floor muscles with or without electrical stimulation in cases of urinary incontinence following 
radical prostatectomy. Revista Brasileira de Fisioterapia. 2007;11(6):481-6. 
10. Kongtragul J, Tukhanon W, Tudpudsa P, Suedee K, Tienchai S, Leewansangtong S, et al. Effects of adding concentration therapy to Kegel exercise to improve 
continence after radical prostatectomy, randomized control. Journal of the Medical Association of Thailand. 2014;97(5):513-7. 
11. Laurienzo CE, Sacomani CAR, Rodrigues TR, de Cassio Zequi SGGCLA. Results of preoperative electrical stimulation of pelvic floor muscles in the continence 
status following radical retropubic prostatectomy. International Brazilian Journal of Urology. 2013;39:182-8. 
12. Laurienzo C, Magnabosco W, Jabur F, Gameiro M, Yamamoto H, Guerra R, et al. Post-prostatectomy urinary incontinence and erectile dysfunction: The role of 
pelvic floor rehabilitation (Abstract number 527). Conference: Annual Meeting of the International Continence Society, ICS Montreal, QU, Canada. Neurourology 
and urodynamics. 2015;34:S449-S50. 
13. Martini M, Bernardini S, Blanc E, Piretta K, Tappero R. Relationship between integrity of pelvic floor function and recovery of continence after laparoscopic prosta-
tectomy and effects of preventive pelvic floor muscle training in males with pelvic floor weakness (Abstract 14). Conference: Annual Congress of the Italian Urody-
namics Society, Turin, Italy. Neurourology and urodynamics. 2011;30(SUPPL 1):11-2. 
14. Morihoro N, Masatsugu I, Shinji K, Kenichi T, Kazumasa M, Shiro B. Effectiveness of sacral surface therapeutic electrical stimulation (SSTES) on early recovery of 
urinary incontinence after laparoscopic radical prostatectomy: a prospective study. Neurourology and urodynamics. 2011;30(6):889-90. 
15. Ng SI. A Randomised Controlled Trial Study of the Efficacy of Intensive Pre-Operative Pelvic Floor Muscle Training to Decrease Post-Prostatectomy Urinary Incon-
tinence (Abstract number OP.4.7Dec.38). International Journal of Urology. 2014;21:A169. 
16. Ocampo-Trujillo A, Carbonell-Gonzalez J, Martinez-Blanco A, Diaz-Hung A, Munoz CA, Ramirez-Velez R. Pre-operative training induces changes in the histomor-
phometry and muscle function of the pelvic floor in patients with indication of radical prostatectomy. Actas Urologicas Espanolas. 2014;38(6):378-84. 
17. Park SW, Kim TN, Nam JK, Ha HK, Shin DG, Lee W, et al. Recovery of overall exercise ability, quality of life, and continence after 12 week combined exercise 
intervention in elderly patients who underwent radical prostatectomy: A randomized controlled study. Urology. 2012;80:299-306. 
153 
18. Pedriali F, Gomes C, Soares L, Urbano M, Moreira E, de AS. The efficacy of pilates compared to pelvic floor muscle training associated with electrical stimulation 
in the recovery of post-prostatectomy urinary incontinence: A randomized controlled trial (Abstract number 306). Neurourology and urodynamics. 2014;33(6):742-
3. 
19. Serda BC, Marcos-Gragera R. Urinary incontinence and prostate cancer: a progressive rehabilitation program design. Rehabil Nurs. 2014;39(6):271-80. 
20. Tienforti D, Sacco E, Marangi F, D’Addessi A, Racioppi M, Galino G, et al. Efficacy of an assisted low-intensity programme of perioperative pelvic floor muscle 
training in improving the recovery of continence after radical prostatectomy: a randomized controlled trial. BJU international. 2012;110:1004-11. 
21. Zopf EM, Bloch W, Machtens S, Zumbe J, Rubben H, Marschner S, et al. Effects of a 15-month supervised exercise program on physical and psychological 
outcomes in prostate cancer patients following prostatectomy: The ProRehab study. Integrative Cancer Therapies. 2015;14(5):409-18. 
22. Fode M, Sonksen J. Penile vibratory stimulation in the treatment of post-prostatectomy incontinence: a randomized pilot study. Neurourology & Urodynamics. 
2015;34(2):117-22. 
23. Burgio KL, Goode PS, Johnson TM, Hammontree L, Ouslander JG, Markland AD, et al. Behavioral vs. drug treatment for overactive bladder in men: The Motive 
Trial. Journal of the American Geriatrics Society. 2011;59(12):2209-16. 
154 
2. PELVIC FLOOR MUSCLE 
TRAINING (PFMT) 
Almost all studies of PFMT in men focused on UI as-
sociated with prostate surgery. In the 5thICI, improve-
ment in the quality of trials included was found when 
compared to earlier reports, although heterogeneity 
and varying outcome measures continued to affect 
the ability to compare trial findings. Studies in the first 
part of this section remain grouped into three types: 
pre-operative interventions, mixed pre- and post-op-
eratives’ studies of all men undergoing prostatectomy 
and studies of post-operative interventions for men 
with established incontinence. A total of 20 new RCTs 
of PFMT alone or combined with other conservative 
interventions focused on prostate surgery were 
added to the 38 studies from the previous ICI reports. 
Nineteen of the new trials involved men pre or post 
RP (N= 1597 randomized), one trial involved men 
post TURP (N= 66 randomized). Recommendations 
are at the end of the section.  
2.1. Pre-Operative RP PFMT 
Trials in this section compared pre-operative inter-
ventions. Three new trials of pre-operative PFMT in-
tervention (313, 314, 320) were identified and added 
to the two previously included trials. Ocampo-Trujillo 
(314) compared pre-operative PFMT with BF (n=8) to 
standard pre-operative teaching (n=8). Laurienzo 
(313) randomized to three groups, reporting group 
numbers for only the 49 of 58 men that completed the 
study: pre-operative PFME plus EStim (n= 17), pre-
operative PFME (n=17) and control which received 
only pre-operative information on prostate anatomy 
(n=15). Collado-Serra (320) also reported group num-
bers for those completing (179 or 193) and compared 
an intervention group receiving pre-operative PFMT 
plus BF (n=87) to a control group (n=92) receiving 
only oral PFME instruction post-surgery followed by 
PFMT plus BF 3 months later.  
Quality of data 
Ocampo-Trujillo (2013) used a centrally randomised, 
single blind approach, with researchers blind to the 
group assignment prior to enrolment. No information 
on sample size analysis or post hoc power analysis 
was provided. This was a very small study that was 
likely underpowered. There were no dropouts from 
the study. Laurienzo (2013) described randomization 
using a computer-generated list. Detail of blinding 
was not provided and a single therapist provided all 
interventions. There was no report of sample size cal-
culation, post hoc power analysis or intention-to-treat 
analysis. Nine dropouts were reported, but the group 
from which they withdrew was not given. Collado 
Serra (2013) study was available only as an abstract 
and did not report how participants were randomized 
or if there was any blinding. There was no information 
on sample size, and no intention-to-treat analysis re-
ported. Only dropouts from the intervention group 
(n=5) were described.  
Results 
Ocampo-Trujillo and colleagues (2013) did not report 
the results of the 24-hour pad test data but did report 
that 6/8 (75%) of the intervention group compared to 
4/8 (50%) of the control did not require pads at 8 
weeks. The authors also report a statistically signifi-
cant difference in objective measures of muscle tis-
sue from the external sphincter of the urethra favour-
ing the intervention group. As no histology samples 
were taken prior to the intervention, the claim that the 
difference is due to the intervention cannot be sup-
ported. Subjective report of symptoms reportedly fa-
voured improvement in the intervention group. Lauri-
enzo (2013) reported no differences between inter-
vention and control groups at any time point (1, 3 and 
6 months post-surgery) on objective measure of in-
continence (one-hour pad test). There were no differ-
ences between the two interventions and one control 
group on subjective report of quality of life. Collado 
Serra (2013) reported improvement in continence at 
week 6, month 3, month 6 and 1-year favouring inter-
vention group, but did not clearly define its primary 
outcome. Significant difference on objective 24-hour 
pad test was only at 3 months favouring the interven-
tion group.  
2.2. Pre-Operative and/or Post-Operative 
RP PFMT, Post RP Continence Status 
Not Established Prior to Intervention 
Trials in this section addressed the effect of PFMT in-
itiated pre-operatively and/or post-operatively but be-
fore post-op continence/incontinence was estab-
lished. In these studies, men were recruited pre-op-
eratively or immediately post-operatively and the in-
vestigators compared a treatment group that received 
the intervention pre-operatively and/or post-opera-
tively RP to a group receiving an intervention only 
post-operatively. Nine new studies (305-307, 309, 
315, 321, 323, 324, 326) were added to the 10 previ-
ously included trials, for a total of 19 trials in the cat-
egory, over three subsections.  
2.2.1 Pre-Operative PFMT Instruction with 
Post-Operative Home PFMT Versus 
Control 
Four new trials (307, 321, 323, 326) were added to 
three previously included studies. In the previous 
consultation, studies varied in support of an earlier re-
turn to continence with PFME plus or minus biofeed-
back. Dijkstra-Eshuis (2015) compared an interven-
tion group that received preo-perative PFMT plus BF 
with home practice and post-operative home PFME 
(n=65) to a control group that received written post-
operative PFME instruction (n=56). Ghanem (2013), 
available only in abstract, compared an intervention 
group with a PFME programme two weeks pre-oper-
atively and continued post-operatively (n=50) to a 
control group that received only a postoperative 
PFME programme (n=50). Detail of the PFME pro-
gramme was not provided. Ng (2014), also only avail-
able in abstract, compared an intervention (of PFMT 
starting 3 weeks pre-operatively to a control group 
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that received standard care. A total of 66 men partic-
ipated, but numbers randomized to each group and 
details of the standard care were not provided. Martini 
(2011), again in abstract only, described an interven-
tion group (n=24) that received five physiotherapy 
guided PFMT sessions 2-3 weeks pre-operatively, 
with continued PFME post-operatively. The control 
group (n=25) received post-operative written instruc-
tion on PFME.  
Quality of data 
Dijkstra-Eshuis and colleagues (2015) reported ade-
quate random allocation concealment. Participants 
and therapists were blinded to randomisation until 
first visit. They also reported results of follow up were 
send to clinic of the single surgeon performing the 
RP, but blinding of outcome assessment is not made 
explicit. Sample size analysis was provided, inten-
tion-to-treat was not addressed. Dropouts in both in-
tervention (n=9/65, 13.6% and control groups 
(n=10/56, 18%) were described. Three studies (321, 
323, 326) were available only as abstracts with ran-
domisation, blinding, sample size calculation and 
dropouts not described. 
Results 
In all new studies, the primary outcome was conti-
nence measured by either the pad test or number of 
pads used, secondary outcomes were self-report of 
symptoms and/or quality of life on standardised ques-
tionnaires. Dijkstra-Eshuis et al. (2015) found no dif-
ferences between intervention and control at any time 
points on the primary objective outcome (24-hour pad 
test) or on secondary self-reported symptom and 
quality of life measures but the trial was stopped prior 
to full recruitment after a planned interim analysis 
showed no demonstrated benefit, with the authors 
concluding that post RP UI is likely due to intrinsic 
sphincter injury and not treatable with exercise. Two 
other studies (321, 326) reported an earlier postoper-
ative return to continence (at 14 weeks and 3 months 
respectively) favouring the intervention group, but the 
effect was not demonstrated later time points. Simi-
larly, Martini (2011), who included only men with 
demonstrated pelvic floor impairment prior to surgery, 
reported significantly less UI on getting up and squat-
ting (no quantification provided) in the intervention 
group at 1 month but not at later time points. 
2.2.2 Pre-Operative PFMT Instruction Fol-
lowed by supervised Post-Operative 
PFMT Versus Post-Operative PFMT 
Two new trials (309, 315) were added to the previous 
four studies in this subsection, making a total of six 
studies included. Tienforti (2012) randomized 34 men 
undergoing RP, but reported only on group assign-
ment for those completing the study. The intervention 
(n=16) was pre-operative and post-operative PFMT 
with BF, started the day before surgery and continu-
ing monthly, with daily home practice, during follow-
up. The control group (n=16) received oral and written 
instructions post-operatively with no monthly follow-
up. Geraerts (2013) compared the intervention (n=91) 
of PFME plus BF and a home program starting 3 
weeks prior to surgery with PFME starting 4 days 
post-operatively to a control group (n=89) that started 
PFMT post-operatively. Both groups received weekly 
post-operative treatment that included BF and blad-
der diary review, with PFMT continuing until conti-
nence achieved.  
Quality of data 
Tienforti (2012) used a computer-generated random-
isation schedule. Information on blinding to group as-
signment and outcome assessment was not pro-
vided. In this small study, no sample size calculation 
or intention-to-treat was reported. Dropouts in each 
group, one in each intervention and control (6% from 
each group) were described. Geraerts (2013) used 
computer generated randomisation using stratifica-
tion for age and surgical approach, blinding to group 
assignment and outcome assessment was not pro-
vided. In this large trial, sample size calculation re-
cruited an adequate sample to power the study. In-
tention-to-treat analysis was not discussed. There 
were n=6/91 (7%) dropouts in the intervention group, 
and n=4/89 (5%) in the control, reasons were pro-
vided.  
Results 
The newer studies continue to report variable results. 
Tienforti (2012) found a significant difference in 
achieving continence at one, three and six months fa-
vouring the intervention group, but this was by self-
report of symptoms, with no objective measure of 
continence included as an outcome. In the Geraerts 
(2013) study, which was larger and of good quality, 
there were no differences between the groups with 
regards to objective duration of UI measured by 24-
hour pad test or self-reported symptoms at any time 
point. The intervention group scored better on impact 
of incontinence at 3 and 6 months, but not at 12 
months follow up.  
2.2.3 Post-Operative PFMT Immediately Be-
fore or After Catheter Removal (No Pre-
Operative Instruction) 
Three new trials (305, 306, 324) were found compar-
ing post-operative PFMT immediately before or after 
catheter removal, bringing the total to six. In the pre-
vious consultation, there was considerable heteroge-
neity in intervention and findings. Ahmed (2012), 
compared three groups, reporting on group assign-
ment only for those completing the trial. Group 1, the 
control group (n=26), received PFME post-opera-
tively. Group 2 (intervention, n=26) started PFME 
plus EStim after catheter removal for 12 weeks, and 
Group 3 (intervention, n=28) started PFME plus ES-
tim and BF after catheter removal for 12 weeks. Mori-
horo (2011) was available only in abstract form, and 
compared an intervention group (n=20) that received 
PFMT with EStim for one month after catheter re-
moval to a control group (n=14) assigned to PFME 
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alone. Burkert (2011), using a 2x2 mixed design, ran-
domized patients and their partners to one interven-
tion group (n=28) that received dyadic PFME plan-
ning or to 3 control groups (n= 29, 29 and 26) that 
received dyadic nutrition planning, individual PFME 
planning or individual nutrition planning.  
Quality of data  
Morohiro (2011) available only as an abstract, did not 
describe randomisation, blinding, sample size calcu-
lation or dropouts. Ahmed (2012) randomised using 
computer generated random numbers in sealed en-
velopes. Surgeons were blinded to randomisation but 
blinding of the outcomes assessor was not clear. 
Sample size was met, and dropouts from each group 
described: control n= 4/26+4 (13%), intervention 
Group 2 n= 2/26+2 (7%) and intervention Group 3 
n=4/28+4 (12.5%). No intention-to-treat analysis was 
undertaken. In the Burkert (2011) study, research as-
sistants were blinded to allocation. Sample size cal-
culation and intention-to-treat were not discussed. 
Dropouts for the intervention group n=5/28 (18%) and 
three control groups (n= 2/29 (7%), 7/29 (24%), 4/26 
(15%) were presented but no reasons for withdrawal 
were provided.  
Results 
Ahmed (2012) reported more men continent at 12 
and 24 weeks post RP in the two intervention groups 
(PFMT plus EStim and PFMT plus EStim and BF) 
compared to PFMT alone using the objective 24-hour 
pad test as primary outcome. Mean leakage was sig-
nificantly lower in intervention Group 3 at 6 through 
24 weeks. Morihoro (2012) found recovery of urinary 
continence favoured the intervention group (PFMT 
with EStim) at 12 months. Incontinence was meas-
ured by subject report of requiring a pad to keep cloth-
ing dry. Burkurt reported only adherence to PFMT 
with no continence data provided. There were no dif-
ferences between the groups.  
Summary  
A total of 9 new trials are now included which apply a 
variety of pre- or immediately post-operative or post-
catheter removal PFMT based interventions (or a 
combination of both, plus or minus BF and EStim). As 
in earlier consultations, differences between interven-
tion and control groups were modest and short term, 
and often reflect self-reported but not objective data 
such as the pad test. Few differences were sustained 
up to 12 months post-surgery. Many of the studies re-
viewed were small, varied in design and quality, and 
had different outcome measures. The two larger stud-
ies that were of better quality (307, 309) found no dif-
ference between intervention and control groups. The 
authors of one of larger study (307) suggested post 
RP UI is likely often due to a mechanism such as in-
trinsic sphincter deficiency that is not amenable to ex-
ercise based treatment. It is possible that this is true 
for some men with persistent UI post RP, and they 
may require surgical rather than conservative inter-
vention. Studies that include evaluation of the extent 
of sphincter function using imaging techniques would 
be helpful in understanding the subpopulations where 
conservative treatments are most helpful. There is 
modest evidence but inconsistent evidence that ther-
apist delivered PFMT with or without BF or EStim be-
fore or after surgery may support an earlier return of 
continence after RP in some men up to 3-6 months 
post-surgery, however this difference is not signifi-
cant at 12 months post-surgery (Level of Evidence: 
2). 
Variation in outcomes measurement remains prob-
lematic. As concluded in the previous consultation, it 
is possible that the emphasis on quantitative out-
comes (i.e. pad test) is not meaningful to participants 
as men appear to find therapy helpful and value the 
direction provided by a therapist. Studies comparing 
the effectiveness of pre- versus post-operative 
PFMT, and the number of sessions required, are 
needed so that practitioners may advise men about 
pre-operative preparation and budget conscious 
health services can make informed decisions on pro-
gramme funding. In designing such studies, the natu-
ral history of UI after radical prostatectomy must be 
considered because the spontaneous recovery rate 
means that sample sizes must be large to detect any 
differences between protocols. As well, attempts to 
identify which men might benefit more, such as in the 
study by Martini (2011) who focused the intervention 
on those with identified pelvic floor impairment, need 
to be undertaken.  
Recommendations  
Some pre-operative instruction or immediate post-op-
erative instruction in PFMT for men undergoing RP 
may be helpful in earlier recovery of continence 
(Grade of Recommendation: B Clarified). 
Use of BF to assist PFMT should remain a thera-
pist/patient decision based on economics and prefer-
ence. (Grade of Recommendation B).  
2.3. Post-Operative RP PFMT for 
Incontinent Men 
Trials in this section addressed the effect of PFMT 
post-operatively after incontinence was established. 
In these studies, incontinent men were recruited at 
variable lengths of time after surgery. 
2.3.1 PFMT with Digital Rectal Feedback 
(DRE) After Radical Prostatectomy 
No new trials were identified to add to the previous 
five trials in which PFMT was taught using digital rec-
tal feedback (DRE) to men incontinent after RP.  
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Summary  
There are no new trials to clarify whether PFMT 
taught by DRE offers any benefit over and above ver-
bal or written instruction, (Level of Evidence: 2).  
Recommendations  
The recommendation is unchanged (Grade of Rec-
ommendation: B). 
2.3.2 PFMT with BF After Radical Prostatec-
tomy 
No new trials were found under this category to add 
to the six previously included trials.  
Recommendations  
The use of BF in clinic, over and above home PFMT, 
should remain a therapist/individual decision based 
on economics and preference. (Grade of Recom-
mendation: B). 
2.3.3 PFMT Plus or minus BF with EStim or 
MStim after Radical Prostatectomy 
Three new trials (311, 322, 325) were added to the 
eight previously included in this section. As in the ear-
lier consultation, a problem of heterogeneity of study 
samples in this category was noted. Kakihara (2007) 
compared an intervention of physiotherapy lead 
PFMT with EStim (n=10) to PFMT alone (n=10) in 
men a minimum 6 months post-surgery (mean 12.3 
months for intervention group, 16.8 months for con-
trol). Pedriali (2014) recruited incontinent men one-
month post RP and assigned them to post-operative 
pilates (n=26) versus PFMT plus EStim (n=28), but 
reported group assignment in only the 54/69 (78%) of 
men completing the study Laurienzo (2015), available 
only in abstract, also included men incontinent one-
month post RP, randomising to three groups: Group 
1 control (no treatment) (n=40), Group 2 PFMT 
(n=41) and Group 3 PFMT plus EStim (n=42).  
Quality of data 
Kakihara (2007) did not provide information on ran-
domisation or blinding. No sample size calculation 
was given. Dropout numbers for each group were 
given, but the reasons for dropping out of the inter-
vention group were not provided. Three participants 
were discharged from the control group at 3, 6 and 12 
months as continence was achieved and were in-
cluded in the final analysis. Pedriali (2014), available 
only as an abstract, did not provide details of random-
isation, blinding, sample size calculation or dropouts. 
Laurienzo (2015) was only available in abstract, but 
did describe randomisation approach, but not blind-
ing, sample size calculation or dropouts.  
Results  
In the Kakihara (2007) trial, there was improvement 
in urine loss on 1-hour pad test in both groups be-
tween baseline and 12 months, but no difference in 
men receiving PFMT with EStim compared to those 
who received only PFMT. Men had undergone urody-
namic testing, and both those with UUI and SUI were 
included. Pedriali (2014) reported 58% of the Pilates 
group and 50% of the EStim plus PFME achieved 
continence, as measured by use of no pads. The dif-
ference was not statistically significant and the au-
thors concluded that Pilates, which includes pelvic 
floor strengthening, is as efficacious as EStim plus 
PFME. Laurienzo (2015) reported no differences be-
tween controls and two intervention groups (PFMT, 
PFMT with EStim) at any time points, objective pad 
test results not provided, subjective reports of quality 
of life and symptoms only.  
Summary  
Data suggest no further benefit of EStim when added 
to PFMT over PFMT alone for men with incontinence 
post RP (Level of Evidence: 2). 
Recommendations  
There does not appear to be any benefit of adding 
EStim to a PFMT programme for men with persistent 
post-prostatectomy incontinence. (Grade of Recom-
mendation: B). 
2.3.4 PFMT Compared to or Plus Other Inter-
ventions After Radical Prostatectomy 
Four new trials (312, 316, 318, 319) were identified 
that combined PFMT post-operatively with other 
novel interventions in men with post prostatectomy in-
continence, adding to the two previously included 
studies. The previous consultation found variation in 
intervention and time since surgery. Zopf (2015) re-
cruited men 6-12 weeks post RP, and assigned them 
to either an intervention of a multimodel exercise pro-
gramme with PFME (n=50) or a control group that re-
ceived no intervention (n=20). Serda (2014), using a 
two group design, randomised men post RP to a com-
bined exercise and PFME intervention group (n=36) 
or control with no intervention (n=33). Time after sur-
gery was not reported. Kongtragul (2014) randomised 
138 incontinent men recruited in hospital after RP. 
Group assignment was reported only for those com-
pleting the study; 68 men were in the intervention 
group with PFME and concentration therapy (no de-
tail provided) starting 3 weeks post-surgery. The con-
trol group (n=67) received only PFME. Baroni (2013) 
was available only in abstract. Men with SUI or mixed 
UI after RP (time after surgery not reported) were as-
signed to an intervention of individual PFMT and 
group treatment (n= 16). Controls (n=24) received 
only individual PFMT.  
Quality of data  
The Zopf (2015) study had intended to randomise 
those who consented, but as all participants refused 
randomisation and gave a group preference, blinding 
of outcome measurement was not described. The au-
thors indicated intention–to-treat analysis was under-
taken but the study did not achieve the calculated 
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sample size and was thus underpowered. Dropouts 
from the intervention group only (n=6/50 12%) were 
described, but reasons were not provided. Serda 
(2014) randomised participants but did describe how 
this was done. Blinding to outcome assessment was 
not reported. Calculated sample size was achieved, 
number of dropouts (intervention group (n=3/36 8%; 
control 0/33) and reason for withdrawal was provided. 
Baroni (2013) was available only in abstract and had 
no detail on randomisation but reported the assessor 
was blinded until assignment. Sample size calcula-
tion and dropouts were not described. Kongtragul 
(2014) did not describe the approach to randomisa-
tion or blinding, but dropouts (intervention n=1/68+1, 
1%; control n=2/67+2, 3%) were described. The 
study did not achieve the number in each group re-
quired for power to detect a difference between 
groups.  
Results  
Zopf (2015) reported a significant improvement in UI, 
as measured by the 20-minute pad test, from base-
line to post testing, but no significant difference be-
tween intervention (exercise plus PFMT) and controls 
(no intervention). However, a significant difference 
between the groups on reported urinary symptoms 
was found. Serda (2014) reported a significant im-
provement in favour of the intervention group (com-
bined exercise and PFME) on self-report of the inten-
sity of urinary symptoms, but did not report the results 
of the 20-minute pad test. Baroni (2013) reported no 
significant difference between intervention and con-
trol on the VAS, number of pads used or home prac-
tice. In the study of concentration exercises plus 
PFME (Kongtragul 2014), significant differences were 
found between intervention and control groups on 
achieving continence measured by the 1-hour pad 
test.  
Summary  
Interventions were varied: general exercise plus 
PFME (316, 318) PFME with concentration therapy 
(not defined by author) (312) and individual PFMT 
compared to individual and group therapy (319). 
There was also heterogeneity of samples in terms of 
time since surgery. There is some early evidence that 
novel interventions, such as general exercise pro-
grammes, use of support groups and concentration 
exercises added to PFME after RP for incontinent 
men may be beneficial, but this is very limited. Some 
of the trials are small and of low quality. Larger stud-
ies of high quality are needed to determine the bene-
fits of these adjuncts to PFME. 
2.4. Pre-Operative TURP PFMT 
No new trials were identified. Little research has been 
dedicated to UI after TURP as the incidence of UI af-
ter TURP is reported to be very low.  
2.5. Pre-Operative and/or Post-Operative 
TURP PFMT 
No new trials were identified.  
Summary  
In the absence of sufficient data from rigorous and 
well-reported trials it is not known if PFMT reduces UI 
following TURP. More systematic investigation of the 
natural history of UI after TURP is probably needed, 
to establish the potential cost/benefit of intervention, 
before further trials are initiated. 
2.6. Post-Operative TURP PFMT for 
Incontinent Men 
One new study (310) was added. The previous con-
sultation reported limited evidence in this area. The 
larger well designed study previously included 
showed no benefit in terms of objective measures of 
incontinence. Hou (2013) reported group assignment 
only for those completing the study. The intervention 
group (n=32) was given instruction in PFME two days 
after surgery when the catheter was removed, and in-
structed to practice daily at home, with weekly tele-
phone reminders. The control group (n=29) activity 
was not described.  
Quality of data 
Approach to randomisation, blinding, sample size cal-
culation and dropouts in the smaller, newly included 
trial (Hou 2013) were not described.  
Results 
Hou (2013) found a statistically significant difference 
in self-report of symptom severity favouring the inter-
vention group at 12 weeks. No objective measure of 
incontinence, such as the pad test, was reported.  
Summary 
There continues to be limited evidence on the benefit 
of PFME post TURP. The new smaller trial suggests 
a potential benefit on perception of symptom severity 
of UI, but no objective data were reported. 
2.7. Factors Affecting Outcome 
Based on the current evidence, it appears that time 
from surgery to implementation of exercises does af-
fect outcome and that by three months after surgery 
less improvement is noted. Future trials should con-
sider analysis to evaluate the effect of sphincter insuf-
ficiency, pelvic floor dysfunction, urethral length, 
length of time from prostatectomy, co-morbid condi-
tions, prior pelvic surgery, medications, other risk fac-
tors (including smoking and alcohol use) on treatment 
outcome.  
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2.8. PFMT for Other LUTS 
2.8.1 PFMT for Post-Micturition Dribble 
(PMD) 
No new trials were identified to add to the two previ-
ously included trials. 
Recommendations 
Offer men with PMD instruction to do a strong PFM 
contraction immediately after voiding, or urethral 
massage to empty the urethra (Grade of Recom-
mendation: C). 
 
3. ELECTRICAL STIMULATION 
(ESTIM) 
An extensive overview of EStim in men is reported in 
the 5th consultation(2). Rectal or surface electrodes 
are most common; surface electrodes are positioned 
over the perineal region. EStim can also be applied 
via the posterior tibialis nerve (PTN). Trials of EStim 
in men post-prostatectomy combined this treatment 
with PFME, and are included in the sections on post-
prostatectomy treatment above. 
3.1. Prevention of UI 
No new trials were identified. There remain no studies 
on the effect of EStim for prevention of non-post pros-
tatectomy UUI or SUI in men.  
3.2. Treatment of UI  
No new trials were added to the nine previously in-
cluded RCTs, four of which included PFME plus ES-
tim post prostatectomy. New trials that combined ES-
tim with PFME were reported in the PFMT section 
above as the separate effects of EStim alone cannot 
be assessed.  
3.2.1 Is EStim Better than No Treatment, Pla-
cebo or Control Treatments? 
No new trials were identified to add to the two previ-
ously included trials. Both previously included trials 
did not separate male and female results. In the con-
tinued absence of sufficient data from rigorous and 
well-reported trials it is not known if EStim, as a stand-
alone treatment for male UUI or SUI, is better than no 
treatment, placebo or control treatments. 
3.2.2 Is One Approach to EStim Better Than 
Another? 
No new trial was identified. No studies comparing ES-
tim protocols were included in previous consultations.  
3.2.3 Is EStim Better Than Other Treat-
ments? 
No new trials were identified. Three studies, two com-
paring EStim to Mstim and one EStim to medication, 
had been included in previous consultations. Details 
of these were provided in the 5th consultation (Moore 
2013): insufficient data exist to establish if EStim is 
better than either intervention. Both studies combined 
male and female data.  
3.2.4 Does the Addition of EStim to Other 
Treatments Add Benefit? 
All of the studies combining EStim with other treat-
ments included the PFMT plus EStim combination, 
and are reviewed under the Pelvic Floor Muscle 
Training section.  
3.3. Other LUTS  
No new studies were identified. No previous studies 
of EStim alone for other LUTS were included in pre-
vious consultations.  
3.4. Factors Affecting Outcome 
The previous consultation identified age, type of in-
continence (SUI post prostatectomy versus OAB and 
UUI) and other factors (types of electrodes, frequency 
and duration of treatment) as potentially affecting out-
comes. No trials have investigated these factors in 
males.  
4. MAGNETIC STIMULATION (MSTIM) 
Although MStim has been used to treat UI after RP 
and to inhibit DO, no new studies were identified.  
4.1. Prevention of UI 
No trials investigating the primary or secondary pre-
vention effects of MStim for men with UI were found. 
4.2. Treatment of UI 
No new trials to add to the three trials (two published, 
one abstract without data) identified and described in 
the 5th consultation were found. Only the two pub-
lished trials were included in the previous consulta-
tion.  
4.2.1 Is MStim Better Than No Treatment, 
Placebo or Control Treatment? 
No studies were found addressing this question. 
4.2.2 Is One Approach to MStim Better Than 
Another? 
No studies were found addressing this question. 
4.2.3 Is MStim Better Than Other Treat-
ments? 
No new studies were identified.  
4.3. Other LUTS 
No studies were found.  
4.4. Factors Affecting Outcome 
The relationship between age (or any other factor, 
such as treatment parameters, treatment adherence, 
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or diagnosis) and the outcome of MStim has yet to be 
determined. 
5. PENILE VIBRATORY 
STIMULATION (PVS) 
This is a novel conservative treatment, based on the 
stimulation of the pudendal nerve via penile vibratory 
stimulation (PVS) to treat SUI in men post prostatec-
tomy.  
PVS has been shown to increase external sphincter 
pressure in men with spinal cord injury (334, 335), 
and vibratory stimulation applied to the perineum in 
healthy women also increased external urethral pres-
sure (336). 
5.1. Prevention of UI 
No trials of prevention were identified.  
5.2. Treatment of UI  
One new trial was identified (308). Fode (2015) ran-
domised 39 men with UI over one-year post RP to two 
groups. Group 1 (n= 19) was the early intervention 
group who received PVS using a commercially avail-
able hand held personal vibrator for 6 weeks. Stimu-
lation was performed on the ventral surface of the pe-
nis once daily with 10 seconds of stimulation followed 
by a ten second pause, repeated 10 times. Group 2 
was the delayed treatment control group, who had no 
intervention the first 6 weeks, but performed PVS in 
the second 6 weeks.  
 Quality of data  
Computer generated randomisation technique was 
described, but blinding of outcome measurement was 
not (308). A sample size calculation was provided, but 
the authors report stopping recruitment early as the 
study was a pilot and the sample achieved was 
thought to be adequate. Drop outs in both early 
(n=4/19, 21%) and delayed (n=5/20, 25%) interven-
tion groups were described, with one of five dropouts 
in the delayed intervention group kept in the analysis, 
although others were not. The participant kept in had 
a pattern of non-compliance over the study, and dis-
continued after 6 weeks.  
Results 
Primary outcome was difference in leakage meas-
ured by 24 pad test. Participants also completed void-
ing diary. Results showed a significant improvement 
in the early intervention group from baseline to 6 
weeks, but not in the delayed intervention group. 
Pooled analysis results from both early and delayed 
intervention groups showed significant overall me-
dian decline in urine loss on 24-hour pad test (p= 
0.07).  
Conclusion  
This was a small pilot study of a novel intervention. 
Further well designed studies are needed to under-
stand the place for PVS in treatment of male UI. No 
recommendation can be made. 
5.3. Other LUTS 
No trials were identified.  
6. SCHEDULED VOIDING REGIMENS 
Scheduled voiding regimens include bladder training, 
timed voiding, habit training and prompted voiding. 
They are frequently combined to achieve maximum 
benefits. Although there is evidence to suggest that 
scheduled voiding regimens, especially bladder train-
ing and timed voiding, are commonly used in the 
treatment of men with UI and other LUTS, there has 
been substantially less research that addresses their 
use in men compared to the literature on their use in 
women, leaving insufficient evidence to comment on 
effectiveness. 
6.1. Prevention of UI 
No trials investigating the preventive effects of sched-
uled voiding regimens for men with UI were found.  
6.2. Treatment of UI 
6.2.1 Bladder Training  
One new trial of a mixed behavioural treatment ap-
proach composed of elements of bladder training 
compared to drug therapy in men with OAB was iden-
tified (317) and added to the five previously included 
trials of bladder training that have included men. Bur-
gio (2011) compared a combined behavioural treat-
ment (PFME, urgency suppression, delayed voiding) 
to drug therapy (n=73) with drug therapy (individually 
titrated extended release oxybutynin) for OAB (n = 
70. This category previously included studies that 
have included BT plus caffeine reduction, BT plus pla-
cebo or anticholinergic drug therapy  
Quality of data 
Burgio and colleagues (2011) used sealed envelopes 
to randomise, blinding of person(s) gathering data on 
outcomes was not described. Sample size analysis 
was not given, but intention-to-treat analysis was un-
dertaken. Dropouts from each group (combined be-
havioural therapy n=9/73, 12%; drug therapy 
n=10/70, 14%) were reported, reasons were not pro-
vided.  
Results 
Primary outcome was 24-hour voiding frequency rec-
orded on a seven-day bladder diary. Secondary out-
comes were other OAB symptoms, perception of im-
provement and satisfaction.  
Results showed that treatment with behavioural strat-
egies (bladder training) compared to pharmacological 
treatment was equivalent. There was no significant 
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difference between incontinence episodes between 
the behaviour and drug therapy groups.  
6.2.2 Timed Voiding  
No new trials were identified. 
6.3. Other LUTS 
One new study was identified for treatment of other 
LUTS in men. The newly included study, described 
above (317) also measured OAB symptoms, with the 
primary outcome being frequency of voiding.  
Quality of data  
 Refer to C.VI.2a above.  
Results  
Primary outcome was 24-hour voiding frequency rec-
orded on a seven-day bladder diary. Secondary out-
comes were other (non UUI) OAB symptoms includ-
ing nocturia and urinary urgency; perception of im-
provement and satisfaction. Treatment with behav-
ioural strategies (bladder training) compared to phar-
macological treatment was equivalent. The behaviour 
therapy group had greater reduction in nocturia epi-
sodes, but urgency scores were lower in the drug 
therapy group.  
Summary 
In men, behavioural treatment may be just as effec-
tive for some LUTS, including UI, as pharmacological 
therapy. Further studies of high quality are needed 
before a recommendation for practice can be sup-
ported.  
6.4. Factors Affecting Outcome 
Age: No new trials were found addressing age as a 
factor affecting outcome.  
Other: No studies were identified on other factors af-
fecting outcome of BT or prompted voiding in men. 
7. COMPLEMENTARY AND 
ALTERNATIVE MEDICINES 
Therapies include acupuncture, relaxation, medita-
tion, imagery, hypnosis, naturopathic and herbal rem-
edies. In previous consultations, only trials of acu-
puncture therapy were found in men with UI. Studies 
were small, objective measured of UI were missing 
and long-term follow-up was lacking, leaving only lim-
ited evidence on the effectiveness of acupuncture for 
men with UI.  
7.1. Prevention of UI 
No new trials were identified on the preventative role 
of complementary therapies in men. 
7.2. Treatment UI 
No new trials were identified.  
7.2.1  What Is the Most Effective Acupunc-
ture Protocol? 
No new trials were identified. 
7.2.2 Acupuncture Versus No Treatment, 
Sham Acupuncture or Any Other Treat-
ment 
No new trials were identified.  
7.3. Other LUTS 
No new trials were identified.  
7.4. Factors Affecting Outcome 
No new trials were identified.  
8. SUMMARY 
Despite the prevalence of UI and LUTS in older men, 
research continues to focus mainly on men following 
radical prostatectomy. Overall, the effect of conserva-
tive treatment (lifestyle interventions, physical thera-
pies, schedule voiding regimes, complementary ther-
apies) for men has received much less research at-
tention compared to women. 
8.1. Recommendations for Practice 
There is generally insufficient Level 1 or 2 evidence 
on which to base recommendations for practice, and 
most recommendations are, in effect hypotheses, 
that need further testing in research. 
Lifestyle interventions 
Weight loss through lifestyle changes should be rec-
ommended to obese and overweight men with UI, 
particularly those with type 2 diabetes. (Grade of 
Recommendation: Grade B New) 
Smoking abstinence should be recommended for 
men with UI (Grade of Recommendation: C New)  
A reduction in caffeine intake is recommended for 
those with incontinence symptoms. (Grade of Rec-
ommendation:  C New) 
Pelvic floor muscle training (PFMT) 
 Some pre-operative or immediate post-operative 
instruction in PFMT for men undergoing radical 
prostatectomy may be helpful in earlier recovery 
of continence. (Grade of Recommendation: B 
Clarified). 
 In men with persistent post-prostatectomy incon-
tinence, PFMT taught by digital rectal examina-
tion (DRE) may be undertaken but it is unclear 
whether this offers any benefit over and above 
verbal or written instruction in PFMT (Grade of 
Recommendation: B Clarified). 
 Use of BF in clinic, over and above home PFMT 
should remain a therapist/patient decision based 
on economics and preference (Grade of Rec-
ommendation: B). 
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 There does not appear to be any benefit of add-
ing EStim to a PFMT programme for men with 
persistent post-prostatectomy incontinence 
(Grade of Recommendation: B).  
 Use of a strong pelvic floor muscle contraction 
immediately after voiding, or urethral massage to 
empty the urethra, should be offered for symp-
toms of post-micturition dribble (Grade of Rec-
ommendation: C). 
Electrical Stimulation (EStim) 
For men with persistent post-prostatectomy inconti-
nence there does not appear to be any benefit of add-
ing EStim to a PFMT programme (Grade of Recom-
mendation: B). 
8.2. Future Research Directions 
Despite recognition that there is much scope for re-
search on the effects of conservative therapies for UI 
and LUTS in men in the 6th consultation, this remains 
largely unexplored. Research that is urgently needed, 
in the opinion of committee members, is highlighted 
with the use of italics. The committee continues to 
support the recommendations that apply to all future 
studies in men, namely: 
 All future intervention studies must be designed 
to allow standardised and comprehensive re-
porting of results based on the ICS and 
CONSORT recommendations. 
 The natural history of UI after radical prostatec-
tomy must be considered in study design as the 
spontaneous recovery rate means that sample 
sizes must be large to detect any differences be-
tween protocols. 
 More research is needed to find out what are the 
most important outcomes for men with UI, so 
such measures can be incorporated as the pri-
mary outcome measures in further trials. 
 Data is needed to establish to the cost, and cost 
effectiveness, of conservative therapies in men 
with UI. 
 Surgical approaches with laparoscopy or robot-
ics offer promising improvements in visualisation 
for nerve-sparing procedures; further research 
should address continence and erectile function 
after these newer surgical procedures. 
8.2.1 Lifestyle Interventions 
 The effects of interventions such as weight, caf-
feine reduction, constipation and physical activ-
ity are priorities for future research. 
8.2.2 Pelvic Floor Muscle Training (PFMT) 
 Further studies to test the hypothesis that pre-
operative proprioceptive training plus PFMT is 
more effective than PFMT alone to prevent UI in 
men undergoing radical prostatectomy. 
 A comparison of pre-operative versus post-oper-
ative PFMT verbal and written feedback to re-
duce prevalence and severity of UI following rad-
ical prostatectomy is needed. 
 Methods of PFMT instruction and supervision re-
quire further investigation. Two areas of re-
search interest are: 
o Whether PFMT taught by DRE offers any 
benefit over and above verbal or written in-
struction. 
o The effect of group exercise as peer support 
may be helpful to a healthy recovery.  
 Future studies should focus on identification of 
men more likely to benefit from conservative in-
terventions, such as those with pelvic floor dys-
function, and screening those with potential in-
trinsic sphincter deficiency post-surgery. This 
might be established using imaging. Men with 
extensive sphincter deficiency should be re-
ferred for urological intervention. Studies of con-
servative measures including PFMT should in-
clude those with milder damage in order to de-
termine efficacy in this group.  
 More systematic investigation of the natural his-
tory of UI after TURP is needed, to establish the 
potential cost/benefit of intervention, before fur-
ther trials are initiated. 
 The relationship between age, or any other factor 
(urethral length, PFM function), and the outcome 
of PFMT for UI in men, and predictors of success 
needs to be investigated.  
8.2.3 Electrical Stimulation (EStim) and Mag-
netic Stimulation (MStim) 
 It is not known if pre- or post-operative EStim or 
MStim has a role in reducing UI after radical 
prostatectomy.  
 RCTs in larger samples, with long-term follow up, 
are needed to investigate all aspects of the ef-
fectiveness of EStim and MStim as a treatment 
for UI in men, including: 
o Either type of stimulation versus no treat-
ment, sham stimulation or other control con-
ditions. 
o Comparisons of both EStim and MStim pro-
tocols. 
o EStim versus MStim. 
o Either type of stimulation versus medication. 
o Whether the addition of either type of stimu-
lation to other treatments adds benefit, in 
particular, the addition of stimulation to 
PFMT. 
o The effect of age, and other factors, on out-
come of stimulation. Older men may have 
more co-morbid conditions than young men 
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and a more pragmatic ap-proach to inclu-
sion in EStim studies is needed. 
8.2.4 Scheduled Voiding Regimens 
 RCTs of voiding regimens and combinations of 
conservative treatments in men with OAB and 
UUI are needed. Further comparison of these 
conservative approaches to drug therapy would 
be helpful for clinicians in recommending treat-
ment to patients. 
 URINARY INCONTINENCE IN 
MEN AND WOMEN 
1. POSTERIOR TIBIAL NERVE 
STIMULATION (PTNS) 
Posterior tibial nerve stimulation (PTNS) is a form of 
peripheral neuromodulation targeted towards symp-
tom relief of OAB and UUI (141). Evidence for the use 
of PTNS for the prevention and treatment of UI in men 
or in adults (study with men and women with results 
combined) is presented below.  
Questions addressed are: 
 Can PTNS prevent UI?  
 Is PTNS better than no treatment, placebo or 
control treatments for UI?  
 Is PTNS better than other treatments for UI? 
 Does the addition of PTNS to other treatments 
add any benefit? 
 What is the best programme of PTNS for UI in 
adults? 
 What is the effect of PTNS on LUTS other than 
UI? 
 What factors might affect the outcome of PTNS? 
A literature search for reports of relevant systematic 
reviews and reports of RCTs and quasi-RCTs was 
performed (see section I). Trial data reported in con-
ference abstracts as well as full text papers were in-
cluded. Since this is a new section for the Conserva-
tive Management chapter no date restrictions were 
applied.  
Eligibility criteria:  
1. Reports of RCTs or quasi-randomised trials of 
PTNS, percutaneous or transcutaneous.  
2. Adult men and women with UI and/or OAB (with 
or without urgency incontinence) presentation of 
data for men only or combined for men and 
women. Trials including women only are pre-
sented in section II.5. 
Evidence overview 
A total of 7 RCTs of posterior tibial nerve stimulation 
(PTNS) in adults were identified (337-343) and one 
Cochrane systematic review of anticholinergic drugs 
versus non-drug active therapies for non-neurogenic 
overactive bladder syndrome in adults (141), in which 
PTNS trials with adults of both sexes and men only 
were included. Only one randomised trial of PTNS in 
men has been reported (344), which addressed post–
stroke neurogenic bladder dysfunction and therefore 
did not meet the inclusion criteria for the conservative 
management chapter. No trials of non-neurogenic 
bladder dysfunction have been reported for men only.  
The trial data is summarised in tables 35 to 38.  
Three randomised trials compared PTNS with a sham 
intervention (337-339). 
Four trials were comparative: 
 Two compared different anticholinergics (340, 
341)  
 Two compared different stimulation protocols 
(342, 343)  
Percutaneous PTNS was used in 5 randomised trials 
(337, 339-342)  
Transcutaneous PTNS was used in 2 (338, 343).  
No direct comparisons of percutaneous and 
transcutaneous PTNS for treatment of UI have been 
undertaken in the adult population or in men only.  
On the basis of the included studies, percutaneous 
PTNS seems to involve a standard protocol with re-
gard to stimulation parameters of frequency and ses-
sion-duration using the Urgent PCTM stimulator. How-
ever, the number of individual sessions, overall dura-
tion of programme and timing of delivery protocols 
may vary. There is also variation between percutane-
ous and transcutaneous stimulation parameters and 
one transcutaneous device study (343) did not report 
stimulation parameters, preventing comparison with 
other results. This variability reflects the limited un-
derstanding of the mechanisms of PTNS, which can-
not be assumed to be identical for both percutaneous 
and transcutaneous routes. Further investigation is 
required for both percutaneous and transcutaneous 
PTNS to determine the most effective type of stimu-
lation and treatment protocols. 
1.1. Prevention of UI 
There have been no studies on the effect of PTNS for 
prevention of UUI/OAB in adults or in men only. 
1.2. Treatment of UI 
1.2.1 Is PTNS Better Than No Treatment, Pla-
cebo or Control Treatments for UI? 
Three randomised controlled trials address this ques-
tion in adult men and women. One RCT (337) is ade-
quately powered whereas Vohra (339) and Booth 
(338) are both pilot RCTs. 
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Quality of evidence  
Computerised randomisation was used in all three 
studies with adequate allocation concealment re-
ported in two (337, 338) and unclear in one (339). 
Subjects and outcome assessors were blinded 
throughout in two studies (337, 338), with blinding un-
clear in one(339). Two studies reported intention-to-
treat analysis (337, 338); the type of analysis was not 
reported in one (339). There was no apparent ine-
quality in loss to follow-up across the groups: in one 
trial (345) seven subjects were lost to follow-up in the 
PTNS and 5 in the sham group thus 94% and 95% 
respectively were analysed. Two of the 30 subjects 
(6.6%), both from the sham group, discontinued in 
one trial (338) and one subject (4.5%) from the control 
group discontinued in the other trial (339). Mild or 
moderate treatment related adverse events were re-
ported by 6 PTNS subjects in one trial (337). They 
included ankle bruising (1 of 110, 0.9%) discomfort at 
needle site (2 of 110, 1.8%) bleeding at the needle 
site (3 of 110, 2.7%) and tingling in the leg (1 of 110, 
0.9%). No subjects in the transcutaneous PTNS trial 
(338) reported adverse events and presence of ad-
verse events was unclear in one study(339). Two tri-
als were reported as pilots with no sample size calcu-
lation (338, 339) and one was adequately powered 
(337) however the payment of subjects for time and 
expense was a potential limitation and the efficacy 
achieved may not be equivalently reflected in trans-
lating to real world practice. Long term follow-up to 3 
years post-initial treatment was reported by Peters 
(345). Overall risk of bias was low in two trials (337, 
338) and high in one (339). 
Results  
No study reported cure rates for UI, however all three 
trials reported improvements. In the SUmiT trial(337) 
37.9% PTNS subjects reported moderate or markedly 
improved urgency incontinence compared to 22.1% 
sham subjects (p=0.02). Voiding diary analysis 
showed PTNS to be statistically superior to sham in 
reducing urge incontinence episodes (p=0.002) from 
a median of 3.0 episodes accompanied by moderate 
to severe urgency per day at baseline, to a median of 
0.3 episodes at 13 weeks (p<0.0001). In the two pilot 
trials Booth (338) reported improved ICIQ-UI SF in 10 
of 15 (67%) transcutaneous PTNS group and 6 of 13 
(46%) sham group (p=0.132, NS); Vohra reported 
significantly reduced UI in 7 of 11 PTNS subjects but 
no estimates of effect size were provided; data was 
not differentiated for men and women. In one large 
trial (337) PTNS subjects reported statistically signifi-
cant improvements in overall bladder symptoms with 
54.5% reporting moderate or markedly improved 
Global Response Assessment (GRA) from baseline 
compared to 20.9% of sham subjects (p<0.001). A 
significant difference between the groups in favour of 
PTNS was found for the OAB-q quality of life scores 
(p=0.006) and the SF-36 general health survey qual-
ity of life scores significantly improved between base-
line and 13 weeks for the PTNS group in the physical 
(p=0.002) and mental (p=0.049) domain scales. One 
pilot trial (339) reported significant improvements in 
quality of life (QoL questionnaires not specified and 
SF-36) but provided no data or figures to support this.  
A prospective study to assess long-term outcomes 
and determine frequency of top-up stimulation ses-
sions required was reported (345). Fifty responders 
to the original trial underwent a fixed 14-week tapered 
stimulation protocol, followed by a personal treatment 
plan aimed at maintaining improvements. Twenty-
nine of 50 (58%) completed the outcomes. 77% of 
these maintained moderate or marked improvement 
in OAB symptoms at three years with a median 1.1 
treatments each month. 
Summary 
The results of two trials, one rigorous, well-reported 
trial and one low quality pilot trial, showed that percu-
taneous PTNS is a safe and more effective interven-
tion than a sham treatment for improving urgency in-
continence in adults with OAB/UUI. 
There is evidence that, with regular treatment, effects 
are sustained for up to 3 years. (Level of Evidence: 
1). 
One small high quality pilot trial indicates that 
transcutaneous PTNS is safe and may be more effec-
tive than sham stimulation for reducing UI and urinary 
symptoms in older adults in institutional care. Further 
studies are needed to determine the effectiveness of 
transcutaneous PTNS. (Level of Evidence: 2). 
Recommendation 
Percutaneous PTNS can be offered to men and 
women (adults) with UUI/OAB who do not achieve 
satisfactory results from first line lifestyle and behav-
ioural intervention and pharmacological therapy. 
(Grade of Recommendation: B New). 
In this population, Transcutaneous PTNS may be a 
useful option to test in the adult with UUI/OAB earlier 
in the algorithm, following lifestyle and behavioural in-
terventions and before more invasive therapies are 
considered. 
1.2.2 Is PTNS Better Than Other Treatments 
for UI? 
One RCT compared PTNS with another treatment for 
UI. The other treatment was extended release tolter-
odine 4mg daily (341). There are no trials comparing 
transcutaneous PTNS with other treatments. 
Quality of evidence  
1:1 randomisation to percutaneous PTNS or toltero-
dine was implemented using a random block design 
stratified by investigational site however the success 
of allocation concealment was unclear. Blinding of 
subjects, clinicians or assessors was not possible 
given the different nature of the interventions. An in-
tention to treat analysis was not undertaken. Seven 
subjects (14%) withdrew from the drug group and 9 
(18%) from the percutaneous PTNS group; none due 
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to adverse effects. Adverse effects were mild or mod-
erate in both groups with 14.3% (7 subjects) from the 
tolterodine arm reporting moderate adverse effects 
and 16.3% (8 subjects) from the percutaneous PTNS 
group. Percutaneous PTNS related adverse events 
included leg cramps, intermittent foot/toe pain, gener-
alised swelling, headache, haematuria, inability to tol-
erate stimulation, worsening incontinence and vaso-
vagal response to needle placement. A sample size 
calculation was provided and the study was ade-
quately powered for a non-inferiority margin of 20% 
in number of voids per 24 hours. Long-term follow-up 
of percutaneous PTNS subjects for nine months after 
initial treatment completion was reported (346). The 
overall risk of bias was high.  
Results  
Data was reported for the whole group with no differ-
entiation by sex. The global response assessment 
(GRA) demonstrated that subjective assessment of 
bladder symptom change compared to baseline was 
statistically significant with 79.5% (35) of the percuta-
neous PTNS group reporting cure (1) or improvement 
(34) and 54.8% (23) of the tolterodine group reporting 
cure (2) or improvement (21) (p=0.01). Both groups 
had improved significantly. Symptoms of UUI re-
ported in the voiding diaries improved significantly in 
both groups however there was no significant differ-
ence between the groups for these measures. Quality 
of life scores showed statistically significant improve-
ments for both treatment groups (P<0.001) but be-
tween group differences were not statistically signifi-
cant. The percutaneous PTNS group reported statis-
tically significantly less dry mouth than the tolterodine 
group (p=0.01) and a non-significant lower rate of 
constipation. 
Follow-up to determine duration of effect up to 12 
months from baseline was offered to percutaneous 
PTNS responders (those who reported a successful 
response to GRA after 12 weeks) (346). Thirty-three 
of the 35 responders chose to continue. The GRA 
showed sustained improvements in 96% at 12 
months with a mean of 21 days between treatment 
sessions.  
Summary  
Evidence from a single RCT indicates that percutane-
ous PTNS may be as effective as tolterodine for ur-
gency UI with an improved side effect profile; how-
ever, design limitations suggest caution and further 
studies are recommended to establish the effects of 
percutaneous PTNS and transcutaneous PTNS in 
comparison to other pharmacological treatments 
(Level of Evidence: 2). 
As there were no trials comparing transcutaneous 
PTNS with another active treatment trials are also 
needed to determine the effects of transcutaneous 
PTNS compared to common anticholinergic drugs 
used to treat UUI/OAB in adults.  
Recommendation 
Percutaneous PTNS can be offered as an alternative 
to tolterodine for OAB/UUI in adult men and women. 
(Grade of Recommendation: B New). 
1.2.3 Does the Addition of PTNS to Other UI 
Treatment Add Any Benefit? 
One RCT was identified (340) that compared percu-
taneous PTNS with percutaneous PTNS and oxy-
butynin for treatment of patients with overactive blad-
der (with or without incontinence) and urodynamically 
diagnosed detrusor overactivity (DO). 
Quality of evidence  
Randomisation following urodynamic studies into per-
cutaneous PTNS group or percutaneous PTNS plus 
5mg daily oxybutynin hydrochloride was reported but 
no description of method of randomisation. Adequacy 
of allocation concealment and blinding of subjects, 
clinicians or assessors was not reported nor was type 
of analysis, which was unclear. It appears that no 
subject dropped out and reported adverse events 
were mild: percutaneous PTNS plus drug group - 
seven reported dry mouth, one blurred vision; percu-
taneous PTNS group – one reported a small haema-
toma, one local tenderness. There was no sample 
size calculation, no long-term follow-up and overall 
risk of bias was high. 
Results 
Four of five subjects receiving percutaneous PTNS 
only and all five subjects receiving percutaneous 
PTNS and oxybutynin, with urgency UI reported cure 
on voiding diary. The numbers were too small for sta-
tistical analysis. Overall treatment response was de-
fined as patient-reported improvement in OAB symp-
toms of frequency, urgency and urge incontinence by 
> 35% and occurred in 61.6% percutaneous PTNS 
group and 83.2% percutaneous PTNS plus oxy-
butynin group. The between group difference was not 
statistically significant. 
Summary 
The evidence is limited to a single low quality trial 
(Level of Evidence: 2) which indicates there may be 
additional effects if oxybutynin is added to a pro-
gramme of percutaneous PTNS. Further trials are 
needed to establish whether the addition of an anti-
cholinergic drug enhances the effectiveness of percu-
taneous PTNS in adults with UUI/OAB and which 
drugs provide the greatest effect.  
As there were no trials comparing transcutaneous 
PTNS added to another active treatment with the ac-
tive treatment alone studies are also needed to deter-
mine the effects of adding transcutaneous PTNS to 
first line lifestyle and behavioural treatments for OAB 
and UUI including bladder training and percutaneous 
PFMT, with these first line lifestyle and behavioural 
treatments alone.  
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Recommendation 
Oxybutynin may be considered in addition to percuta-
neous PTNS in adults with DO. (Grade of Recom-
mendation: B New).  
This hypothesis needs to be investigated further with 
high quality trials 
1.2.4 What is the Best PTNS Protocol for UI 
in Adults? 
Two RCTs compared different stimulation protocols 
(342, 343). Details are provided in table 38.  
Quality of the evidence 
Randomisation methods were not described for either 
study. Allocation concealment could not be deter-
mined from the reports and blinding of subjects or cli-
nicians was not possible with this design. Neither 
study reported the type of analysis undertaken. Pri-
mary outcomes were reported at the end of the (342) 
treatment protocol. No long-term follow up was re-
ported. Withdrawals were high (29.2 %) in the Seth 
(343) pilot trial, with 8 of the 14 withdrawals being de-
vice related, although no significant adverse events 
occurred. There were no withdrawals in the Finazzi-
Agro trial and no adverse events reported.  
Results  
In the Finazzi-Agro (342) trial 4 of 11 (36%) subjects 
with UI in the weekly percutaneous PTNS group and 
5 of 11 (45%) subjects with UI in the 3 X weekly per-
cutaneous PTNS group reported complete cure after 
treatment. Overall success of >50% reduction in mic-
turition episodes/24 hours or (if incontinent) UI epi-
sodes/24 hours was confirmed for 11 of 17 (63%) 
subjects in the weekly percutaneous PTNS group and 
12 of 18 (67%) subjects in the 3 times weekly percu-
taneous PTNS group. Subjective improvement was 
reported after 6-8 sessions, regardless of frequency 
of delivery. In the Seth (343) trial 18 of 34 (54%) sub-
jects who completed the 12week protocol were re-
sponders, who rated their improvement as moderate 
to significant on the General Response Assessment 
(GRA). Statistically significant improvements in ICIQ-
OAB (p=0.001) and ICIQ LUTSqol (p=0.000) were re-
ported for both daily and weekly stimulation groups. 
There were no statistically significant differences in 
ICIQ or bladder diary parameters between those with 
idiopathic and OAB of neurogenic origin.  
Summary 
Two small trials indicate that no additional benefit is 
conferred by a more than once weekly stimulation 
protocol for percutaneous or transcutaneous PTNS. 
However, it is possible that symptom improvement 
may be more rapid with a more frequent delivery pro-
tocol (Level of Evidence: 2).  
Further rigorous and well-reported trials are needed 
to establish the most effective timing and duration of 
PTNS protocols.  
Recommendation 
Percutaneous or transcutaneous PTNS should be de-
livered at least once weekly and the protocol deter-
mined by patient preference. (Grade of Recommen-
dation: B New). 
1.3. What is the Effect of PTNS on LUTS 
Other Than UI? 
No trials were identified that analysed the effect of 
PTNS in adults or men with other LUTS alone i.e. fre-
quency of voiding, urgency, nocturia and integrated 
reporting of UI and other LUTS was a feature of all 
studies. For percutaneous PTNS compared with 
sham percutaneous PTNS, in one large well reported 
trial, the percutaneous PTNS group reported statisti-
cally significant improvements in voiding diary symp-
toms of frequency, night-time voids and voids with 
moderate to severe urgency, compared to the sham 
group (337). A small pilot trial reported reduced day 
and night time frequency and urgency after 12 weekly 
30 minute percutaneous PTNS sessions by 63% of 
percutaneous PTNS subjects, although no EStimates 
of effect size were provided. The elimination of detru-
sor overactivity on repeat urodynamic testing was 
also shown (339).  
For transcutaneous PTNS compared with sham 
transcutaneous PTNS one trial in care home resi-
dents (338) reported statistically significantly im-
proved total American Urological Association Symp-
tom Index AUASI urinary symptom scores for 87% of 
the transcutaneous PTNS group compared to 31% 
sham group (p<0.001).  
When comparing percutaneous PTNS with another 
treatment one trial (341) reported significant reduc-
tion in bladder diary reports of void frequency, noctu-
ria, moderate to severe urgency episodes in both 
groups and no between group differences.  
One trial comparing two percutaneous PTNS proto-
cols (342) reported a statistically significant reduction 
in frequency (p=0.01) for both once and three times 
weekly treatment regimes.  
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Table 35 Summary of data on PTNS vs no treatment in man and women 
Study Comparator groups N Study population Modality details or parameters Outcomes Follow up 
Percutaneous posterior tibial nerve stimulation 
Peters  
(2010) (1) 
Treatment group: Percutaneous 
PTNS 
Active electrode:  
34 gauge needle provides 
sensation. 
Inactive electrode: calcaneal 
surface electrode.  
Control group: Sham 
Percutaneous PTNS  
Placebo needle with sensation of 
insertion. Inactive 
220 Adults (>18) with OAB 
symptoms 
Males: 46 
Females: 174 
Results reported together 
Pulse width: not reported 
Frequency: 20 Hz 
Intensity:  
0.5-9mA according to sensory & 
motor response. 
Duration: 30 minutes 
Number sessions: 12 
Programme length: 12 weeks 
Primary outcome: 
Moderate/marked improvement 
in 7 level GRA at week 13 
Secondary outcomes:  
Change in individual GRA 
symptoms 
3-day voiding diary parameters 
OABq scores 
SF-36 QoL scores 
Week 13 
Vohra (2002) 
(2) 
Treatment group: Percutaneous 
PTNS 
Active electrode:  
34 gauge needle provides 
sensation. 
Inactive electrode: calcaneal 
surface electrode.  
Control group: Sham 
Percutaneous PTNS 
Described as ‘PTNS treatment 
without nerve stimulation’ 
22 Adults with urgency 
frequency syndrome of > 6 
months and 
urodynamic detrusor 
overactivity 
Males: not reported 
Females: not reported 
Results reported together 
Pulse width: not reported 
Frequency: 20 Hz 
Intensity:  
0.5-10mA according to sensory & 
motor response. 
Duration: 30 minutes 
Number sessions: 12 
Programme length: 12 weeks 
  
Micturition diary 
QOL questionnaires  
Repeat urodynamics 
SF-36 
 
. 
 
12 weeks 
Transcutaneous posterior tibial nerve stimulation  
Booth 2013 (3) Treatment group: Transcutaneous 
PTNS 
Active: Surface electrode medial 
malleolus provides sensation.  
Inactive: surface electrode 10cm 
proximal to medial malleolus,  
Control group: Sham 
Transcutaneous PTNS 
Surface electrodes X2 positioned 
below lateral malleolus and 10cm 
30 Older adults (>65) resident 
in care homes with urinary 
symptoms and/or 
incontinence 
Males: 6 
Females: 24 
Results reported together  
Pulse width: 200 μS 
Frequency: 10 Hz 
Intensity: 1-50mA according to 
sensory & motor threshold and 
subject comfort. 
Duration: 30 minutes 
Number sessions: 12 
Programme length: 6 weeks 
 
AUASI 
ICIQ-UI SF 
PVR 
 
 
Week 6 
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Footnotes; GRA : Global Response Assessment, UUI : urinary urge incontinence, OABq : Overactive Bladder Questionnaire, SF-36 : 36-Item Short Form Health Survey; 
AUASI : American Urological Association Symptom Index; ICIQ-UI SF : International Consultation on Incontinence Questionnaire on Urinary Incontinence Short Form; 
PVR : post-void residual urine volume; PTNS: Posterior tibial nerve stimulation 
1. Peters KM, Carrico DJ, Perez-Marrero R, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy 
in the treatment of overactive bladder syndrome: results from the SUmiT trial. The Journal of urology. 2010;183(4):1438. 
2. Vohra AK, Britchford A, Neale E, Husain I, Waterfall N, editors. The efficacy of stoller afferent nerve stimulation in frequency/urgency syndrome: A randomised 
control trial. Proceedings of the International Continence Society (ICS) 32nd Annual Meeting, Aug 28-30; 2002. 
3. Booth J, Hagen S, McClurg D, Norton C, MacInnes C, Collins B, et al. A feasibility study of transcutaneous posterior tibial nerve stimulation for bladder and bowel 
dysfunction in elderly adults in residential care. Journal Of The American Medical Directors Association. 2013;14(4):270. 
 
Table 36 Summary of data on PTNS vs other active treatments in men and women 
Author, year Comparator groups N Study population  Modality details or 
parameters 
Outcomes/results Follow up 
Peters (2009) (1) Treatment group: Percutaneous 
PTNS 
Active electrode: 34 gauge needle 
provides sensation. 
Inactive electrode: calcaneal 
surface electrode.  
Comparator treatment group: 
Daily tolterodine ER 4mg 
100 Adults with urinary 
frequency of at least 8 
voids/24 hours 
Males: 6 
Females: 94  
Results reported 
together.  
Pulse width: not reported 
Frequency: 20 Hz 
Intensity:  
0.5-9mA according to sensory 
& motor response. 
Duration: 30 minutes 
Number sessions: 12 
Programme length: 12 weeks  
Primary outcome: mean reduction in 
number of urinary voids in 24 hours 
Secondary outcomes: change in 24 
hour UUI episodes, number of voids 
causing waking, daily voided volume, 
episodes of urgency. 
OABq Investigator & subject OAB 
ratings using GRA. 
12 weeks 
Footnotes; GRA : Global Response Assessment, UUI : urinary urge incontinence, OABq : Overactive Bladder Questionnaire ER : extended release PTNS : Posterior tibial 
nerve stimulation 
1. Peters KM, MacDiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, et al. Randomised trial of percutaneous tibial nerve stimulation versus extended-
release tolteridine: Results from the overactive bladder innovative thereapy trial. Journla of Urology. 2009;182(3):1055-61. 
  
proximal to avoid posterior tibial 
nerve current applied 2 mA 
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Table 37 Summary of data on PTNS + another active vs PTNS 
Author, year Comparator groups N Study population Modality details or parameters Outcomes/results Follow up 
Karademir 
2005 (1) 
Treatment group: 
Percutaneous PTNS plus oral 
oxybutynin hydrochloride 5mg daily 
Active electrode:  
34 gauge needle provides 
sensation. 
Inactive electrode: calcaneal 
surface electrode.  
Comparator treatment group: 
Percutaneous PTNS 
Active electrode:  
34 gauge needle provides 
sensation. Inactive electrode: 
calcaneal surface electrode.  
43 Adults with > 6 month 
history of OAB symptoms 
and DO on UDS 
 
Males: 5 
Females: 38 
Results reported together  
Pulse width: 200 μS 
Frequency: 20 Hz 
Intensity:  
0.5-9mA according to sensory & 
motor response. 
Duration: 60 minutes 
Number sessions: 8 
Programme length: 8 weeks  
 
 
 
 
 
Outcomes measured with Bristol 
Urinary Questionnaire and voiding 
diary. 
  
Improvements in symptoms by 
>70%, 35-70% and <35% 
represented complete remission, 
partial remission and no response. 
 
 
8 weeks 
Posterior tibial nerve stimulation: PTNS 
1. Karademir K, Baykal K, Sen B, Senkul T, Iseri C, Erden D. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. 
Scandinavian journal of urology and nephrology. 2005;39(3):230.
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1.4. Factors Affecting Outcomes 
None of the included percutaneous PTNS trials ad-
dressed the effect of age or any other factor on pre-
diction of outcome of PTNS. Effectiveness of 
transcutaneous PTNS in   older adults resident in care 
homes was the focus of one study where the mean 
age was 84.2 years (338). The adherence to the 
transcutaneous PTNS was 100% for all participants, 
with no adverse effects reported and a response to 
therapy similar to that found with younger groups. A 
prospective study (347) of prognostic factors for suc-
cessful percutaneous PTNS showed that gender, 
age, weight, body mass index, indication for percuta-
neous PTNS, duration of symptoms, number and 
type of previous treatments, number of UI epi-
sodes/24 hours, voiding frequency/24 hours and total 
IQoL scores were all unrelated to the success or not 
of percutaneous PTNS in men and women with OAB, 
non-obstructive urinary retention or chronic pelvic 
pain. A low Mental Component Summary Score on 
the SF-36 was a negative predictive factor for suc-
cess of percutaneous PTNS, both subjectively and 
objectively. Additionally patients with detrusor over-
activity had poorer outcomes than those without, as 
did those with low bladder capacity at baseline (143). 
This means that there is no reason to exclude older 
adults, those with a long symptom history, weight dif-
ficulties, severe symptoms or failure of previous treat-
ments and they should be offered PTNS where indi-
cated, except where recognised contraindications to 
PTNS, such as a cardiac pacemaker are present. 
Only in those patients with poor mental health and/or 
DO and/or low capacity bladders at baseline should 
the possibility of limited success be considered.  
New factors are emerging which may influence un-
derstanding of potential effects for different diagnostic 
groups. In one pilot study (343) urinary neurotrophin 
levels (nerve growth factor and brain derived neu-
rotrophic factor) were measured. Results indicated 
that for idiopathic OAB higher levels of nerve growth 
factor at baseline may predict poor response to 
transcutaneous PTNS. Level of brain derived neu-
rotrophic factor significantly reduced over the treat-
ment course in those who responded to transcutane-
ous PTNS, which suggests a potential biomarker for 
response in idiopathic OAB but the reduction was not 
seen in responders with neurological disease. Further 
investigation is required to fully understand the influ-
ence of these patient factors. 
Summary   
The evidence on which to base recommendations for 
best practice in the use of PTNS to treat OAB/UUI in 
men and women is sparse, for both percutaneous 
and transcutaneous PTNS. However it is sufficiently 
robust to support the use of percutaneous PTNS 
when less intensive and invasive behavioral treat-
ment options have failed (Level of Evidence: 1) and 
there is the suggestion that percutaneous PTNS may 
be as effective as some drug therapy, making it a vi-
able alternative (Level of Evidence: 2).  
Only two small trials investigated transcutaneous 
PTNS but the promising results indicate that further 
well-designed and reported trials would allow deci-
sions to be made about the place of transcutaneous 
PTNS in the treatment algorithms for OAB/UUI in men 
and women.   
Health economic information is required to establish 
the cost effectiveness of the different forms of PTNS, 
particularly in comparison to pharmacotherapy.  
Recommendations for practice:  
In adults with OAB/UUI percutaneous PTNS is better 
for improving UUI than no treatment or sham and 
should be offered to adults with UUI/OAB who do not 
achieve satisfactory results from first-line lifestyle and 
behavioral interventions or drug therapy.  (Grade of 
Recommendation: B New)  
At least weekly PTNS sessions should be offered dur-
ing an active treatment program with regular top-ups 
provided to sustain benefits for up to three years. 
(Grade of Recommendation: B New)  
Transcutaneous PTNS is a safe treatment option and 
may be offered to frail older adults with UI or urinary 
symptoms however definitive evidence of effective-
ness is needed. (Grade of Recommendation: C 
New) 
Percutaneous PTNS can be offered as an alternative 
to tolterodine for OAB/UUI in adult men and women. 
(Grade of Recommendation: B New). 
Oxybutynin may be considered in addition to percuta-
neous PTNS in adults with DO. (Grade of Recom-
mendation: B New).  
Future research directions: 
Currently available evidence compares percutaneous 
PTNS with older antimuscarinics.  Future rigorous tri-
als should compare percutaneous PTNS with other 
commonly used antimuscarinics and beta 3 adrener-
gic agonists for efficacy and adverse effect profiles, 
in men and women with OAB/UUI.  
The effectiveness of adding drug therapy to percuta-
neous PTNS should be investigated in high quality tri-
als with adults with OAB/UUI. 
Definitive evidence of the effectiveness of transcuta-
neous PTNS to treat OAB/UUI in adults is needed 
and its place in the treatment algorithm defined. 
Research comparing transcutaneous PTNS with all 
types of drug therapy is required. 
Direct comparison of percutaneous PTNS and 
transcutaneous PTNS to treat OAB/UUI in adults 
should be investigated.  
Further rigorous and well-reported trials are needed 
to establish the most effective dose of percutaneous 
PTNS and transcutaneous PTNS, including the tim-
ing and duration of PTNS protocols. 
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Table 38 Summary of data PTNS protocols comparisons 
Footnotes; GRA : Global Response Assessment, UDS : Urodynamic studies; SF-36 :36-Item Short Form Health Survey; ICIQ-OAB : International Consultation on Incon-
tinence Questionnaire on Overactive Bladder; ICIQ-LUTSqol : International Consultation on Incontinence Quality of Life questionnaire; BD parameters : bladder diary 
parameters; PTNS: Posterior tibial nerve stimulation 
1. Finazzi Agrò E, Campagna A, Sciobica F, Petta F, Germani S, Zuccalà A, et al. Posterior tibial nerve stimulation: is the once-a-week protocol the best option? 
Minerva urologica e nefrologica = The Italian journal of urology and nephrology. 2005;57(2):119. 
2. Seth J, Gonzales G, Haslam C, Ochulor J, Elneil S, Vashisht A, editors. Single centre randomised pilot study of two regimens (30mins daily or 30 mins weekly for 
12 weeks) of Transcutaneous Tibial Nerve Stimulation using an adhesive skin patch for the treatment of Overactive Bladder (OAB) Symptoms  Proceedings of the 
44th Annual Meeting of the International Continence Society (ICS), 2014 Oct 20-24; 2014. 
Author, year Comparator N Study population Modality details or parameters Outcomes Follow up 
Percutaneous posterior tibial nerve stimulation  
Finazzi-Agro 
2005 (1) 
Treatment group A: weekly 
Percutaneous PTNS 
Active electrode:  
34 gauge needle provides sensation. 
Inactive electrode: calcaneal surface 
electrode.  
Comparator treatment group B: 3 x 
weekly Percutaneous PTNS 
Active electrode:  
34 gauge needle provides sensation. 
Inactive electrode: calcaneal surface 
electrode.  
35 Adults with refractory OAB 
syndrome 
Males : 7 
Females: 28 
Results reported together 
 
Pulse width: not reported 
Frequency: 20 Hz 
Intensity:  
0.5-9mA according to sensory & 
motor response. 
Duration: 30 minutes 
Number sessions: 12 
Programme length: 12 weeks 
(Group A);  
4 weeks (Group B) 
 
24 hour BD 
IQoL 
SF36 
UDS 
Success defined as those 
who reported  
micturition 
episodes/24hours or 
incontinence episodes/24 
hours reduced by >50% 
 
4 weeks (3X 
weekly PTNS) 
 
12 weeks  
(1 X weekly 
PTNS) 
Transcutaneous posterior tibial nerve stimulation     
Seth 
2014 (2) 
Treatment group  
Transcutaneous PTNS using GekoTM 
device weekly 
Comparator treatment group 
Transcutaneous PTNS using GekoTM 
device daily 
48 
 
Adults with idiopathic (24 
subjects) or neuropathic 
(24 subjects) OAB  
Males NR 
Females NR 
Results reported together 
Pulse width: not reported 
Frequency: not reported 
Intensity: not reported 
Duration: 30 minutes 
Number sessions: 12 (weekly 
group), 84 (daily group) 
Programme length: 12 weeks  
Outcomes: Responder 
defined as those rating 
moderate to significant 
improvement on GRA at 
12 weeks  
Change in individual 
GRA symptoms 
ICIQ-OAB,  
ICIQ-LUTSqol 
BD parameters 
12 weeks 
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